Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.14.14.14 - aromatase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
46, XX Disorders of Sex Development
A case of female pseudohermaphroditism caused by aromatase deficiency.
A new cause of female pseudohermaphroditism: placental aromatase deficiency.
Female pseudohermaphroditism associated with a novel homozygous G-to-A (V370-to-M) substitution in the P-450 aromatase gene.
Abortion, Spontaneous
Polymorphisms in estrogen metabolism and estrogen pathway genes and the risk of miscarriage.
Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility.
Acidosis
Breast cancer: Lesser-known facets and hypotheses.
Fragrance compounds: The wolves in sheep's clothings.
Acne Vulgaris
Aromatase Deficiency due to a Novel Mutation in
Aromatase Deficiency in Two Siblings with 46, XX Karyotype Raised as Different Genders: A Novel Mutation (p.R115X) in CYP19A1 Gene
Mild cutaneous manifestation in two young women with extraordinary hyperandrogenemia.
The Associations of Androgen-Related Genes CYP21A2 and CYP19A1 with Severe Acne Vulgaris in Patients from Southwest China.
Acquired Immunodeficiency Syndrome
A review on diverse heterocyclic compounds as the privileged scaffolds in non-steroidal aromatase inhibitors.
Acromegaly
Aromatase enzyme expression in acromegaly and its possible relationship with disease prognosis.
Acute Coronary Syndrome
Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data.
Adenocarcinoma
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma.
Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor.
Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors.
Aromatase activity in microsomes from rat ventral prostate and Dunning R3327H rat prostatic adenocarcinoma.
Aromatization of testosterone by epithelial tumor cells cultured from patients with ovarian carcinoma.
Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.
Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity.
Estrogen secreting adrenal adenocarcinoma in an 18-month-old boy: aromatase activity, protein expression, mRNA and utilization of gonadal type promoter.
Estrogen synthesis in human colon cancer epithelial cells.
Expression of aromatase and 5-alpha-reductase genes in endometrial adenocarcinoma.
Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report.
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study.
[Expressions of aromatase protein and sex hormone receptor in endometrial lesions.]
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
Adenocarcinoma of Lung
Association of a genetic variant of CYP19A1 with multicentric development of lung adenocarcinomas.
EGFR L858R Mutation and Polymorphisms of Genes related to Estrogen Biosynthesis and Metabolism in Never-smoking Female Lung Adenocarcinoma Patients.
Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment.
Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutations.
Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma.
Adenocarcinoma, Bronchiolo-Alveolar
Association of CYP19A1 polymorphisms with risks for atypical adenomatous hyperplasia and bronchioloalveolar carcinoma in the lungs.
Adenocarcinoma, Mucinous
Aromatase inhibitor for the treatment of primary mucinous carcinoma of the skin with distant metastasis.
Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.
Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions.
Adenoma
Achievement of fertility in an infertile man with resistant macroprolactinoma using high dose of bromocriptine and a combination of hCG and an aromatase inhibitor.
Aromatase enzyme expression in acromegaly and its possible relationship with disease prognosis.
Aromatase in human common epithelial ovarian neoplasms.
Aromatase p450 expression in a feminizing adrenal adenoma presenting as isosexual precocious puberty.
Estrogen biosynthesis in human H295 adrenocortical carcinoma cells.
G-protein Coupled Estrogen Receptor Expression in Growth Hormone Secreting and Non-Functioning Adenomas.
Gonadotroph adenomas in men produce biologically active follicle-stimulating hormone.
Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Locally produced estrogen through aromatization might enhance tissue expression of pituitary tumor transforming gene and fibroblast growth factor 2 in growth hormone-secreting adenomas.
Mild cutaneous manifestation in two young women with extraordinary hyperandrogenemia.
Optimization of a classical aromatase activity assay and application in normal, adenomatous and malignant breast parenchyma.
Adenomyoma
Aromatase inhibitor treatment of menorrhagia and subsequent pregnancy in a patient with familial hyperparathyroidism-jaw tumor syndrome.
Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: A randomized controlled trial.
Adenomyosis
Adenomyosis: a systematic review of medical treatment.
Adenomyosis: the pathophysiology of an oestrogen-dependent disease.
Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study.
Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: A randomized controlled trial.
Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist.
Current and Future Medical Therapies for Adenomyosis.
Detection of aromatase cytochrome P-450 in endometrial biopsy specimens as a diagnostic test for endometriosis.
Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis.
Editor's Note: Badawy AM, Elnashar AM, and Mosbah AA. Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica, 2012;91:489-495.
Effect of a hormone-releasing intrauterine system (Mirena(®)) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection.
Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis.
Endometrial aromatase mRNA as a possible screening tool for advanced endometriosis and adenomyosis.
Endometriosis: the pathophysiology as an estrogen-dependent disease.
Estrogen biosynthesis in human uterine adenomyosis.
Estrogen degrades Scribble in endometrial epithelial cells through E3 ubiquitin ligase HECW1 in the development of diffuse adenomyosis†.
Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium.
Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas.
High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome.
Pharmacological Treatment for Symptomatic Adenomyosis: A Systematic Review.
Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium.
Role of medical therapy in the management of uterine adenomyosis.
Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report.
The effect of oral contraceptives on aromatase and Cox-2 expression in the endometrium of patients with idiopathic menorrhagia or adenomyosis.
Two cases of endometrial cancer arising from adenomyosis during aromatase inhibitors therapy after mastectomy.
Urogynecologic conditions: pelvic organ prolapse.
[Cytochrome P-450 aromatase expression in the ectopic and eutopic endometrium in endometriosis]
[Role of estrogen, estrogen receptors, and aromatase in the pathogenesis of uterine adenomyosis].
Adrenal Gland Neoplasms
Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma.
Adrenal Hyperplasia, Congenital
11-Oxygenated Estrogens Are a Novel Class of Human Estrogens but Do not Contribute to the Circulating Estrogen Pool.
46,XX DSD and Antley-Bixler syndrome due to novel mutations in the cytochrome P450 oxidoreductase gene.
46,XX DSD due to Androgen Excess in Monogenic Disorders of Steroidogenesis: Genetic, Biochemical, and Clinical Features.
A novel homozygous CYP19A1 gene mutation: Aromatase deficiency mimicking congenital adrenal hyperplasia in an infant without obvious maternal virilisation.
Ambiguous genitalia, impaired steroidogenesis, and Antley-Bixler syndrome in a patient with P450 oxidoreductase deficiency.
Aromatase deficiency in an adolescent girl misdiagnosed as congenital adrenal hyperplasia in infancy and childhood.
Aromatase Deficiency in Two Siblings with 46, XX Karyotype Raised as Different Genders: A Novel Mutation (p.R115X) in CYP19A1 Gene
Aromatase Inhibitor as Treatment for Severely Advanced Bone Age in Congenital Adrenal Hyperplasia: A Case Report.
Aromatase Inhibitor Increases the Height of Patients with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.
Aromatase inhibitors in pediatrics.
Fertility issues in the management of patients with disorders of sex development.
Genetic and Clinical Spectrum of Aromatase Deficiency in Infancy, Childhood and Adolescence.
Growth Hormone With Aromatase Inhibitor May Improve Height in CYP11B1 Congenital Adrenal Hyperplasia.
Macroorchidism in childhood and adolescence: an update.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Use of an aromatase inhibitor in children with congenital adrenal hyperplasia: Impact of anastrozole on bone mineral density and visceral adipose tissue.
[Macroorchidism: A case report.]
Adrenocortical Adenoma
Expression of aromatase and estrogen receptors in human adrenocortical tumors.
Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease.
Major hyperestrogenism in a feminizing adrenocortical adenoma despite a moderate overexpression of the aromatase enzyme.
Oestrogen producing adrenocortical adenoma: clinical, biochemical and immunohistochemical studies.
Adrenocortical Carcinoma
2,3,7,8-Tetrachlorodibenzo-p-dioxin and diindolylmethanes differentially induce cytochrome P450 1A1, 1B1, and 19 in H295R human adrenocortical carcinoma cells.
2-Chloro-s-triazine herbicides induce aromatase (CYP19) activity in H295R human adrenocortical carcinoma cells: a novel mechanism for estrogenicity?
Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma.
Aromatase activity in an estrogen-producing adrenocortical carcinoma in a young man.
Effect of epidermal growth factor and prostaglandin on the expression of aromatase (CYP19) in human adrenocortical carcinoma cell line NCI-H295R cells.
Effects of bisphenol A-related diphenylalkanes on vitellogenin production in male carp (Cyprinus carpio) hepatocytes and aromatase (CYP19) activity in human H295R adrenocortical carcinoma cells.
Effects of fifteen PBDE metabolites, DE71, DE79 and TBBPA on steroidogenesis in the H295R cell line.
Effects of lactone derivatives on aromatase (CYP19) activity in H295R human adrenocortical and (anti)androgenicity in transfected LNCaP human prostate cancer cells.
Effects of Neonicotinoids on Promoter-Specific Expression and Activity of Aromatase (CYP19) in Human Adrenocortical Carcinoma (H295R) and Primary Umbilical Vein Endothelial (HUVEC) Cells.
Evaluation of a bioluminescent mouse model expressing aromatase PII-promoter-controlled luciferase as a tool for the study of endocrine disrupting chemicals.
Expression of aromatase and estrogen receptors in human adrenocortical tumors.
Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease.
Forskolin up-regulates aromatase (CYP19) activity and gene transcripts in the human adrenocortical carcinoma cell line H295R.
Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells.
Induction and inhibition of aromatase (CYP19) activity by various classes of pesticides in H295R human adrenocortical carcinoma cells.
Inhibition and induction of aromatase (CYP19) activity by brominated flame retardants in H295R human adrenocortical carcinoma cells.
Inhibition of aromatase activity by methyl sulfonyl PCB metabolites in primary culture of human mammary fibroblasts.
Mono-(2-ethylhexyl) phthalate (MEHP) induces nuclear receptor 4A subfamily in NCI-H295R cells: a possible mechanism of aromatase suppression by MEHP.
The effects of the standardized extracts of Ginkgo biloba on steroidogenesis pathways and aromatase activity in H295R human adrenocortical carcinoma cells.
Adrenocortical Hyperfunction
Vertebral fractures cascade: potential causes and risk factors.
Agranulocytosis
Effect of aminoglutethimide on neutrophils in rats: implications for idiosyncratic drug-induced blood dyscrasias.
Alopecia
5?-Reductase isozymes and aromatase mRNA levels in plucked hair from young women with female pattern hair loss.
A prospective study of aromatase inhibitor therapy initiation and self-reported side effects.
Alopecia With Endocrine Therapies in Patients With Cancer.
Aromatase inhibitor therapy and hair loss among breast cancer survivors.
Aromatase inhibitor-induced hair loss in two adolescents.
Association between smoking and hair loss: another opportunity for health education against smoking?
Association of Single Nucleotide Polymorphisms in the CYP19A1 Gene with Female Pattern Hair Loss in a Chinese Population.
Biochemical mechanisms regulating human hair growth.
Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia.
Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.
Expression of androgen receptor coactivator ARA70/ELE1 in androgenic alopecia.
Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss.
Investigation of variants of the aromatase gene (CYP19A1) in female pattern hair loss.
Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview.
Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres.
Steroid chemistry and hormone controls during the hair follicle cycle.
[Androgenetic alopecia]
[Hormones and hair growth]
Alzheimer Disease
A new day dawns: women without oestrogen or is a balance best?
Aromatase and interleukin-10 genetic variants interactively modulate Alzheimer's disease risk.
Aromatase enzyme and Alzheimer's disease. Studio prospettico in 54 pazienti affetti da iperparatiroidismo primitivo.
Aromatase variants modify risk for Alzheimer's disease in a multiethnic female cohort.
Aromatase/Seladin-1 Interactions in Human Neuronal Cell Culture, the Hippocampus of Healthy Rats and Transgenic Alzheimer's Disease Mice.
Association between aromatase in human brains and personality traits.
Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer.
Association between rs10046, rs1143704, rs767199, rs727479, rs1065778, rs1062033, rs1008805, and rs700519 polymorphisms in aromatase (CYP19A1) gene and Alzheimer's disease risk: a systematic review and meta-analysis involving 11,051 subjects.
Association of the aromatase gene with Alzheimer's disease in women.
CYP19 haplotypes increase risk for Alzheimer's disease.
Diminished aromatase immunoreactivity in the hypothalamus, but not in the basal forebrain nuclei in Alzheimer's disease.
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Genetic targeting aromatase in male amyloid precursor protein transgenic mice down-regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairment.
Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk.
Interactions of Aromatase and Seladin-1: A Neurosteroidogenic and Gender Perspective.
Neuroblastoma and Alzheimer's disease brain cells contain aromatase activity.
Polymorphisms in the CYP19 gene confer increased risk for Alzheimer disease.
The CYP19A1 rs3751592 variant confers susceptibility to Alzheimer disease in the Chinese Han population.
The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease.
The sex-specific associations of the aromatase gene with Alzheimer's disease and its interaction with IL10 in the Epistasis Project.
Androgen-Insensitivity Syndrome
Androgen dependent stimulation of aromatase activity in genital skin fibroblasts from normals and patients with androgen insensitivity.
Evaluation of boys with marked breast development at puberty.
Incomplete testicular feminization syndrome: studies of 17 beta-oestradiol-binding activity and aromatase activity in cultured genital fibroblasts showing impaired dihydrotestosterone-binding.
Incomplete testicular feminization syndrome: studies on androgen receptor(AR) function, AR gene analysis, and aromatase activities at puberty and long-term observations of clinical and hormonal features from infancy to puberty.
Increased peripheral aromatase activity in prepubertal children with partial androgen insensitivity syndrome.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Anemia
Patients' preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments.
Anencephaly
Quantitative evaluation of human placental aromatase in abnormal pregnancy--anencephalus and hydatidiform mole.
Aneurysm
Everolimus.
Angiofibroma
Aromatase may play a critical role in the pathogenesis of juvenile nasopharyngeal angiofibroma.
Angiomyolipoma
Everolimus.
Anovulation
Acute dietary restriction in heifers alters expression of genes regulating exposure and response to gonadotrophins and IGF in dominant follicles.
Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS.
Di-(2-ethylhexyl) phthalate and Mono-(2-ethylhexyl) phthalate Inhibit Growth and Reduce Estradiol Levels of Antral Follicles In Vitro.
Hypothyroidism affects lipid and glycogen content and peroxisome proliferator-activated receptor ? expression in the ovary of the rabbit.
Ovulation triggers in anovulatory women undergoing ovulation induction.
The effects of an aromatase inhibitor and a 5 alpha-reductase inhibitor upon the occurrence of polyovular follicles, persistent anovulation, and permanent vaginal stratification in mice treated neonatally with testosterone.
The use of D-chiro-Inositol in clinical practice.
Antiphospholipid Syndrome
Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.
Antley-Bixler Syndrome Phenotype
Akhenaten and the strange physiques of Egypt's 18th dynasty.
Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.
Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients.
Anus Neoplasms
Sexual dysfunction and infertility as late effects of cancer treatment.
Aortic Aneurysm, Abdominal
Aromatase is required for female abdominal aortic aneurysm protection.
Autoradiography screening of potential positron emission tomography tracers for asymptomatic abdominal aortic aneurysms.
aromatase deficiency
46,XX DSD due to Androgen Excess in Monogenic Disorders of Steroidogenesis: Genetic, Biochemical, and Clinical Features.
A 43-year-old male with untreated panhypopituitarism due to absence of the pituitary stalk: from dwarf to giant.
A case of Aromatase deficiency due to a novel CYP19A1 mutation.
A case of female pseudohermaphroditism caused by aromatase deficiency.
A large cohort of disorders of sex development and their genetic characteristics: 6 novel mutations in known genes.
A new cause of female pseudohermaphroditism: placental aromatase deficiency.
A novel compound heterozygous mutation of the aromatase gene in an adult man: reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome.
A novel compound heterozygous variant in CYP19A1 resulting in aromatase deficiency with normal ovarian tissue.
A novel homozygous CYP19A1 gene mutation: Aromatase deficiency mimicking congenital adrenal hyperplasia in an infant without obvious maternal virilisation.
A novel mutation in the human aromatase gene: insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment.
A Novel Null Mutation in P450 Aromatase Gene (CYP19A1) Associated with Development of Hypoplastic Ovaries in Humans.
A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom).
Abnormal steroidogenesis and aromatase activity in preeclampsia.
Accelerated Pubertal Tempo in a 46,XY Aromatase-Deficient Patient.
Altered umbilical sex steroids in preterm infants born small for gestational age.
Ambiguous genitalia, impaired steroidogenesis, and Antley-Bixler syndrome in a patient with P450 oxidoreductase deficiency.
An Intron 9 CYP19 Gene Variant (IVS9+5G>A), Present in an Aromatase-Deficient Girl, Affects Normal Splicing and Is Also Present in Normal Human Steroidogenic Tissues.
Aromatase activity and bone homeostasis in men.
Aromatase and estrogen receptor ? deficiency.
Aromatase deficiency and estrogen resistance: from molecular genetics to clinic.
Aromatase deficiency and its consequences.
Aromatase deficiency caused by a novel P450arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy.
Aromatase deficiency causes altered expression of molecules critical for calcium reabsorption in the kidneys of female mice *.
Aromatase deficiency confers paradoxical postischemic cardioprotection.
Aromatase deficiency due to a functional variant in the placenta promoter and a novel missense mutation in the CYP19A1 gene.
Aromatase Deficiency due to a Homozygous CYP19A1 Mutation in a 46,XX Egyptian Patient with Ambiguous Genitalia.
Aromatase Deficiency due to a Novel Mutation in
Aromatase deficiency in a Chinese adult man caused by novel compound heterozygous CYP19A1 mutations: effects of estrogen replacement therapy on the bone, lipid, liver and glucose metabolism.
Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood.
Aromatase deficiency in a male patient - Case report and review of the literature.
Aromatase deficiency in an adolescent girl misdiagnosed as congenital adrenal hyperplasia in infancy and childhood.
Aromatase deficiency in an Ontario Old Order Mennonite family.
Aromatase deficiency in hematopoietic cells improves glucose tolerance in male mice through skeletal muscle-specific effects.
Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens.
Aromatase deficiency in men: a clinical perspective.
Aromatase Deficiency in Two Siblings with 46, XX Karyotype Raised as Different Genders: A Novel Mutation (p.R115X) in CYP19A1 Gene
Aromatase deficiency inhibits the permeability transition in mouse liver mitochondria.
Aromatase deficiency, a rare syndrome: case report.
Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature.
Aromatase deficiency: a novel compound heterozygous mutation identified in a Chinese girl with severe phenotype and obvious maternal virilization.
Aromatase deficiency: a rare cause of maternal virilisation and ambiguous genitalia in neonates.
Aromatase deficiency: an unusual cause for primary amenorrhea with virilization.
Aromatase Deficiency: Rare Cause of Virilization.
Aromatase expression and role of estrogens in male gonad : a review.
Aromatase research and its clinical significance.
Bilateral osteonecrosis of the femoral head in an adult man affected by congenital estrogen deficiency.
Biochemical and molecular genetic analyses on placental aromatase (P-450AROM) deficiency.
Bone has a sexually dimorphic response to aromatase deficiency.
Bone metabolism in men: Role of aromatase activity.
Brain aromatase is neuroprotective.
Characterization of a novel CYP19A1 (aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46,XY brother, but no virilization of the mother during pregnancies.
Child with '46, XX' disorder of sex development: clues to diagnose aromatase deficiency.
Cholesterol feeding prevents adiposity in the obese female aromatase knockout (ArKO) mouse.
Clinical review 78: Aromatase deficiency in women and men: would you have predicted the phenotypes?
Congenital disorders of estrogen biosynthesis and action.
Congenital estrogen deficiency in men: a new syndrome with different phenotypes; clinical and therapeutic implications in men.
Congenital estrogen deficiency: in search of the estrogen role in human male reproduction.
Congenital hypopituitarism as a cause of undetectable estriol levels in the maternal triple-marker screen.
CYP17 polymorphism and tamoxifen-induced hepatic steatosis.
Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.
Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients.
Disproportional body growth in female estrogen receptor-alpha-inactivated mice.
Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment.
Effect of estrogen replacement on insulin sensitivity, serum lipid and bone resorption marker in hypogonadal males.
Effect of testosterone and estradiol in a man with aromatase deficiency.
Effects of estrogen replacement therapy on bone and glucose metabolism in a male with congenital aromatase deficiency.
Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys.
Elucidation of estrogen receptor function in bone with the use of mouse models.
Erratum: aromatase deficiency, a rare syndrome: case report.
Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia.
Estradiol in elderly men.
Estrogen and adiposity--utilizing models of aromatase deficiency to explore the relationship.
Estrogen replacement therapy in a man with congenital aromatase deficiency: effects of different doses of transdermal estradiol on bone mineral density and hormonal parameters.
Estrogen: consequences and implications of human mutations in synthesis and action.
Estrogens and growth: review.
Estrogens and male reproduction.
Estrogens are essential for male pubertal periosteal bone expansion.
Estrogens as regulators of bone health in men.
Estrogens--male hormones?
Fertility issues in the management of patients with disorders of sex development.
Five New Cases of 46,XX Aromatase Deficiency: Clinical Follow-Up From Birth to Puberty, a Novel Mutation, and a Founder Effect.
Genetic analysis of human placental aromatase deficiency.
Genetic and Clinical Spectrum of Aromatase Deficiency in Infancy, Childhood and Adolescence.
Genetic mutations resulting in estrogen insufficiency in the male.
Genetic mutations resulting in loss of aromatase activity in humans and mice.
Genetic studies to characterize the origin of the mutation in placental aromatase deficiency.
Gestational Hyperandrogenism in Developmental Programming.
GPR30 deficiency causes increased bone mass, mineralization, and growth plate proliferative activity in male mice.
Growth and hormonal profile from birth to adolescence of a girl with aromatase deficiency.
Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors.
Hormonal regulation of growth plate cartilage.
Human gene mutations. Gene symbol: CYP19. Disease: Aromatase deficiency.
Human models of aromatase deficiency.
Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback.
Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene.
Hypothesis: Persistently elevated hCG causes gestational ovarian overstimulation associated with prolonged postpartum hyperandrogenism in mothers of aromatase-deficient babies.
Impact of aromatase absence on murine intraocular pressure and retinal ganglion cells.
Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene.
Impact of Estrogen Replacement throughout Childhood on Growth, Pituitary-Gonadal Axis and Bone in a 46,XX Patient with CYP19A1 Deficiency.
Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency.
Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?
Macroorchidism in childhood and adolescence: an update.
Maternal exposure to imazalil disrupts the endocrine system in F1 generation mice.
Metformin, Estrogen Replacement Therapy and Gonadotropin Inhibition Fail to Improve Insulin Sensitivity in a Girl with Aromatase Deficiency.
Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries.
Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR: Expanding the PORD Phenotype.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Mutation of cyp19a1b results in sterile males due to efferent duct obstruction in Nile tilapia.
Myocardial and cardiomyocyte stress resilience is enhanced in aromatase-deficient female mouse hearts through CaMKII? activation.
Neurological effects of aromatase deficiency in the mouse.
No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome.
Novel CYP19A1 Mutations Extend the Genotype-Phenotype Correlation and Reveal the Impact on Ovarian Function.
Novel human pathological mutations. Gene symbol: CYP19A1. Disease: Aromatase deficiency.
Oestradiol replacement treatment and glucose homeostasis in two men with congenital aromatase deficiency: evidence for a role of oestradiol and sex steroids imbalance on insulin sensitivity in men.
Oestrogen modulation of the effect of 8-OH-DPAT on prepulse inhibition: effects of aromatase deficiency and castration in mice.
Of mice and men: the evolving phenotype of aromatase deficiency.
Osteoporosis: gender differences and similarities.
Ovarian and uterine development and hormonal feedback mechanism in a 46 XX patient with CYP19A1 deficiency under low dose estrogen replacement.
Ovarian cysts in prepubertal girls.
Ovarian steroidogenesis in Japanese patients with polycystic ovary syndrome.
Pediatric endocrinology update: an overview. The essential roles of estrogens in pubertal growth, epiphyseal fusion and bone turnover: lessons from mutations in the genes for aromatase and the estrogen receptor.
Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia.
Pituitary function in a man with congenital aromatase deficiency: effect of different doses of transdermal E2 on basal and stimulated pituitary hormones.
Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype.
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Recent experimental and clinical findings in the skeleton associated with loss of estrogen hormone or estrogen receptor activity.
Recognizing rare disorders: aromatase deficiency.
Recurrent severe hyperandrogenism during pregnancy: a case report.
Retraction. Neurological effects of aromatase deficiency in the mouse.
Role of estrogen and androgen in pubertal skeletal physiology.
Role of estrogen on bone in the human male: insights from the natural models of congenital estrogen deficiency.
Role of oestrogen in male sexual behaviour: insights from the natural model of aromatase deficiency.
Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males.
Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals.
Sex steroids and bone health status in men.
Sex steroids and sexual desire in a man with a novel mutation of aromatase gene and hypogonadism.
Sex steroids and the acquisition of bone mass.
Sex- and age-related response to aromatase deficiency in bone.
Short stature homeobox-containing gene duplication on the der(X) chromosome in a female with 45,X/46,X, der(X), gonadal dysgenesis, and tall stature.
Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone.
Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic.
Steroid profiling in preeclamptic women: evidence for aromatase deficiency.
Tall stature without growth hormone: four male patients with aromatase deficiency.
Testosterone action on erythropoiesis does not require its aromatization to estrogen: Insights from the testosterone and estrogen treatment of two aromatase-deficient men.
The aromatase cytochrome P-450 and its clinical impact.
The cytochrome P450 aromatase lacking exon 5 is associated with a phenotype of nonclassic aromatase deficiency and is also present in normal human steroidogenic tissues.
The effects of long-term raloxifene and estradiol treatments on bone in a patient with congenital aromatase deficiency.
THE EFFECTS OF MATERNAL HYPOTHYROIDISM ON THE IMMUNOREACTIVITY OF CYTOCHROME P450 AROMATASE IN THE POSTNATAL RAT TESTICLES.
The effects of oestrogen exposure on bone mass in male to female transsexuals.
The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals.
The essential role of the aromatase/p450arom.
The estrogen receptor in the growth plate: implications for pubertal growth.
The influence of estrogen on growth.
The role of Eralpha and ERbeta in the prostate: insights from genetic models and isoform-selective ligands.
The role of estrogens in male skeletal development.
Unusual Virilization in Girls with Juvenile Granulosa Cell Tumors of the Ovary Is Related to Intratumoral Aromatase Deficiency.
Variable phenotypes associated with aromatase (CYP19) insufficiency in humans.
[Aromatase deficiency]
[Estrogen resistance and aromatase deficiency in humans]
[Estrogens and male sexuality: efficiency of antiestrogens in case of hypothalamic hypogonadism and late onset hypogonadism].
[Macroorchidism: A case report.]
[PADAM from the urologic viewpoint]
[Pathophysiology of disease caused by mutation in estrogen receptors]
[Puberty and bone metabolism]
[Rare forms of female pseudohermaphroditism: when to investigate?]
[Sex differentiation of central nervous system--brain of man and woman]
Arrhythmias, Cardiac
Aromatase deficiency confers paradoxical postischemic cardioprotection.
The Relationship between Estrogen and Nitric Oxide in the Prevention of Cardiac and Vascular Anomalies in the Developing Zebrafish (Danio Rerio).
Arteriosclerosis
[Important functions of estrogens in men--breakthrough in contemporary medicine]
Arteriovenous Malformations
Extensive Osler-Rendu disease in a breast cancer patient: increasing hepatic arteriovenous malformations under endocrine therapy mimicking liver metastases.
Resolution of Uterine Arteriovenous Malformation and Maintenance of Reproduction in 20 Women Treated With a GnRH Agonist Concomitantly With an Aromatase Inhibitor and Tranexamic Acid.
Arthralgia
"I feel like I am 100 years old!" managing arthralgias from aromatase inhibitors.
(557) Auricular point acupressure to manage aromatase inhibitor-induced arthralgia in postmenopausal breast cancer survivors.
A cross-sectional survey of pain catastrophising and acupuncture use among breast cancer survivors.
A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.
A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.
A qualitative exploration of the impact of yoga on breast cancer survivors with aromatase inhibitor-associated arthralgias.
A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use.
A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102.
A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer.
Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia.
Acupuncture for Aromatase Inhibitor-Induced Arthralgia: A Systematic Review.
Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients.
Acupuncture for Arthralgia Induced by Aromatase Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis.
Acupuncture for cancer pain and related symptoms.
Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysis.
Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study.
Acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer.
Adaptation of an Evidence-Based Arthritis Program for Breast Cancer Survivors on Aromatase Inhibitor Therapy Who Experience Joint Pain.
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias.
Advising Women Undergoing Treatment for Breast Cancer: A Narrative Review.
Anastrozole-associated joint pain and other symptoms in patients with breast cancer.
Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity.
Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors.
Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients.
Aromatase inhibitor-associated arthralgia syndrome.
Aromatase Inhibitor-Associated Arthralgias.
Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.
Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors.
Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
Aromatase inhibitor-induced arthralgia: a review.
Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.
Aromatase inhibitor-induced arthralgia: Is vitamin D deficiency responsible?
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer.
Aromatase inhibitor-induced joint pain: melatonin's role.
Aromatase inhibitors and arthralgia.
Aromatase inhibitors and arthralgia: a growing pain?
Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors.
Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation.
Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?
Arthralgia and aromatase inhibitors.
Arthralgia Associated with Autoimmune Abnormalities under Aromatase Inhibitor Therapy: Outcome after Cessation of Treatment.
Arthralgia During Aromatase Inhibitor Treatment in Early Breast Cancer Patients: Prevalence, Impact, and Recognition by Healthcare Providers.
Arthralgia in 329 Patients Taking Aromatase Inhibitors.
Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study.
Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.
Auricular Point Acupressure to Manage Aromatase Inhibitor-Induced Arthralgia in Postmenopausal Breast Cancer Survivors: A Pilot Study.
Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.
Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy.
Combined use of vitamin D and omega-3 fatty acid in breast cancer patients might be more beneficial for reducing aromatase inhibitors-associated arthralgia.
Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a protocol for a systematic review and network meta-analysis.
Current management of aromatase inhibitor-induced arthralgia.
Current Opinion of Aromatase Inhibitor-induced Arthralgia in Breast Cancer in the UK.
Current role and safety profile of aromatase inhibitors in early breast cancer.
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
Development and validation of the Penn Arthralgia Aging Scale among breast cancer survivors.
Drug insight: autoimmune effects of medications-what's new?
Effect of acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer: A meta-analysis of randomized controlled trials.
Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.
Effect of concurrent prescription antiarthralgia pharmacotherapy on persistence to aromatase inhibitors in treatment-naive postmenopausal females.
Effect of Tart Cherry on Aromatase Inhibitor-Induced Arthralgia (AIA) in Nonmetastatic Hormone-Positive Breast Cancer Patients: A Randomized Double-Blind Placebo-Controlled Trial.
Effectiveness, safety, and economic evaluation of adjuvant moxibustion therapy for aromatase inhibitor-induced arthralgia of postmenopausal breast cancer stage I to III patients: Study protocol for a prospective, randomized, assessor-blind, usual-care controlled, parallel-group, pilot clinical trial.
Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review.
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors.
Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the Hormones and Physical Exercise (HOPE) study.
Exercise for secondary prevention of breast cancer: moving from evidence to changing clinical practice.
Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study.
Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors.
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.
Genetic Predictors of Response to Acupuncture for Aromatase Inhibitor-Associated Arthralgia Among Breast Cancer Survivors.
Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.
Getting a grip on aromatase inhibitor-associated arthralgias.
Hormonal prevention of breast cancer.
Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis.
Immune-mediated syndromes following intravenous bisphosphonate therapy.
Impact of Yoga on Functional Outcomes in Breast Cancer Survivors With Aromatase Inhibitor-Associated Arthralgias.
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Interventions for the Treatment of Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: A Systematic Review and Meta-analysis.
Joint pain and falls among women with breast cancer on aromatase inhibitors.
Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.
Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
Management of aromatase inhibitor-induced arthralgia.
Management of arthralgias associated with aromatase inhibitor therapy.
Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study.
Managing the toxicities of the aromatase inhibitors.
Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients.
Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.
New views on treatment of aromatase inhibitors induced arthralgia.
Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue.
Nordic Walking as an Exercise Intervention to Reduce Pain in Women With Aromatase Inhibitor-Associated Arthralgia: A Feasibility Study.
Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).
Oncology Acupuncture for Chronic Pain in Cancer Survivors: A Reflection on the American Society of Clinical Oncology Chronic Pain Guideline.
Online discussion of drug side effects and discontinuation among breast cancer survivors.
Overview of long term care of breast cancer survivors.
Pain in cancer survivors; filling in the gaps.
Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.
Pilot study of Iyengar yoga for management of aromatase inhibitor-associated arthralgia in women with breast cancer.
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis.
Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.
Randomized Controlled Trial of a Home-Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors.
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
Randomized Exercise Trial of Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors.
Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study).
Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
Recent advances in oncology acupuncture and safety considerations in practice.
Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy.
Reply to correspondence concerning "Acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer".
Rheumatic disorders and functional disability with aromatase inhibitor therapy.
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Shear wave elastography detects novel imaging biomarkers of aromatase inhibitor-induced joint pain: a pilot study.
Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.
Sonographic and Electrodiagnostic Evaluations in Patients With Aromatase Inhibitor-Related Arthralgia.
Symptoms: Aromatase Inhibitor Induced Arthralgias.
Tai chi for well-being of breast cancer survivors with aromatase inhibitor-associated arthralgias: a feasibility study.
The aromatase inhibitors in early breast cancer: who, when, and why?
The Effect of Exercise on the Alleviation of Side Effects Induced by Aromatase Inhibitors in Postmenopausal Breast Cancer Patients.
The efficacy of acupoint stimulation for the management of therapy-related adverse events in patients with breast cancer: a systematic review.
The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia.
Therapeutic options for aromatase inhibitor-associated arthralgia in breast cancer survivors: A systematic review of systematic reviews, evidence mapping, and network meta-analysis.
Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.
Tolerance of adjuvant letrozole outside of clinical trials.
Treatment with Ruta graveolens 5CH and Rhus toxicodendron 9CH may reduce joint pain and stiffness linked to aromatase inhibitors in women with early breast cancer: results of a pilot observational study.
Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia.
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.
Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.
Yoga versus massage in the treatment of aromatase inhibitor-associated knee joint pain in breast cancer survivors: a randomized controlled trial.
[Surveillance following curative therapy for breast cancer]
[Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
Arthritis
A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer.
Adaptation of an Evidence-Based Arthritis Program for Breast Cancer Survivors on Aromatase Inhibitor Therapy Who Experience Joint Pain.
Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer.
Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis.
Drug insight: autoimmune effects of medications-what's new?
Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis.
Relation between placental growth factor-1 (PlGF-1) and vascularization, DHEAS to DHEA conversion, or aromatase expression in patients with arthritis.
The management of secondary osteoporosis.
Arthritis, Rheumatoid
Accelerated cutaneous nodulosis associated with aromatase inhibitor therapy in a patient with rheumatoid arthritis.
Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology.
Predictors of fragility fracture and low bone mineral density in patients with a history of parental fracture.
RANK ligand inhibition with denosumab for the management of osteoporosis.
Rheumatoid arthritis and aromatase inhibitors.
Rheumatoid arthritis: a complication of aromatase inhibitor therapy?
Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity.
The effect of antiestrogen agents on risk of autoimmune disorders in patients with breast cancer.
Thrombotic risk and immobility in residents of long-term care facilities.
Asthenozoospermia
Differential expression of mRNA aromatase in ejaculated spermatozoa from infertile men in relation to either asthenozoospermia or teratozoospermia.
Astrocytoma
Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas.
Association of ST6GAL1 and CYP19A1 polymorphisms in the 3'-UTR with astrocytoma risk and prognosis in a Chinese Han population.
Everolimus.
Atherosclerosis
Aromatase in atherosclerotic lesions of human aorta.
Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis.
Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase.
The discrepancy of aromatase expression in epicardial adipose tissue between CHD and non-CHD patients.
Use of Network Pharmacology to Explore the Mechanism of Gegen (Puerariae lobatae Radix) in the Treatment of Type 2 Diabetes Mellitus Associated with Hyperlipidemia.
Atrophic Vaginitis
Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.
Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors.
The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis.
Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer.
Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy.
Avian Leukosis
Characterization of the endogenous retrovirus insertion in CYP19A1 associated with henny feathering in chicken.
Azoospermia
Aromatase inhibitors for male infertility.
Male infertility due to testicular disorders.
Serum bioactive follicle-stimulating hormone in men with idiopathic azoospermia and oligospermia.
Testicular Testosterone and Estradiol Concentrations and Aromatase Expression in Men with Nonobstructive Azoospermia.
Biliary Atresia
Aromatase in normal and diseased liver.
Bisphosphonate-Associated Osteonecrosis of the Jaw
An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw.
Bone Diseases
[Non-corticosteroid drug-induced metabolic bone disease]
Bone Diseases, Metabolic
A TA repeat polymorphism in the estrogen receptor gene is associated with osteoporotic fractures but polymorphisms in the first exon and intron are not.
Antihormonal potential of selected D-homo and D-seco estratriene derivatives.
Aromatase deficiency in men: a clinical perspective.
Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline.
Bone targeted therapies in early breast cancer.
Correlation of rs749292 and rs700518 polymorphisms in the aromatase gene (CYP19A1) with osteoporosis in postmenopausal Polish women.
Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study.
Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Estrogens and bone health in men.
Estrogens and health in males.
Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
Low bone density in breast cancer survivors in Korea: Prevalence, risk factors and associations with health-related quality of life.
NCCN Task Force Report: Bone Health and Cancer Care.
The gene for aromatase, a rate-limiting enzyme for local estrogen biosynthesis, is a downstream target gene of runx2 in skeletal tissues.
The role of activation functions 1 and 2 of estrogen receptor-a for the effects of estradiol and Selective Estrogen Receptor Modulators (SERMs) in male mice.
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
[The significance of estrogens on metabolism of bone in men]
Bone Neoplasms
Colocalization of aromatase in spinal cord astrocytes: differences in expression and relationship to mechanical and thermal hyperalgesia in murine models of a painful and a non-painful bone tumor.
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Bone Resorption
Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption.
Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis.
Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer.
Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
High-dose eicosapentaenoic acid and docosahexaenoic acid supplementation reduces bone resorption in postmenopausal breast cancer survivors on aromatase inhibitors: a pilot study.
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men.
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice.
[Bone effects of bisphosphonates and denosumab treatments in breast or prostate cancer].
Brain Diseases
Estrogens are neuroprotective factors for hypertensive encephalopathy.
In vivo visualization of aromatase in animals and humans.
Brain Injuries
A Quantification of the Injury-Induced Changes in Central Aromatase, Oestrogenic Milieu and Steroid Receptor Expression in the Zebra Finch.
Aromatase enzyme and Alzheimer's disease. Studio prospettico in 54 pazienti affetti da iperparatiroidismo primitivo.
Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair.
Aromatase expression by reactive astroglia is neuroprotective.
Aromatase, the enzyme responsible for estrogen biosynthesis, is expressed by human and rat glioblastomas.
Aromatase: a neuroprotective enzyme.
Astrocyte-Derived Estrogen Regulates Reactive Astrogliosis and is Neuroprotective following Ischemic Brain Injury.
Central Administration of Indomethacin Mitigates the Injury-Induced Upregulation of Aromatase Expression and Estradiol Content in the Zebra Finch Brain.
Glial aromatization increases the expression of bone morphogenetic protein-2 in the injured zebra finch brain.
Increased P450 aromatase levels in post-menopausal women after acute ischemic stroke.
Molecular characterization of the injury-induced aromatase transcript in the adult zebra finch brain.
Brain Ischemia
Aromatase and neuroinflammation in rat focal brain ischemia.
Astrocyte-Derived Estrogen Regulates Reactive Astrogliosis and is Neuroprotective following Ischemic Brain Injury.
Brain-derived estrogen exerts anti-inflammatory and neuroprotective actions in the rat hippocampus.
Indinavir inhibits the expression of cytoplasmic aromatase and nuclear SREBP in the hippocampus of reperfusion injury-induced ischemic rats.
Megestrol acetate inhibits the expression of cytoplasmic aromatase through nuclear C/EBP? in reperfusion injury-induced ischemic rat hippocampus.
Neuron-Derived Estrogen Is Critical for Astrocyte Activation and Neuroprotection of the Ischemic Brain.
Brain Neoplasms
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.
Pre-clinical Pharmacological Evaluation of Letrozole as a Novel Treatment for Gliomas.
Breast Cyst
Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells.
Regulation of aromatase activity within the breast.
Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha.
Breast Diseases
Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases.
[Local production of estrogen via aromatase and estrone sulfatase in breast cancer tissue]
[Therapeutic progress in gynecology: organic diseases]
Breast Neoplasms
"Atypical" atypical femur fractures and use of bisphosphonates.
"I feel like I am 100 years old!" managing arthralgias from aromatase inhibitors.
"Lazarus Response" to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion.
"Winging It": How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment.
(557) Auricular point acupressure to manage aromatase inhibitor-induced arthralgia in postmenopausal breast cancer survivors.
(Anti)estrogenic effects of phytochemicals on human primary mammary fibroblasts, MCF-7 cells and their co-culture.
1,25-dihydroxyvitamin D3 regulates estrogen metabolism in cultured keratinocytes.
1-pentyl-3-(4-aminophenyl)pyrrolidine-2,5-dione, a selective aromatase inhibitor: in vivo studies.
1-[(Benzofuran-2-yl)phenylmethyl]triazoles as steroidogenic inhibitors: synthesis and in vitro inhibition of human placental CYP19 aromatase.
1. Estrogen antagonists. Aromatase inhibitors, their pharmacology and application.
17 Beta-hydroxysteroid dehydrogenase and aromatase activity in breast fat from women with benign and malignant breast tumours.
18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study.
18F-Fluoroestradiol (18F-FES)-PET imaging in a Phase II trial of vorinostat to restore endocrine sensitivity in ER+/HER2- metastatic breast cancer.
18F-Fluoroestradiol.
1?,25-Dihydroxyvitamin D(3) exerts tissue-specific effects on estrogen and androgen metabolism.
3D-QSAR study of steroidal and azaheterocyclic human aromatase inhibitors using quantitative profile of protein-ligand interactions.
4- and 6-(p-Sulphamoylphenyl)androstenediones: Studies of aromatase inhibitor-based oestrone sulphatase inhibition.
4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.
4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer.
4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer.
4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells.
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production.
6-Hydroximinoandrostenedione, a new specific inhibitor of estrogen biosynthesis and its effect on T47D human breast cancer cells.
6beta,19-Bridged androstenedione analogs as aromatase inhibitors.
7 alpha-substituted androstenediones as effective in vitro and in vivo inhibitors of aromatase.
7alpha-Arylaliphatic androsta-1,4-diene-3,17-diones as enzyme-activated irreversible inhibitors of aromatase.
A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines.
A case of erythrocytosis in a patient treated with an aromatase inhibitor for breast cancer.
A case of uterine tumour resembling ovarian sex cord tumour responding to second-line, single agent anastrazole.
A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis.
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer.
A cross-sectional survey of pain catastrophising and acupuncture use among breast cancer survivors.
A decade of letrozole: FACE.
A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors.
A favorable view: progress in cancer prevention and screening.
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.
A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance.
A humanized pattern of aromatase expression is associated with mammary hyperplasia in mice.
A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity.
A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription.
A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer.
A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase.
A new clinically-relevant rat model of letrozole-induced chronic nociceptive disorders.
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene.
A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors ? and ?.
A New Therapeutic Strategy against Hormone-Dependent Breast Cancer: The Preclinical Development of a Dual Aromatase and Sulfatase Inhibitor.
A newly developed hexamethylmelamine derivative, SAE9 with both antitumor and aromatase-inhibitory activity.
A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women.
A novel GC-MS methodology to evaluate aromatase activity in human placental microsomes: a comparative study with the standard radiometric assay.
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I.3 and II by disrupting a transcriptional complex in breast adipose fibroblasts.
A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor ?B Pathways with Hybrid Drugs for Breast Cancer Therapy.
A nuclear receptor system constituted by RAR and RXR induces aromatase activity in MCF-7 human breast cancer cells.
A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
A peptide derived from alpha-fetoprotein inhibits the proliferation induced by estradiol in mammary tumor cells in culture.
A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting.
A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition.
A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy.
A Pilot Study Comparing the Effect of Flaxseed, Aromatase Inhibitor, and the Combination on Breast Tumor Biomarkers.
A pilot study of website information regarding aromatase inhibitors: dietary supplement interactions.
A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.
A Polymorphism at the 3'-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma.
A Pooled Analysis of Fall Incidence From Placebo-controlled Trials of Denosumab.
A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.
A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.
A prospective randomised study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer.
A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
A qualitative exploration of the impact of yoga on breast cancer survivors with aromatase inhibitor-associated arthralgias.
A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer.
A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer.
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use.
A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer.
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
A randomized trial to increase physical activity in breast cancer survivors.
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102.
A rare CYP19 (aromatase) variant may increase the risk of breast cancer.
A retrospective study on screening and management of osteoporosis in breast cancer women treated with aromatase inhibitors in Libya.
A review of coumarin derivatives in pharmacotherapy of breast cancer.
A review of exemestane in the management of breast cancer.
A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
A review of the newer aromatase inhibitors in the management of metastatic breast cancer.
A review of the physiology behind letrozole applications in infertility: are current protocols optimal?
A review of the use of exemestane in early breast cancer.
A review on diverse heterocyclic compounds as the privileged scaffolds in non-steroidal aromatase inhibitors.
A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer.
A role for the androgen receptor in the treatment of male breast cancer.
A Role of CREB in BRCA1 Constitutive Promoter Activity and Aromatase Basal Expression.
A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors.
A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer.
A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors.
A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors.
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.
A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients.
A study of estrogen signaling using DNA microarray in human breast cancer.
A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
A suite of activity-based probes for human cytochrome P450 enzymes.
A summary of second-line randomized studies of aromatase inhibitors.
A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer.
A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer.
A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer.
A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups.
Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor.
Aberrant expression of aromatase in breast cancer tissues.
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer†.
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
Abnormal production of androgens in women with breast cancer.
Absence of the K303R estrogen receptor ? mutation in breast cancer patients exhibiting different responses to aromatase inhibitor anastrozole neoadjuvant treatment.
Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more?
Acceleration of mammary neoplasia in aromatase transgenic mice by 7,12-dimethylbenz[a]anthracene.
Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer.
Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.
Acidic Exopolysaccharide Produced from Marine Bacillus amyloliquefaciens 3MS 2017 for the Protection and Treatment of Breast Cancer.
ACOG Committee Opinion No. 738 Summary: Aromatase Inhibitors in Gynecologic Practice.
ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER? metastatic breast cancer.
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.
Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer.
Activation of aromatase expression by retinoic acid eceptor-related orphan receptor (ROR)alpha in breast cancer cells: Identification of a novel ror response element.
Active site acidic residues and structural analysis of modelled human aromatase: A potential drug target for breast cancer.
Active site acidic residues and structural analysis of modelled human aromatase: a potential drug target for breast cancer.
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.
Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial.
Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia.
Acupuncture for Aromatase Inhibitor-Induced Arthralgia: A Systematic Review.
Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients.
Acupuncture for Arthralgia Induced by Aromatase Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis.
Acupuncture for joint symptoms related to aromatase inhibitor therapy in postmenopausal women with early-stage breast cancer: a narrative review.
Acupuncture for symptoms management in Korean breast cancer survivors: a prospective pilot study.
Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysis.
Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study.
Acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer.
Acupuncture versus medication for pain management: a cross-sectional study of breast cancer survivors.
Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: case report and review of the literature.
Acute but not sustained aromatase inhibition displays antidepressant properties.
Acute Effect of High-dose Isoflavones from Pueraria lobata (Willd.) Ohwi on Lipid and Bone Metabolism in Ovariectomized Mice.
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Adaptation of an Evidence-Based Arthritis Program for Breast Cancer Survivors on Aromatase Inhibitor Therapy Who Experience Joint Pain.
Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.
Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance.
Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.
Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.
Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment.
Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer.
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.
Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication.
Adherence to endocrine therapy for breast cancer.
Adherence to long-term adjuvant hormonal therapy for breast cancer.
Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives.
Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women.
Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Adjuvant aromatase inhibitor options in overweight and obese postmenopausal women with breast cancer.
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Adjuvant Aromatase Inhibitor Therapy in Patients with Stage I Breast Cancer at a Regional Oncology Center in Israel: Implementation of a 'Switching' Policy in Postmenopausal Patients after Initial Tamoxifen.
Adjuvant aromatase inhibitor therapy: outcomes and safety.
Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
Adjuvant aromatase inhibitors for breast cancer.
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Adjuvant Aromatase Inhibitors in Early Breast Cancer May Not Increase the Risk of Falls.
Adjuvant Aromatase Inhibitors or Tamoxifen following Chemotherapy for Perimenopausal Breast Cancer Patients.
Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients.
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.
Adjuvant endocrine therapy for breast cancer: how long is long enough?
Adjuvant endocrine therapy for early breast cancer.
Adjuvant endocrine therapy for early breast cancer: the story so far.
Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update.
Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women.
Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis.
Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
Adjuvant endocrine therapy in post menopausal women: pharmacological evaluation using decision analysis approach in a Japanese hospital setting.
Adjuvant Endocrine Therapy of Perimenopausal and Recently Postmenopausal Women With Hormone Receptor-Positive Breast Cancer.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
Adjuvant Hormonal Therapy in Women with Early-stage Breast Cancer.
Adjuvant Hormonotherapy and Cardiovascular Risk in Post-Menopausal Women with Breast Cancer: A Large Population-Based Cohort Study.
Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis.
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
Adjuvant therapy for breast cancer.
Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001.
Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Adjuvant therapy with aromatase inhibitors in postmenopausal, estrogen receptor- positive breast cancer patients: upfront or sequential?
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials.
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Adjuvant trials: Aromatase inhibitors in early breast cancer--are they alike?
Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
Advances in adjuvant endocrine therapy for postmenopausal women.
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs).
Advances in breast oncology: the 2002 ASCO meeting.
Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer.
Adverse bone effects during pharmacological breast cancer therapy.
Adverse Drug Event-based Stratification of Tumor Mutations: A Case Study of Breast Cancer Patients Receiving Aromatase Inhibitors.
Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy.
Adverse Effects of Aromatase Inhibition on the Brain and Behavior in a Nonhuman Primate.
Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin (review).
Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias.
Advising Women Undergoing Treatment for Breast Cancer: A Narrative Review.
Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany.
Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
AIB1:ER? transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
AIs Recommended for Breast Cancer Prevention.
AKR1C3 (type 5 17?-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
AKT-dependent sugar addiction by benzyl isothiocyanate in breast cancer cells.
Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial.
All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause.
Alleviating anastrozole induced bone toxicity by selenium nanoparticles in SD rats.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Alteration at transcriptional level of cardiac renin-angiotensin system by letrozole treatment.
Altering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitors.
Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial.
Alternative oral exemestane formulation: Improved dissolution and permeation.
Alternative use of multiple exons 1 of aromatase gene in cancerous and normal breast tissues from women over the age of 80 years.
American Society for Reproductive Medicine--56th annual meeting.
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction.
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.
Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis.
AMP-activated protein kinase and energy balance in breast cancer.
Amphiregulin retains ER? expression in acquired aromatase inhibitor resistant breast cancer cells.
AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells.
Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors.
An "Omics" Approach to Determine the Mechanisms of Acquired Aromatase Inhibitor Resistance.
An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.
An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors.
An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients.
An evaluation of fulvestrant for the treatment of metastatic breast cancer.
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition.
An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells.
An integrated view of aromatase and its inhibition.
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole.
An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples.
An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range.
An update on breast cancer prevention trials.
An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor- positive early breast cancer.
Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study.
Analysis of the aromatase cytochrome P450 gene in human breast cancers.
Analysis of the effects of different alcohols on MCF-7 human breast cancer cells.
Analysis of the rs10046 polymorphism of aromatase (CYP19) in premenopausal onset of human breast cancer.
Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management.
Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction between SLC38A7 and ALPPL2.
Anastrozole for breast cancer: recent advances and ongoing challenges.
Anastrozole for malignant and benign conditions: present applications and future therapeutic integrations.
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor ?.
Anastrozole in the management of breast cancer.
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Anastrozole may aid breast cancer prevention.
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Anastrozole-associated joint pain and other symptoms in patients with breast cancer.
Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer.
Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events.
Anastrozole-induced liver injury after a prolonged latency: a very rare complication of a commonly prescribed medication.
Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report.
Anastrozole.
Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
Anastrozole: a new gold standard of hormonal treatment for breast cancer?
Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.
Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer.
Anastrozole: in early breast cancer.
Anastrozole: licence extension. No advantage over tamoxifen in advanced-stage breast cancer.
Anastrozole: new indication. Adjuvant treatment of non metastatic breast cancer: useful for some patients.
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Androgens influence estrogen-induced responses in human breast carcinoma cells through cytochrome P450 aromatase.
Andrographolide is an Alternative Treatment to Overcome Resistance in ER-Positive Breast Cancer via Cholesterol Biosynthesis Pathway.
Anti-aromatase activity of phytochemicals in white button mushrooms (Agaricus bisporus).
Anti-aromatase chemicals in red wine.
Anti-aromatase effect of resveratrol and melatonin on hormonal positive breast cancer cells co-cultured with breast adipose fibroblasts.
Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer.
Anti-estrogens in the treatment of breast cancer: current status and future directions.
Anti-oestrogenic chemoprevention of breast cancer-the need to progress.
Anti-tumor effect of Shu-Gan-Liang-Xue decoction in breast cancer is related to the inhibition of aromatase and steroid sulfatase expression.
Anti-tumor efficacy of new 7?-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
Anti-tumour effect of aromatase inhibitor, CGS16949A, on human breast cancer cells.
Antiaromatase agents: evolving role in adjuvant therapy.
Antiaromatase agents: preclinical data and neoadjuvant therapy.
Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: A population-based study.
Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer.
Antiresorptive therapy in the management of cancer treatment-induced bone loss.
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors in rats.
Apoptosis and Autophagy in Breast Cancer Cells following Exemestane Treatment.
Application of aromatase inhibitors in endocrine responsive breast cancers.
Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature.
Appraising adjuvant aromatase inhibitor therapy.
AR collaborates with ER? in aromatase inhibitor-resistant breast cancer.
Are all aromatase inhibitors alike?
Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Are all aromatase inhibitors the same? A review of the current evidence.
Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
Are aromatase inhibitors superior to antiestrogens?
Are differences in the available aromatase inhibitors and inactivators significant?
Are estring(®) and vagifem(®) equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy?
Are patients with newly diagnosed breast cancer getting appropriate DEXA scans? A District General Hospital experience.
Are previous episodes of bacterial vaginosis a predictor for vaginal symptoms in breast cancer patients treated with aromatase inhibitors?
Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence.
ARIMIDEX: a new oral, once-a-day aromatase inhibitor.
ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer.
Arimidex: a potent and selective fourth-generation aromatase inhibitor.
AroER Tri-Screen Is a Biologically Relevant Assay for Endocrine Disrupting Chemicals Modulating the Activity of Aromatase and/or the Estrogen Receptor.
AroER tri-screen™ is a novel functional assay to estimate both estrogenic and estrogen precursor activity of chemicals or biological specimens.
Aromatase (CYP19) inhibition by biflavonoids obtained from the branches of Garcinia gardneriana (Clusiaceae).
Aromatase Acetylation Patterns and Altered Activity in Response to Sirtuin Inhibition.
Aromatase activity and CYP19 gene expression in breast cancers.
Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging.
Aromatase activity and expression in breast cancer and benign breast tissue stromal cells.
Aromatase activity and interleukin-6 production by normal and malignant breast tissues.
Aromatase activity and the effect of estradiol and testosterone on DNA synthesis in endometrial carcinoma cell lines.
Aromatase activity in adipose tissue from breast quadrants: a link with tumour site.
Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases.
Aromatase activity in breast tissue.
Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies.
Aromatase activity in primary and metastatic human breast cancer.
Aromatase activity in the breast and other peripheral tissues and its therapeutic regulation.
Aromatase activity, serum oestradiol and their correlation with demographic indices.
Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma.
Aromatase and aromatase inhibitors.
Aromatase and breast cancer susceptibility.
Aromatase and breast cancer.
Aromatase and breast cancer: W39R, an inactive protein.
Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review.
Aromatase and COX in breast cancer: enzyme inhibitors and beyond.
Aromatase and COX-2 expression in human breast cancers.
Aromatase and cyclooxygenases: enzymes in breast cancer.
Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates.
Aromatase and its inhibitors in breast cancer treatment--overview and perspective.
Aromatase and its inhibitors--an overview.
Aromatase and its inhibitors.
Aromatase and its inhibitors: significance for breast cancer therapy.
Aromatase and prostaglandin inter-relationships in breast adipose tissue: significance for breast cancer development.
Aromatase and the breast: regulation and clinical aspects.
Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor.
Aromatase excess in cancers of breast, endometrium and ovary.
Aromatase Explains Why Testosterone Increases Breast Cancer Rate.
Aromatase expression and its localization in human breast cancer.
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
Aromatase expression in atypical ductal hyperplasia in women.
Aromatase expression in health and disease.
Aromatase expression in women's cancers.
Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells.
Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction.
Aromatase gene expression in adipose tissue: relationship to breast cancer.
Aromatase gene is amplified in MCF-7 human breast cancer cells.
Aromatase Imaging with [N-methyl-C-11]vorozole PET in Healthy Men and Women.
Aromatase immunoreactivity is increased in mammographically dense regions of the breast.
Aromatase in aging women.
Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors.
Aromatase in breast cancer tissue--localization and relationship with reproductive status of patients.
Aromatase in colon carcinoma.
Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations.
Aromatase in human breast carcinoma.
Aromatase in the context of breast and endometrial cancer. A review.
Aromatase in the normal breast and breast cancer.
Aromatase inactivation by 2-substituted derivatives of the suicide substrate androsta-1,4-diene-3,17-dione.
Aromatase induction in tamoxifen-resistant breast cancer: Role of phosphoinositide 3-kinase-dependent CREB activation.
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.
Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention.
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production.
Aromatase inhibition by 2-methyl indole hydrazone derivatives evaluated via molecular docking and in vitro activity studies.
Aromatase inhibition by an 11,13-dihydroderivative of a sesquiterpene lactone.
Aromatase inhibition for breast cancer treatment.
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer.
Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane.
Aromatase inhibition: translation into a successful therapeutic approach.
Aromatase inhibitor adjuvant chemotherapy of breast cancer results in cancer therapy induced bone loss.
Aromatase inhibitor agents in breast cancer: evolving practices in hormonal therapy treatment.
Aromatase inhibitor and bone.
Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity.
Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors.
Aromatase inhibitor development and hormone therapy: a perspective.
Aromatase inhibitor development for treatment of breast cancer.
Aromatase inhibitor letrozole downregulates steroid receptor coactivator-1 in specific brain regions that primarily related to memory, neuroendocrine and integration.
Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
Aromatase inhibitor strategies in metastatic breast cancer.
Aromatase inhibitor therapy and hair loss among breast cancer survivors.
Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
Aromatase inhibitor treatment for breast cancer: short-term effect on bone health.
Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1.
Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients.
Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis.
Aromatase inhibitor withdrawal response in metastatic breast cancer.
Aromatase inhibitor-associated arthralgia syndrome.
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer.
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
Aromatase inhibitor-associated musculoskeletal pain: taking 'AIM' at a symptom in breast cancer survivors.
Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors.
Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event.
Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
Aromatase inhibitor-induced arthralgia: a review.
Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Aromatase Inhibitor-Induced Carpal Tunnel Syndrome: Results From the ATAC Trial.
Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer.
Aromatase inhibitor-induced joint pain: melatonin's role.
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.
Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis.
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors.
Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors.
Aromatase inhibitors and bisphosphonates reduce deaths from breast cancer, studies show.
Aromatase inhibitors and bone health in women with breast cancer.
Aromatase inhibitors and bone health.
Aromatase inhibitors and bone loss.
Aromatase inhibitors and breast cancer prevention.
Aromatase inhibitors and breast cancer treatment.
Aromatase inhibitors and breast cancer.
Aromatase inhibitors and breast cancer: time for a change?
Aromatase inhibitors and calcium absorption in early stage breast cancer.
Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter.
Aromatase inhibitors and inactivators for breast cancer therapy.
Aromatase inhibitors and inactivators for breast cancer treatment.
Aromatase inhibitors and inactivators in breast cancer.
Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.
Aromatase inhibitors and mood disturbances.
Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.
Aromatase inhibitors and other novel agents in breast cancer treatment.
Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology.
Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis.
Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis.
Aromatase inhibitors and the endometrium.
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.
Aromatase inhibitors and the treatment of breast cancer.
Aromatase inhibitors and their antitumor effects in model systems.
Aromatase inhibitors and their application in breast cancer treatment*.
Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
Aromatase inhibitors and their potential clinical significance.
Aromatase inhibitors and xenograft studies.
Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis.
Aromatase inhibitors as add-on treatment for men with epilepsy.
Aromatase inhibitors as adjuvant therapies in patients with breast cancer.
Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer.
Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer.
Aromatase inhibitors as adjuvant therapy in breast cancer.
Aromatase inhibitors as adjuvant treatment of breast cancer.
Aromatase inhibitors as new endocrine therapy for breast cancer.
Aromatase inhibitors as solely treatment in postmenopausal breast cancer patients.
Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population.
Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer.
Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.
Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study.
Aromatase Inhibitors Evolution as Potential class of drugs in the treatment of Postmenopausal Breast Cancer Women.
Aromatase inhibitors for adjuvant treatment of postmenopausal breast cancer.
Aromatase inhibitors for breast cancer in postmenopausal women.
Aromatase inhibitors for breast cancer prevention.
Aromatase inhibitors for breast cancer.
Aromatase inhibitors for breast cancer: different structures, same effects?
Aromatase inhibitors for breast cancer: lessons from the laboratory.
Aromatase inhibitors for breast cancer: pharmacoeconomic considerations.
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Aromatase inhibitors for early breast cancer therapy: A choice of effective treatment strategies.
Aromatase inhibitors for hormonal therapy of early-stage breast cancer.
Aromatase Inhibitors for Ovarian Stimulation in Patients with Breast Cancer.
Aromatase inhibitors for ovulation induction and ovarian stimulation.
Aromatase inhibitors for prevention of breast cancer in postmenopausal women: a narrative review.
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Aromatase inhibitors for the treatment and prevention of breast cancer.
Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch.
Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
Aromatase inhibitors for therapy of advanced breast cancer.
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Aromatase inhibitors for treatment of postmenopausal patients with breast cancer.
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review.
Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
Aromatase inhibitors in advanced breast cancer.
Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications.
Aromatase inhibitors in advanced breast cancer: there are efficacy differences.
Aromatase inhibitors in breast cancer prevention.
Aromatase inhibitors in breast cancer therapy.
Aromatase inhibitors in breast cancer.
Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness.
Aromatase inhibitors in breast cancer: an overview.
Aromatase inhibitors in breast cancer: an update.
Aromatase inhibitors in breast cancer: current and evolving roles.
Aromatase inhibitors in clinical practice: current status and a look to the future.
Aromatase inhibitors in early breast cancer therapy.
Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.
Aromatase inhibitors in early breast cancer treatment.
Aromatase inhibitors in early breast-cancer treatment: The story so far.
Aromatase inhibitors in early hormone receptor-positive breast cancer : what is the optimal initiation time for the maximum benefit?
Aromatase inhibitors in male breast cancer: a pooled analysis.
Aromatase inhibitors in malignant diseases of aging.
Aromatase inhibitors in metastatic breast cancer.
Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels.
Aromatase inhibitors in ovarian stimulation.
Aromatase inhibitors in post-menopausal metastatic breast carcinoma.
Aromatase inhibitors in postmenopausal breast cancer patients.
Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters.
Aromatase inhibitors in premenopausal breast cancer.
Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects.
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer.
Aromatase inhibitors in the breast cancer clinic: focus on exemestane.
Aromatase inhibitors in the breast cancer therapy and their potential using in the prevention setting.
Aromatase inhibitors in the management of early breast cancer.
Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit.
Aromatase inhibitors in the management of early breast cancer: the TEAM trial.
Aromatase Inhibitors in the Prevention of Breast Cancer.
Aromatase inhibitors in the treatment and prevention of breast cancer.
Aromatase inhibitors in the treatment of advanced breast cancer.
Aromatase inhibitors in the treatment of advanced breast cancer. Introduction.
Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update.
Aromatase inhibitors in the treatment of breast cancer.
Aromatase inhibitors in the treatment of early and advanced breast cancer.
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Aromatase inhibitors in the treatment of postmenopausal breast cancer.
Aromatase inhibitors induce spine synapse loss in the hippocampus of ovariectomized mice.
Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review.
Aromatase inhibitors might be more effective when they are given 2-3 months later after the administration of luteinizing hormone-releasing hormone agonists in younger premenopausal breast cancer patients.
Aromatase inhibitors plus ovarian function suppression versus tamoxifen plus ovarian function suppression for premenopausal women with early stage breast cancer: a systematic review and meta-analysis.
Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients.
Aromatase inhibitors to augment height: continued caution and study required.
Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study.
Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy.
Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings.
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer.
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.
Aromatase inhibitors--mechanisms of steroidal inhibitors.
Aromatase inhibitors--socio-economical issues.
Aromatase inhibitors--socioeconomical issues.
Aromatase inhibitors-induced bone loss in early breast cancer.
Aromatase Inhibitors-Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects.
Aromatase inhibitors.
Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones.
Aromatase inhibitors: a new paradigm in breast cancer treatment.
Aromatase inhibitors: a new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women.
Aromatase inhibitors: a safety comparison.
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
Aromatase inhibitors: assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression.
Aromatase inhibitors: basic and clinical studies.
Aromatase inhibitors: cellular and molecular effects.
Aromatase inhibitors: changing the face of endocrine therapy for breast cancer.
Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Aromatase inhibitors: current status.
Aromatase inhibitors: from bench to bedside and back.
Aromatase inhibitors: future directions.
Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer.
Aromatase inhibitors: new endocrine treatment of breast cancer.
Aromatase inhibitors: past, present and future in breast cancer therapy.
Aromatase inhibitors: past, present and future.
Aromatase Inhibitors: Potential Reproductive Implications.
Aromatase inhibitors: prediction of response and nature of resistance.
Aromatase inhibitors: rationale and use in breast cancer.
Aromatase inhibitors: Role in postmenopausal breast cancer.
Aromatase inhibitors: structural features and biochemical characterization.
Aromatase inhibitors: The unexpected breast cancer treatment.
Aromatase inhibitors: treatment of advanced breast cancer.
Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells.
Aromatase over expression transgenic murine models for aromatase inhibitor studies.
Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands.
Aromatase overexpression enhances the stimulatory effects of adrenal androgens on MCF7 breast cancer cells.
Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer.
Aromatase overexpression induces malignant changes in estrogen receptor ? negative MCF-10A cells.
Aromatase regulation and breast cancer.
Aromatase research and its clinical significance.
Aromatase resistance mechanisms in model systems in vivo.
Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women.
Aromatase, aromatase inhibitors, and breast cancer.
Aromatase, breast cancer and obesity: a complex interaction.
Aromatase, CYP1B1 and Fatty Acid Synthase Expression in Breast Tumors of BRCA1 Mutation Carriers.
Aromatase, its inhibitors and their use in breast cancer treatment.
Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.
Arthralgia During Aromatase Inhibitor Treatment in Early Breast Cancer Patients: Prevalence, Impact, and Recognition by Healthcare Providers.
Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer.
Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary.
Assessment of bone health in breast cancer patients starting adjuvant aromatase inhibitors: A quality improvement clinical audit.
Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study.
Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors.
Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment.
Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient Compliance.
Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients.
Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer.
Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer.
Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors.
Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case-control study of 11,412 women.
Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer.
Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
Association of aromatase inhibitors with coronary heart disease in women with early breast cancer.
Association of CYP19 polymorphisms with breast cancer risk: A case-control study.
Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Association of estrogen receptor alpha (ER?) gene polymorphisms with endometrial thickness and lipid profile in women with breast cancer treated with aromatase inhibitors.
Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.
Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: the Breast Cancer Health Disparities Study.
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.
Attenuated peripheral endothelial function among women treated with aromatase inhibitors for breast cancer.
Auricular Point Acupressure to Manage Aromatase Inhibitor-Induced Arthralgia in Postmenopausal Breast Cancer Survivors: A Pilot Study.
Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.
Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells.
Automated discovery of drug treatment patterns for endocrine therapy of breast cancer within an electronic medical record.
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Balanced dual acting compounds targeting aromatase and estrogen receptor ? as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer.
Base mediated synthesis of functionalized 2-(alkynyl)arylnitriles and their molecular docking study with aromatase receptor.
Baseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at initiation of aromatase inhibitor therapy: A descriptive study.
Basic research for hormone-sensitivity of breast cancer.
Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen resistant breast cancer; implications for treatment of advanced disease.
BCAR1 expression improves prediction of biochemical reccurence after radical prostatectomy.
BCMA (TNFRSF17) Induces APRIL and BAFF Mediated Breast Cancer Cell Stemness.
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
Benefits and adverse effects of endocrine therapy.
Beyond the C18 frontier: Androgen and glucocorticoid metabolism in breast cancer tissues: The role of non-typical steroid hormones in breast cancer development and progression.
Bicalutamide Plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer.
Bicyclic derivatives of the potent dual aromatase-steroid sulfatase inhibitor 2-bromo-4-{[(4-cyanophenyl)(4h-1,2,4-triazol-4-yl)amino]methyl}phenylsulfamate: synthesis, SAR, crystal structure, and in vitro and in vivo activities.
Bilateral de quervain syndrome after aromatase inhibitor administration: a case report and review of the literature.
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Bilateral Salpingo-Oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors.
Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
Binding features of steroidal and nonsteroidal inhibitors.
Binding mode of triazole derivatives as aromatase inhibitors based on docking, protein ligand interaction fingerprinting, and molecular dynamics simulation studies.
Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway.
Biochemical and biological characterization of a novel anti-aromatase coumarin derivative.
Biochemical and pharmacological development of steroidal inhibitors of aromatase.
Biochemical control of breast aromatase.
Biochemistry and pharmacology of 7alpha-substituted androstenediones as aromatase inhibitors.
Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast.
Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer.
Biological determinants of endocrine resistance in breast cancer.
Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells.
Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Biological rationale for endocrine therapy in breast cancer.
Biological roles of estrogen and progesterone in human endometrial carcinoma--new developments in potential endocrine therapy for endometrial cancer.
Biological significance of aromatase activity in human breast tumors.
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Bis(4-hydroxy-2H-chromen-2-one) Coumarin Induces Apoptosis in MCF-7 Human Breast Cancer Cells Through Aromatase Inhibition.
Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis.
Bisphosphonates in oncology.
Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy: results from a meta-analysis.
Black tea polyphenol theaflavins inhibit aromatase activity and attenuate tamoxifen resistance in HER2/neu-transfected human breast cancer cells through tyrosine kinase suppression.
Blocking oestradiol synthesis pathways with potent and selective coumarin derivatives.
Body mass index and aromatase inhibitors: a step forward in individualizing therapy for breast cancer patients?
Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors.
Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.
Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors.
Bone health during endocrine therapy for cancer.
Bone health evaluation one year after aromatase inhibitors completion.
Bone health history in breast cancer patients on aromatase inhibitors.
Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.
Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline.
Bone health in the elderly cancer patient: A SIOG position paper.
Bone health in women with breast cancer.
Bone health in women with early-stage breast cancer.
Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors.
Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
Bone Mineral Density at the Time of Initiating Aromatase Inhibitor Therapy Is Associated With Decreased Fractures in Women With Breast Cancer.
Bone mineral density in early breast cancer patients.
Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors.
Bone Mineral Density Testing Disparities Among Patients With Breast Cancer Prescribed Aromatase Inhibitors.
Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis.
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption.
Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis.
Bone scan alterations in aromatase inhibitor-treated patients.
Bone targeted therapies in advanced breast cancer.
Bone targeted therapies in early breast cancer.
Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate.
Bone turnover markers in postmenopausal breast cancer treated with fulvestrant--a pilot study.
Bone-Targeted Therapy in Early Breast Cancer.
Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer.
Boronic-targeted albumin-shell oily-core nanocapsules for synergistic aromatase inhibitor/herbal breast cancer therapy.
Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.
Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.
BRCA1 Breast Cancer Risk Is Modified by CYP19 Polymorphisms in Ashkenazi Jews.
BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells.
Breast cancer and expression of aromatase in breast adipose tissue.
Breast cancer and osteoporosis.
Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status.
Breast cancer bone metastasis and current small therapeutics.
Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
Breast cancer chemoprevention: old and new approaches.
Breast Cancer Endocrine Therapy Promotes Weight Gain With Distinct Adipose Tissue Effects in Lean and Obese Female Mice.
Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective.
Breast cancer in limited-resource countries: treatment and allocation of resources.
Breast cancer in men: should aromatase inhibitors become first-line hormonal treatment?
Breast cancer patients receiving denosumab during adjuvant aromatase inhibitors treatment: who are the "inadequate responders" patients to denosumab?
Breast cancer prevention in high-risk women.
Breast cancer prevention trials: large and small trials.
Breast cancer prevention with selective estrogen receptor modulators: a perspective.
Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.
Breast cancer prevention.
Breast Cancer Prevention: Time for Change.
Breast Cancer Risk - Genes, Environment and Clinics.
Breast cancer risk reduction: Notable achievements and remaining challenges.
Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.
Breast cancer treatment and sulfotransferase.
Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity.
Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy.
Breast Cancer: Abemaciclib effective in combination with aromatase inhibition.
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
Breast cancer: aromatase inhibitors take on tamoxifen.
Breast cancer: Aromatase inhibitors--bone health assessment is crucial.
Breast cancer: Current and future endocrine therapies.
Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Breast carcinomas with immunocytochemical detection of aromatase in fine-needle aspirates: report of three cases.
Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer.
Breast tumor aromatase: functional role and transcriptional regulation.
Bs23 targeted therapy.
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
By the way, doctor. I've had an ER-positive breast cancer tumor removed. Now I am getting ready for follow-up therapy. I've heard that the aromatase inhibitors are better than tamoxifen. What is your opinion?
Can a single model explain both breast cancer and prostate cancer?
Can aromatase inhibitors cause forgetfulness in women with breast cancer ?
Can Exercise Ameliorate Aromatase Inhibitor-Induced Cognitive Decline in Breast Cancer Patients?
Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada.
Cancer treatment-induced bone loss in breast and prostate cancer.
Cancer treatment-induced bone loss.
Cancer treatment-related bone disease.
Cancer vaccine THERATOPE- Biomira.
Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Cardiac arrhythmia considerations of hormone cancer therapies.
Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients.
Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer.
Cardiovascular Disease After Aromatase Inhibitor Use.
Cardiovascular Health among Black and White Breast Cancer Patients Initiating Aromatase Inhibitor Therapy.
Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer.
Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors.
CC chemokine ligand 2 (CCL2) stimulates aromatase gene expression in mammary adipose tissue.
CCAAT/enhancer binding protein delta up-regulates aromatase promoters I.3/II in breast cancer epithelial cells.
CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer.
CDK 4/6 inhibitor induced lung injury: a case report and review of literature.
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience.
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer.
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer.
Cell density is a critical determinant of aromatase expression in adipose stromal cells.
Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen.
Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole.
CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study.
Challenges in defining predictive markers for response to endocrine therapy in breast cancer.
Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors.
Challenges of measuring accurate estradiol levels in aromatase inhibitor-treated postmenopausal breast cancer patients on vaginal estrogen therapy.
Change in serum oestradiol and testosterone concentrations after mastectomy for breast cancer with high aromatase activity.
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.
Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.
Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole.
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
Changes in Cardiac Autonomic Modulation in Women with Breast Cancer Using Aromatase Inhibitors and the Relation with Biochemical Variables.
Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance.
Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors.
Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane.
Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.
Characterization of a novel silencer element in the human aromatase gene PII promoter.
Characterization of a silencer element in the human aromatase gene.
Characterization of aromatase binding agents from the dichloromethane extract of Corydalis yanhusuo using ultrafiltration and liquid chromatography tandem mass spectrometry.
Chemical inhibitor anticancer drugs regulate mechanical properties and cytoskeletal structure of non-invasive and invasive breast cancer cell lines: Study of effects of Letrozole, Exemestane, and Everolimus.
Chemoprevention for Breast Cancer.
Chemoprevention of breast cancer.
Chemoprevention of breast cancer: current status and future prospects.
Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond.
Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.
Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.
Chemoprevention with aromatase inhibitors--trial strategies.
Chemopreventive and Anticancer Property of Selenoproteins in Obese Breast Cancer.
Chemopreventive effects of anastrozole in a premenopausal breast cancer model.
Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model.
Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.
Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol?
Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting.
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.
Circulating melatonin and the risk of breast and endometrial cancer in women.
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib.
Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients.
Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study.
Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series.
Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients - a jungle?
Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer.
Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study.
Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer.
Clinical importance of intratumoral aromatase.
Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer.
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.
Clinical overview of anastrozole--a new selective oral aromatase inhibitor.
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.
Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Clinical significance of aromatase protein expression in axillary node negative breast cancer.
Clinical Significance of Female-hormones and Cytokines in Breast Cancer Patients Complicated with Aromatase Inhibitor-related Osteoarthropathy - Efficacy of Vitamin E.
Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer.
Clinical trials in cancer prevention: current results and perspectives for the future.
Clinical trials update: Medical management of advanced breast cancer.
Clinical use of aromatase inhibitors in human breast carcinoma.
Clinical use of aromatase inhibitors in the treatment of advanced breast cancer.
Clinical use of aromatase inhibitors in the treatment of breast cancer.
Clinical use of aromatase inhibitors in the treatment of breast cancers.
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Clinical utilities of aromatase inhibitors in breast cancer.
Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer.
Clinical utility of exemestane in the treatment of breast cancer.
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer.
Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis.
Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer.
Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is up-regulated in breast cancer tissue.
Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor treated ER-positive breast cancer.
Closing remarks to the conference, Aromatase: New Perspectives for Breast Cancer.
Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model.
Coadministrating luteolin minimizes the side effects of the aromatase inhibitor letrozole.
Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma.
Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors.
Cognitive Effects of Aromatase and Possible Role in Memory Disorders.
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors.
Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality.
Collagen and prostaglandin E? regulate aromatase expression through the PI3K/AKT/IKK and the MAP kinase pathways in adipose stromal cells.
Collision tumor: invasive ductal carcinoma in association with mucosa-associated lymphoid tissue (MALT) lymphoma in the same breast.
Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study.
Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance.
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.
Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
Combined use of vitamin D and omega-3 fatty acid in breast cancer patients might be more beneficial for reducing aromatase inhibitors-associated arthralgia.
Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review).
Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols.
Combining luteinising hormone releasing hormone agonists and aromatase inhibitors in breast cancer.
Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
CoMFA, LeapFrog and blind docking studies on sulfonanilide derivatives acting as selective aromatase expression regulators.
Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice.
Committee Opinion No. 663: Aromatase Inhibitors in Gynecologic Practice.
Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer.
Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans.
Comparative economic analysis of aromatase inhibitors and tamoxifen in the treatment of hormone-dependent breast cancer.
Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Comparative molecular field analysis of non-steroidal aromatase inhibitors: an extended model for two different structural classes.
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.
Comparative studies of aromatase inhibitors in cultured human breast cancer cells.
Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis.
Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience.
Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer.
Comparing exercise responses to aerobic plus resistance training between postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy women.
Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment.
Comparison of biochemical aromatase activity with aromatase immunohistochemistry in human breast carcinomas.
Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study.
Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues.
Comparison of in vitro and in vivo haemotoxic effects of aminoglutethimide and glutethimide.
Comparison of Increased Aromatase versus ER{alpha} in the Generation of Mammary Hyperplasia and Cancer.
Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy.
Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.
Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a protocol for a systematic review and network meta-analysis.
Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line.
Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer.
Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study.
Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Comprehensive and Automated Linear Interaction Energy Based Binding-Affinity Prediction for Multifarious Cytochrome P450 Aromatase Inhibitors.
Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.
Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers.
Computational methods for the design of potent aromatase inhibitors.
Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients.
Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues.
Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer.
Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature.
Concomitant occurence of multiple autoantibodies against human cytochromes P450.
Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by these Genes.
Concurrent administration of aromatase inhibitors with chemotherapy might show better outcome in high risk hormone-receptor positive early-stage breast cancer patients.
Concurrent use of aromatase inhibitors and hypofractionated radiation therapy.
Conference on aromatase: new perspectives for breast cancer. Key Biscayne, Florida/Dec 6-9, 1981.
Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review.
Confounder factors masking a Leydig-cell ovarian tumor in a post-menopausal woman treated for androgen-positive receptor breast cancer.
Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk.
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.
Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors.
Contralateral prophylactic mastectomy for patients with unilateral breast cancer.
Contribution of aromatase to the deoxyribonucleic acid synthesis of MCF-7 human breast cancer cells and its suppression by aromatase inhibitors.
Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.
Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry.
Control and expression of oestrone sulphatase activities in human breast cancer.
Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors.
Control of aromatase activity in breast tumours: the role of the immune system.
Control of aromatase in breast cancer cells and its importance for tumor growth.
Controlled ovarian hyperstimulation for fertility preservation in women with breast cancer: Practical issues.
Controversies in Adjuvant Endocrine Therapy for Breast Cancer.
Controversies in design and interpretation of adjuvant clinical trials.
Controversies of aromatase localization in human breast cancer--stromal versus parenchymal cells.
Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Correction to: Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Correction: Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.
Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial.
Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens.
Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide.
Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
CORRIGENDUM to "Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study".
Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER? metastatic breast cancer.
Cost Effectiveness Analysis of Everolimus + Exemestane for Patients with Advanced Breast Cancer with Positive Estrogen Receptor (ER +), HER2-, Refractory to Non-Steroidal Aromatase Inhibitors (NSAIS) in Chile.
Cost Effectiveness of Fracture Prevention in Postmenopausal Women Who Receive Aromatase Inhibitors for Early Breast Cancer.
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older.
Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma.
Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.
Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.
Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer.
Cost-effectiveness of letrozole in the treatment of advanced breast cancer.
Cost-effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer.
Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer.
Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.
Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?
COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.
COX2 induction: a mechanism of endocrine breast cancer resistance?
CpG dinucleotide methylation of the CYP19 I.3/II promoter modulates cAMP-stimulated aromatase activity.
Cross-resistance to different aromatase inhibitors in breast cancer treatment.
Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
Crown-Like Structures in Breast Adipose Tissue: Early Evidence and Current Issues in Breast Cancer.
Crystal engineering of exemestane to obtain a co-crystal with enhanced urease inhibition activity.
Crystallographic and molecular modeling studies on 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione and its butyl analogue, inhibitors of mammalian aromatase. Comparison with natural substrates: prediction of enantioselectivity for N-alkyl derivatives.
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Current comprehensive assessment and management of women at increased risk for breast cancer.
Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Current concepts: breast cancer chemoprevention.
Current controversies in extended adjuvant endocrine therapy for early breast cancer.
Current directions for COX-2 inhibition in breast cancer.
Current management of aromatase inhibitor-induced arthralgia.
Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players.
Current NCI-sponsored Cooperative Group trials of endocrine therapies in breast cancer.
Current Opinion of Aromatase Inhibitor-induced Arthralgia in Breast Cancer in the UK.
Current perspectives on aromatase inhibitors in breast cancer.
Current role and safety profile of aromatase inhibitors in early breast cancer.
Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review).
Current Status of Aromatase Inhibitors in the Management of Breast Cancer and Critique of the NCIC MA-17 Trial.
Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.
Current status of hormonal treatments for metastatic breast cancer in postmenopausal women.
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Current strategies for anticancer chemoprevention and chemoprotection.
Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer.
Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer.
Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: A case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
Cutaneous leukocytoclastic vasculitis associated with letrozole.
Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment.
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?
Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer.
Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention.
Cyclooxygenase-2 and chemoprevention of breast cancer.
Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells.
Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer.
CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.
CYP19A1 gene expression in the peripheral blood of Brazilian women with breast cancer relapse.
CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy.
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
CYP19A1 rs10046 pharmacogenetics in postmenopausal breast cancer patients treated with aromatase inhibitors: One-year follow-up.
CYP1A2 - a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
CYR61 contributes to poor response to letrozole in ER positive breast carcinoma.
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.
Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
Data of aromatase inhibitors alone and in combination with raloxifene on microarchitecture of lumbar vertebrae and strength test in femoral diaphysis of VCD treated ovotoxic mice.
David Kupfer and the metabolism connection: on aromatase inhibitors and tamoxifen.
DAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation.
Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.
Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.
Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients.
Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.
Definition of postmenopausal status, age of the breast cancer patients and the outcome of aromatase inhibitors treatment.
Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts.
Denosumab in breast cancer patients receiving aromatase inhibitors: A single-center observational study of effectiveness in adjuvant setting.
Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis.
Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study.
Denosumab: A bone antiresorptive drug.
Denosumab: in cancer treatment-induced bone loss.
Depot GnRH-agonist trigger for breast-cancer patient undergoing ovarian stimulation resulted in mature oocytes for cryopreservation: a case report.
Depsidones inhibit aromatase activity and tumor cell proliferation in a co-culture of human primary breast adipose fibroblasts and T47D breast tumor cells.
Des-acyl ghrelin inhibits the capacity of macrophages to stimulate the expression of aromatase in breast adipose stromal cells.
Design and synthesis of carbon-11-labeled dual aromatase-steroid sulfatase inhibitors as new potential PET agents for imaging of aromatase and steroid sulfatase expression in breast cancer.
Design and Synthesis of Norendoxifen Analogues with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities.
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Design, Synthesis, and Biological Evaluation of 2-(2-Bromo-3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole Derivatives as Possible Anti-Breast Cancer Agents.
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.
Design, Synthesis, and Biological Evaluation of New Azole Derivatives as Potent Aromatase Inhibitors with Potential Effects against Breast Cancer.
Design, synthesis, antioxidant, and anti-breast cancer activities of novel diethyl(alkyl/aryl/heteroarylamino)(4-(pyridin-2-yl)phenyl)methylphosphonates.
Design, synthesis, docking study and cytotoxic activity evaluation of some novel letrozole analogs.
Design, synthesis, in vitro and in silico studies of some novel thiazole-dihydrofuran derivatives as aromatase inhibitors.
Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase chain reaction.
Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation.
Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.
Determination of 4-hydroxyandrostenedione in plasma and urine by extractive alkylation and electron-capture gas chromatography.
Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of exemestane in human plasma.
Development and validation of stability indicating method for the determination of exemestane by reverse phase high performance liquid chromatography.
Development and validation of the Penn Arthralgia Aging Scale among breast cancer survivors.
Development of a new class of aromatase inhibitors: design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives.
Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients.
Development of a validated HPTLC-bioautographic method for evaluation of aromatase inhibitory activity of plant extracts and their constituents.
Development of CDK4/6 Inhibitors: A Five Years Update.
Development of tolerance to the CNS effects of aminoglutethimide in mice.
Diagnostics and Therapy for Malignant (Degenerate) Colon Endometriosis - Three Case Reports.
Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data.
Dietary administration of the licorice flavonoid isoliquiritigenin deters the growth of MCF-7 cells overexpressing aromatase.
Dietary flavones and flavonones display differential effects on aromatase (CYP19) transcription in the breast cancer cells MCF-7.
Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.
Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole - of clinical importance?
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.
Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells.
Differential profile of letrozole and exemestane on bone turnover markers in vinylcyclohexene diepoxide treated ovotoxic female mice.
Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer.
Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.
Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months.
Discovery of a multi-target compound for estrogen receptor-positive (ER+) breast cancer: Involvement of aromatase and ERs.
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
Discovery of novel aromatase inhibitors using a homogeneous time-resolved fluorescence assay.
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Diverse flavonoids from the roots of Millettia brandisiana.
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
Do aromatase inhibitors have adverse effects on cognitive function?
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Docking and 3D-QSAR studies of diverse classes of human aromatase (CYP19) inhibitors.
Does a higher ratio of serum calcium to magnesium increase the risk for postmenopausal breast cancer?
Does Aromatase Inhibitors Cause Sjogren's Syndrome and Polyneuropathy?
Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk.
Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers.
Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Down-regulation of promoter 1.3 activity of the human aromatase gene in breast tissue by zinc-finger protein, snail (SnaH).
Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib.
Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression.
Drug and hormone interactions of aromatase inhibitors.
Drug induced vitiligo-like depigmentation from a CDK 4/6 inhibitor.
Drug Repurposing for Breast Cancer Therapy: Old Weapon for New Battle.
Drug safety evaluation of exemestane.
Drug update: letrozole: A new aromatase inhibitor for metastatic breast cancer.
Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.
Drug-induced osteoporosis: mechanisms and clinical implications.
Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.
Drugs Causing Bone Loss.
Dry eye syndrome in aromatase inhibitor users.
Dry eyes and AIs: If you don't ask you won't find out.
Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity.
Dual Aromatase-Sulphatase Inhibitors (DASIs) for the Treatment of Hormone Dependent Breast Cancer.
Dual effects of phytoestrogens result in u-shaped dose-response curves.
Ductal carcinoma in situ of the breast: a surgical perspective.
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
Duration of aromatase inhibitor treatment in breast cancer: the role of the 'carryover effect'.
DVL regulation of tissue-specific aromatase transcripts in breast cancer.
DVL1 and DVL3 differentially localize to CYP19A1 promoters and regulate aromatase mRNA in breast cancer cells.
Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.
Early breast cancer in the elderly: assessment and management considerations.
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Early Denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: A case-control retrospective study.
Early enrichment of ESR1 mutations and the impact on gene expression in pre-surgical primary breast cancer treated with aromatase inhibitors.
Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy.
Early phase II study of the new aromatase inhibitor YM511 in postmenopausal patients with breast cancer. Difficulty in clinical dose recommendation based on preclinical and phase I findings.
Early recurrence risk: aromatase inhibitors versus tamoxifen.
Early stage breast cancer treatment and prognostic factors: Post San Antonio Breast Cancer Symposium 2016.
Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients.
Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore.
Economic evaluation of aromatase inhibitors for the treatment of breast cancer.
Economic Evaluation of Fulvestrant 500 mg Versus Generic Nonsteroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer in the United Kingdom.
Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden.
Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting.
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Effect of a switch of aromatase inhibitors to another aromatase inhibitor or tamoxifen on musculoskeletal symptoms in breast cancer; Which is the best?
Effect of acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer: A meta-analysis of randomized controlled trials.
Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.
Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients.
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
Effect of androstenedione on growth of untransfected and aromatase-transfected MCF-7 cells in culture.
Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor-Positive Breast Cancer and Their Relationship with Antiproliferative Response.
Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.
Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
Effect of Aromatase Inhibitor Therapy on the Cardiovascular Health of Black and White Breast Cancer Patients.
Effect of Aromatase Inhibitors on Background Parenchymal Enhancement and Amount of Fibroglandular Tissue at Breast MR Imaging.
Effect of aromatase inhibitors on bone mineral density in Japanese breast cancer population.
Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma.
Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer.
Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat.
Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism-A systematic review.
Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study.
Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.
Effect of Denosumab on Glucose Homeostasis in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors: A Pilot Study.
Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Effect of endocrine therapy on quality of life and cognitive functions in patients with breast cancer.
Effect of Estrogen Depletion on Pain Sensitivity in Aromatase Inhibitor-Treated Women With Early-Stage Breast Cancer.
Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.
Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy.
Effect of Hispolon from Phellinus lonicerinus (Agaricomycetes) on Estrogen Receptors, Aromatase, and Cyclooxygenase II in MCF-7 Breast Cancer Cells.
Effect of Hop (Humulus lupulus L.) Flavonoids on Aromatase (Estrogen Synthase) Activity.
Effect of Letrozole on Plasma Lipids, Triglycerides, and Estradiol in Postmenopausal Women with Metastatic Breast Cancer.
Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples.
Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer.
Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial.
Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review.
Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1? and Relation to Clinical Response.
Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.
Effect of selumetinib on the growth of anastrozole-resistant tumors.
Effect of sildenafil on human aromatase activity: From in vitro structural analysis to catalysis and inhibition in cells.
Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer.
Effect of Tart Cherry on Aromatase Inhibitor-Induced Arthralgia (AIA) in Nonmetastatic Hormone-Positive Breast Cancer Patients: A Randomized Double-Blind Placebo-Controlled Trial.
Effect of the aromatase inhibitor, MEN 11066, on growth of two different MCF-7 sublines.
Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.
Effect of tibolone (Org OD14) and its metabolites on aromatase and estrone sulfatase activity in human breast adipose stromal cells and in MCF-7 and T47D breast cancer cells.
Effect of Traditional Chinese Medicine on Musculoskeletal Symptoms in Breast Cancer: A Systematic Review and Meta-Analysis.
Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors.
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
Effective anti-aromatase therapy to battle against estrogen-mediated breast cancer: Comparative SAR/QSAR assessment on steroidal aromatase inhibitors.
Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Effectively nursing patients receiving aromatase inhibitor therapy.
Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study.
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.
Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation.
Effectiveness, safety, and economic evaluation of adjuvant moxibustion therapy for aromatase inhibitor-induced arthralgia of postmenopausal breast cancer stage I to III patients: Study protocol for a prospective, randomized, assessor-blind, usual-care controlled, parallel-group, pilot clinical trial.
Effects of 3-[N-(2-chlorobenzyl)amino]-6-(1H-imidazol-1-yl) pyridazine dihydrochloride on various aromatase enzyme systems and experimental breast cancer.
Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro.
Effects of Adiposity and Exercise on Breast Tissue and Systemic Metabo-Inflammatory Factors in Women at High Risk or Diagnosed with Breast Cancer.
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Effects of anastrozole on Ki-67 antigen expression in the vaginal epithelium of female rats in persistent estrus.
Effects of anastrozole on lipid metabolism compared with tamoxifen in rats.
Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer.
Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer.
Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model.
Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer.
Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane.
Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.
Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat.
Effects of conditioned medium from different cultured cell types on aromatase expression in adipose stromal cells.
Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines.
Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma - an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy.
Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms.
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.
Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy.
Effects of exercise on physical outcomes of breast cancer survivors receiving hormone therapy - A systematic review and meta-analysis.
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
Effects of menopausal hormonal therapy on occult breast tumors.
Effects of modified Shu-Gan-Liang-Xue decoction combined with anastrozole on osteoblastic proliferation and differentiation of MC3T3-E1 cells.
Effects of Neonicotinoid Pesticides on Promoter-Specific Aromatase (CYP19) Expression in Hs578t Breast Cancer Cells and the Role of the VEGF Pathway.
Effects of Neonicotinoids on Promoter-Specific Expression and Activity of Aromatase (CYP19) in Human Adrenocortical Carcinoma (H295R) and Primary Umbilical Vein Endothelial (HUVEC) Cells.
Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors.
Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Effects of phytoestrogens on aromatase, 3beta and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells.
Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression.
Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice.
Effects of resistance plus aerobic training on body composition and metabolic markers in older breast cancer survivors undergoing aromatase inhibitor therapy.
Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.
Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: Aromatase inhibition and autophagy.
Effects of systemic inflammation on relapse in early breast cancer.
Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data.
Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action.
Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione in MCF-7 human mammary carcinoma cell culture.
Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.
Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats.
Effects of the traditional Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: a study protocol for a multicenter, randomized, controlled clinical trial.
Effects of third-generation aromatase inhibitors on bone.
Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer.
Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator.
Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Efficacy and economics of hormonal therapies for advanced breast cancer.
Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Efficacy and safety of aromatase inhibitors in early breast cancer.
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.
Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy.
Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
Efficacy of a combined alendronate and calcitriol agent (Maxmarvil(®)) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer.
Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: A Retrospective Review.
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
Efficacy of exemestane after nonsteroidal aromatase inhibitor use in metastatic breast cancer patients.
Efficacy of exemestane in korean patients with metastatic breast cancer after failure of nonsteroidal aromatase inhibitors.
Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis.
Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Efficacy of high-dose toremifene therapy in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors:a retrospective, single-institution study.
Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review.
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
Egonol gentiobioside and egonol gentiotrioside from Styrax perkinsiae promote the biosynthesis of estrogen by aromatase.
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.
Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.
Elevated incidence of fractures in women with invasive breast cancer.
Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
Eligibility, compliance and persistence of sequential therapy with aromatase inhibitors following 2-3 years of tamoxifen in endocrine adjuvant breast cancer therapy.
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.
Emerging bone health issues in women with breast cancer in Hawai'i.
Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17.
Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
Emerging drugs for the management of cancer treatment induced bone loss.
Emerging role of aromatase inhibitors in the adjuvant setting.
Emerging role of aromatase inhibitors in the treatment of breast cancer.
Emerging treatment combinations: integrating therapy into clinical practice.
Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer.
Endocrine disorders associated with inappropriately high aromatase expression.
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy.
Endocrine therapies for patients with recurrent breast cancer: predictive factors for responses to first- and second-line endocrine therapies.
Endocrine therapy after aromatase inhibitor therapy in breast cancer.
Endocrine therapy and other targeted therapies for metastatic breast cancer.
Endocrine therapy for advanced breast cancer.
Endocrine therapy for breast cancer prevention in high-risk women: clinical and economic considerations.
Endocrine Therapy for Early Breast Cancer: Updated Review.
Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement.
Endocrine therapy for the treatment of postmenopausal women with breast cancer.
Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size.
Endocrine therapy of breast and prostate cancer.
Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Endocrine therapy toxicity: management options.
Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D.
Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.
Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors.
Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer.
Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.
Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Endogenous steroid hormones and local aromatase activity in the breast.
Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors.
Endometrial pathology in breast cancer patients: Effect of different treatments on ultrasonographic, hysteroscopic and histological findings.
Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients.
Endoplasmic reticulum stress and oncomir-associated chemotherapeutic drug resistance mechanisms in breast cancer tumors.
Endoxifen shows promise in breast cancer.
Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer.
Enhanced bioavailability of exemestane via proliposomes based transdermal delivery.
Enhanced expression of aromatase in p53-inactivated mammary epithelial cells.
Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer.
Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature.
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
Enhancing the adjuvant treatment of hormone receptor positive breast cancer.
Enhancing the efficacy of hormonal agents with selected targeted agents.
Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange.
Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.
Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer.
Epitope characterization of an aromatase monoclonal antibody suitable for the assessment of intratumoral aromatase activity.
ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future.
ER?-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
ErbB receptor signaling and therapeutic resistance to aromatase inhibitors.
Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Erratum to: Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Erratum to: The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom.
Erratum to: The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer.
Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer.
Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.
Erythrocyte alpha-tocopherol in breast cancer patients treated with letrozol.
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer.
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials.
ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.
ESR1 mutations in breast cancer.
ESR1 Mutations Prevalent in Some Breast Cancers.
Establishment of an analytical method for simultaneous quantitation of CDK4/6 inhibitors, aromatase inhibitors, and an estrogen receptor antagonist in human plasma using LC-ESI-MS/MS.
Estradiol as an anti-aromatase agent in human breast cancer cells.
Estradiol formation from testosterone by continuously cultured human breast cancer cells.
Estradiol measurement in translational studies of breast cancer.
Estradiol suppresses phosphorylation of ER? serine 167 through upregulation of PP2A in breast cancer cells.
Estrogen biosynthesis in breast adipose tissue during menstrual cycle in women with and without breast cancer.
Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy.
Estrogen deprivation for breast cancer prevention.
Estrogen metabolites and breast cancer.
Estrogen production and action.
Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible?
Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review.
Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer.
Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer.
Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy.
Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.
Estrogen Receptor-? Activation in Combination with Letrozole Blocks the Growth of Breast Cancer Tumors Resistant to Letrozole Therapy.
Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis.
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
Estrogen signaling and prediction of endocrine therapy.
Estrogen signaling: An emanating therapeutic target for breast cancer treatment.
Estrogen synthesis in human breast tumor and its inhibition by testololactone and bromoandrostenedione.
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells.
Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal.
Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
Estrogen-related genes and their contribution to racial differences in breast cancer risk.
Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.
Estrogens and PTP1B Function in a Novel Pathway to Regulate Aromatase Enzymatic Activity in Breast Cancer Cells.
Estrogens mediate cardiac hypertrophy in a stimulus-dependent manner.
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Ethanol stimulates proliferation, ERalpha and aromatase expression in MCF-7 human breast cancer cells.
Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study.
Etiology, assessment, and management of aromatase inhibitor-related musculoskeletal symptoms.
Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
Evaluating bone mass and bone quality in patients with breast cancer.
Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.
Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion.
Evaluating triptorelin as a treatment option for breast cancer.
Evaluation of 6,7-aziridinyl steroids and related compounds as inhibitors of aromatase (P-450arom).
Evaluation of Active Hexose Correlated Compound (AHCC) in Combination With Anticancer Hormones in Orthotopic Breast Cancer Models.
Evaluation of aromatase inhibitor on radiation induced pulmonary fibrosis via TGF- ?/Smad 3 and TGF- ?/PDGF pathways in rats.
Evaluation of Changes in Tumor Shadows and Microcalcifications on Mammography Following KORTUC II, a New Radiosensitization Treatment without any Surgical Procedure for Elderly Patients with Stage I and II Breast Cancer.
Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer.
Evaluation of fulvestrant in clinical practice: use of an electronic data registry.
Evaluation of Local CYP17A1 and CYP19A1 Expression Levels as Prognostic Factors in Postmenopausal Invasive Ductal Breast Cancer Cases.
Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
Evaluation of periodontal health in breast cancer patients undergoing tamoxifen or aromatase inhibitors drugs therapy: A cross-sectional study.
Evaluation of synthesized coumarin derivatives on aromatase inhibitory activity.
Evaluation of Synthesized Ester or Amide Coumarin Derivatives on Aromatase Inhibitory Activity.
Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.
Everolimus Boosts Endocrine Therapy for Breast Cancer.
Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis.
Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Everolimus plus exemestane as first-line therapy in HR?, HER2? advanced breast cancer in BOLERO-2.
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2.
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Everolimus-associated Acute Kidney Injury in Patients with Metastatic Breast Cancer.
Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
Everolimus.
Everolimus: a new hope for patients with breast cancer.
Everolimus: side effect profile and management of toxicities in breast cancer.
Evidence for Enhanced Exosome Production in Aromatase Inhibitor-Resistant Breast Cancer Cells.
Evolution of endocrine adjuvant therapy for early breast cancer.
Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
Examination of the use of Exemestane in patients with metastatic breast cancer.
Examining factors associated with adherence to hormonal therapy in breast cancer patients.
Examining quality of life issues in relation to endocrine therapy for breast cancer.
Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer.
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
Exemestane and aromatase inhibitors in the management of advanced breast cancer.
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety.
Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells.
Exemestane as First-Line Therapy in Postmenopausal Women With Recurrent or Metastatic Breast Cancer.
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).
Exemestane Attenuates Hepatic Fibrosis in Rats by Inhibiting Activation of Hepatic Stellate Cells and Promoting the Secretion of Interleukin 10.
Exemestane for breast cancer prevention: a feasible strategy?
Exemestane for breast-cancer prevention in postmenopausal women.
Exemestane for primary prevention of breast cancer in postmenopausal women.
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.
Exemestane in advanced breast cancer.
Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure.
Exemestane in postmenopausal women with early or advanced breast cancer: a review.
Exemestane in the prevention setting.
Exemestane induced cholestatic liver injury - A case report.
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy: A comparative study with Exemestane.
Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.
Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti-aromatase activity assay examining exemestane and its derivatives.
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial.
Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen.
Exemestane, a new steroidal aromatase inhibitor of clinical relevance.
Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option.
Exemestane-induced subclinical hypothyroidism : a case report.
Exemestane.
Exemestane: a milestone against breast cancer.
Exemestane: a novel aromatase inactivator for breast cancer.
Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.
Exemestane: a review of its clinical efficacy and safety.
Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Exemestane: a review of its use in postmenopausal women with breast cancer.
Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
Exemestane: One part of the chemopreventive spectrum for ER-positive breast cancer.
Exemestane: treatment of breast cancer with selective inactivation of aromatase.
Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the Hormones and Physical Exercise (HOPE) study.
Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study.
Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Exercise Therapies for Preventing or Treating Aromatase Inhibitor-Induced Musculoskeletal Symptoms in Early Breast Cancer.
Exogenous and endogenous hormones, mammographic density and breast cancer risk: can mammographic density be considered an intermediate marker of risk?
Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
Experience with aromatase inhibitors in the treatment of advanced breast cancer.
Experience with exemestane in the treatment of early and advanced breast cancer.
Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies.
Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.
Exploring benzcyclo derivatives as potent aromatase inhibitors using ligand-based modeling studies.
Exploring breast cancer therapies. Comparing aromatase inhibitors to current therapies.
Exploring new chemical functionalities to improve aromatase inhibition of steroids.
Exploring the chemical space of aromatase inhibitors.
Expression and purification of a recombinant form of human aromatase from Escherichia coli.
Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients.
Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer An immunocytochemical study.
Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer.
Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers.
Expression of COX-2 and steroid converting enzymes in breast cancer.
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy.
Expression of estrogen receptors-beta and aromatase activity in primary mammary gland tumors.
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression.
Expression of the forkhead transcription factor FOXL2 correlates with good prognosis in breast cancer patients treated with tamoxifen.
Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.
Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis.
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.
Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer.
Extended adjuvant endocrine therapy of early breast cancer.
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Extended Adjuvant Therapy With Aromatase Inhibitors for Early Breast Cancer: A Meta-analysis of Randomized Controlled Trials.
Extended Aromatase Inhibitors in Hormone-Receptor-Positive Breast Cancer.
Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials.
Extending aromatase inhibitor sensitivity in hormone resistant breast cancer.
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Extra five years of aromatase inhibitors increases disease-free survival in breast cancer.
Extra virgin olive oil potentiates the effects of aromatase inhibitors via glutathione depletion in estrogen receptor-positive human breast cancer (MCF-7) cells.
Extragonadal synthesis of sex steroids: intracrinology.
Extranuclear expression of hormone receptors in primary breast cancer.
FACE: the barefaced facts of AI potency.
Facile synthesis of chrysin-derivatives with promising activities as aromatase inhibitors.
Factors Associated with Calcium Absorption in Postmenopausal Women: A Post Hoc Analysis of Dual-Isotope Studies.
Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial.
Factors influencing aromatase activity in the breast.
Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer.
Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease.
Farnesoid X Receptor (FXR) from normal to malignant state.
Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells.
Farnesyl transferase inhibitors in the treatment of breast cancer.
Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors.
FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer.
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy.
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients.
Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors.
Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer.
Fertility after breast cancer treatment.
Fertility preservation options for female patients with malignancies.
Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer.
Final 5-year results of Z-FAST trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole.
First clinical experience with CDK4/6 inhibitors in breast cancer therapy.
First generation aromatase inhibitors--aminoglutethimide and testololactone.
First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial.
First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta.
Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report.
Flavonoids as prospective aromatase inhibitors in breast cancer prevention/therapy.
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Formestane as treatment of advanced breast cancer in elderly women.
Formestane in the treatment of advanced postmenopausal breast cancer.
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
Formestane: an effective first-line endocrine treatment for advanced breast cancer.
Formestane: effective therapy in postmenopausal women with advanced breast cancer.
Formulation and biopharmaceutical evaluation of a transdermal patch containing letrozole.
Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application.
Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells.
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
FPSE-HPLC-DAD method for the quantification of anticancer drugs in human whole blood, plasma, and urine.
Fracture incidence after 3 years of aromatase inhibitor therapy.
Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients.
Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
Fractures due to Aromatase Inhibitor Therapy for Breast Cancer: A Real-World Analysis of FAERS Data in the Past 15 Years.
Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy.
French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies.
From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures.
From nonsteroidal aromatase inhibitors to multifunctional drug candidates: classic and innovative strategies for the treatment of breast cancer.
From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target.
From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors.
Fulvestrant ('Faslodex')--a new hormonal treatment for advanced breast cancer.
Fulvestrant ('Faslodex'): Current and future role in breast cancer management.
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Fulvestrant (Faslodex): current status in the therapy of breast cancer.
Fulvestrant - a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer.
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience.
Fulvestrant in advanced breast cancer: evidence to date and place in therapy.
Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
Fulvestrant in management of hormone receptor-positive metastatic breast cancer.
Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials.
Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: north central cancer treatment group trial n0032.
Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Fulvestrant.
Fulvestrant: a review of its development, pre-clinical and clinical data.
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer.
Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.
Functional activation of the estrogen receptor-? and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
Functional genomics based on germline genome-wide association studies of endocrine therapy for breast cancer.
Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer.
Future directions in cancer prevention.
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Future uses for aromatase inhibitors in breast cancer.
GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.
Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients.
Gene regulation studies of aromatase expression in breast cancer and adipose stromal cells.
Generic entry of aromatase inhibitors and pharmaceutical access: Initiation of hormonal therapy, timeliness of initiation, and drug choice.
Genesis and Outcome of a Breast Cancer Trial to Develop the Aromatase Inhibitor, Anastrozole.
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.
Genetic modeling of estrogen metabolism as a risk factor of hormone-dependent disorders.
Genetic modelling of the estrogen metabolism as a risk factor of hormone-dependent disorders.
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.
Genetic polymorphisms of ESR1, ESR2, CYP17A1, and CYP19A1 and the risk of breast cancer: a case control study from North India.
Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.
Genetic Predictors of Response to Acupuncture for Aromatase Inhibitor-Associated Arthralgia Among Breast Cancer Survivors.
Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast Cancer: A Biological Pathway Analysis.
Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.
Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.
Genetic variation in the androgen estrogen conversion pathway in relation to breast cancer prognosticators.
Genetics of androgen metabolism in women with infertility and hypoandrogenism.
Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model.
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors.
Genomic index of sensitivity to endocrine therapy for breast cancer.
Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment.
Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells.
Genomic Profiling of the Steroidogenic Acute Regulatory Protein in Breast Cancer: In Silico Assessments and a Mechanistic Perspective.
Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.
Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis.
Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
Ginkgo biloba extract EGb 761-mediated inhibition of aromatase for the treatment of hormone-dependent breast cancer.
Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1.
GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation.
Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer.
Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer.
GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
GPCR Modulation in Breast Cancer.
GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patients.
Grape seed extract is an aromatase inhibitor and a suppressor of aromatase expression.
Grip Strength in Women Being Treated for Breast Cancer and Receiving Adjuvant Endocrine Therapy: Systematic Review.
Grover disease (transient acantholytic dermatosis) induced by anastrozole.
Growth factor signaling enhances aromatase activity of breast cancer cells via post-transcriptional mechanisms.
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Growth inhibitory efficacy and anti-aromatase activity of Tabebuia avellanedae in a model for post-menopausal Luminal A breast cancer.
Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening.
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer: a consensus of Lithuanian medical oncologists, radiation oncologists, endocrinologists, and family medicine physicians.
Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor.
Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations.
Hair analysis to discriminate voluntary doping vs inadvertent ingestion of the aromatase inhibitor letrozole.
Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis.
Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer.
Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.
Health State Utility Assessment for Breast Cancer.
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer.
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine Resistance.
Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole.
HER2 and hormone receptor-positive breast cancer-blocking the right target.
HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
HIF-1? stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma.
High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy.
High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer.
High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.
High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.
High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy.
High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients.
High yield of oocytes without an increase in circulating estradiol levels in breast cancer patients treated with follicle-stimulating hormone and aromatase inhibitor in standard gonadotropin-releasing hormone analogue protocols.
High-dose eicosapentaenoic acid and docosahexaenoic acid supplementation reduces bone resorption in postmenopausal breast cancer survivors on aromatase inhibitors: a pilot study.
High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors.
High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: A multicenter phase II study.
Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors.
Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer.
Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.
Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template.
Histoculture drug response assay, a possible examination system for predicting the antitumor effect of aromatase inhibitors in patients with breast cancer.
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring.
History of Aromatase: Saga of an Important Biologic Mediator and Therapeutic Target.
History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response.
Hormonal carcinogenesis.
Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer.
Hormonal enzymatic systems in normal and cancerous human breast: control, prognostic factors, and clinical applications.
Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
Hormonal modulation of ESR1 mutant metastasis.
Hormonal prevention of breast cancer.
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women.
Hormonal therapy for primary breast cancer: scientific rationale and status of clinical research.
Hormonal therapy in early and advanced breast cancer.
Hormonal therapy in postmenopausal women with breast cancer.
Hormonal-therapy in patients with stage-iv breast-cancer at diagnosis.
Hormone Receptor-Positive Breast Cancer Choroidal Infiltrates before and after Systemic Aromatase Inhibitor Therapy.
Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health.
Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance.
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
How we maintain bone health in early-stage breast cancer patients on aromatase inhibitors.
Human aromatase: gene resequencing and functional genomics.
Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications.
Human trophoblast xenografts in athymic mice: a model for peripheral aromatization.
Hyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in mice.
Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity.
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Hydrophilic interaction liquid chromatography-tandem mass spectrometry determination of estrogen conjugates in human urine.
Hypovitaminosis D is a Predictor of Aromatase Inhibitor Musculoskeletal Symptoms.
Hysteroscopic Evaluation of Endometrial Changes in Breast Cancer Women with or without Hormone Therapies: Results from a Large Multicenter Cohort Study.
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Identification and characterization of a cAMP-responsive element in the region upstream from promoter 1.3 of the human aromatase gene.
Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane.
Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells.
Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells.
Identification of estrogen-responsive genes based on the DNA binding properties of estrogen receptors using high-throughput sequencing technology.
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.
Identification of Novel Scaffolds with Dual Role as Antiepileptic and Anti-Breast Cancer.
Identification of PARP-1, Histone H1 and SIRT-1 as New Regulators of Breast Cancer-Related Aromatase Promoter I.3/II.
Identification of the aromatase in the breast carcinoma cell lines T47D and MCF-7.
Identification of the aromatase inhibitor aminoglutethimide in urine by gas chromatography/mass spectrometry.
Identification of the aromatase inhibitor letrozole in urine by gas chromatography/mass spectrometry.
Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
Identifying adherence barriers to oral endocrine therapy among breast cancer survivors.
Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen.
Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.
Identifying menopause in breast cancer patients: considerations and implications.
Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21.
IKKbeta mediates cell shape-induced aromatase expression and estrogen biosynthesis in adipose stromal cells.
IL-10 suppresses TNF-?-induced expression of human aromatase gene in mammary adipose tissue.
Imidazolylmethylbenzophenones as highly potent aromatase inhibitors.
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis.
Immunochemical specificity of placental NADPH cytochrome c (P-450) reductase in neoplastic and non-neoplastic human tissue.
Immunohistochemical analysis of aromatase in metastatic lymph nodes of breast cancer.
Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues.
Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.
Immunohistochemical study of KiSS1 and KiSS1R expression in human primary breast cancer: Association with breast cancer receptor status, proliferation markers and clinicopathological features.
Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders.
Immunological Therapies Can Relieve Aromatase Inhibitor-Related Joint Symptoms in Breast Cancer Survivors.
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors.
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer.
Impact of aromatase inhibitors on bone health in breast cancer patients.
Impact of Aromatase protein variants and drug interactions in breast cancer: a molecular docking approach.
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).
Impact of body mass index on breast cancer in accordance with the life-stage of women.
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Impact of body mass index on the efficacy of endocrine therapy in patients with metastatic breast cancer - A retrospective two-center cohort study.
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.
Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers.
Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer.
Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo.
Impact of hormonal therapy and other adjuvant therapies on contralateral breast volume change after implant-based breast reconstruction.
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.
Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic review.
Impact of obesity on mammary gland inflammation and local estrogen production.
Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions.
Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer.
Impact of R264C and R264H polymorphisms in human aromatase function.
Impact of sex hormones dysregulation and adiposity on the outcome of postmenopausal breast cancer patients.
Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-hydroexemestane in Healthy Volunteers.
Impact of Yoga on Functional Outcomes in Breast Cancer Survivors With Aromatase Inhibitor-Associated Arthralgias.
Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort.
Implications of first-line adjuvant treatment with aromatase inhibitors in recurrent metastatic breast cancer.
Importance of local aromatase activity in hormone-dependent breast cancer: a review.
Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-? and progesterone receptor-b.
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
Improvement of treatment outcomes after implementation of comprehensive pharmaceutical care in breast cancer patients receiving everolimus and exemestane.
Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy.
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: A randomised controlled trial to evaluate the effect of short message service (SMS) reminder.
Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: study protocol of a randomised controlled trial to evaluate the effect of short message service (SMS) reminder.
In brief: An aromatase inhibitor is reported to prevent postmenopausal breast cancer.
In postmenopausal women with breast cancer treated with aromatase inhibitors, denosumab reduced fractures.
In silico analysis of nsSNPs in CYP19A1 gene affecting breast cancer associated aromatase enzyme.
In Silico Molecular Interaction Studies of Chitosan Polymer with Aromatase Inhibitor: Leads to Letrozole Nanoparticles for the Treatment of Breast Cancer.
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology.
In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.
In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients.
In situ production of estrogens in human breast carcinoma.
In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells.
In vitro and in vivo metabolic investigation of the Palbociclib by UHPLC-Q-TOF/MS/MS and in silico toxicity studies of its metabolites.
In vitro evaluation of estrogenic, antiestrogenic and antitumor effects of amentoflavone.
In Vitro P450-Mediated Metabolism of Exemestane.
In vitro screening of inhibition of PPAR-? activity as a first step in identification of potential breast carcinogens.
In vivo and in vitro effects of the antifungal agent miconazole on estrogen biosynthesis in human breast cancer.
In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6.
In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
In-vitro Cytotoxicity and Aromatase Inhibitory Activity of Flavonoids: Synthesis, Molecular Docking and In-silico ADME Prediction.
Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons.
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.
Incidence and Treatment Efficacy of Trigger Finger in the Breast Cancer Population on Aromatase Inhibitors.
Incidence of comorbidities in women with breast cancer treated with tamoxifen or an aromatase inhibitor: an Australian population-based cohort study.
Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors.
Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor.
Increased 5?-Reductase Type 2 Expression in Human Breast Carcinoma following Aromatase Inhibitor Therapy: The Correlation with Decreased Tumor Cell Proliferation.
Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma.
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Increased Fracture Rate in Women With Breast Cancer: a Review of the Hidden Risk.
Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates.
Increased frequency of ESR1 mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor.
Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment.
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women.
Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors.
Increased use of oral chemotherapy drugs spurs increased attention to patient compliance.
Indications and limitations of third-generation aromatase inhibitors.
Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.
Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13.
Induction of apoptosis in hormone refractory breast cancer: horizontal modulation is superior to vertical.
Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women.
Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide.
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer.
Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer.
Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study.
Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients.
Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients.
Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology.
Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole.
Influence of CYP19A1 gene expression levels in women with breast cancer: a systematic review of the literature.
Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.
Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients.
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
Influence of the carbamate fungicide benomyl on the gene expression and activity of aromatase in the human breast carcinoma cell line MCF-7.
Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients.
Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.
Inhibition of aromatase activity in human placental microsomes by 13-retro-antiprogestins.
Inhibition of aromatase activity in MCF-7aro human breast cancer cells by the natural androgens testosterone and androstenedione.
Inhibition of Aromatase and ?-Amylase by Flavonoids and Proanthocyanidins from Sorghum bicolor Bran Extracts.
Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
Inhibition of aromatase expression by a psoralen-linked triplex-forming oligonucleotide targeted to a coding sequence.
Inhibition of aromatase transcription via promoter II by short heterodimer partner in human preadipocytes.
Inhibition of aromatase with CGS 16949A in postmenopausal women.
Inhibition of aromatase: insights from recent studies.
Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.
Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen.
Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer.
Inhibition of estrogen synthesis in human breast tumors by testololactone and bromoandrostenedione.
Inhibition of estrogen-induced mammary tumor formation in MMTV-aromatase transgenic mice by 4-chlorophenylacetate.
Inhibition of estrone sulfatase by aromatase inhibitor-based estrogen 3-sulfamates.
Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts.
Inhibition of oestrogen biosynthesis induces mild anxiety in C57BL/6J ovariectomized female mice.
Inhibition of oestrogen synthesis in postmenopausal women with breast cancer.
Inhibition of testosterone aromatization by the indole-3-carbinol derivative CTet in CYP19A1-overexpressing MCF-7 breast cancer cells.
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
Inhibition of tumor necrosis factor alpha-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol.
Inhibitors of steroidogenic enzymes for the treatment of breast cancer.
Inhibitory effect of a novel non-steroidal aromatase inhibitor, YM511 on the proliferation of MCF-7 human breast cancer cell.
Inhibitory effect of chrysin on estrogen biosynthesis by suppression of enzyme aromatase (CYP19): A systematic review.
Inhibitory Effect of Luteolin on Estrogen Biosynthesis in Human Ovarian Granulosa Cells by Suppression of Aromatase (CYP19).
Inhibitory Effects of Calcitriol on the Growth of MCF-7 Breast Cancer Xenografts in Nude Mice: Selective Modulation of Aromatase Expression in vivo.
Inhibitory effects of Scutellaria barbata D. Don. and Euonymus alatus Sieb. on aromatase activity of human leiomyomal cells.
Initial studies with [11C]vorozole positron emission tomography detect over-expression of intra-tumoral aromatase in breast cancer.
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
Initialization of adjuvant hormonal treatment for breast cancer.
Initiation of exemestane in two warfarin-treated patients leading to elevation and variability of INR.
Insight into the binding interactions of CYP450 aromatase inhibitors with their target enzyme: a combined molecular docking and molecular dynamics study.
Insight into the enzyme-inhibitor interactions of the first experimentally determined human aromatase.
Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.
INSIGHTS ON AROMATASE IMMUNOHISTOCHEMISTRY: VARIATIONS BETWEEN INTRINSIC MOLECULAR SUBTYPES OF BREAST CANCERS.
Insights on the interaction mechanism of exemestane to three digestive enzymes by multi-spectroscopy and molecular docking.
Insomnia caused by aromatase inhibitors; a therapeutic challenge in patients with breast cancer.
Insomnia in breast cancer: Independent symptom or symptom cluster?
Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer.
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Integrated in silico-in vitro strategy for screening of some traditional Egyptian plants for human aromatase inhibitors.
Integration of ER?-PELP1-HER2 signaling by LSD1 (KDM1A/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer.
Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
Interaction between MUC1 and STAT1 drives IFITM1 overexpression in aromatase inhibitor-resistant breast cancer cells and mediates estrogen-induced apoptosis.
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.
Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface.
Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer.
Interactions of antioestrogens and aromatase inhibitors.
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells.
Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer.
Interventions for the Treatment of Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: A Systematic Review and Meta-analysis.
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors.
Intracrine mechanism of estrogen synthesis in breast cancer.
Intracrinology of breast microenvironment: hormonal status in nipple aspirate fluid and its relationship to breast cancer.
Intracrinology of estrogens and androgens in breast carcinoma.
Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast.
Intratumoral aromatase as a prognostic factor in human breast carcinoma.
Intratumoral aromatase model: the effects of letrozole (CGS 20267).
Intratumoral estrogen production in breast carcinoma: significance of aromatase.
Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer.
Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.
Introduction to the conference, Aromatase: New Perspectives for Breast Cancer.
Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole.
Investigation of the adolescent female breast transcriptome and the impact of obesity.
Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers.
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer.
Irreversible aromatase inactivation: treatment for breast cancer.
Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?
Is tamoxifen associated with an increased risk for thromboembolic complications in patients undergoing microvascular breast reconstruction?
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Is there a growing role for endocrine therapy in the treatment of breast cancer?
Is there a role for estrogen activity assays? Recombinant cell bioassay for estrogen: Development and applications.
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.
Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.
Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
Joint pain and falls among women with breast cancer on aromatase inhibitors.
Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.
Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
Joint problems in breast cancer patients receiving adjuvant aromatase inhibitor.
JunD and JunB Integrate Prostaglandin E2 Activation of Breast Cancer-Associated Proximal Aromatase Promoters.
Keratinocyte growth factor (KGF) induces aromatase activity in cultured MCF-7 human breast cancer cells.
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24?weeks of aromatase inhibition.
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
KiSS1/GPR54 and estrogen-related gene expression profiles in primary breast cancer.
Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?
Lack of genomic rearrangements involving the aromatase gene CYP19A1 in breast cancer.
Lack of inhibition of placental estrone sulfatase and aromatase enzymes by vitamin D3 and its analogs.
Lactoferrin-decorated vs PEGylated zein nanospheres for combined aromatase inhibitor and herbal therapy of breast cancer.
Landmark trials in endocrine adjuvant therapy for breast carcinoma.
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer.
Lapatinib for advanced or metastatic breast cancer.
Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2.
Late Endobronchial Pulmonary Metastasis in a Patient with Breast Cancer.
Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
LC-MS-MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format.
Lead optimization of 4-(thio)-chromenone 6-O-sulfamate analogs using QSAR, molecular docking and DFT - a combined approach as steroidal sulfatase inhibitors.
Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors.
Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.
Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line.
Leptin induces CREB-dependent aromatase activation through COX-2 expression in breast cancer cells.
Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells.
Leptin is overexpressed in the tumor microenvironment of obese patients with estrogen receptor positive breast cancer.
Leptin regulation of the p53-HIF1?/PKM2-aromatase axis in breast adipose stromal cells: a novel mechanism for the obesity-breast cancer link.
Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages.
Leptin signaling in breast cancer: an overview.
Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients.
Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.
Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells.
Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells.
Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.
Letrozole for the management of breast cancer.
Letrozole improves the sensitivity of breast cancer cells overexpressing aromatase to cisplatin via down-regulation of FEN1.
Letrozole in the neoadjuvant setting: the P024 trial.
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
Letrozole Potentiates Mitochondrial and Dendritic Spine Impairments Induced by ? Amyloid.
Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy.
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Letrozole Suppresses the Fusion of Osteoclast Precursors through Inhibition of p38-Mediated DC-STAMP Pathway.
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Letrozole-induced functional changes in carcinoma-associated fibroblasts and their influence on breast cancer cell biology.
Letrozole-induced necrotising leukocytoclastic small vessel vasculitis: First report of a case in the UK.
Letrozole.
Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Letrozole: a review of its use in postmenopausal women with breast cancer.
Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer.
Letrozole: a well-tolerated and effective treatment for breast cancer.
Letrozole: advancing hormone therapy in breast cancer.
Letrozole: present and future role in the treatment of breast cancer.
Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer.
Lichen Sclerosus in a Breast Cancer Survivor on an Aromatase Inhibitor: A Case Report.
Life following aromatase inhibitors--where now for endocrine sequencing?
Lifestyle Interventions for Breast Cancer Prevention.
Ligands for the peroxisomal proliferator-activated receptor gamma and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose.
Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes.
Liquid chromatography tandem mass spectrometry determination of free and conjugated estrogens in breast cancer patients before and after exemestane treatment.
Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes.
Living with chronic pain: perceptions of breast cancer survivors.
Local adipocytes enable estrogen-dependent breast cancer growth: Role of leptin and aromatase.
Local aromatase activity alterations in breast cancer tissues: A potential way of decision support for clinicians.
Local aromatase expression in human prostate is altered in malignancy.
Local biosynthesis and metabolism of oestrogens in the human breast.
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells.
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor.
Long-term consequences of ovarian ablation for premenopausal breast cancer.
Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Long-term efficacy and safety of exemestane in the treatment of breast cancer.
Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review.
Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.
Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.
Long-Term Follow-Up of the Intergroup Exemestane Study.
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Long-term outcomes of aromatase inhibition for breast cancer.
Long-term safety of aromatase inhibitors in the treatment of breast cancer.
Long-Term Side Effects of Breast Cancer on Force Production Parameters.
Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study.
Longer Times of Receipt of Adjuvant Endocrine Therapy Correspond to Improved Functional Capacity and Lower Adiposity in Women Receiving Adjuvant Therapy.
Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors.
Loss of estrogen inactivation in colonic cancer.
Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.
Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion.
Low-dose environmental endocrine disruptors, increase aromatase activity, estradiol biosynthesis and cell proliferation in human breast cells.
Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer.
Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.
Lung cancer chemoprevention: difficulties, promise and potential agents?
Major clinical research advances in gynecologic cancer in 2011.
Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer.
Male breast cancer.
Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta.
Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.
Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness.
Management issues for elderly patients with breast cancer.
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.
Management of aromatase inhibitor-induced arthralgia.
Management of arthralgias associated with aromatase inhibitor therapy.
Management of bone disease in patients undergoing hormonal therapy for breast cancer.
Management of bone disease in women after breast cancer.
Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
Management of bone loss induced by aromatase inhibitors.
Management of cancer treatment-induced bone loss.
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Management of early breast cancer--the current approach.
Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview.
Management of Male Breast Cancer: ASCO Guideline.
Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.
Management options of breast cancer related osteoporosis.
Managing aromatase inhibitor-associated bone loss in breast cancer.
Managing aromatase inhibitors in breast cancer survivors: not just for oncologists.
Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study.
Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition.
Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy.
Managing menopausal symptoms and associated clinical issues in breast cancer survivors.
Managing patients on endocrine therapy: focus on quality-of-life issues.
Managing the risk of osteoporosis in women with a history of early breast cancer.
Managing the toxicities of the aromatase inhibitors.
Mandibular indexes and fractal properties on the panoramic radiographs of the patients using aromatase inhibitors.
Marked heterogeneity of aromatase activity in human malignant melanoma tissue.
Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer.
MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors.
MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.
Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo.
Measuring estrogens in women, men, and children: Recent advances 2012-2017.
Mechanical phenotype is important for stromal aromatase expression.
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Mechanism of inhibition of estrogen biosynthesis by azole fungicides.
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.
Mechanisms of allosteric and mixed mode aromatase inhibitors.
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.
Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA.
Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation.
Mechanisms of resistance to aromatase inhibitors.
Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance.
Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture.
Mechanisms of the Anti-Cancer and Anti-Inflammatory Actions of Vitamin D.
Mechanisms underlying differential response to estrogen-induced apoptosis in long-term estrogen-deprived breast cancer cells.
Mechanistic insight of drug resistance with special focus on iron in estrogen receptor positive breast cancer.
Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
Melatonin as an Oncostatic Molecule Based on Its Anti-Aromatase Role in Breast Cancer.
Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells.
Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells.
Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity.
Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production.
Melatonin modulates aromatase activity and expression in endothelial cells.
Melatonin modulates aromatase activity in MCF-7 human breast cancer cells.
Melatonin promotes differentiation of 3T3-L1 fibroblasts.
Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts.
Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.
Menopausal symptoms and adjuvant therapy-associated adverse events.
Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy.
Menopause is a determinant of breast aromatase expression and its associations with BMI, inflammation and systemic markers.
Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women.
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.
Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.
Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer.
Metabolic Activity in the Insular Cortex and Hypothalamus Predicts Hot Flashes: An FDG-PET Study.
Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors.
Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.
Metabolism and toxicological implications of commonly used chemopreventive drugs against breast cancer/carcinogenesis.
Metabolism of 4-hydroxyandrostenedione and 4-hydroxytestosterone: Mass spectrometric identification of urinary metabolites.
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase.
Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.
Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modelling to aid decision making.
Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients.
Methylation of dietary flavones increases their metabolic stability and chemopreventive effects.
Methylseleninic acid is a novel suppressor of aromatase expression.
Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
Micellar electrokinetic chromatographic study of the separation of an aromatase inhibitor and a tryciclic antidepressant in the breast cancer treatment.
Microbial transformation of anti-cancer wsteroid exemestane and cytotoxicity of its metabolites against cancer cell lines.
MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Microvascular breast reconstruction and thromboembolic events in patients on hormone therapy: Audit of practice from a tertiary referral centre.
miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.
Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.
Mixed estrogenic and anti-estrogenic activities of yuehchukene--a bis-indole alkaloid.
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
Modeling hot flushes and quality of life in breast cancer survivors.
Modeling of diarylalkyl-imidazole and diarylalkyl-triazole derivatives as potent aromatase inhibitors for treatment of hormone-dependent cancer.
Modification of abdominal fat distribution after aromatase inhibitor therapy in breast cancer patients visualized using 3-d computed tomography volumetry.
Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.
Modulation of aromatase expression in human breast tissue.
Modulation of aromatase expression in the breast tissue by ERR alpha-1 orphan receptor.
Modulation of breast cancer cell survival by aromatase inhibiting hop (Humulus lupulus L.) flavonoids.
Modulation of CYP19 expression by cabbage juices and their active components: indole-3-carbinol and 3,3'-diindolylmethene in human breast epithelial cell lines.
Modulation of Delta9-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase.
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Modulation of oestrone sulphatase activity in breast cancer cell lines by growth factors.
Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype.
Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Molecular analysis of aberrant expression of aromatase in breast cancer tissues.
Molecular and epidemiological analyses of abnormal expression of aromatase in breast cancer.
Molecular Barcode Sequencing of the Whole Ligand Binding Domain of the ESR1 Gene in Cell-Free DNA from Patients with Metastatic Breast Cancer.
Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase.
Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.
Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Molecular characterization of aromatase.
Molecular docking and 3D-QSAR based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer.
Molecular docking and QSAR studies of aromatase inhibitor androstenedione derivatives.
Molecular mechanisms of aromatase inhibition by new A, D-ring modified steroids.
Molecular Modeling Evaluation of Non-Steroidal Aromatase Inhibitors(†).
Molecular Pathways: Adipose Inflammation as a Mediator of Obesity-Associated Cancer.
Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents.
Molecular profiling of aromatase inhibitor-treated post-menopausal breast tumors identifies immune-related correlates of resistance.
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Molecular simulations of aromatase reveal new insights into the mechanism of ligand binding.
Molecular therapy of breast cancer: progress and future directions.
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
mTOR function and therapeutic targeting in breast cancer.
mTOR inhibitors in advanced breast cancer: ready for prime time?
Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.
Multiple forms of aromatase and response of breast cancer aromatase to antiplacental aromatase II antibodies.
Multiple rebound-associated vertebral fractures after denosumab discontinuation: is prompt antiresorptive therapy always recommended, even when the risk of fracture seems low? A case report.
Musculoskeletal adverse events associated with adjuvant aromatase inhibitors.
Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors.
Myocardial Function in Premenopausal Women Treated With Ovarian Function Suppression and an Aromatase Inhibitor.
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.
Nandrolone and stanozolol upregulate aromatase expression and further increase IGF-I-dependent effects on MCF-7 breast cancer cell proliferation.
Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies.
Natural compounds with aromatase inhibitory activity: an update.
Natural products as aromatase inhibitors.
NCCN breast cancer clinical practice guidelines in oncology: an update.
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
NCCN Task Force Report: Bone Health in Cancer Care.
Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer.
Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study.
Neo-adjuvant hormonal therapy.
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer: NACED-Randomized Multicenter Phase II Trial.
Neoadjuvant endocrine therapy as a drug development strategy.
Neoadjuvant endocrine therapy for breast cancer: an overlooked option?
Neoadjuvant endocrine therapy for breast cancer: medical perspectives.
Neoadjuvant endocrine therapy in primary breast cancer.
Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?
Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG).
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer.
Neoplastic effects of exemestane in premenopausal breast cancer model.
Network-guided prediction of aromatase inhibitor response in breast cancer.
Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer.
New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation.
New agents in development for breast cancer.
New and emerging concepts in the use of denosumab for the treatment of osteoporosis.
New and translational perspectives of oestrogen deprivation in breast cancer.
New approaches to the endocrine prevention and treatment of breast cancer.
New approaches to the understanding of tamoxifen action and resistance.
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
New aromatase inhibitors for breast cancer.
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.
New aromatase inhibitors in the treatment of advanced breast cancer.
New azolyl-derivatives as multitargeting agents against breast cancer and fungal infections: synthesis, biological evaluation and docking study.
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
New development in intracrinology of breast carcinoma.
New development in intracrinology of breast carcinoma: therapeutic horizons after aromatase inhibitors.
New developments in endocrine therapy: role of adjuvant therapy for early breast cancer.
New developments in intracrinology of human breast cancer: estrogen sulfatase and sulfotransferase.
New directions for drug-resistant breast cancer: the CDK4/6 inhibitors.
New drugs for the treatment of cancer, 1990-2001.
New drugs in breast cancer.
New generation aromatase inhibitors in breast cancer. Weighing out potential costs and benefits.
New Hormonal Therapies for Breast Cancer.
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17.
New ruthenium(II)-letrozole complexes as anticancer therapeutics.
New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death.
New views on treatment of aromatase inhibitors induced arthralgia.
NewsCAP: The USPSTF recommends tamoxifen, raloxifene, or aromatase inhibitors for women at high breast cancer risk.
NICE recommends aromatase inhibitors for early breast cancer.
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
No associations between aromatase gene polymorphisms and breast cancer risk in Saudi patients.
Nomegestrol acetate is an anti-aromatase agent in human MCF-7aro breast cancer cells.
Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice.
Non-Steroidal Aromatase Inhibitors Based on a Biphenyl Scaffold: Synthesis, in vitro SAR, and Molecular Modelling.
Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer.
Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study.
Nonsteroidal Aromatase Inhibitors for the Treatment of Breast Cancer: An Update.
Nonsteroidal aromatase inhibitors: recent advances.
Nordic Walking as an Exercise Intervention to Reduce Pain in Women With Aromatase Inhibitor-Associated Arthralgia: A Feasibility Study.
Notch Signaling Pathway and Endocrine Resistance in Breast Cancer.
Novel Agents for the Management of Endocrine Resistant Breast Cancer.
Novel aromatase and 5 alpha-reductase inhibitors.
Novel Aromatase Inhibitors By Structure-Guided Design.
Novel aromatase inhibitors selection using induced fit docking and extra precision methods: Potential clinical use in ER-alpha-positive breast cancer.
Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.
Novel endocrine therapies in breast cancer.
Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design.
Novel non-steroidal aromatase inhibitors: are there new perspectives in the treatment of breast cancer?
Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer.
Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification.
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.
NSABP breast cancer clinical trials: recent results and future directions.
NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions.
Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.
Obacunone exhibits anti-proliferative and anti-aromatase activity in vitro by inhibiting the p38 MAPK signaling pathway in MCF-7 human breast adenocarcinoma cells.
Obesity and breast cancer - Role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue.
Obesity and breast cancer: mechanisms and therapeutic implications.
Obesity and breast cancer: progress to understanding the relationship.
Obesity and breast cancer: role of inflammation and aromatase.
Obesity and outcome of post-menopausal women receiving adjuvant letrozole for breast cancer.
Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland.
Obesity, aromatase and breast cancer.
Obesity-Altered Adipose Stem Cells Promote ER? Breast Cancer Metastasis through Estrogen Independent Pathways.
Obesity-associated Breast Cancer: Analysis of risk factors.
Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production.
Occult breast tumor reservoir: biological properties and clinical significance.
Ocular Surface Disease in Breast Cancer Patients Using Aromatase Inhibitors.
Oestrogen formation in breast: clinical and biological importance.
Oestrogen producing enzymes and mammary carcinogenesis: a review.
Oestrone sulphatase activity in normal and malignant breast tissues: relationship with tumour location.
Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).
On the significance of in situ production of oestrogens in human breast cancer tissue.
Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status.
Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction.
Online discussion of drug side effects and discontinuation among breast cancer survivors.
Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen.
Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis.
Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?
Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study.
Optimal treatment strategies in hormone-responsive early breast cancer: the role of aromatase inhibitors.
Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol.
Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects.
Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting.
Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer.
Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer.
Oral Endocrine Therapy Nonadherence, Adverse Effects, Decisional Support, and Decisional Needs in Women With Breast Cancer.
Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Oral health-related concerns, behavior, and communication with health care providers of patients with breast cancer: impact of different treatments.
Organization of the human aromatase p450 (CYP19) gene.
Organoruthenium(II) Complexes Bearing an Aromatase Inhibitor: Synthesis, Characterization, in Vitro Biological Activity and in Vivo Toxicity in Zebrafish Embryos.
Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer.
Origin of aromatase inhibitory activity via proteochemometric modeling.
Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review.
Osteopenia and osteoporosis in women with breast cancer.
Osteoporosis in breast and prostate cancer survivors.
Osteoporosis management in patients with breast cancer: EMAS position statement.
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments.
Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis.
Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer.
Ovarian suppression failure during GnRH agonist treatment: A report of three breast cancer patients.
Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation.
Over expression of aromatase protein is highly related to MMPs levels in human breast carcinomas.
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients.
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Overview of recent development of aromatase inhibitors.
Overview of resistance to systemic therapy in patients with breast cancer.
Overview of the pharmacology of the aromatase inactivator exemestane.
P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
p53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis.
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series.
Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Paracrine-stimulated gene expression profile favors estradiol production in breast tumors.
Paradox CA 15-3 increase in metastatic breast cancer patients treated with everolimus: a change of paradigm in a case series.
Paradoxal metabolic flare detected by 18F-fluorodeoxyglucose positron emission tomography in a patient with metastatic breast cancer treated with aromatase inhibitor and biphosphonate.
Paradoxical effect of estradiol: it can block its own bioformation in human breast cancer cells.
Patient and physician perceptions on continuing aromatase inhibitors beyond the 5-year mark.
Patient and provider determinants associated with the prescription of adjuvant hormonal therapies following a diagnosis of breast cancer in Medicaid-enrolled patients.
Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.
Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors.
Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms.
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).
Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
Patients' preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments.
Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.
PCP4/PEP19 upregulates aromatase gene expression via CYP19A1 promoter I.1 in human breast cancer SK-BR-3 cells.
PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
Perceptions of Racially and Ethnically Diverse Women at High Risk of Breast Cancer Regarding the Use of a Web-Based Decision Aid for Chemoprevention: Qualitative Study Nested Within a Randomized Controlled Trial.
Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Periodontal health in breast cancer patients on aromatase inhibitors versus postmenopausal controls: a longitudinal analysis.
Periodontal Health in Women With Early Stage Postmenopausal Breast Cancer Newly on Aromatase Inhibitors: A Pilot Study.
Perioperative Use of Antiestrogen Therapies in Breast Reconstruction: A Systematic Review and Treatment Recommendations.
Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis.
Personalized adjuvant therapies: Lessons from the past: The opening address by the St. Gallen 2013 award recipient.
Personalizing aromatase inhibitor therapy in patients with breast cancer.
Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
PET probe with Aggregation Induced Emission characteristics for the specific turn-on of aromatase.
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.
Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.
Pharmacogenetics of aromatase inhibitors in endocrine responsive breast cancer: lessons learnt from tamoxifen and CYP2D6 genotyping.
Pharmacogenetics of aromatase inhibitors.
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
Pharmacogenomics of endocrine therapy in breast cancer.
Pharmacogenomics of tamoxifen and aromatase inhibitors.
Pharmacogenomics of third-generation aromatase inhibitors.
Pharmacokinetic comparison of 2 formulations of anastrozole (1 mg) in healthy Korean male volunteers: a randomized, single-dose, 2-period, 2-sequence, crossover study.
Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
Pharmacokinetics and metabolism of formestane in breast cancer patients.
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.
Pharmacokinetics of 4-hydroxyandrostenedione in man after intramuscular injection of different formulations and the effect of this drug on plasma aromatizable androgens and 17beta-estradiol concentrations.
Pharmacokinetics of third-generation aromatase inhibitors.
Pharmacological breast cancer therapy (review).
Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Pharmacology and clinical experience with exemestane.
Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer.
Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
Pharmacology of arthralgia with estrogen deprivation.
Pharmacophore mapping of flavone derivatives for aromatase inhibition.
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio.
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
Phase II clinical trial of high-dose toremifene as primary hormone therapy in aromatase inhibitor-resistant breast cancer.
Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR).
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.
Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer.
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer.
Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer.
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.
Phosphorylation processes controlling aromatase activity in breast cancer: an update.
Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study.
Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors.
Physician and Patient Barriers to Breast Cancer Preventive Therapy.
Physicians' influence on breast cancer patient compliance.
Phytochemicals for breast cancer prevention by targeting aromatase.
Phytochemicals: Current strategies for treating breast cancer.
Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model.
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pictilisib Stalls Advanced ER+/PR+ Breast Cancer.
Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.
Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms.
Pilot study of Iyengar yoga for management of aromatase inhibitor-associated arthralgia in women with breast cancer.
Pioglitazone, a PPAR? Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1.
Pivotal trials of letrozole: a new aromatase inhibitor.
Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
Plasma estrone and estrone sulphate in breast cancer patients treated with the aromatase inhibitor CGS 16949A.
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients.
Polymeric Nanoparticles of Aromatase Inhibitors: A Comprehensive Review.
Polymorphic genetic variations of Cytochrome P450 19A1 and T-cell leukemia 1A genes in the Tamil population.
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Polymorphisms in Phase I (CYP450) Genes CYP1A1 (rs4646421), CYP1B1 (rs1056836), CYP19A1 (rs749292) and CYP2C8 (rs1058930) and Their Relation to Risk of Breast Cancer: A Case-Control Study in Mazandaran Province in North of Iran.
Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk.
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study.
Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
Polyphenolic natural products and natural product-inspired steroidal mimics as aromatase inhibitors.
Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro.
Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.
Population Pharmacokinetics of Palbociclib in aReal-World Situation.
Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue.
Positive Association of Polymorphisms in Estrogen Biosynthesis Gene, CYP19A1, and Metabolism, GST, in Breast Cancer Susceptibility.
Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers.
Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
Postmenopausal breast cancer, androgens, and aromatase inhibitors.
Postmenopausal Breast Cancer, Aromatase Inhibitors, and Bone Health: What the Surgeon Should Know.
Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.
Postmenopausal osteoporosis, breast cancer, and aromatase inhibitor.
Postmenopausal testosterone therapy and breast cancer risk.
Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
Postmenopausal women with hormone receptor-positive breast cancer: Balancing benefit and toxicity from aromatase inhibitors.
Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
Potency and specificity of CGS-16949A as an aromatase inhibitor.
Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates.
Potent and selective aromatase inhibitor: in vitro and in vivo studies with s-triazine derivative SEF19.
Potent aromatase inhibitors and molecular mechanism of inhibitory action.
Potential effect of Olea europea leaves, Sonchus oleraceus leaves and Mangifera indica peel extracts on aromatase activity in human placental microsomes and CYP19A1 expression in MCF-7 cell line: Comparative study.
Potential implications of adjuvant endocrine therapy for the oral health of postmenopausal women with breast cancer.
Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer.
Potential role of aromatase inhibitors in the treatment of endometriosis.
Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen.
Potential utility of natural products as regulators of breast cancer-associated aromatase promoters.
PPAR? agonists target aromatase via both PGE2 and BRCA1.
Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer.
Practices and Attitudes Regarding Women Undergoing Fertility Preservation: A Survey of the National Physicians Cooperative.
Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor.
Pre-clinical applications of transgenic mouse mammary cancer models.
Pre-clinical Pharmacological Evaluation of Letrozole as a Novel Treatment for Gliomas.
Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer.
Pre-menopausal breast cancer and aromatase inhibitors: treating a new generation of women.
Precautions for Patients Taking Aromatase Inhibitors.
Preclinical and clinical development of palbociclib and future perspectives.
Preclinical and clinical studies of novel breast cancer drugs targeting molecules involved in protein kinase C signaling, the putative metastasis-suppressor gene Cap43 and the Y-box binding protein-1.
Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors.
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory.
Predicting response: identifying molecular determinants of endocrine response and resistance in breast cancer.
Predicting the Benefit of Adjuvant Aromatase Inhibitor Therapy in Postmenopausal Breast Cancer Patients with Phosphorylated S6K1 Expression Status.
Prediction of aromatase inhibitory activity using the efficient linear method (ELM).
Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial.
Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study.
Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study.
Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.
Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer.
Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients.
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Predictors of response to aromatase inhibitors.
Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.
Predictors of yoga use among patients with breast cancer.
Preliminary clinical application of an aromatase inhibitor and a gonadotropin-releasing hormone agonist combination for inoperable endometrial cancer patients with comorbidities: case report and literature review.
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Preliminary experience with pure antiestrogens.
Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure.
Preoperative (neoadjuvant) systemic treatment of breast cancer.
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
Preparation and characterization of letrozole-loaded poly(d,l-lactide) nanoparticles for drug delivery in breast cancer therapy.
Preparation and pharmacological profile of 7-(alpha-azolylbenzyl)-1H-indoles and indolines as new aromatase inhibitors.
Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.
Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines.
Prescription pattern of aromatase inhibitors for the adjuvant therapy of breast cancer in Germany - results of the second survey among gynaecologists and medical oncologists.
Prescription pattern of aromatase inhibitors in the adjuvant setting in Germany--final results of a survey among german breast cancer specialists.
Prescription Patterns, Initiation, and 5-Year Adherence to Adjuvant Hormonal Therapy Among Commercially Insured Patients With Breast Cancer.
Presence of alternatively spliced transcripts of aromatase gene in human breast cancer.
Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients.
Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors.
Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors.
Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis.
Prevalence of bisphosphonate therapy in women with breast cancer treated with aromatase inhibitors in Germany?.
Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.
Preventative therapies for healthy women at high risk of breast cancer.
Preventing invasive breast cancer using endocrine therapy.
Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Prevention and treatment of bone loss in patients with nonmetastatic breast or prostate cancer who receive hormonal ablation therapy.
Prevention and treatment of breast cancer by suppressing aromatase activity and expression.
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.
Prevention of breast cancer using SERMs and aromatase inhibitors.
Prevention of breast cancer: current state of the science and future opportunities.
Prevention of ER-negative breast cancer.
Prevention of hormone-related cancers: breast cancer.
Prevention of osteoporosis after breast cancer.
Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: Rationale and design of a randomized controlled trial.
Prevention strategies with aromatase inhibitors.
Prevention, diagnosis and treatment of osteoporosis following menopause induced due to oncological disease.
Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies.
Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole.
Preventive effects of letrozole in the model of premenopausal mammary carcinogenesis.
Preventive Therapy for Breast Cancer.
Primarily tamoxifen-unresponsive, steroid receptor-positive breast cancer may respond to an aromatase inhibition: a pilot study.
Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients.
Primary hormone treatment in postmenopausal women with breast cancer.
Probing the origins of aromatase inhibitory activity of disubstituted coumarins via QSAR and molecular docking.
Proceedings of the 5th Kuwait International Pharmacy Conference (5th KIPC), Faculty of Pharmacy, Health Sciences Center, Kuwait University, Kuwait, February 1-3, 2015.
Profile of Steroid Receptors and Increased Aromatase Immunoexpression in Canine Inflammatory Mammary Cancer as a Potential Therapeutic Target.
Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer.
Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.
Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight.
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
Prognostic and predictive value of TFF1 for adjuvant endocrine therapy in Chinese women with early ER positive breast cancer: Comparing aromatase inhibitors with tamoxifen.
Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.
Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor.
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer.
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.
Prognostic value of breast cancer aromatase.
Progress in endocrine approaches to the treatment and prevention of breast cancer.
Progress in preventive therapy for cancer: a reminiscence and personal viewpoint.
Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Progression of endocrine therapies for breast cancer: where are we headed?
Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Promoter-specific effects of metformin on aromatase transcript expression.
Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant.
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.
Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
Prostaglandin E(2) induces breast cancer related aromatase promoters via activation of p38 and c-Jun NH(2)-terminal kinase in adipose fibroblasts.
Prostaglandin E2 Inhibits p53 in Human Breast Adipose Stromal Cells: A Novel Mechanism for the Regulation of Aromatase in Obesity and Breast Cancer.
Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes.
Prostaglandin J2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: potential implications for breast cancer therapy.
Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation.
Protein kinase A-dependent synergism between GATA factors and the nuclear receptor, liver receptor homolog-1, regulates human aromatase (CYP19) PII promoter activity in breast cancer cells.
Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.
Protocol for Exercise Program in Cancer and Cognition (EPICC): A randomized controlled trial of the effects of aerobic exercise on cognitive function in postmenopausal women with breast cancer receiving aromatase inhibitor therapy.
Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer.
Pure antiestrogens and breast cancer.
Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature.
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
QSAR modeling of aromatase inhibitory activity of 1-substituted 1,2,3-triazole analogs of letrozole.
Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study.
Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer.
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.
Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer.
Quality of life issues in relation to the aromatase inhibitor.
Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer.
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Quantitative assessment of mammographic breast density: relationship with breast cancer risk.
Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast.
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
Quantitative Proteomic Profiling Identifies a Potential Novel Chaperone Marker in Resistant Breast Cancer.
Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab.
Quinone-related hexacyclic by-products in the production process of exemestane.
Racial Differences in Depressive Symptoms and Self-Rated Health among Breast Cancer Survivors on Aromatase Inhibitor Therapy.
Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.
Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus.
Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
Rainbow trout, Oncorhynchus mykiss, as a model for aromatase inhibition.
Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer.
Randomized Controlled Trial of a Home-Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors.
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Randomized Exercise Trial of Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors.
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study).
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study.
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.
Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Randomized Trial Of Exercise On Body Composition In Breast Cancer Survivors Taking Aromatase Inhibitors: 1285 Board #6 June 2, 8: 00 AM - 10: 00 AM.
Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105.
Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer.
Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.
Rapid and Sensitive Liquid Chromatographic Method for Determination of Anastrozole in Different Polymer-Lipid Hybrid Nanoparticles.
Rapid estradiol/ERalpha signaling enhances aromatase enzymatic activity in breast cancer cells.
Rapid estrogen effects on aromatase phosphorylation in breast cancer cells.
Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer.
Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer.
Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.
RE: Adjuvant Aromatase Inhibitors or Tamoxifen following Chemotherapy for Perimenopausal Breast Cancer Patients.
Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.
Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Real-World Palbociclib Use in HR+/HER2- Advanced Breast Cancer in Canada: The IRIS Study.
Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: a literature review.
Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
Receipt of psychological counseling and integrative medicine services among breast cancer survivors with anxiety.
Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer.
Recent advances in aromatase inhibitor therapy for breast cancer.
Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
Recent advances in oncology acupuncture and safety considerations in practice.
Recent advances in the management of primary breast cancers.
Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.
Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.
Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer.
Recent developments in aromatase inhibition as a potential treatment for oestrogen-dependent breast cancer.
Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer.
Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Recent progress in development of aromatase inhibitors.
Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.
Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.
Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer.
Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES).
Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target.
Recovery of reproductive function in rats treated with the aromatase inhibitor fadrozole.
Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Reducing the risk of late recurrence in hormone-responsive breast cancer.
Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
Regression of choroidal metastases from breast carcinoma using aromatase inhibitors.
Regression of late onset choroidal metastasis from a breast carcinoma with letrozole.
Regulation of arachidonic acid metabolism, aromatase activity and growth in human breast cancer cells by interleukin-1beta and phorbol ester: dissociation of a mediatory role for prostaglandin E2 in the autocrine control of cell function.
Regulation of aromatase activity by cytokines, PGE2 and 2-methoxyoestrone-3-O-sulphamate in fibroblasts derived from normal and malignant breast tissues.
Regulation of aromatase activity within the breast.
Regulation of aromatase and sulphatase in breast tumour cells.
Regulation of aromatase by nuclear receptors.
Regulation of aromatase expression in breast cancer tissue.
Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy.
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.
Regulation of aromatase expression in human tissues.
Regulation of aromatase expression: Potential therapeutic insight into breast cancer treatment.
Regulation of aromatase induction by nuclear receptor coregulator PELP1.
Regulation of aromatase promoter activity in human breast tissue by nuclear receptors.
Regulation of breast cancer-associated aromatase promoters.
Regulatory nodes that integrate and coordinate signaling as potential targets for breast cancer therapy.
Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy.
Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches.
Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer.
Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
Relationship between physical activity practice and metabolic profile of postmenopausal women under treatment with aromatase inhibitors for breast cancer.
Relationship between tumour aromatase activity, tumour characteristics and response to therapy.
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
Relevance of Aromatase Inhibitors in Breast Cancer Treatment.
Reply to 'Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature' by Delea et al.
Reply to the Letter to the Editor on "Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients", by I. Cohen Ann Oncol 2005; 16: 1399.
Reporter gene assay demonstrates functional differences in estrogen receptor activity in purified breast cancer cells: a pilot study.
Reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits.
Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.
Resistance of the ovary to blockade of aromatization with aminoglutethimide.
Resistance to Aromatase Inhibitors in Breast Cancer.
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Resistance to Targeted Therapies in Breast Cancer.
Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report.
Resonance Raman Spectroscopy of the Oxygenated Intermediates of Human CYP19A1 Implicates a Compound I Intermediate in the Final Lyase Step.
Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase-estrogen receptor axis.
Retinol inhibits aromatase activity and expression in vitro.
RETRACTED ARTICLE: Cost-effectiveness of dual energy X-ray absorptiometry (DXA) plus anti-resorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.
Retraction: Aromatase Inhibitor-mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study.
Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant.
Review of studies on estrogen biosynthesis in the human.
Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer.
Rheumatic disorders and functional disability with aromatase inhibitor therapy.
Rheumatoid arthritis and aromatase inhibitors.
Rheumatoid arthritis: a complication of aromatase inhibitor therapy?
Ribociclib Approved for Advanced Breast Cancer.
Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ribociclib: First Global Approval.
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial.
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors.
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States.
Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
Risks and benefits of bisphosphonates.
Risks versus benefits in the clinical application of aromatase inhibitors.
Rivizor--a new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failure.
Role of anastrozole in adjuvant therapy for postmenopausal patients.
Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
Role of antiestrogens and aromatase inhibitors in breast cancer treatment.
Role of aromatase activation on sodium arsenite-induced proliferation, migration, and invasion of MDA-MB-231 and MDA-MB-453 breast cancer cell lines.
Role of aromatase inhibitors in advanced breast cancer.
Role of aromatase inhibitors in breast cancer.
Role of aromatase inhibitors in the treatment of breast cancer.
Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer.
Role of biologic markers in patient selection and application to disease prevention.
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer.
Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer.
Role of CRE-binding protein (CREB) in aromatase expression in breast adipose.
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women.
Role of hormones in cancer prevention.
Role of human 3?-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C3) in the extrahepatic metabolism of the steroidal aromatase inactivator Formestane.
Role of inflammation in obesity-related breast cancer.
Role of melatonin in the epigenetic regulation of breast cancer.
Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women.
Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer.
Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast.
Role of the UGT2B17 deletion in exemestane pharmacogenetics.
Roles for miRNAs in endocrine resistance in breast cancer.
Roles of autophagy in breast cancer treatment: Target, bystander or benefactor.
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
Ropinirole, a potential drug for systematic repositioning based on side effect profile for management and treatment of breast cancer.
Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.
RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
RU54115, a tight-binding aromatase inhibitor potentially useful for the treatment of breast cancer.
S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.
S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Safety issues surrounding the use of aromatase inhibitors in breast cancer.
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
Safety of aromatase inhibitor therapy in breast cancer.
Safety of aromatase inhibitors in the adjuvant setting.
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Safety of mTOR inhibitors in breast cancer.
Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial.
Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer.
Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study.
Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer.
Saving the bones in breast cancer: aromatase inhibitor-induced osteoporosis.
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Screening for osteoporosis after breast cancer: for whom, why and when.
Screening for Osteoporosis in Postmenopausal Women With Breast Cancer Receiving Aromatase Inhibitors: Less Is More?
Screening of potential cancer preventing chemicals as aromatase inhibitors in an in vitro assay.
Second generation aromatase inhibitor--4-hydroxyandrostenedione.
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.
Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole - First Case Report and another Example of an Immunocompromised District.
Selective Dual Inhibitors of CYP19 and CYP11B2: Targeting Cardiovascular Diseases Hiding in the Shadow of Breast Cancer.
Selective estrogen receptor modulation: concept and consequences in cancer.
Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention.
Selective estrogen-receptor modulators in 2001.
Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara.
Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Selective regulation of aromatase expression for drug discovery.
Selective spatial upregulation of intratumoral stromal aromatase in breast cancer patients: evidence for imbalance of local estrogen metabolism.
Selective transcriptional regulation of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells.
Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis.
Sequence-function correlation of aromatase and its interaction with reductase.
Sequencing of aromatase inhibitors.
Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer.
Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer.
Sequential adjuvant hormone therapy in postmenopausal breast cancer: rationale and clinical results.
Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study.
Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
SERMs for the treatment and prevention of breast cancer.
Serum apelin levels and body composition changes in breast cancer patients treated with an aromatase inhibitor.
Serum atrial natriuretic peptide: a suspected biomarker of breast cancer.
Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration.
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs).
Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane.
Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Severe immune thrombocytopenia during formestane treatment.
Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A.
Sex steroid-producing enzymes in human breast cancer.
Sex, eyes, and vision: male/female distinctions in ophthalmic disorders.
Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer.
Sexual dysfunction and infertility as late effects of cancer treatment.
Sexual Dysfunction in Survivorship; the Impact of Menopause and Endocrine Therapy.
Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer.
Sexual outcomes of aromatase inhibitor therapy in women with breast cancer: time for intervention.
Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.
Shear wave elastography detects novel imaging biomarkers of aromatase inhibitor-induced joint pain: a pilot study.
Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.
Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
Should aromatase inhibitors replace tamoxifen?
Should tamoxifen be used in breast cancer prevention?
Should We Offer Medication to Reduce Breast Cancer Risk?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Should women be advised to take prophylactic endocrine treatment outside of a clinical trial setting?
Shu-Gan-Liang-Xue Decoction Simultaneously Down-regulates Expressions of Aromatase and Steroid Sulfatase in Estrogen Receptor Positive Breast Cancer Cells.
Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens.
Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells.
Significance of aromatase activity in human breast cancer.
Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal Women.
Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment.
Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000.
Simple tandem repeat (TTTA)n polymorphism in CYP19 (aromatase) gene and breast cancer risk in Nigerian women.
Simultaneous quantification of abemaciclib and letrozole in rat plasma: method development, validation and pharmacokinetic application.
Singapore Cancer Network (SCAN) Guidelines for Bisphosphonate Use in the Adjuvant Breast Cancer Setting.
Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
Single CpG site methylation controls estrogen receptor gene transcription and correlates with hormone therapy resistance.
Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
Single or Multiple Access Channels to the CYP450s Active Site? An Answer from Free Energy Simulations of the Human Aromatase Enzyme.
Single- and Multi-Locus Association Tests Incorporating Phenotype Heterogeneity.
SIRT1 Positively Regulates Breast Cancer Associated Human Aromatase (CYP19A1) Expression.
Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance.
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Skeletal health in breast cancer survivors.
Skeletal health in postmenopausal survivors of early breast cancer.
SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
Sodium/potasium ATPase (Na(+), K(+)-ATPase) and ouabain/related cardiac glycosides: a new paradigm for development of anti- breast cancer drugs?
Sonographic and Electrodiagnostic Evaluations in Patients With Aromatase Inhibitor-Related Arthralgia.
Sources of estrogen and their importance.
SPANosomes as delivery vehicles for small interfering RNA (siRNA).
Special considerations in the evaluation and management of breast cancer in men.
Special issues related to breast cancer adjuvant therapy in older women.
Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.
Starfish polysaccharides downregulate metastatic activity through the MAPK signaling pathway in MCF-7 human breast cancer cells.
Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.
Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.
Statins and Breast Cancer: Future Directions in Chemoprevention.
Status of aromatase inhibitors in relation to other breast cancer treatment modalities.
Steroid and growth factor modulation of aromatase activity in MCF7 and T47D breast carcinoma cell lines.
Steroid dynamics in the normal and carcinomatous mammary gland.
Steroid enzyme and receptor expression and regulations in breast tumor samples - A statistical evaluation of public data.
Steroid modulation of aromatase activity in human cultured breast carcinoma cells.
Steroid sulfatase inhibitors: promising new therapy for breast cancer.
Steroid sulfatase inhibitors: Promising new tools for breast cancer therapy?
Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
Steroid sulphatase inhibitors for breast cancer therapy.
Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.
Steroid-metabolizing enzymes in human breast cancer cells. II. 5 alpha-Reductase, 3 alpha-hydroxysteroid oxidoreductase, and 17 beta-hydroxysteroid oxidoreductase.
Steroidal alkaloids efficient aromatase inhibitors with potential for the treatment of postmenopausal breast cancer.
Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1.
Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study.
Steroidal aromatase inhibitors inhibit growth of hormone-dependent breast cancer cells by inducing cell cycle arrest and apoptosis.
Steroidal carbonitriles as potential aromatase inhibitors.
Steroidal Metabolites Transformed by Marchantia polymorpha Cultures Block Breast Cancer Estrogen Biosynthesis.
Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha.
Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line.
Stimulation of human tumor xenograft growth by local estrogen biosynthesis in stromal cells.
Stopping treatment can reverse acquired resistance to letrozole.
Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options.
Strategies to prevent chemotherapy-induced bone loss in women with breast cancer.
Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial.
Stromal spindle cells contain aromatase in human breast tumors.
Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.
Structural basis for androgen specificity and oestrogen synthesis in human aromatase.
Structural insights into anticancer activity of D-ring modified estrone derivatives using their lipophilicity in estimation of SAR and molecular docking studies.
Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.
Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design.
Structure-activity relationships and binding model of novel aromatase inhibitors.
Structure-activity relationships of 2-, 4-, or 6-substituted estrogens as aromatase inhibitors.
Structure-activity relationships of estrogen derivatives as aromatase inhibitors. Effects of heterocyclic substituents.
Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation.
Structure-based design of potent aromatase inhibitors by high-throughput docking.
Structure-function studies of aromatase and its inhibitors: a progress report.
Studies on aromatase inhibitors. I. Synthesis and biological evaluation of 4-amino-4H-1,2,4-triazole derivatives.
Studies on non-steroidal inhibitors of aromatase enzyme; 4-(aryl/heteroaryl)-2-(pyrimidin-2-yl)thiazole derivatives.
Study design and methods for the using exercise to relieve joint pain and improve AI adherence in older breast cancer survivors (REJOIN) trial.
Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention.
Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women.
Subepithelial Corneal Deposits Associated with Exemestane.
Successful treatment of three synchronous primary malignant tumours-reflection on surgical, pathological and oncological aspects and decision making.
Successful Use of Biweekly Gemcitabine Plus Nab-Paclitaxel in Two Male Patients With Stage IV Breast Cancer: Case Reports and Review of the Literature.
Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer.
Suitable trial designs and cohorts for preventive breast cancer agents.
Sulindac, a Nonselective NSAID, Reduces Breast Density in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors.
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer.
Summary of aromatase inhibitor trials: the past and future.
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: Hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy.
Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial.
Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition.
Suppression of Nuclear Factor-?B by Glucocorticoid Receptor Blocks Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells.
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Surgical and oncological outcome after skin-sparing mastectomy and immediate breast reconstruction.
Surgical Findings and Outcomes in Premenopausal Breast Cancer Patients Undergoing Oophorectomy: A Multicenter Review From the Fellows' Pelvic Research Network.
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.
Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitors.
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Sushi Domain-Containing Protein 3: A Potential Target for Breast Cancer.
Sweet's Syndrome Induced by Aromatase Inhibitor in the Treatment of Early Breast Cancer.
Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials.
Switching to aromatase inhibitors in early breast cancer.
Switching to letrozole versus continued tamoxifen therapy in treatment of postmenopausal women with early breast cancer.
Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer.
Symptom Clusters in Women With Breast Cancer During the First 18 Months of Adjuvant Therapy.
Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer.
Symptoms: Aromatase Inhibitor Induced Arthralgias.
Synchronous presentation of breast cancer and hepatocellular carcinoma in a postmenopausal woman: dual action of aromatase inhibitor on breast and hepatic cancer cells?
Synergistic activity of letrozole and sorafenib on breast cancer cells.
Synergistic effect of CGS16949A and 5-fluorouracil on a human breast cancer cell line.
Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines.
Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione).
Synthesis and aromatase inhibitory activity of flavanones.
Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones.
Synthesis and Bioconversions of Formestane.
Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.
Synthesis and biological characterization of 3-(imidazol-1-ylmethyl)piperidine sulfonamides as aromatase inhibitors.
Synthesis and biological evaluation of (+/-)-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer.
Synthesis and Biological Evaluation of 1-(Diarylmethyl)-1H-1,2,4-triazoles and 1-(Diarylmethyl)-1H-imidazoles as a Novel Class of Anti-Mitotic Agent for Activity in Breast Cancer.
Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells.
Synthesis and docking study of benzimidazole-triazolothiadiazine hybrids as aromatase inhibitors.
Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors.
Synthesis and evaluation of novel 4-amino-4,6-androstadiene-3,17-dione: an analog of formestane.
Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug.
Synthesis of carbon-11 labeled sulfonanilide analogues as new potential PET agents for imaging of aromatase in breast cancer.
Synthesis of carbon-11-labeled casimiroin analogues as new potential PET agents for imaging of quinone reductase 2 and aromatase expression in breast cancer.
Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.
Synthesis, Aromatase Inhibitory, Antiproliferative and Molecular Modeling Studies of Functionally Diverse D-Ring Pregnenolone Pyrazoles.
Synthesis, structure elucidation, and biochemical evaluation of 7 alpha- and 7 beta-arylaliphatic-substituted androst-4-ene-3,17-diones as inhibitors of aromatase.
Synthesis, structure-activity relationships and molecular docking studies of phenyldiazenyl sulfonamides as aromatase inhibitors.
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer.
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Systemic therapy for breast cancer.
Systemic therapy.
Systemic treatment of breast cancer. Two decades of progress.
Systemic treatment of patients with early breast cancer: recent updates and state of the art.
T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients.
Tai chi for well-being of breast cancer survivors with aromatase inhibitor-associated arthralgias: a feasibility study.
Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Tamoxifen (selective estrogen-receptor modulators) and aromatase inhibitors as potential perioperative thrombotic risk factors in free flap breast reconstruction.
Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection.
Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature.
Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer.
Tamoxifen or aromatase inhibitors in breast cancer: efficacy and safety.
Tamoxifen Resistance: Emerging Molecular Targets.
Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Tamoxifen versus aromatase inhibitors for breast cancer prevention.
Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention.
Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
Tamoxifen--the treatment of choice. Why look for alternatives?
Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
Targeted cancer therapy--are the days of systemic chemotherapy numbered?
Targeted therapies in breast cancer.
Targeted Therapies: Treatment Options for Patients With Metastatic Breast Cancer.
Targeted therapy for breast cancer.
Targeting Aberrant p70S6K Activation for Estrogen Receptor Negative Breast Cancer Prevention.
Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast Cancer.
Targeting CDK4 and CDK6: From Discovery to Therapy.
Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death.
Targeting mixed lineage kinases in ER-positive breast cancer cells leads to G2/M cell cycle arrest and apoptosis.
Targeting the Breast Cancer Kinome.
Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient Population.
Targeting the HER/EGFR/ErbB Family to Prevent Breast Cancer.
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-?B Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response.
Testosterone and risk of breast cancer: appraisal of existing evidence.
Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.
Thalassosterol, a New Cytotoxic Aromatase Inhibitor Ergosterol Derivative from the Red Sea Seagrass Thalassodendron ciliatum.
The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer.
The adjuvant endocrine treatment revolution: focus on anastrozole.
The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy.
The Alternative Non-Coding Exons 1 of Aromatase (Cyp19) Gene Modulate Gene Expression in a Post-Transcriptional Manner.
The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.
The anti-aromatase effect of progesterone and of its natural metabolites 20alpha- and 5alpha-dihydroprogesterone in the MCF-7aro breast cancer cell line.
The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels.
The aromatase inhibitor letrozole restores FADS2 function in ER+ MCF7 human breast cancer cells.
The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: Ready for prime time?
The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer.
The aromatase inhibitors in early breast cancer: who, when and why?
The aromatase inhibitors in early breast cancer: who, when, and why?
The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
The association of osteoporosis knowledge and beliefs with preventive behaviors in postmenopausal breast cancer survivors.
The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
The beneficial androgenic action of steroidal aromatase inactivators in estrogen-dependent breast cancer after failure of nonsteroidal drugs.
The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer.
The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
The case for aromatase inhibitors use in Oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in Breast Cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
The causes and treatment of bone loss associated with carcinoma of the breast.
The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression.
The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.
The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
The circular RNome of primary breast cancer.
The citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice.
The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer.
The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.
The concurrent use of aromatase inhibitors and radiotherapy induces echocardiographic changes in patients with breast cancer.
The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death.
The control and biological importance of intratumoural aromatase in breast cancer.
The critical iron-oxygen intermediate in human aromatase.
The current status of aromatase inhibitors in the management of breast cancer.
The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers.
The CYP19A1 rs700519 Polymorphism and Breast Cancer Susceptibility in China: A Case-Control Study and Updated Meta-Analysis.
The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.
The direct proliferative stimulus of dehydroepiandrosterone on MCF7 breast cancer cells is potentiated by overexpression of aromatase.
The economic consequences of breast cancer adjuvant hormonal treatments.
The effect of adipocyte-macrophage cross-talk in obesity-related breast cancer.
The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer.
The effect of antiestrogen agents on risk of autoimmune disorders in patients with breast cancer.
The effect of aromatase inhibition on the cognitive function of older patients with breast cancer.
The effect of aromatase inhibitors on bone metabolism.
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results.
The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-beta 1 in metastatic human breast cancer: an immunocytochemical study.
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors :a systematic review and meta-analysis.
The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors.
The Effect of Exercise on the Alleviation of Side Effects Induced by Aromatase Inhibitors in Postmenopausal Breast Cancer Patients.
The effect of grape seed extract on estrogen levels of postmenopausal women: a pilot study.
The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications.
The effect of medroxyprogesterone acetate on aromatase and DNA polymerase alpha activities in breast tumours.
The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China.
The Effect of Risedronate on Hip Structural Geometry in Chemotherapy-Induced Postmenopausal Women on SERMs versus Aromatase Inhibitors: a Two Year Trial.
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy.
The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer.
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer.
The effects of Nobiletin, Hesperetin, and Letrozole in a combination on the activity and expression of aromatase in breast cancer cells.
The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
The effects of systemic aromatase inhibitors on meibomian glands and corneal structure.
The effects of the standardized extracts of Ginkgo biloba on steroidogenesis pathways and aromatase activity in H295R human adrenocortical carcinoma cells.
The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer.
The efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss for postmenopausal women with early breast cancer: a systematic review and meta-analysis.
The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer.
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
The emerging role of the new aromatase inhibitors in the treatment of breast cancer.
The endocrine prevention of breast cancer.
The Endocrine Society Centennial: 40 years of Aromatase Inhibitors as Targeted Therapy for Breast Cancer.
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators.
The Evolutionary Tale and Future Directions of Aromatase Inhibitors in Breast Carcinoma.
The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
The evolving role of aromatase inhibitors in adjuvant breast cancer therapy.
The evolving role of aromatase inhibitors in breast cancer.
The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.
The evolving role of letrozole in the adjuvant setting: First results from the large, phase III, randomized trial BIG 1-98.
The expanding use of third-generation aromatase inhibitors: what the general internist needs to know.
The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival.
The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.
The fight against tamoxifen resistance in breast cancer therapy: a new target in the battle?
The future of fulvestrant ("Faslodex").
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.
The human breast cancer cell line MDA-MB231 produces an aromatase stimulating activity.
The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters.
The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory.
The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.
The impact of an exercise program on quality of life in older breast cancer survivors undergoing aromatase inhibitor therapy: a randomized controlled trial.
The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions.
The impact of Catechol-O-methyl transferase knockdown on the cell proliferation of hormone-responsive cancers.
The impact of CYP19A1 variants and haplotypes on breast cancer risk, clinicopathological features and prognosis.
The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First-year results from the Compliance of ARomatase Inhibitors AssessmenT In Daily practice through Educational approach (CARIATIDE) study.
The impact of generic aromatase inhibitors on initiation, adherence, and persistence among women with breast cancer: Applying multi-state models to understand the dynamics of adherence.
The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer.
The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom.
The impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors.
The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.
The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
The importance of local synthesis of estrogen within the breast.
The increasing use of prophylactic mastectomy in the prevention of breast cancer.
The individual or combinational effects of Hesperetin and Letrozole on the activity and expression of aromatase in MCF-7 cells.
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.
The influence of endocrine treatments for breast cancer on health-related quality of life.
The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.
The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells.
The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
The inhibition of aromatase alters the mechanical and rheological properties of non-small-cell lung cancer cell lines affecting cell migration.
The interaction between aromatase, metalloproteinase 2,9 and cd44 in breast cancer.
The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy.
The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer.
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat.
The intracellular control of aromatase activity by 5 alpha-reduced androgens in human breast carcinoma cells in culture.
The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.
The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer.
The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7.
The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers.
The management of secondary osteoporosis.
The menopause, hormone replacement therapy and breast cancer.
The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial.
The NFkappaB pathway and endocrine-resistant breast cancer.
The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study.
The oestrogen-dependent biology of breast cancer. Sensitivity and resistance to aromatase inhibitors revisited: a molecular perspective.
The orphan nuclear receptor LRH-1 promotes breast cancer motility and invasion.
The overexpression of int-5/Aromatase, a novel MMTV integration locus gene, is responsible for D2 mammary tumor cell proliferation.
The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis.
The path to implementation of personalized medicine of aromatase inhibitors in patients with breast cancer.
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer.
The pharmacology of letrozole.
The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase.
The plant polyphenol butein inhibits testosterone-induced proliferation in breast cancer cells expressing aromatase.
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice.
The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum.
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
The potential adverse effects of aromatase inhibitors on wound healing: in vitro and in vivo evidence.
The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
The potential for aromatase inhibition in breast cancer prevention.
The potential of aromatase inhibitors in breast cancer prevention.
The potential role of estrogen in aromatase regulation in the breast.
The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)--a potent, selective aromatase inhibitor.
The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy: A Population-Based Cohort Study.
The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors.
The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression.
The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells.
The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2.
The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease.
The relationship between growth and androstenedione metabolism in four cell lines of human breast carcinoma cells in culture.
The Relationship Between Insomnia and Cognitive Impairment in Breast Cancer Survivors.
The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study.
The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
The relevance of preclinical models to the treatment of postmenopausal breast cancer.
The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop.
The Role of Androgens in Normal and Malignant Breast Tissue.
The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
The role of aromasin in the hormonal therapy of breast cancer.
The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
The role of aromatase in breast tumors.
The role of aromatase inactivators in the treatment of breast cancer.
The role of aromatase inhibitor (AI) in the treatment of breast cancer.
The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
The role of aromatase inhibitors in breast cancer.
The role of aromatase inhibitors in early breast cancer.
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
The role of COX-2 inhibition in breast cancer treatment and prevention.
The role of cyclooxygenase-2-dependent signaling via cyclic AMP response element activation on aromatase up-regulation by o,p'-DDT in human breast cancer cells.
The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer.
The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non Metastatic Breast Cancer
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
The role of genetic variability in drug metabolism pathways in breast cancer prognosis.
The role of Geriatric screening tool (G8) in predicting side effect in older patients during therapy with aromatase inhibitor.
The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.
The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model.
The role of kisspeptin on aromatase expression in breast cancer.
The role of letrozole (Femara(R)) in breast cancer therapy: A clinical review.
The Role of Long Noncoding RNAs in Antiestrogen Resistance in Breast Cancer: An Overview and Update.
The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer.
The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
The role of soybean extracts and isoflavones in hormone-dependent breast cancer: aromatase activity and biological effects.
The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis.
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
The SEEM: selective estrogen enzyme modulators in breast cancer.
The selective estrogen enzyme modulator (SEEM) in breast cancer.
The selective estrogen enzyme modulators in breast cancer: a review.
The significance of the expression of ERRalpha as a potential biomarker in breast cancer.
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.
The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells.
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.
The therapeutic potential of aromatase inhibitors.
The Therapeutic Potential of mTOR Inhibitors in Breast Cancer.
The therapeutic potential of novel aromatase inhibitors in breast cancer.
The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study.
The turnover of estrogen receptor ? by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.
The Use and Concurrent Use of Side Effect Controlling Medications Among Women on Aromatase Inhibitors.
The use of aromatase inhibitors in adjuvant therapy for early breast cancer.
The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
The use of concurrent hormonotherapy and radiotherapy does not deteriorate radiation-induced cardiac toxicity.
The use of simvastatin with aromasin in an ovariectomized rat model: effects on the skeletal system.
The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
The validation of new aromatase monoclonal antibodies for immunohistochemistry--a correlation with biochemical activities in 46 cases of breast cancer.
The Vascular Endothelial Growth Factor Receptor Inhibitor PTK787/ZK222584 Inhibits Aromatase.
The VES-13 and G-8 tools as predictors of toxicity associated with aromatase inhibitors in the adjuvant treatment of breast cancer in elderly patients: A single-center study.
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Theoretical Study of the Mechanism of Exemestane Hydroxylation Catalyzed by Human Aromatase Enzyme.
Theory-Guided Randomized Neural Networks for Decoding Medication-Taking Behavior.
Therapeutic approaches for protecting bone health in patients with breast cancer.
Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.
Therapeutic observations in MCF-7 aromatase xenografts.
Therapeutic options for aromatase inhibitor-associated arthralgia in breast cancer survivors: A systematic review of systematic reviews, evidence mapping, and network meta-analysis.
Therapeutic Options in the Management of Aromatase Inhibitor-Associated Bone Loss.
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
Third generation aromatase inhibitors and inactivators in the treatment and prevention of breast cancer
Third generation aromatase inhibitors in metastatic breast cancer patients failing tamoxifen. Randomized comparisons with megestrol acetate: a critical review.
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO).
Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors.
Tibolone and its delta-4, 7alpha-methyl norethisterone metabolite are reversible inhibitors of human aromatase.
Time and geographical variations in utilisation of endocrine therapy for breast cancer in Australia.
Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.
Time for a change in breast cancer therapy?
Tissue androgens and the endocrine autonomy of breast cancer.
Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.
Tissue-Selective Regulation of Aromatase Expression by Calcitriol: Implications for Breast Cancer Therapy.
Tissue-specific estrogen biosynthesis and metabolism.
Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis.
Tissue-specific regulation of aromatase promoter II by the orphan nuclear receptor LRH-1 in breast adipose stromal fibroblasts.
To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
Tobacco alkaloid derivatives as inhibitors of breast cancer aromatase.
Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
Tolerance of adjuvant letrozole outside of clinical trials.
Topical estrogen prescribing patterns for urogenital atrophy among women with breast cancer: results of a national provider survey.
Topical Estrogen Prescription Fill Rates for Women With a History of Breast Cancer Who Are Taking Hormone Therapy.
Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I/II Study.
Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model.
Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
Towards optimal management of ductal carcinoma in situ of the breast.
Towards understanding aromatase inhibitory activity via QSAR modeling.
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis.
Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysis.
Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors.
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
Transcriptional control of local estrogen formation by aromatase in the breast.
Transcriptional regulation of aromatase expression in human breast tissue.
Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells.
Transgenic introduction of androgen receptor into estrogen-receptor-, progesterone-receptor-, and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation.
Transient over-expression of estrogen receptor-alpha in breast cancer cells promotes cell survival and estrogen-independent growth.
Translational approaches for the prevention of estrogen receptor-negative breast cancer.
Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.
Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
Trastuzumab.
Treating elderly patients with hormone sensitive breast cancer: what do the data show?
Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
Treatment algorithms for hormone receptor-positive advanced breast cancer.
Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione.
Treatment of advanced breast cancer with formestane.
Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
Treatment of breast cancer with aromatase inhibitors--current status and future prospects.
Treatment of established breast cancer in post-menopausal women: role of aromatase inhibitors.
Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).
Treatment options in HR?/HER2? advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Treatment persistence evaluation of tamoxifen and aromatase inhibitors in breast cancer patients in early and late stage disease.
Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer.
Treatment sequence of aromatase inhibitors and radiotherapy and long-term outcomes of breast cancer patients.
Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.
Treatment with aromatase inhibitors and markers of cardiovascular disease.
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.
Treatment with Ruta graveolens 5CH and Rhus toxicodendron 9CH may reduce joint pain and stiffness linked to aromatase inhibitors in women with early breast cancer: results of a pilot observational study.
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.
Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer.
Trichostatin A down-regulates CYP19 transcript and protein levels in MCF-7 breast cancer cells.
Triggering of Suicidal Erythrocyte Death by Exemestane.
Trilostane in advanced breast cancer.
TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression.
Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.
Tumor biology in estrogen receptor-positive, human epidermal growth factor receptor type 2-negative breast cancer: Mind the menopausal status.
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors.
Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells.
Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer.
Tumour Lysis Syndrome in Occult Breast Cancer Treated With Letrozole - A Rare Occurrence. A Case Report and Review.
Twenty-years experience with de novo metastatic breast cancer.
Two cases of polycystic ovary syndrome with onset of severe ovarian hyperstimulation syndrome following controlled ovarian stimulation with aromatase inhibitors for fertility preservation before breast cancer treatment.
Two natural products, trans-phytol and (22E)-ergosta-6,9,22-triene-3?,5?,8?-triol, inhibit the biosynthesis of estrogen in human ovarian granulosa cells by aromatase (CYP19).
Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.
Ultrasensitive Serum Estradiol Measurement by Liquid Chromatography-Mass Spectrometry in Postmenopausal Women and Mice.
Understanding and optimizing bone health in breast cancer.
Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Understanding the mechanisms of aromatase inhibitor resistance.
Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
Unprovoked Vestibular Burning in Late Estrogen-Deprived Menopause: A Case Series.
Unravelling exemestane: From biology to clinical prospects.
Unveiling the mechanism of action behind the anti-cancer properties of cannabinoids in ER+ breast cancer cells: Impact on aromatase and steroid receptors.
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes.
Update of the BIG 1-98 Trial: where do we stand?
Update on alternative therapies for vulvovaginal atrophy.
Update on aromatase inhibitors in breast cancer.
Update on breast cancer prevention.
Update on clinical role of tamoxifen.
Update on endocrine therapy for breast cancer.
Update on estrogens and the skeleton.
Update on extended adjuvant therapy options in breast cancer.
Update on identifying and managing osteoporosis in women with breast cancer.
Update on the use of aromatase inhibitors in breast cancer.
Update on the use of aromatase inhibitors in early-stage breast cancer.
Updates on managing advanced breast cancer with palbociclib combination therapy.
Upfront adjuvant aromatase inhibitors in women with lobular breast cancer.
Upregulation of AIB1, aromatase and ER? provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival.
Urinary lead exposure and breast cancer risk in a population-based case-control study.
Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer.
Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.
Use of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer at German Breast Cancer Centers and University Hospitals - Results of an Enquiry (Adjuvant Endocrine Therapy Enquiry).
Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients.
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.
Use of aromatase inhibitors in breast carcinoma.
Use of Aromatase Inhibitors in IVF for Fertility Preservation of Non-Breast Cancer Patients: A Case Series.
Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density.
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Use of aromatase inhibitors in the adjuvant treatment of breast cancer.
Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.
Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body.
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Use of MR-based trabecular bone microstructure analysis at the distal radius for osteoporosis diagnostics: a study in post-menopausal women with breast cancer and treated with aromatase inhibitor.
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.
Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer.
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.
Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome.
Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole.
Usefulness of 22-oxa-1,25-dihydroxyvitamin D-3 (OCT) as a single agent or combined therapy with aromatase inhibitor (CGS 16949A) on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention.
Using multigene tests to select treatment for early-stage breast cancer.
Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Vaginal Atrophy in Breast Cancer Survivors: Attitude and Approaches Among Oncologists.
Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients.
Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer.
Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy.
Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.
Vaginal Gene Expression During Treatment With Aromatase Inhibitors.
Vaginal tamoxifen for treatment of vulvar and vaginal atrophy: Pharmacokinetics and local tolerance in a rabbit model over 28?days.
Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Vaginal Testosterone for Management of Aromatase Inhibitor-Related Sexual Dysfunction: An Integrative Review.
Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia.
Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
Vascular effects of aromatase inhibitors: data from clinical trials.
Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study.
Verapamil as a culprit of palbociclib toxicity.
Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy.
Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors.
Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase.
Vitamin D Compounds PRI-2191 and PRI-2205 Enhance Anastrozole Activity in Human Breast Cancer Models.
Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Vitamin D Deficiency in Postmenopausal Breast Cancer Survivors.
Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy.
Vitamin D intake may be a predictor of response to aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
Vitamin D supplementation and response to aromatase inhibitors in postmenopausal women with hormone-receptor positive breast cancer.
Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.
VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats.
Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group).
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group.
Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
Weight gain increases human aromatase expression in mammary gland.
Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors.
What do we know about the mechanisms of aromatase inhibitor resistance?
What is new in the surgical management and prevention of breast cancer?
Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel.
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation.
Whole Body Vibration Exposure on Markers of Bone Turnover, Body Composition, and Physical Functioning in Breast Cancer Patients Receiving Aromatase Inhibitor Therapy: A Randomized Controlled Trial.
Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes.
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1?,25-dihydroxyvitamin D3.
Withdrawal: EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells: Evidence of a BRCA1 and p300 exchange.
X-ray Structure of Human Aromatase Reveals An Androgen-Specific Active Site.
Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity.
Xenograft models for aromatase inhibitor studies.
Yoga versus massage in the treatment of aromatase inhibitor-associated knee joint pain in breast cancer survivors: a randomized controlled trial.
Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan.
Zeranol stimulates proliferation and aromatase activation in human breast preadipocytes.
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Zoledronic Acid Effectively Prevents Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results.
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Zoledronic acid inhibits aromatase activity and phosphorylation: Potential mechanism for additive zoledronic acid and letrozole drug interaction.
[ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
[A case of advanced breast cancer with multiple bone metastases responding to docetaxel and high-dose toremifene as fourth-line chemo-endocrine therapy]
[A case of aromatase inhibitor-tolerant metastatic breast cancer revealing complete remission with high-dose toremifene therapy].
[A Case of Cecal Cancer with Para-Aortic Lymph Node Metastasis and Peritoneum Dissemination Treated with Curative Resection after mFOLFOX6 plus Panitumumab Chemotherapy].
[A case of liver metastasis of breast cancer responding to letrozole].
[A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy]
[A Case of Recurrent Breast Cancer with Drug-Induced Interstitial Pneumonia Triggered by the Switch from an Original to a Generic Aromatase Inhibitor].
[A Case of Simultaneous Double Cancer with Gastric Metastasis of Breast Cancer and Lung Cancer].
[A combined effect of fadrozole and tamoxifen in postmenopausal patients with recurrent breast cancer: a preliminary report: Japanese Cooperative Study Group of Fadrozole and Tamoxifen]
[A cost-effectiveness study of first-line hormone therapy in post-menopausal patients with metastatic breast cancer on neoadjuvant treatment]
[A meta-analysis of the effectiveness of aromatase inhibitors as adjuvant treatment for postmenopausal patients with breast cancer]
[A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors].
[A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer].
[A successful case of advanced breast cancer of the elderly treated with the only breast-hormone therapy as PST]
[Activation of aromatase gene expression by RORalpha and GR expression in breast cancer tissue].
[Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer]
[Adjuvant chemotherapy of early stage breast cancer]
[Adjuvant endocrine therapy for breast cancer]
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: To lead, to switch or to extend?]
[An elderly advanced breast cancer with a good response to anastrozole]
[An immunohistochemical study of aromatase, estrogen 4-hydroxylase and fatty acid synthetase in breast cancer tissues from BRCA1 mutation carriers]
[Antiestrogen therapy in the treatment of breast neoplasms]
[Aromatase activity and its gene expression in tumor tissue of smokers and non-smokers with breast cancer]
[Aromatase activity in breast cancer tissue: the role of a cellular substrate]
[Aromatase activity in lymphocytes of cancer patients and healthy subjects]
[Aromatase and breast cancer]
[Aromatase antagonists in breast cancer]
[Aromatase expression in invasive and in situ ductal carcinoma present in the same breast.]
[Aromatase gene expression and its modifying factors in breast tumor tissue]
[Aromatase inhibitors and arthralgia].
[Aromatase inhibitors and inactivators in the treatment of advanced breast cancer]
[Aromatase inhibitors for metastasing breast cancer in postmenopausal women. A survey of a Cochrane review]
[Aromatase inhibitors in adjuvant setting in breast cancer]
[Aromatase inhibitors in advanced breast cancer]
[Aromatase inhibitors in breast cancer therapy]
[Aromatase inhibitors in risk reduction of breast cancer: potential use in premenopausal women]
[Aromatase inhibitors in the adjuvant therapy of breast cancer]
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas]
[Aromatase inhibitors in the adjuvant treatment of early breast cancer. Is there still a place for tamoxifen?]
[Aromatase inhibitors in the adjuvant treatment of postmenopausal patients with early breast cancer: a little, a lot or no way?]
[Aromatase inhibitors in the therapy for breast cancer]
[Aromatase inhibitors in the treatment of breast cancer]
[Aromatase inhibitors--new applications in gynecology]
[Aromatase inhibitors--new horizons in breast cancer endocrine therapy]
[Aromatase inhibitors--new possibilities in treatment of breast carcinoma]
[Aromatase inhibitors: a review of clinical trials]
[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer]
[Aromatase inhibitors: pharmacological aspects]
[Aromatase inhibitors]
[Assessment of the quality of life of women with breast cancer in adjuvant treatment with tamoxifen or aromatase inhibitors--a randomized trial].
[Association of CYP19A1 gene rs7176005 single nucleotide polymorphism with breast cancer risk and clinicopathologic features of tumor].
[Bone and calcium metabolism associated with malignancy. Clinical Characteristics and Treatment of Cancer Treatment Induced Bone Loss(CTIBL)in Breast Cancer.]
[Bone and calcium metabolism associated with malignancy. Endocrine therapy of breast cancer.]
[Bone and Men's Health. Effects of aromatase inhibitors on human osteoblasts]
[Breast cancer adjuvant endocrine treatment].
[Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)]
[Cancer treatment-induced bone loss. Treatment for breast cancer]
[CGS 20267 (Letrozole), a new aromatase inhibitor: early phase II study for postmenopausal women with advanced breast cancer]
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group]
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group]
[Chemo/endocrine therapy for breast cancer patients]
[Chemoprevention of breast cancer: a literature review and report on the current status in Germany]
[Chemoprevention of breast cancer: exemestane ready to be tested in study setting].
[Circulating Levels of Estradiol in Breast Cancer Patients Treated with Aromatase Inhibitors and Their Clinical Implications].
[Clinical study of anastrozole in the treatment of postmenopausal women with advanced breast cancer]
[Clinical study of aromatase inhibitors in advanced breast cancer]
[Clinical trial on exemestane in the treatment of postmenopausal women with advanced breast cancer]
[Clinicopathological significance of aromatase expression in breast cancers]
[Combination of trastuzumab, aromatase inhibitor and anti-cancer drugs obtained a good prognosis for an inoperable stage III B breast cancer patient with giant skin ulceration].
[Consensus recommendations for the clinical application of CDK4/6 inhibitors in patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer].
[Correlation between tumor tissue aromatase, histological pattern and reproductive status in patients with breast cancer]
[Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cancer]
[Current adjuvant endocrine treatment of breast cancer]
[Current developments in systemic therapy of breast carcinoma]
[CURRENT PERSPECTIVE ON SYSTEMIC THERAPY FOR BREAST CANCER].
[Current status and prospectives of aromatase inhibitors in the treatment of advanced breast cancer]
[Current status of breast cancer chemoprevention]
[CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients]
[Determination of intratumoral estrone (E1) and estradiol (E2) in primary breast cancer tissues by sensitive HPLC-RIA]
[Developments in endocrine therapy for breast cancer]
[Effect of aromatase inhibitors on bone metabolism]
[Effect of R264C polymorphism in CYP19A1 gene on BRCA1/2-negative hereditary breast cancer from Shanghai population of China.]
[Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer].
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
[Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors]
[Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor].
[Efficacy of oxycodone against anti-cancer agent-induced pain in breast cancer patients during adjuvant treatment before and after surgery].
[Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment]
[Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
[Endocrine therapy for breast cancer: past and present].
[Endocrine therapy of causation: role of aromatase inhibitors in breast cancer]
[Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model].
[Evaluation of aromatase inhibitors' side effects in clinical and experimental studies]
[Evaluation of menopause and treatment choice of breast cancer patients before endocrine therapy].
[Evaluation of Patient Adherence to Anastrozole Therapy for Breast Cancer].
[Everolimus Plus Exemestane in Postmenopausal Patients with Estrogen-Receptor-Positive Advanced Breast Cancer - Japanese Subgroup Analysis ofBOLERO -2].
[Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer]
[Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].
[Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients]
[Fertility preservation in women with oncologic disease].
[Fulvestrant (Faslodex®) for hormone sensitive breast cancer. A review].
[Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer]
[Growth inhibition of MCF-7 human breast cancer cells by aromatase inhibitors]
[Hormonal therapy with aromatase inhibitor in advanced breast cancer]
[Hormone therapy in breast cancer: the end of tamoxifen?]
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
[Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor-Resistant Metastatic Breast Cancer].
[Indoleamine 2,3-dioxygenase activity during toremifene therapy for aromatase inhibitor-resistant metastatic breast cancer].
[Interrelationship between response to neoadjuvant hormone therapy and hormonal-metabolic status in breast cancer patients]
[Intracrinology of human breast carcinoma and aromatase]
[Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer]
[Late phase II study of CGS16949A, a new aromatase inhibitor--a multicentral cooperative study (Western Japan Group)]
[Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents]
[Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]
[Local production of estrogen via aromatase and estrone sulfatase in breast cancer tissue]
[Management of aromatase inhibitor-related bone health in postmenopausal patients with early breast cancer: Chinese expert consensus].
[Metabolic effect of tobacco smoke and "switching" the estrogen effect: mechanism of increased genotoxicity]
[Metformin does not suppress the aromatase expression in breast cancer tissue of patients with concurrent type 2 diabetes].
[Molecular mechanism of inhibition of sodium butyrate on activation of tumor associated aromatase promoters]
[Natural remedies and hormone preparations--potential risk for breast cancer patients. A study surveys the use of agents which possibly counteract with the treatment]
[Neoadjuvant endocrine therapy for breast cancer: an overview]
[New developments in hormonal therapy for breast cancer]
[New developments in the hormonal treatment of breast cancer in postmenopausal women]
[New drugs in metastatic breast cancer--1997]
[New drugs in therapy of breast carcinoma: current status and outlook]
[New period of systemic treatment for breast cancer]
[On "2015 Guidelines for Prevention and Treatment of Osteoporosis" . Osteoporosis associated with sex hormone depletion treatment].
[Oncology]
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole]
[Pancytopenia, hepatosplenomegaly and dry cough after breast cancer]
[Pharmacological and clinical profile of exemestane (Aromasin), a novel irreversible aromatase inhibitor]
[Phase I study of CGS16949A--a new aromatase inhibitor. Cooperative Study Group for CGS16949A]
[Phase II study of CGS16949A, a new aromatase inhibitor--a dose finding study]
[Potential for using aromatase inhibitors for preventing breast cancer]
[Preclinical evaluation of aromatase inhibitors antitumor activity]
[Pregnancy after Treatment of Breast Cancer].
[Prevention and treatment of aromatase inhibitor-associated bone loss by shugan jiangu recipe in postmenopausal women with breast cancer: a clinical study].
[Progress in breast cancer treatment over a quarter of a century]
[Progress in study of the structure, catalytic mechanism and inhibitors of aromatase].
[Quantitative competitive RT-PCR method in analysis of aromatase expression in breast cancer]
[Recent evidence about aromatase in the breast carcinoma]
[Risks associated with phytoestrogen dietary supplementation and adjuvant hormonal therapy for breast cancer].
[Role for aromatase inhibitors as adjuvant treatment of breast cancer in menopaused women: facts and questions in 2005]
[San Antonio Breast Cancer Symposium -- highlights 2004]
[Secondary osteoporosis. Cancer treatment-induced bone loss.]
[Sequential changes in hormone levels in postmenopausal breast cancer patients under long-term treatment with an aromatase inhibitor. Kanagawa AI Study Group]
[Steroid sulfatase inhibitor]
[Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen]
[Synthesis and biological evaluation of indole derivatives acting as anti-inflammatory or antitumoral drugs]
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects]
[Tamoxifen in the adjuvant setting for breast cancer: Reflexions about the risk of uterine carcinosarcoma.]
[The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer].
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile]
[The use of aromatase inhibitors in children]
[Therapeutic advances in breast cancer]
[Therapeutic progress in gynecology: organic diseases]
[Treatment effect of breast cancer and prostate cancer on bone.]
[Treatment of bone loss associated with breast cancer:a review.]
[Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
[Tumor tissue aromatase and estrogen levels versus clinical course of endometrial cancer]
[Two new therapeutic principles in the management of breast cancer and colorectal cancer: selective oral aromatase inhibition and thymidilate synthase inhibition]
[Use of aromatase and its inhibitors in dealing with different oncological pathologies other than breast cancer]
Breast Neoplasms, Male
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study.
Aromatase expression and its localization in human breast cancer.
Aromatase inhibition in male breast cancer patients: biological and clinical implications.
Aromatase inhibitors and male breast cancer.
Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations.
Aromatase inhibitors in male breast cancer: a pooled analysis.
Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series.
Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature.
Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray.
Contemporary systemic therapy for male breast cancer.
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors.
Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer.
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Leuprolide acetate plus aromatase inhibition for male breast cancer.
Male breast cancer is not congruent with the female disease.
Male breast carcinoma: increased awareness needed.
Pharmacotherapy for male breast cancer.
Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis.
Successful Use of Biweekly Gemcitabine Plus Nab-Paclitaxel in Two Male Patients With Stage IV Breast Cancer: Case Reports and Review of the Literature.
Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.
[Biological and clinical implications of aromatase inhibitors in early male breast cancer patients].
Brenner Tumor
Brenner tumor of the ovary: immunoanalysis of steroidogenic enzymes in 23 cases.
Carcinogenesis
4-Hydroxyandrostenedione in the prophylaxis of N-methyl-N-nitrosourea induced mammary tumourigenesis.
A novel nonradioactive method for measuring aromatase activity using a human ovarian granulosa-like tumor cell line and an estrone ELISA.
Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: A population-based study.
Aromatase and prostate cancer.
Aromatase expression is increased in BRCA1 mutation carriers.
Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention.
Aromatase inhibition by 2-methyl indole hydrazone derivatives evaluated via molecular docking and in vitro activity studies.
Aromatase overexpression induces malignant changes in estrogen receptor ? negative MCF-10A cells.
Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affecting normal physiology.
Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone.
Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.
Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats.
Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications.
Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis.
Cytochrome P450 aromatase expression in human seminoma.
Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor.
Dietary Supplementation with Methylseleninic Acid Inhibits Mammary Tumorigenesis and Metastasis in Male MMTV-PyMT Mice.
Differential expression of steroidogenic factor-1/adrenal 4 binding protein and liver receptor homolog-1 (LRH-1)/fetoprotein transcription factor in the rat testis: LRH-1 as a potential regulator of testicular aromatase expression.
Effect of the aromatase inhibitor vorozole on estrogen and progesterone receptor content of rat mammary carcinomas induced by 1-methyl-1-nitrosourea.
Effects of aminoglutethimide, alone and in combination with surgical castration, on pancreatic carcinogenesis in rats and hamsters.
Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms.
Effects of high fat diet-induced obesity on mammary tumorigenesis in the PyMT/MMTV murine model.
Effects of tamoxifen, an antiestrogen, on rat prostate carcinogenesis by 3,2'-dimethyl-4-aminobiphenyl and testosterone do not support an estrogen role in testosterone promotion.
Elevated aromatase expression correlates with cervical carcinoma progression.
Estrogen and prostate cancer: An eclipsed truth in an androgen-dominated scenario.
Estrogen receptor alpha is required for mammary development and the induction of mammary hyperplasia and epigenetic alterations in the aromatase transgenic mice.
Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer.
Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.
HER-2/neu x aromatase double transgenic mice model: the effects of aromatase overexpression on mammary tumorigenesis.
High TGFbeta1, estrogen receptor, and aromatase gene expression in a large cell calcifying sertoli cell tumor (LCCSCT): implications for the mechanism of oncogenesis.
Histamine H4 receptor as a novel therapeutic target for the treatment of Leydig-cell tumours in prepubertal boys.
Induction of quinone reductase by tamoxifen or DPN protects against mammary tumorigenesis.
Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?
Local adipocytes enable estrogen-dependent breast cancer growth: Role of leptin and aromatase.
Lung cancer in women in 21th century.
Mammary steroid metabolizing enzymes in relation to hyperplasia and tumorigenesis in the dog.
New insights on the role of hormonal therapy in ovarian cancer.
Obacunone exhibits anti-proliferative and anti-aromatase activity in vitro by inhibiting the p38 MAPK signaling pathway in MCF-7 human breast adenocarcinoma cells.
Oestrogen producing enzymes and mammary carcinogenesis: a review.
Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice.
Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis.
Polymorphisms in androgen metabolism genes AR, CYP1B1, CYP19, and SRD5A2and prostate cancer risk and aggressiveness in Bulgarian patients.
Polymorphisms in the CYP19A1 (Aromatase) gene and endometrial cancer risk in Chinese women.
Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro.
Preventive effects of letrozole in the model of premenopausal mammary carcinogenesis.
Rainbow trout, Oncorhynchus mykiss, as a model for aromatase inhibition.
Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast.
Side effects of anastrozole in the experimental pre-menopausal mammary carcinogenesis.
Stroma-mediated expression of estrogen and its role in cancer.
Synthesis of Resveratrol Derivatives and In Vitro Screening for Potential Cancer Chemopreventive Activities.
The citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice.
The CYP19A1 (TTTA)n Repeat Polymorphism May Affect the Prostate Cancer Risk: Evidence from a Meta-Analysis.
The CYP19A1 rs700519 Polymorphism and Breast Cancer Susceptibility in China: A Case-Control Study and Updated Meta-Analysis.
The interaction between aromatase, metalloproteinase 2,9 and cd44 in breast cancer.
Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis.
Zeranol stimulates proliferation and aromatase activation in human breast preadipocytes.
[Aromatase inhibitors in risk reduction of breast cancer: potential use in premenopausal women]
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
Carcinoma
7 alpha-substituted androstenediones as effective in vitro and in vivo inhibitors of aromatase.
7,8-Dihydroxycoumarin exerts antitumor potential on DMBA-induced mammary carcinogenesis by inhibiting ER?, PR, EGFR, and IGF1R: involvement of MAPK1/2-JNK1/2-Akt pathway.
A comparison of human H295R and rat R2C cell lines as in vitro screening tools for effects on aromatase.
A novel nonradioactive method for measuring aromatase activity using a human ovarian granulosa-like tumor cell line and an estrone ELISA.
Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma.
Adverse Drug Event-based Stratification of Tumor Mutations: A Case Study of Breast Cancer Patients Receiving Aromatase Inhibitors.
Antitumor and endocrine effects of an aromatase inhibitor (CGS 16949A) on DMBA-induced rat mammary tumor.
Aromatase activity in an estrogen-producing adrenocortical carcinoma in a young man.
Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma.
Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast.
Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study.
Aromatase cytochrome P450 gene expression in endometrial carcinoma.
Aromatase expression and its localization in human breast cancer.
Aromatase expression in normal human oral keratinocytes and oral squamous cell carcinoma.
Aromatase in colon carcinoma.
Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations.
Aromatase in human common epithelial ovarian neoplasms.
Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies.
Aromatase in human liver and its diseases.
Aromatase in human lung carcinoma.
Aromatase in hyperplasia and carcinoma of the human prostate.
Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures.
Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report.
Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
Aromatase inhibitors: their biochemistry and clinical potential.
Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells.
Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women.
Biochemical and pharmacological development of steroidal inhibitors of aromatase.
Biochemistry and pharmacology of 7alpha-substituted androstenediones as aromatase inhibitors.
Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast.
Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland.
Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole.
Clinicopathological Significance of Estrogen Receptor ? and Estrogen Synthesizing/Metabolizing Enzymes in Urothelial Carcinoma of Urinary Bladder.
Co-expression of estrogen receptor beta and aromatase in Japanese lung cancer patients: Gender-dependent clinical outcome.
Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma.
Comparison of Increased Aromatase versus ER{alpha} in the Generation of Mammary Hyperplasia and Cancer.
Controversies of aromatase localization in human breast cancer--stromal versus parenchymal cells.
Correlation of aromatase activity and steroid receptors in human ovarian carcinoma.
Cytochrome P450 aromatase gene (CYP19) expression in gastric cancer.
De novo expression of aromatase in gastric carcinoma. Light and electron microscopic immunohistochemical and immunoblot study.
Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
Effect of combined lignan phytoestrogen and melatonin treatment on secretion of steroid hormones by adrenal carcinoma cells.
Effect of the aromatase inhibitor vorozole on estrogen and progesterone receptor content of rat mammary carcinomas induced by 1-methyl-1-nitrosourea.
Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma.
Effects of bisphenol A-related diphenylalkanes on vitellogenin production in male carp (Cyprinus carpio) hepatocytes and aromatase (CYP19) activity in human H295R adrenocortical carcinoma cells.
Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat.
Effects of Femara and Tamoxifen on Proliferation of FM3A Cells in Culture.
Effects of Obesity and Obesity-Related Molecules on Canine Mammary Gland Tumors.
Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione in MCF-7 human mammary carcinoma cell culture.
Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione on 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.
Elevated aromatase expression correlates with cervical carcinoma progression.
Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors.
Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review.
Epitope characterization of an aromatase monoclonal antibody suitable for the assessment of intratumoral aromatase activity.
Estrogen biosynthesis in human H295 adrenocortical carcinoma cells.
Estrogen secreting adrenal adenocarcinoma in an 18-month-old boy: aromatase activity, protein expression, mRNA and utilization of gonadal type promoter.
Everolimus.
Expression of aromatase and estrogen receptors in human adrenocortical tumors.
Flavonoid inhibition of aromatase enzyme activity in human preadipocytes.
From Endocrinology to Intracrinology.
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis.
Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders.
Immunolocalization of aromatase in human breast disorders using different antibodies.
Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival.
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology.
Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation.
Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.
Inhibition of aromatase activity and growth suppression by 4-methoxy-4-androstene-3,17-dione in an androgen sensitive human prostatic carcinoma cell line.
Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer.
Intratumoral aromatase in human breast, endometrial, and ovarian malignancies.
Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
Intratumoral estrogen production in breast carcinoma: significance of aromatase.
Intratumoral localization and activity of 17?-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor.
Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment.
Lack of evidence for aromatase expression in human ovarian epithelial carcinoma.
Multiple parameter analyses of human ovarian cancer: morphology, immunohistochemistry, steroid hormone receptors and aromatase.
Oestrogen receptor ? in adenoid cystic carcinoma of salivary glands.
Oestrogens and androgen receptors in oral squamous cell carcinoma.
Optimization of a classical aromatase activity assay and application in normal, adenomatous and malignant breast parenchyma.
Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma.
Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Retinol inhibits aromatase activity and expression in vitro.
Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.
Sex steroid-producing enzymes in human breast cancer.
Sex-steroid enzymes, aromatase and 5 alpha-reductase in the pancreas: a comparison of normal adult, foetal and malignant tissue.
Targeting the HER/EGFR/ErbB Family to Prevent Breast Cancer.
The effects of anastrozole on the proliferation of FM3A cells.
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells.
Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma.
Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5alpha-reductase and steroid aromatase.
[Aromatase activities of endometrial carcinomas and both basic and clinical analyses of endometrial hyperplasia as a premalignant disease]
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole]
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
Carcinoma in Situ
Targeting the HER/EGFR/ErbB Family to Prevent Breast Cancer.
Carcinoma, Adenoid Cystic
Oestrogen receptor ? in adenoid cystic carcinoma of salivary glands.
Carcinoma, Adenosquamous
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
Carcinoma, Ductal
Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma.
Aromatase inhibitors and breast cancer prevention.
Aromatase inhibitors for hormonal therapy of early-stage breast cancer.
Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer.
Breast Ductal Carcinoma In Situ: A Literature Review of Adjuvant Hormonal Therapy.
Bs18 dcis and treatment.
Comparison of Increased Aromatase versus ER{alpha} in the Generation of Mammary Hyperplasia and Cancer.
Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma.
Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer.
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.
Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.
Local aromatase activity alterations in breast cancer tissues: A potential way of decision support for clinicians.
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast.
Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer.
Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast.
The interaction between aromatase, metalloproteinase 2,9 and cd44 in breast cancer.
The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
The validation of new aromatase monoclonal antibodies for immunohistochemistry--a correlation with biochemical activities in 46 cases of breast cancer.
[Aromatase expression in invasive and in situ ductal carcinoma present in the same breast.]
Carcinoma, Embryonal
Microsomal aromatase in testicular tumour tissue: increased activity in choriocarcinoma compared to embryonal carcinoma.
Carcinoma, Endometrioid
Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer.
Carcinoma, Hepatocellular
A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype.
Aromatase (CYP19) promoter gene polymorphism and risk of nonviral hepatitis-related hepatocellular carcinoma.
Aromatase activity in human hepatocellular carcinoma. Relationship with the degree of histologic differentiation.
Aromatase in human liver and its diseases.
Aromatase inhibitors may be effective in the management of advanced hepatocellular carcinoma.
Estrogen biosynthesis in human liver--a comparison of aromatase activity for C-19 steroids in fetal liver, adult liver and hepatoma tissues of human subjects.
Estrogen signalling through amphiregulin may be implicated in human hepatocellular carcinoma.
High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child.
Immunochemical specificity of placental NADPH cytochrome c (P-450) reductase in neoplastic and non-neoplastic human tissue.
Local estrogen formation by nontumoral, cirrhotic, and malignant human liver tissues and cells.
Merlin, the product of NF2 gene, is associated with aromatase expression and estrogen formation in human liver tissues and liver cancer cells.
Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma.
Synchronous presentation of breast cancer and hepatocellular carcinoma in a postmenopausal woman: dual action of aromatase inhibitor on breast and hepatic cancer cells?
The use of rat Leydig tumor (R2C) and human hepatoma (HEPG2) cells to evaluate potential inhibitors of rat and human steroid aromatase.
Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor.
Carcinoma, Intraductal, Noninfiltrating
Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast.
Aromatase expression in atypical ductal hyperplasia in women.
Aromatase inhibitors and breast cancer prevention.
Aromatase inhibitors for hormonal therapy of early-stage breast cancer.
Breast Ductal Carcinoma In Situ: A Literature Review of Adjuvant Hormonal Therapy.
Bs18 dcis and treatment.
Cell polarity, epithelial-mesenchymal transition, and cell-fate decision gene expression in ductal carcinoma in situ.
Comparison of Increased Aromatase versus ER{alpha} in the Generation of Mammary Hyperplasia and Cancer.
Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Current management of ductal carcinoma in situ of the breast.
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
DCIS and aromatase inhibitors.
Ductal carcinoma in situ: trends in treatment over time in the US.
Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ.
Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer.
Immunolocalization of thymidylate synthase as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.
Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.
Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
Quantitative assessment of mammographic breast density: relationship with breast cancer risk.
Recent advances and current controversies in the management of DCIS of the breast.
Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast.
Tamoxifen Initiation After Ductal Carcinoma In Situ.
The interaction between aromatase, metalloproteinase 2,9 and cd44 in breast cancer.
The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
Towards optimal management of ductal carcinoma in situ of the breast.
Treatment of ductal carcinoma in situ of the breast: review of recent advances and future prospects.
[Aromatase expression in invasive and in situ ductal carcinoma present in the same breast.]
Carcinoma, Lobular
Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma.
Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K Variant.
Carcinoma, Non-Small-Cell Lung
Aromatase in human lung carcinoma.
Aromatase inhibitors in human lung cancer therapy.
Changes in aromatase (CYP19) gene promoter usage in non-small cell lung cancer.
Estrogen receptor 1 gene expression and its combination with estrogen receptor 2 or aromatase expression predicts survival in non-small cell lung cancer.
Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.
Expression of aromatase CYP19 and its relationship with parameters in NSCLC.
Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer.
Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment.
Prognostic relevance of estrogen receptor ?, ? and aromatase expression in non-small cell lung cancer.
Targeting aromatase and estrogen signaling in human non-small cell lung cancer.
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Carcinoma, Ovarian Epithelial
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
Aromatase expression in ovarian epithelial cancers.
Aromatase inhibitors in gynecologic cancers.
Endocrine therapy in epithelial ovarian cancer.
From Endocrinology to Intracrinology.
Lack of evidence for aromatase expression in human ovarian epithelial carcinoma.
Carcinoma, Papillary
Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved.
Carcinoma, Renal Cell
Everolimus.
Carcinoma, Squamous Cell
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
Carcinosarcoma
Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report.
Cardiotoxicity
Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter.
Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.
Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients.
Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer.
Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer.
Cardiovascular Diseases
Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner.
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.
Aromatase inhibitors as potential cancer chemopreventives.
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review.
Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study.
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition.
Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients.
Cardiovascular Disease After Aromatase Inhibitor Use.
Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment.
Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels.
Effect of Aromatase Inhibitor Therapy on the Cardiovascular Health of Black and White Breast Cancer Patients.
Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.
Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer.
Improving quality of life after breast cancer: prevention of other diseases.
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis.
Treatment with aromatase inhibitors and markers of cardiovascular disease.
Carney Complex
High TGFbeta1, estrogen receptor, and aromatase gene expression in a large cell calcifying sertoli cell tumor (LCCSCT): implications for the mechanism of oncogenesis.
Carotid Stenosis
Treatment with aromatase inhibitors and markers of cardiovascular disease.
Carpal Tunnel Syndrome
Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice.
Aromatase Inhibitor-Induced Carpal Tunnel Syndrome: Results From the ATAC Trial.
Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis.
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer.
Correction to: Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice.
Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
Rheumatic disorders and functional disability with aromatase inhibitor therapy.
Cataract
Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer.
Estradiol biosynthesis in canine lens epithelial cells.
Cecal Neoplasms
[A Case of Cecal Cancer with Para-Aortic Lymph Node Metastasis and Peritoneum Dissemination Treated with Curative Resection after mFOLFOX6 plus Panitumumab Chemotherapy].
Cerebral Infarction
Aromatase and neuroinflammation in rat focal brain ischemia.
Chickenpox
Aromatase Derived Estradiol Within the Thalamus Modulates Pain Induced by Varicella Zoster Virus.
Corrigendum: Aromatase Derived Estradiol Within the Thalamus Modulates Pain Induced by Varicella Zoster Virus.
Cholangiocarcinoma
The Importance of CYP19A1 in Estrogen Receptor-Positive Cholangiocarcinoma.
Cholangitis
Aromatase in normal and diseased liver.
Cholangitis, Sclerosing
Aromatase in normal and diseased liver.
Cholera
Aromatization of androgens by human adipose tissue in vitro.
Differential effects of luteinizing hormone-releasing hormone on follicle-stimulating hormone-dependent responses in rat granulosa cells and Sertoli cells in vitro.
Factors affecting the conversion of androstenedione to estrogens by human fetal hepatocytes in monolayer culture.
Gonadotropic regulation of aromatase activity in the adult rat testis.
Modulation of FSH-controlled steroidogenesis in rat granulosa cells: direct in-vitro effects of LHRH and ICI-118630.
Progestins inhibit FSH-stimulated granulosa estrogen production at a post-cAMP site.
Regulation of aromatase cytochrome P-450 and 17 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels in choriocarcinoma cells.
Site of action of androgens on follicle-stimulating hormone-induced aromatase activity in cultured rat granulosa cells.
The role of cyclic AMP in the induction of estrogen and progestin synthesis in cultured granulosa cells.
[Regulation of aromatase in human choriocarcinoma cells]
Cholestasis, Intrahepatic
Intrahepatic cholestasis of pregnancy impairs the activities of human placental xenobiotic and steroid metabolizing enzymes in vitro.
Chondrosarcoma
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo.
Choriocarcinoma
17alpha-methyl testosterone is a competitive inhibitor of aromatase activity in Jar choriocarcinoma cells and macrophage-like THP-1 cells in culture.
Aromatase in the human choriocarcinoma JEG-3: inhibition by R 76 713 in cultured cells and in tumors grown in nude mice.
Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production.
Aromatase inhibition by 7-substituted steroids in human choriocarcinoma cell culture.
Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures.
Aromatase inhibition by R 83 842, the dextro isomer of R 76 713, in JEG-3 choriocarcinoma grown in ovariectomized nude mice.
Aromatase inhibition in JAr choriocarcinoma cells by 7alpha-arylaliphatic androgens.
Assessment of steroidogenic pathways that do not require testosterone as intermediate.
Biochemical and pharmacological development of steroidal inhibitors of aromatase.
Biochemistry and pharmacology of 7alpha-substituted androstenediones as aromatase inhibitors.
Characterization of a cis-acting regulatory element involved in human-aromatase P-450 gene expression.
Characterization of steroid production in cultured human choriocarcinoma cells.
Currently used pesticides and their mixtures affect the function of sex hormone receptors and aromatase enzyme activity.
Cytotoxicity and aromatase (CYP19) activity modulation by organochlorines in human placental JEG-3 and JAR choriocarcinoma cells.
Differential toxicity of alkylphenols in JEG-3 human placental cells: alteration of P450 aromatase and cell lipid composition.
Effect of triptolide on aromatase activity in human placental microsomes and human placental JEG-3 cells.
Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity.
Effects of some persistent halogenated environmental contaminants on aromatase (CYP19) activity in the human choriocarcinoma cell line JEG-3.
Endocrine disruption induced by organotin compounds; organotins function as a powerful agonist for nuclear receptors rather than an aromatase inhibitor.
Estrogen synthetase (aromatase) in cultured human term placental cells and neoplastic human trophoblast.
Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Induction of aromatase gene expression in human placental choriocarcinoma (JAR) cells by phorbol esters.
Inhibition of cyclic AMP-triggered aromatase gene expression in human choriocarcinoma cells by antisense oligodeoxynucleotide.
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors.
Lack of aromatisation of the 3-keto-4-ene metabolite of tibolone to an estrogenic derivative.
Let-7g inhibits synthesis of estradiol by downregulating activity of aromatase in JEG3 cells.
Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture.
Microsomal aromatase in testicular tumour tissue: increased activity in choriocarcinoma compared to embryonal carcinoma.
Modulation of aromatase activity and mRNA by various selected pesticides in the human choriocarcinoma JEG-3 cell line.
Modulation of aromatase activity by diet polyphenolic compounds.
Modulation of estradiol synthesis and aromatase activity in human choriocarcinoma JEG-3 cells exposed to tetrabromobisphenol A.
Molecular cloning of a cDNA showing alternative splicing of the 5'-untranslated sequence of mRNA for human aromatase P-450.
Molecular targets of organotin compounds in endocrine disruption: do organotin compounds function as aromatase inhibitors in mammals?
Nicotine, cotinine, and anabasine inhibit aromatase in human trophoblast in vitro.
No evidence for the in vivo activity of aromatase-inhibiting flavonoids.
Peripheral precocious puberty in a girl with an intracranial hCG-producing tumor: case report and literature review.
Pharmacology of vorozole.
Placental Aromatase Is Deficient in Placental Ischemia and Preeclampsia.
Prostaglandin J2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: potential implications for breast cancer therapy.
Regulation of aromatase cytochrome P-450 and 17 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels in choriocarcinoma cells.
Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women.
Role of protein kinase A in regulating steroid sulfate uptake for estrogen production in human placental choriocarcinoma cells.
Selective aromatase inhibition by pyridoglutethimide, an analogue of aminoglutethimide.
Serotonin and serotonin reuptake inhibitors alter placental aromatase.
Steroidal inhibitors as chemical probes of the active site of aromatase.
Stimulation of serotonergic 5-HT(2A) receptor signaling increases placental aromatase (CYP19) activity and expression in BeWo and JEG-3 human choriocarcinoma cells.
The Inhibitory Effects of the Standardized Extracts of Ginkgo biloba on Aromatase Activity in JEG-3 Human Choriocarcinoma Cells.
Tibolone and its delta-4, 7alpha-methyl norethisterone metabolite are reversible inhibitors of human aromatase.
Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions.
Trialkyltin compounds enhance human CG secretion and aromatase activity in human placental choriocarcinoma cells.
[Regulation of aromatase in human choriocarcinoma cells]
Colonic Neoplasms
CYP19A1 single nucleotide polymorphism associations with CYP19A1, NF?B1, and IL6 gene expression in human normal colon and normal liver samples.
Effect of butyrate on aromatase cytochrome P450 levels in HT29, DLD-1 and LoVo colon cancer cells.
Fractionation of polyphenol-enriched apple juice extracts to identify constituents with cancer chemopreventive potential.
mRNA expression level of CDH2, LEP, POSTN, TIMP1 and VEGFC modulates 5-fluorouracil resistance in colon cancer cells.
Colorectal Neoplasms
Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.
Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women.
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk.
Variation in the CYP19A1 gene and risk of colon and rectal cancer.
[Two new therapeutic principles in the management of breast cancer and colorectal cancer: selective oral aromatase inhibition and thymidilate synthase inhibition]
Communicable Diseases
Thrombotic risk and immobility in residents of long-term care facilities.
Web Resources for Pharmacogenomics.
Congenital Abnormalities
Aromatase Inhibitors for Ovarian Stimulation in Patients with Breast Cancer.
Aromatase inhibitors in pediatrics.
Drugs in infertility and fetal safety.
Use of aromatase inhibitors in children and adolescents: what's new?
Contracture
Immediate breast reconstruction surgery with expander/direct implant and use of acellular dermal matrix: Does hormone therapy increases the risk of infection?
Coronary Artery Disease
CYP19A1 polymorphisms associated with coronary artery disease and circulating sex hormone levels in a Chinese population.
Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure.
Genetic Variant in the CYP19A1 Gene Associated with Coronary Artery Disease.
The discrepancy of aromatase expression in epicardial adipose tissue between CHD and non-CHD patients.
Coronary Disease
A new day dawns: women without oestrogen or is a balance best?
A Potential Role for Aromatase Levels in Coronary Heart Disease.
Association of aromatase inhibitors with coronary heart disease in women with early breast cancer.
Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use.
Identification of a CYP19 Gene Single-Nucleotide Polymorphism Associated with a Reduced Risk of Coronary Heart Disease.
The discrepancy of aromatase expression in epicardial adipose tissue between CHD and non-CHD patients.
Craniosynostoses
Akhenaten and the strange physiques of Egypt's 18th dynasty.
The breasts of Tutankhamun.
Cryptococcosis
Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report.
Cryptorchidism
Altered expression of CYP17A1 and CYP19A1 in undescended testes of dogs with unilateral cryptorchidism.
Altered structure and function of reproductive organs in transgenic male mice overexpressing human aromatase.
Expression of aromatase and oestrogen receptors in reproductive tissues of the stallion and a single cryptorchid visualised by means of immunohistochemistry.
Cushing Syndrome
Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11?-hydroxylase.
Cystadenocarcinoma, Mucinous
Lack of evidence for aromatase expression in human ovarian epithelial carcinoma.
Liver Receptor Homologue-1 expression in ovarian epithelial and granulosa cell tumours.
Cystadenocarcinoma, Serous
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis.
Lack of evidence for aromatase expression in human ovarian epithelial carcinoma.
Liver Receptor Homologue-1 expression in ovarian epithelial and granulosa cell tumours.
Cystadenoma, Mucinous
Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women.
Cysticercosis
Inhibition of p-450 aromatase prevents feminisation and induces protection during cysticercosis.
Modified expression of steroid 5 alpha-reductase as well as aromatase, but not cholesterol side-chain cleavage enzyme, in the reproductive system of male mice during (Taenia crassiceps) cysticercosis.
Cystitis
Vaginal Estrogen Therapy for Patients with Breast Cancer.
Cysts
An Analysis of ESR2 and CYP19A1 Gene Expression Levels in Women With Endometriosis.
An epigenetic disorder may cause aberrant expression of aromatase gene in endometriotic stromal cells.
Aromatase expression in ovarian epithelial cancers.
Aromatase inhibitor for treatment of a recurrent abdominal wall endometrioma in a postmenopausal woman.
Cell-specific knockout of steroidogenic factor 1 reveals its essential roles in gonadal function.
Demethylation of a nonpromoter cytosine-phosphate-guanine island in the aromatase gene may cause the aberrant up-regulation in endometriotic tissues.
Effects of phytoestrogens on the ovarian and pituitary phenotypes of estrogen-deficient female aromatase knockout mice.
Exposure to ethinyl estradiol prenatally and/or after sexual maturity induces endometriotic and precancerous lesions in uteri and ovaries of mice.
Immunocytochemical localization of aromatase in immature rat ovaries treated with PMSG and hCG, and in pregnant rat ovaries.
Immunolocalization of aromatase in human minor salivary glands of the lower lip with primary Sjögren's syndrome.
Induction of ovarian cysts in progesterone-synchronized immature rats: evidence that suppression of follicular aromatase activity is not a prerequisite for the induction of cystic follicles.
Inflammatory status influences aromatase and steroid receptor expression in endometriosis.
Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aromatase expression.
Novel CYP19A1 Mutations Extend the Genotype-Phenotype Correlation and Reveal the Impact on Ovarian Function.
Ovarian cysts in prepubertal girls.
Spatially heterogeneous expression of aromatase P450 through promoter II is closely correlated with the level of steroidogenic factor-1 transcript in endometrioma tissues.
The steroid hormone environment during primordial follicle formation in perinatal mouse ovaries.
Use of estrogen antagonists and aromatase inhibitors in endometriosis.
Dehydration
Dehydrogenation of indoline by cytochrome P450 enzymes: a novel "aromatase" process.
Thrombotic risk and immobility in residents of long-term care facilities.
Dementia
Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer.
Correction to: Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Long-term use of tamoxifen reduces the risk of dementia: a nationwide population-based cohort study.
Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study.
Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
Demyelinating Diseases
Aromatase expression in the cerebellum of the dog infected with canine distemper virus.
Dental Plaque
Periodontal health in breast cancer patients on aromatase inhibitors versus postmenopausal controls: a longitudinal analysis.
Depression, Postpartum
Aromatase inhibitors and bipolar mood disorder: a case report.
Dermatitis
Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events.
Diabetes Complications
Use of Network Pharmacology to Explore the Mechanism of Gegen (Puerariae lobatae Radix) in the Treatment of Type 2 Diabetes Mellitus Associated with Hyperlipidemia.
Diabetes Mellitus
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.
Association of CYP19A1 and CYP1A2 genetic polymorphisms with type 2 diabetes mellitus risk in the Chinese Han population.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Betaine ameliorates impaired steroidogenesis and apoptosis in mice granulosa cells induced by high glucose concentration.
Drug-induced osteoporosis: mechanisms and clinical implications.
Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer.
Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
Diabetes Mellitus, Type 2
Association of CYP19A1 and CYP1A2 genetic polymorphisms with type 2 diabetes mellitus risk in the Chinese Han population.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Breast Cancer Endocrine Therapy Promotes Weight Gain With Distinct Adipose Tissue Effects in Lean and Obese Female Mice.
Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone.
Drug-induced osteoporosis: mechanisms and clinical implications.
Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes.
Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis.
The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women.
The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer.
The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease.
Diabetic Nephropathies
Angiotensin blockade attenuates diabetic nephropathy in hypogonadal adult male rats.
Diabetic Retinopathy
Association of CYP19A1 and CYP1A2 genetic polymorphisms with type 2 diabetes mellitus risk in the Chinese Han population.
Disorder of Sex Development, 46,XY
Increased peripheral aromatase activity in prepubertal children with partial androgen insensitivity syndrome.
Disorders of Sex Development
A case of female pseudohermaphroditism caused by aromatase deficiency.
Aromatase Deficiency due to a Homozygous CYP19A1 Mutation in a 46,XX Egyptian Patient with Ambiguous Genitalia.
Aromatase Deficiency due to a Novel Mutation in
Aromatase deficiency in an Ontario Old Order Mennonite family.
Aromatase Deficiency in Two Siblings with 46, XX Karyotype Raised as Different Genders: A Novel Mutation (p.R115X) in CYP19A1 Gene
Aromatase deficiency: a novel compound heterozygous mutation identified in a Chinese girl with severe phenotype and obvious maternal virilization.
Aromatase deficiency: a rare cause of maternal virilisation and ambiguous genitalia in neonates.
Evidence of endocrine alteration in the red mullet, Mullus barbatus from the NW Mediterranean.
Female pseudohermaphroditism associated with a novel homozygous G-to-A (V370-to-M) substitution in the P-450 aromatase gene.
Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene.
Intersex condition and molecular markers of endocrine disruption in relation with burdens of emerging pollutants in thicklip grey mullets (Chelon labrosus) from Basque estuaries (South-East Bay of Biscay).
Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR: Expanding the PORD Phenotype.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Sex change strategy and the aromatase genes.
Sex differences in autophagy-mediated diseases: toward precision medicine.
Sexual differentiation of gonads as a function of temperature in the turtle Emys orbicularis: endocrine function, intersexuality and growth.
Temperature-dependent sex determination and gonadal differentiation in reptiles.
The cytochrome P450 aromatase lacking exon 5 is associated with a phenotype of nonclassic aromatase deficiency and is also present in normal human steroidogenic tissues.
Variable phenotypes associated with aromatase (CYP19) insufficiency in humans.
[Aromatase deficiency]
[Efficacy and safety of letrozole in treatment of male children with disorders of sex development].
Distemper
Aromatase expression in the cerebellum of the dog infected with canine distemper virus.
Drug Eruptions
Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole - First Case Report and another Example of an Immunocompromised District.
Drug-Related Side Effects and Adverse Reactions
Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
Joint symptoms, aromatase inhibitor-related adverse reactions, are indirectly associated with decreased serum estradiol.
Tamoxifen and the risk of Parkinsonism: a case/non-case study.
TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-?B Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response.
Dry Eye Syndromes
Dry eye signs and symptoms in aromatase inhibitor treatment and the relationship with pain.
Dry eye signs and symptoms in patients on aromatase inhibitor therapy.
Dry eye syndrome in aromatase inhibitor users.
Dry eyes and AIs: If you don't ask you won't find out.
Dysgerminoma
Lack of evidence for aromatase expression in human ovarian epithelial carcinoma.
Dyslexia
Polymorphisms in DCDC2 and S100B associate with developmental dyslexia.
The aromatase gene CYP19A1: several genetic and functional lines of evidence supporting a role in reading, speech and language.
Dyslipidemias
Aromatase deficiency in a male patient - Case report and review of the literature.
Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection.
Dyspareunia
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy.
Managing the toxicities of the aromatase inhibitors.
Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.
Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer.
Sexuality and quality of life in women with a prior diagnosis of breast cancer after risk-reducing salpingo-oophorectomy.
The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
Vaginal Estrogen Therapy for Patients with Breast Cancer.
[Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
Dyspnea
Hormonal approaches to breast cancer treatment and prevention: an overview.
Endometrial Hyperplasia
Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies.
Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity.
Functional investigation on aromatase in endometrial hyperplasia in polycystic ovary syndrome cases.
In situ estrogen metabolism in proliferative endometria from untreated women with polycystic ovarian syndrome with and without endometrial hyperplasia.
Letrozole as primary therapy for endometrial hyperplasia in young women.
Prognostic significance of estrogen and progesterone receptor expression in LNG-IUS (Mirena) treatment of endometrial hyperplasia: an immunohistochemical study.
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer.
The use of D-chiro-Inositol in clinical practice.
[Aromatase activities of endometrial carcinomas and both basic and clinical analyses of endometrial hyperplasia as a premalignant disease]
[Expressions of aromatase protein and sex hormone receptor in endometrial lesions.]
Endometrial Neoplasms
A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer.
A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors.
Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer.
ACOG Committee Opinion No. 738 Summary: Aromatase Inhibitors in Gynecologic Practice.
ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.
Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17?-estradiol biosynthesis in endometrial carcinoma microenvironment.
Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology.
Altered expression of lysophosphatidic acid receptors, in association with the synthesis of estrogens and androgens in type 1 endometrial cancer biology.
Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy.
Aromatase activity and concentrations of cortisol, progesterone and testosterone in breast and abdominal adipose tissue.
Aromatase activity and the effect of estradiol and testosterone on DNA synthesis in endometrial carcinoma cell lines.
Aromatase and comparative response to its inhibitors in two types of endometrial cancer.
Aromatase cytochrome P450 gene expression in endometrial carcinoma.
Aromatase expression and regulation in breast and endometrial cancer.
Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study.
Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival.
Aromatase expression was not detected by immunohistochemistry in endometrial cancer.
Aromatase in aging women.
Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies.
Aromatase in the context of breast and endometrial cancer. A review.
Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers?
Aromatase inhibitor letrozole in synergy with curcumin in the inhibition of xenografted endometrial carcinoma growth.
Aromatase inhibitor use during ovarian stimulation suppresses growth of uterine endometrial cancer in xenograft mouse model.
Aromatase inhibitors and the endometrium.
Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study.
Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.
Aromatase inhibitors in gynecologic cancers.
Aromatase inhibitors in malignant diseases of aging.
Aromatase inhibitors may reduce endometrial cancer risk.
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
Association between genetic polymorphisms and endometrial cancer risk: a systematic review.
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
Biological roles of estrogen and progesterone in human endometrial carcinoma--new developments in potential endocrine therapy for endometrial cancer.
Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice.
Committee Opinion No. 663: Aromatase Inhibitors in Gynecologic Practice.
Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes.
Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis.
Cyclooxygenase inhibitors may be more effective in hormone-dependent endometrial cancers: interaction between cyclooxygenase and aromatase.
CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity.
CYP19 (aromatase) haplotypes and endometrial cancer risk.
CYP19 gene expression and aromatase activity in endometrial cancer tissue: importance of the type of the disease.
CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer.
De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor.
Decreased expression of aromatase in the Ishikawa and RL95-2 cells by the isoflavone, puerarin, is associated with inhibition of c-jun expression and AP-1 activity.
Decreased risk of breast cancer associated with oral bisphosphonate therapy.
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.
Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma.
Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione on 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.
Endocrine disorders associated with inappropriately high aromatase expression.
Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors.
Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders.
Estrogen formation in endometrial and cervix cancer cell lines: Involvement of aromatase, steroid sulfatase and 17beta-hydroxysteroid dehydrogenases (types 1, 5, 7 and 12).
Estrogen production and action.
Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells.
Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction.
Estrogen synthesis in normal and malignant human endometrium.
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO).
Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer.
Expression of enzyme associated with steroid hormone synthesis and local production of steroid hormone in endometrial carcinoma cells.
Expression of estrogen receptors (?, ?), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus.
Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
Hormone therapy for patients with advanced or recurrent endometrial cancer.
Hysteroscopic Evaluation of Endometrial Changes in Breast Cancer Women with or without Hormone Therapies: Results from a Large Multicenter Cohort Study.
Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer.
Interaction between CYP19A1 polymorphisms and body mass index in the risk of endometrial cancer in postmenopausal Japanese women.
Interaction of soy food and tea consumption with CYP19A1 genetic polymorphisms in the development of endometrial cancer.
Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
Is aromatase cytochrome P450 involved in the pathogenesis of endometrioid endometrial cancer?
Leptin promotes human endometrial carcinoma cell proliferation by enhancing aromatase (P450arom) expression and estradiol formation.
Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma.
Local biosynthesis of estrogen in human endometrial carcinoma through tumor-stromal cell interactions.
Major clinical research advances in gynecologic cancer in 2011.
MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma.
Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects.
Neoadjuvant treatment of endometrial cancer using anastrozole: A randomised pilot study.
No evidence of a role for PPARgamma Pro12Ala polymorphism in endometrial cancer susceptibility.
Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation.
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
Polymerase chain reaction amplification fails to detect aromatase cytochrome P450 transcripts in normal human endometrium or decidua.
Polymorphisms in the CYP19A1 (Aromatase) gene and endometrial cancer risk in Chinese women.
Potent enzyme-activated inhibition of aromatase by a 7 alpha-substituted C19 steroid.
Preliminary clinical application of an aromatase inhibitor and a gonadotropin-releasing hormone agonist combination for inoperable endometrial cancer patients with comorbidities: case report and literature review.
Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.
SERMs for the treatment and prevention of breast cancer.
Successful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone.
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Synthesis and biochemical studies of 7-substituted 4,6-androstadiene-3,17-diones as aromatase inhibitors.
The Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome: Can CYP19A1 Variants Be Used to Predict Treatment Efficacy?
The nuclear receptors SF1 and LRH1 are expressed in endometrial cancer cells and regulate steroidogenic gene transcription by cooperating with AP-1 factors.
The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer.
The role of tissue steroids in regulating aromatase and oestradiol 17 beta-hydroxysteroid dehydrogenase activities in breast and endometrial cancer.
The sulfatase pathway as estrogen supply in endometrial cancer.
The therapeutic significance of aromatase inhibitors in endometrial carcinoma.
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis.
Two cases of endometrial cancer arising from adenomyosis during aromatase inhibitors therapy after mastectomy.
Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium.
Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study.
Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review.
Variants in hormone biosynthesis genes and risk of endometrial cancer.
Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan.
[Antiestrogen therapy of patients with uterine cancer]
[Aromatase (P450AROM) mRNA expression in normal, hyperplastic and malignant endometrium and aromatase activity in endometrial cancer tissue culture]
[Aromatase activities of endometrial carcinomas and both basic and clinical analyses of endometrial hyperplasia as a premalignant disease]
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas]
[Comparison of letrozole and exemestane used in non-adjuvant therapy of endometrial carcinoma]
[Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma]
[Efficacy of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer].
[Evaluation of aromatase inhibitors' side effects in clinical and experimental studies]
[Hormone-associated properties and plasticity of omental fat: the relation with clinical-morphological features of endometrial cancer in patients with different obesity phenotypes].
[Inhibiting effect of letrozole combined with curcumin on xenografted endometrial carcinoma growth in nude mice]
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole]
[Prospects for using aromatase inhibitors in treating endometrial cancer patients]
[Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
[Tumor tissue aromatase and estrogen levels versus clinical course of endometrial cancer]
Endometriosis
A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis.
A comparison of two months pretreatment with GnRH agonists with or without an aromatase inhibitor in women with ultrasound-diagnosed ovarian endometriomas undergoing IVF.
A predictive model for endometriosis.
A Review of the Epigenetic Contributions to Endometriosis.
Aberrant DNA methylation status of endometriosis: Epigenetics as the pathogenesis, biomarker and therapeutic target.
Absence of aromatase protein and mRNA expression in endometriosis.
ACOG Committee Opinion No. 738 Summary: Aromatase Inhibitors in Gynecologic Practice.
ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.
Activin A Stimulates Aromatase via the ALK4-Smad Pathway in Endometriosis.
Adenomyosis: the pathophysiology of an oestrogen-dependent disease.
Advances in pharmacotherapy for treating endometriosis.
Advances in the medical treatment of adolescent endometriosis.
An Analysis of ESR2 and CYP19A1 Gene Expression Levels in Women With Endometriosis.
An assessment of the multifactorial profile of steroid-metabolizing enzymes and steroid receptors in the eutopic endometrium during moderate to severe ovarian endometriosis.
Analysis of aromatase and 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression in deep endometriosis and eutopic endometrium using laser capture microdissection.
Anastrazole and oral contraceptives: a novel treatment for endometriosis.
Anastrozole and celecoxib for endometriosis treatment, good to keep them apart?
Anastrozole and levonorgrestrel-releasing intrauterine device in the treatment of endometriosis: a randomized clinical trial.
Androstenedione up-regulation of endometrial aromatase expression via local conversion to estrogen: potential relevance to the pathogenesis of endometriosis.
Are aromatase inhibitors effective in endometriosis treatment?
Aromatase and endometriosis.
Aromatase and endometriosis: estrogens play a role.
Aromatase and other steroidogenic genes in endometriosis: translational aspects.
Aromatase as a target for treating endometriosis.
Aromatase as a therapeutic target in endometriosis.
Aromatase expression in endometriosis.
Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis.
Aromatase expression in endometriotic tissues and its relationship to clinical and analytical findings.
Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study.
Aromatase in endometriosis and uterine leiomyomata.
Aromatase inhibitor (anastrozole) affects growth of endometrioma cells in culture.
Aromatase inhibitor for treatment of a recurrent abdominal wall endometrioma in a postmenopausal woman.
Aromatase inhibitor regulates let-7 expression and let-7f-induced cell migration in endometrial cells from women with endometriosis.
Aromatase inhibitor treatment limits progression of peritoneal endometriosis in baboons.
Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions--old answers?
Aromatase Inhibitors for Endometriosis-Associated Infertility; Do We Have Sufficient Evidence?
Aromatase inhibitors for the treatment of endometriosis.
Aromatase inhibitors for the treatment of endometriosis: a systematic review about efficacy, safety and early clinical development.
Aromatase inhibitors in post-menopausal endometriosis.
Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review.
Aromatase inhibitors in the treatment of bladder endometriosis.
Aromatase inhibitors in the treatment of endometriosis.
Aromatase inhibitors in the treatment of severe endometriosis.
Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists.
Aromatase Inhibitors: Potential Reproductive Implications.
Aromatase inhibitors: the next generation of therapeutics for endometriosis?
Aromatase P450 messenger RNA expression in eutopic endometrium is not a specific marker for pelvic endometriosis.
Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target.
Aromatase: Contributions to Physiology and Disease in Women and Men.
Association between CYP19A1, GSTM1, GSTT1, and GSTP1 genetic polymorphisms and the development of endometriosis in a Chinese population.
Association between single nucleotide polymorphism of the CYP19A1 and ESR2 genes and endometriosis.
Blocking oestradiol synthesis pathways with potent and selective coumarin derivatives.
c-fos gene and protein expression in pelvic endometriosis: a local marker of estrogen action.
C-Jun NH2-Terminal Kinase and p38 Inhibition Suppresses Prostaglandin E2-Stimulated Aromatase and Estrogen Receptor Levels in Human Endometriosis.
Clotrimazole reduces endometriosis and the estrogen concentration by downregulating aromatase.
Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study.
Combined Effect of the PGR +331C?>?T, CYP17A1 -34A?>?G and CYP19A1 1531G?>?A Polymorphisms on the Risk of Developing Endometriosis.
Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice.
Committee Opinion No. 663: Aromatase Inhibitors in Gynecologic Practice.
Correlation between aromatase expression in the eutopic endometrium of symptomatic patients and the presence of endometriosis.
CYP19 gene variant confers susceptibility to endometriosis-associated infertility in Chinese women.
Danazol inhibits aromatase activity of endometriosis-derived stromal cells by a competitive mechanism.
Decreased expression of aromatase in the Ishikawa and RL95-2 cells by the isoflavone, puerarin, is associated with inhibition of c-jun expression and AP-1 activity.
Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol.
Demethylation of a nonpromoter cytosine-phosphate-guanine island in the aromatase gene may cause the aberrant up-regulation in endometriotic tissues.
Detection of aromatase cytochrome P-450 in endometrial biopsy specimens as a diagnostic test for endometriosis.
Detection of endometriosis using immunocytochemistry of P450 Aromatase expressions in eutopic endometrial cells obtained from menstrual sloughing: a diagnostic study.
Diagnosis and treatment of endometriosis.
Dienogest reduces HSD17?1 expression and activity in endometriosis.
Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis.
Dienogest, a synthetic progestin, down-regulates expression of CYP19A1 and inflammatory and neuroangiogenesis factors through progesterone receptor isoforms A and B in endometriotic cells.
Dienogest, a synthetic progestin, inhibits prostaglandin E(2) production and aromatase expression by human endometrial epithelial cells in a spheroid culture system.
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection.
Down-regulation of the CYP19A1 gene in cumulus cells of infertile women with endometriosis.
Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis.
Effect of letrozole on estradiol production and P450 aromatase messenger RNA expression of cultured luteinized granulosa cells from women with and without endometriosis.
Effect of local aromatase inhibition in endometriosis using a new chick embryo chorioallantoic membrane model.
Effect of Yikun Neiyi Wan on the expression of aromatase P450, COX-2, and ER related receptor in endometrial cells in vitro from patients with endometriosis.
Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis.
Effects of progestins on local estradiol biosynthesis and action in the Z-12 endometriotic epithelial cell line.
Emerging drugs for endometriosis.
Endocrine disorders associated with inappropriately high aromatase expression.
Endometrial and peritoneal expression of aromatase, cytokines, and adhesion factors in women with endometriosis.
Endometrial aromatase mRNA as a possible screening tool for advanced endometriosis and adenomyosis.
Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders.
Endometrial seedlings. A survival instinct? Immunomodulation and its role in the pathophysiology of endometriosis.
Endometriosis after menopause: physiopathology and management of an uncommon condition.
Endometriosis as a detrimental condition for granulosa cell steroidogenesis and development: From molecular alterations to clinical impact.
Endometriosis: novel etiopathogenetic concepts and clinical perspectives.
Endometriosis: the pathophysiology as an estrogen-dependent disease.
Endometriosis: the ultimate hormonal disease.
Endometriosis: the way forward.
Epigenetic alterations of CYP19A1 gene in Cumulus cells and its relevance to infertility in endometriosis.
Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance.
Estrogen production and metabolism in endometriosis.
Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis.
Estrogen receptor-? immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis.
Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis.
Expression of aromatase (P450 aromatase/CYP19) in peritoneal and ovarian endometriotic tissues and deep endometriotic (adenomyotic) nodules of the rectovaginal septum.
Expression of aromatase and estrogen sulfotransferase in eutopic and ectopic endometrium: evidence for unbalanced estradiol production in endometriosis.
Expression of aromatase cytochrome P450 in eutopic endometrium and its application as a diagnostic test for endometriosis.
Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium.
Expression of scavenger receptor class B1 in endometrium and endometriosis.
Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility.
Farnesoid X Receptor Agonist GW4064 Inhibits Aromatase and ER? Expression in Human Endometriotic Stromal Cells.
From pathogenesis to clinical practice: Emerging medical treatments for endometriosis.
Functional Expression of FSH Receptor in Endometriotic Lesions.
Future perspectives in the medical treatment of endometriosis.
Genetic or enzymatic disruption of aromatase inhibits the growth of ectopic uterine tissue.
Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas.
Gonadotropin-Releasing Hormone Agonist Reduces Aromatase Cytochrome P450 and Cyclooxygenase-2 in Ovarian Endometrioma and Eutopic Endometrium of Patients with Endometriosis.
High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome.
Identification of common mechanisms between endometriosis and ovarian cancer.
IGF-I stimulates ER? and aromatase expression via IGF1R/PI3K/AKT-mediated transcriptional activation in endometriosis.
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis.
Immunomodulators and aromatase inhibitors: are they the next generation of treatment for endometriosis?
Induction of endometriosis in the marmoset monkey (Callithrix jacchus).
Inflammatory status influences aromatase and steroid receptor expression in endometriosis.
Inhibition of aromatase: insights from recent studies.
Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy.
Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial explants and insulin-like growth factor-I gene expression in rats with experimental endometriosis.
Initial endometriosis showing direct morphologic evidence of metaplasia in the pathogenesis of ovarian endometriosis.
Interleukin-4 and Prostaglandin E2 Synergistically Up-Regulate 3?-Hydroxysteroid Dehydrogenase Type 2 in Endometrioma Stromal Cells.
Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aromatase expression.
Investigational drugs for the treatment of endometriosis, an update on recent developments.
Is aromatase expression in the endometrium the cause of endometriosis and related infertility?
Leptin, its receptor and aromatase expression in deep infiltrating endometriosis.
Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis.
Letrozole and norethisterone acetate in colorectal endometriosis.
Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis.
Letrozole stimulates the growth of human endometrial explants cultured in three-dimensional fibrin matrix.
Lipoxin A4 inhibits the development of endometriosis in a mouse model by suppressing local estradiol synthesis.
Liver receptor homologue-1 and steroidogenic factor-1 expression in cultured granulosa cells from patients with endometriosis: A preliminary study.
Macrophage migration inhibitory factor is involved in a positive feedback loop increasing aromatase expression in endometriosis.
Management of recurrent implantation failure by gonadotropin-releasing hormone agonist and aromatase inhibitor suppression, in women without evidence of endometriosis.
Mechanisms of excessive estrogen formation in endometriosis.
Medical treatment in the management of deep endometriosis infiltrating the proximal rectum and sigmoid colon: a comprehensive literature review.
Medical treatment of endometriosis.
microRNA Let-7b: A Novel treatment for endometriosis.
MicroRNA23a and MicroRNA23b Deregulation Derepresses SF-1 and Upregulates Estrogen Signaling in Ovarian Endometriosis.
Molecular approach to common causes of female infertility.
Molecular basis for treating endometriosis with aromatase inhibitors.
Molecular biology of endometriosis: from aromatase to genomic abnormalities.
Mouse model for endometriosis is characterized by proliferation and inflammation but not epithelial-to-mesenchymal transition and fibrosis.
New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.
Novel therapeutic targets to improve IVF outcomes in endometriosis patients: a review and future prospects.
Patients with endometriosis and patients with poor ovarian reserve have abnormal follicle-stimulating hormone receptor signaling pathways.
Peroxisome proliferator-activated receptor ? agonist suppresses human telomerase reverse transcriptase expression and aromatase activity in eutopic endometrial stromal cells from endometriosis.
Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Alpha Enhances Local Estrogen Biosynthesis by Stimulating Aromatase Activity in Endometriosis.
Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor.
Pharmacological treatment of endometriosis: experience with aromatase inhibitors.
Polymorphic variants of CYP17 and CYP19A and risk of infertility in endometriosis.
Polymorphisms and endometriosis: a systematic review and meta-analyses.
Polymorphisms in ESR1, ESR2 and HSD17B1 genes are associated with fertility status in endometriosis.
Polymorphisms in the 3'UTR Region of ESR2 and CYP19A1 Genes in Women With Endometriosis.
Post-menopausal endometriosis with inferior vena cava invasion requiring surgical management.
Potential role of aromatase inhibitors in the treatment of endometriosis.
Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium.
Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells.
Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis.
Providing new insights into the endometriosisassociated cancer arising in episiotomy scars.
Reduced aromatase activity in granulosa cells of women with endometriosis undergoing assisted reproduction techniques.
Reduced preovulatory granulosa cell steroidogenesis in women with endometriosis.
Reduction in Endometrioma Size with Three Months of Aromatase Inhibition and Progestin Add-Back.
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.
Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta in endometriosis is associated with overexpression of aromatase.
Regulation of Inflammation Pathways and Inflammasome by Sex Steroid Hormones in Endometriosis.
Role of aromatase in endometrial disease.
Role of inflammation and aromatase expression in the eutopic endometrium and its relationship with the development of endometriosis.
Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women.
Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study.
Safety of medical treatments for endometriosis.
Screening of a panel of steroid-related genes showed polymorphisms of aromatase genes confer susceptibility to advanced stage endometriosis in the Taiwanese Han population.
Selective estrogen-receptor modulators and aromatase inhibitors: promising new medical therapies for endometriosis?
Serum dioxin-like compounds and aromatase (CYP19) expression in endometriotic tissues.
Seven Hormonal Biomarkers for Diagnosing Endometriosis: Meta-Analysis and Adjusted Indirect Comparison of Diagnostic Test Accuracy.
Smad3/4 Binding to Promoter II of P450arom So As to Regulate Aromatase Expression in Endometriosis.
Spatially heterogeneous expression of aromatase P450 through promoter II is closely correlated with the level of steroidogenic factor-1 transcript in endometrioma tissues.
Steroid receptor and aromatase expression in baboon endometriotic lesions.
Steroidogenic factor-1 and endometriosis.
Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element.
Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats.
Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor.
Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients.
Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor.
SULFATION PATHWAYS: Contribution of intracrine oestrogens to the aetiology of endometriosis.
Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis.
The effect of oral contraceptives on aromatase expression in the eutopic endometrium of patients with endometriosis.
The effects of dietary phytoestrogens on aromatase activity in human endometrial stromal cells.
The emerging use of aromatase inhibitors for endometriosis treatment.
The Genetic Background of Endometriosis: Can ESR2 and CYP19A1 Genes Be a Potential Risk Factor for Its Development?
The use of D-chiro-Inositol in clinical practice.
Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study.
Treatment of endometriosis without aromatase inhibitors.
Treatment of severe postmenopausal endometriosis with an aromatase inhibitor.
Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman.
Upstream stimulatory factor-2 regulates steroidogenic factor-1 expression in endometriosis.
Urogynecologic conditions: pelvic organ prolapse.
Use of aromatase inhibitors in practice of gynecology.
Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review.
Use of estrogen antagonists and aromatase inhibitors in endometriosis.
[Aromatase and endometriosis: Myth or reality?]
[Aromatase inhibitors--is it a new opportunity in the treatment of infertility?]
[Aromatase inhibitors--new applications in gynecology]
[Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis]
[Cellular localization of aromatase in human endometrium]
[Comparison of steroid metabolism markers in endometrium of women with endometriosis, endometrial hyperplasia and without pathological changes of endometrium]
[Correlation between polymorphism of CYP19A1, GSTM1, GSTT1 and GSTP1 gene and endometriosis].
[Cytochrome P-450 aromatase expression in the ectopic and eutopic endometrium in endometriosis]
[Diagnostic value of the detection of aromatase cytochrome P450 and CA125 for endometriosis]
[Endometriosis and aromatase inhibitor]
[ENDOMETRIOSIS: A NEW APPROACH TO ETIOLOGY AND PATHOGENESIS (REVIEW)].
[Expressions of aromatase P450 and estrogen receptor in eutopic and ectopic endometrium in endometriosis and their correlation with endometriosis]
[Inhibitory effect on estrogen production and its influence on invasive ability of human endometrial cells of endometriosis by medicated serum of SLW]
[Inhibitory effects of Sanlengwan on aromatase and cyclooxygenase-2 in rats of endometriosis]
[New medical treatments for painful endometriosis: CNGOF-HAS Endometriosis Guidelines].
[Perspectives on endometriosis: new physiopathologic approaches and treatments]
[Pharmacotherapy for pelvic endometriosis in women]
[Semiquantitative analysis of mRNA aromatase expression in eutopic endometrium as a diagnostic marker of endometriosis and estrogen dependent diseases]
[The therapy of endometriosis. New prospects]
[Treatment of endometriosis by aromatase inhibitors: Efficacy and side effects.]
Endometritis
Defining Postpartum Uterine Disease and the Mechanisms of Infection and Immunity in the Female Reproductive Tract in Cattle.
Enophthalmos
Orbital fat regeneration following hormonal treatment of metastatic breast carcinoma.
Ependymoma
Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole.
Treatment of ovarian anaplastic ependymoma by an aromatase inhibitor.
Epididymitis
The effect of obesity on human reproductive health and foetal life.
Epilepsy
A comparison of anastrozole and testosterone versus placebo and testosterone for treatment of sexual dysfunction in men with epilepsy and hypogonadism.
Aromatase inhibition, testosterone, and seizures.
Aromatase inhibitors as add-on treatment for men with epilepsy.
Interactions of Aromatase and Seladin-1: A Neurosteroidogenic and Gender Perspective.
Is the role of estrogens and estrogen receptors in epilepsy still underestimated?
Mass spectrometric assay and physiological-pharmacological activity of androgenic neurosteroids.
Neuroprotection by estradiol: a role of aromatase against spine synapse loss after blockade of GABA(A) receptors.
Psychoneuroendocrine aspects of temporolimbic epilepsy. Part II: Epilepsy and reproductive steroids.
Reproductive and sexual dysfunction in men with epilepsy.
Erectile Dysfunction
Obesity, An Enemy of Male Fertility: A Mini Review.
The association between elevated serum oestradiol levels and clinically significant erectile dysfunction in men presenting for andrological evaluation.
The effect of obesity on human reproductive health and foetal life.
Erythema
Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole - First Case Report and another Example of an Immunocompromised District.
Erythema Multiforme
Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer.
Erythema Nodosum
Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.
Esophageal Neoplasms
MassARRAY analysis of twelve cancer related SNPs in esophageal squamous cell carcinoma in J&K, India.
Essential Hypertension
Association study of aromatase gene (CYP19A1) in essential hypertension.
Exanthema
Role of aromatase inhibitors in the treatment of breast cancer.
Towards understanding aromatase inhibitory activity via QSAR modeling.
Fatty Liver
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Fecal Incontinence
Aromatase Inhibitors Are Associated With Low Sexual Desire Causing Distress and Fecal Incontinence in Women: An Observational Study.
Fetal Death
Fetal death in mice lacking 5alpha-reductase type 1 caused by estrogen excess.
Fetal Growth Retardation
Altered umbilical sex steroids in preterm infants born small for gestational age.
Intrauterine growth restriction alters hippocampal expression and chromatin structure of Cyp19a1 variants.
Placental ESRRG-CYP19A1 Expressions and Circulating 17-Beta Estradiol in IUGR Pregnancies.
Fetal Macrosomia
Association between rankl [RS9594759] and IL10 [RS1800896] Genes polymorphism and deciduous tooth eruption terms in Ukrainians born macrosomic.
Fibroadenoma
Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma.
Fibroma
Immunohistochemical studies of steroidogenic enzymes (aromatase, 17 alpha-hydroxylase and cholesterol side-chain cleavage cytochromes P-450) in sex cord-stromal tumors of the ovary.
Response of estrogen receptor-positive intraabdominal fibromatosis to aromatase inhibitor therapy.
Testicular sex cord-stromal lesions: immunohistochemical analysis of cytokeratin, vimentin and steroidogenic enzymes.
Fibromatosis, Aggressive
Complete response to exemestane in a patient with a desmoid tumor.
Fertility preservation and PGT-M in women with familial adenomatous polyposis-associated desmoid tumours.
Fibrosarcoma
Colocalization of aromatase in spinal cord astrocytes: differences in expression and relationship to mechanical and thermal hyperalgesia in murine models of a painful and a non-painful bone tumor.
Fibrous Dysplasia, Polyostotic
Anastrozole plus leuprorelin in early maturing girls with compromised growth: the "GAIL" study.
Aromatase inhibitors in pediatrics.
Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome.
Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome.
Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study.
Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome.
Luteinizing hormone-releasing hormone (LHRH)-independent precocious puberty unresponsive to LHRH agonist therapy in two girls lacking features of the McCune-Albright syndrome.
Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome.
Testolactone treatment of precocious puberty in McCune-Albright syndrome.
The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome.
Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.
[Efficacy and safety of letrozole in treatment of McCune-Albright syndrome girls with peripheral precocious puberty].
Follicular Cyst
Induction of ovarian cysts in progesterone-synchronized immature rats: evidence that suppression of follicular aromatase activity is not a prerequisite for the induction of cystic follicles.
[Precocious puberty and ovarian follicular cysts]
Fractures, Spontaneous
[On "2015 Guidelines for Prevention and Treatment of Osteoporosis" . Osteoporosis associated with sex hormone depletion treatment].
Gastroparesis
Acupuncture for cancer pain and related symptoms.
Genetic Diseases, Inborn
Aromatase Deficiency due to a Novel Mutation in
Aromatase excess syndrome: a rare autosomal dominant disorder leading to pre- or peri-pubertal onset gynecomastia.
Congenital hypopituitarism as a cause of undetectable estriol levels in the maternal triple-marker screen.
Genetic analysis of human placental aromatase deficiency.
Genital Diseases, Female
Correlation between bone mineral density and endometrial thickness over time in women with breast cancer history.
Germinoma
Aromatase expression in human germinomas with possible biological effects.
Giant Cell Tumor of Bone
Denosumab: A bone antiresorptive drug.
Giant Cell Tumors
Denosumab: A bone antiresorptive drug.
Gingival Overgrowth
Estrogen suppression induces papillary gingival overgrowth in pregnant baboons.
Glioblastoma
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.
Aromatase, the enzyme responsible for estrogen biosynthesis, is expressed by human and rat glioblastomas.
Do steroid hormones play a role in the etiology of glioma?
High expression of estrogen receptor alpha and aromatase in glial tumor cells is associated with gender-independent survival benefits in glioblastoma patients.
Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells.
Pre-clinical Pharmacological Evaluation of Letrozole as a Novel Treatment for Gliomas.
Glioma
Do steroid hormones play a role in the etiology of glioma?
Effects of morphine on testosterone levels in rat C6 glioma cells: modulation by anastrozole.
Effects of vitamin D in the nervous system: Special focus on interaction with steroid hormone signalling and a possible role in the treatment of brain cancer.
Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: Application of physiologically-based pharmacokinetic modeling to gain quantitative insights.
Inhibitory effects of melatonin on sulfatase and 17beta-hydroxysteroid dehydrogenase activity and expression in glioma cells.
Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells.
Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats.
Pre-clinical Pharmacological Evaluation of Letrozole as a Novel Treatment for Gliomas.
Selective transcriptional regulation of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells.
The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis.
Glucose Intolerance
Accelerated conversion of dehydroepiandrosterone sulfate to estrogen in a patient with Crow-Fukase syndrome and diabetes mellitus.
Effect of Pregnancy on Paroxetine-Induced Adiposity and Glucose Intolerance in Mice.
Hepatic glucose intolerance precedes hepatic steatosis in the male aromatase knockout (ArKO) mouse.
Increased adipose tissue in male and female estrogen receptor-alpha knockout mice.
Role of aromatase inhibitors in glucose intolerance of obese men.
Serotonin transporter deficiency drives estrogen-dependent obesity and glucose intolerance.
The role of estrogen and estrogen receptor-alpha in male adipose tissue.
Glucose Metabolism Disorders
Maternal lipopolysaccharide exposure results in glucose metabolism disorders and sex hormone imbalance in male offspring.
Gonadal Dysgenesis
A large cohort of disorders of sex development and their genetic characteristics: 6 novel mutations in known genes.
Fertility issues in the management of patients with disorders of sex development.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals.
Granular Cell Tumor
Aromatase inhibitors prevent spontaneous granular cell tumors in the distal female reproductive tract of Sprague-Dawley rats.
Granulosa Cell Tumor
Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.
Aromatase Inhibitor Therapy As Effective Rescue in a Patient With Tamoxifen-Refractory Metastatic Granulosa Cell Tumor of the Ovary.
Aromatase inhibitors in gynecologic cancers.
Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature.
Aromatase inhibitors--a viable option for recurrent granulosa cell tumour of ovary: overview and case report.
Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter.
Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer.
Expression of P450 Aromatase in Granulosa Cell Tumors and Sertoli-Stromal Cell Tumors of the Ovary: Which Cells Are Responsible for Estrogenesis?
Immunohistochemical studies of steroidogenic enzymes (aromatase, 17 alpha-hydroxylase and cholesterol side-chain cleavage cytochromes P-450) in sex cord-stromal tumors of the ovary.
Liver Receptor Homologue-1 expression in ovarian epithelial and granulosa cell tumours.
Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.
Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor.
Unusual Virilization in Girls with Juvenile Granulosa Cell Tumors of the Ovary Is Related to Intratumoral Aromatase Deficiency.
Growth Hormone-Secreting Pituitary Adenoma
Aromatase enzyme expression in acromegaly and its possible relationship with disease prognosis.
Gynecomastia
An aroma of complexity: how the unique genetics of aromatase (CYP19A1) explain diverse phenotypes from hens and hyenas to human gynecomastia, and testicular and other tumors.
An open label, dose response study to determine the effect of a dietary supplement on dihydrotestosterone, testosterone and estradiol levels in healthy males.
Aromatase activity in human skin fibroblasts grown in cell culture.
Aromatase and gynecomastia.
Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study.
Aromatase Excess Syndrome in a Family with Upstream Deletion of CYP19A1.
Aromatase excess syndrome presenting with prepubertal gynecomastia in an Egyptian child with type 1 neurofibromatosis.
Aromatase excess syndrome: a rare autosomal dominant disorder leading to pre- or peri-pubertal onset gynecomastia.
Aromatase Excess Syndrome: Identification of Cryptic Duplications and Deletions Leading to Gain of Function of CYP19A1 and Assessment of Phenotypic Determinants.
Aromatase expression in the human male.
Aromatase inhibitors in male sex.
Aromatase inhibitors in pediatrics.
Aromatase inhibitors: past, present and future.
Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affecting normal physiology.
Association between gynecomastia and aromatase (CYP19) polymorphisms.
Combined surgical and medical treatment in an adolescent with severe gynecomastia due to excessive estradiol secretion: a case report.
Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred.
Endocrine disorders associated with inappropriately high aromatase expression.
Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene.
Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Familial gynecomastia with increased extraglandular aromatization of plasma carbon19-steroids.
Genetic variants of estrogen beta and leptin receptors may cause gynecomastia in adolescent.
Gonadotropin Treatment For The Male Hypogonadotropic Hypogonadism.
Gynecomastia due to hormone therapy for advanced prostate cancer: a report of ten surgically treated cases and a review of treatment options.
Gynecomastia in prepubertal and pubertal men.
Gynecomastia.
High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child.
Increased aromatase activity in pubic skin fibroblasts from patients with isolated gynecomastia.
Leptin levels in boys with pubertal gynecomastia.
Long-term effect of aromatase inhibition in aromatase excess syndrome.
Management of prepubertal gynecomastia in two monozygotic twins with peutz-jeghers syndrome: from aromatase inhibitors to subcutaneous mastectomy.
Molecular bases and phenotypic determinants of aromatase excess syndrome.
Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma.
On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production.
Overexpression of aromatase associated with loss of heterozygosity of the STK11 gene accounts for prepubertal gynecomastia in boys with Peutz Jeghers Syndrome.
Overexpression of aromatase in transgenic male mice results in the induction of gynecomastia and other biochemical changes in mammary glands.
Possible involvement of aromatase overexpression induced by cyclo-oxygenase-2 in the pathogenesis of idiopathic gynecomastia.
Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor.
Prepubertal Gynecomastia in Two Monozygotic Twins with Peutz-Jeghers Syndrome: Two Years' Treatment with Anastrozole and Genetic Study.
Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene.
Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
Sertoli Cell Tumor of Testes in a Child with Peutz-Jeghers syndrome.
Serum inhibin B concentration in a prepubertal boy with gynecomastia and Peutz-Jeghers syndrome.
The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription.
The breasts of Tutankhamun.
The role of Ad-36 as a risk factor in males with gynecomastia.
Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole.
Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole.
Understanding the pathological manifestations of aromatase excess syndrome: lessons for clinical diagnosis.
Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development.
Use of aromatase inhibitors in large cell calcifying sertoli cell tumors: effects on gynecomastia, growth velocity, and bone age.
Use of letrozole as a chemopreventive agent in aromatase overexpressing transgenic mice.
[Hormonal profile of idiopathic gynecomastia in young adults. Apropos of 488 cases]
[The use of aromatase inhibitors in children]
Hallucinations
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Hamartoma
Delayed closure of epiphyseal cartilages induced by the aromatase inhibitor anastrozole. Would it help short children grow up?
Head and Neck Neoplasms
Recent advances in oncology acupuncture and safety considerations in practice.
Head Injuries, Penetrating
A Quantification of the Injury-Induced Changes in Central Aromatase, Oestrogenic Milieu and Steroid Receptor Expression in the Zebra Finch.
Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair.
Heart Diseases
Association of aromatase inhibitors with coronary heart disease in women with early breast cancer.
Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis.
Heart Failure
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
Thrombotic risk and immobility in residents of long-term care facilities.
Heart Failure, Systolic
Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure.
Hemangiosarcoma
Radiogenic angiosarcoma of the breast: case report and systematic review of the literature.
Hemophilia A
Immune-mediated syndromes following intravenous bisphosphonate therapy.
Hepatitis
Aromatase in human liver and its diseases.
Hepatitis B
Aromatase in normal and diseased liver.
Hepatitis C
Aromatase in normal and diseased liver.
Hepatitis, Alcoholic
Aromatase in normal and diseased liver.
Hepatolenticular Degeneration
Endocrine studies of the ovulatory disturbances in Wilson's disease (hepatolenticular degeneration).
Herpes Zoster
Aromatase Derived Estradiol Within the Thalamus Modulates Pain Induced by Varicella Zoster Virus.
Aromatase expression in the normal human adult adrenal and in adrenocortical tumors: biochemical, immunohistochemical, and molecular studies.
Aromatase immunoreactivity in the rat brain: gonadectomy-sensitive hypothalamic neurons and an unresponsive "limbic ring" of the lateral septum-bed nucleus-amygdala complex.
Corrigendum: Aromatase Derived Estradiol Within the Thalamus Modulates Pain Induced by Varicella Zoster Virus.
Expression of the IGF and the aromatase/estrogen receptor systems in human adrenal tissues from early infancy to late puberty: Implications for the development of adrenarche.
Gonado-histopathological changes, intersex and endocrine disruptor responses in relation to contaminant burden in Tilapia species from Ogun River, Nigeria.
Morphometric characteristics of preantral and antral follicles and expression of factors involved in folliculogenesis in ovaries of adult baboons (Papio anubis).
Hirsutism
Aromatase Deficiency in Two Siblings with 46, XX Karyotype Raised as Different Genders: A Novel Mutation (p.R115X) in CYP19A1 Gene
Estradiol assays--The path ahead.
Idiopathic hirsutism: local and peripheral expression of aromatase (CYP19A) and 5?-reductase genes (SRD5A1 and SRD5A2).
Sex steroids, adiposity and smoking in the pathogenesis of idiopathic hirsutism and polycystic ovary syndrome.
Variable clinical and hormonal manifestations of hyperandrogenemia.
Hydatidiform Mole
Low aromatase activity in microsomes from complete hydatidiform mole.
Quantitative evaluation of human placental aromatase in abnormal pregnancy--anencephalus and hydatidiform mole.
[Estrogen biosynthesis in human female adipose tissue in vitro]
Hydronephrosis
Retroperitoneal leiomyomata as a cause of bilateral hydronephrosis and lumbosciatic pain.
Hyperaldosteronism
Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?
Hyperalgesia
Aromatase inhibition exacerbates pain and reactive gliosis in the dorsal horn of the spinal cord of female rats caused by spinothalamic tract injury.
Colocalization of aromatase in spinal cord astrocytes: differences in expression and relationship to mechanical and thermal hyperalgesia in murine models of a painful and a non-painful bone tumor.
Expression of aromatase in the rostral ventromedial medulla and its role in the regulation of visceral pain.
Pharmacological Modulation of Endogenous Opioid Activity to Attenuate Neuropathic Pain in Rats.
The relationship of bone-tumor-induced spinal cord astrocyte activation and aromatase expression to mechanical hyperalgesia and cold hypersensitivity in intact female and ovariectomized mice.
Hyperandrogenism
Aromatase inhibitors in pediatrics.
Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women.
Extra-Ovarian Gonadotropin Negative Feedback Revealed by Aromatase Inhibition in Female Marmoset Monkeys.
Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women.
Gestational Hyperandrogenism in Developmental Programming.
Growth factor-mediated regulation of aromatase activity in human skin fibroblasts.
Hyperandrogenic states in pregnancy.
Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Pathophysiological mechanisms of gonadotropins- and steroid hormones-related genes in etiology of polycystic ovary syndrome.
Pregnancy outcomes in women with congenital virilizing adrenal hyperplasia.
Serum insulin-like factor 3 levels during puberty in healthy boys and boys with Klinefelter syndrome.
SNP rs2470152 in CYP19 is correlated to aromatase activity in Chinese polycystic ovary syndrome patients.
The role of AMH in the pathophysiology of polycystic ovarian syndrome.
Unusual Virilization in Girls with Juvenile Granulosa Cell Tumors of the Ovary Is Related to Intratumoral Aromatase Deficiency.
Hypercalcemia
Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Usefulness of 22-oxa-1,25-dihydroxyvitamin D-3 (OCT) as a single agent or combined therapy with aromatase inhibitor (CGS 16949A) on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Hypercholesterolemia
Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients.
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
Hyperglycemia
Hyperglycemia perturbs biochemical networks in human trophoblast BeWo cells.
Hyperinsulinism
CYP19 gene expression in subcutaneous adipose tissue is associated with blood pressure in women with polycystic ovary syndrome.
Hepatic glucose intolerance precedes hepatic steatosis in the male aromatase knockout (ArKO) mouse.
Insulin increases 17 beta-estradiol production by the dominant follicle of the first postpartum follicle wave in dairy cows.
The effect of insulin on aromatase activity in isolated human endometrial glands and stroma.
The effects of experimental hyperinsulinemia on steroid secretion, ovarian [125I]insulin binding, and ovarian [125I]insulin-like growth-factor I binding in the rat.
[Obesity and cancer]
Hyperlipidemias
Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients.
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Hyperparathyroidism
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Hyperparathyroidism, Primary
Vertebral fractures cascade: potential causes and risk factors.
Hyperprolactinemia
In vitro effects of prolactin and dexamethasone on rat Leydig cell aromatase activity.
Long-term hyperprolactinaemia reduces basal but not androgen-stimulated oestradiol production in small antral follicles of the rat ovary.
Menometrorrhagia, infertility, elevated serum estradiol, and hyperprolactinemia resulting from increased aromatase activity (MIEHA syndrome).
Testicular response to human chorionic gonadotrophin in chronic hyperprolactinaemia.
The effects of prolactin on rat ovarian function.
The effects of prolactin on rat testicular steroidogenic enzyme activities.
Hypersensitivity
Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways.
Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.
Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.
Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.
The relationship of bone-tumor-induced spinal cord astrocyte activation and aromatase expression to mechanical hyperalgesia and cold hypersensitivity in intact female and ovariectomized mice.
Use of aromatase inhibitors in breast carcinoma.
Hypersensitivity, Delayed
Delayed hypersensitivity reactions to multiple aromatase inhibitors followed by successful desensitization to letrozole.
Hypertension
19-Nor-corticosteroids in genetic hypertension. Effects of inhibitors of 11 beta, 18, 19-hydroxylase activity.
A genetic polymorphism in the CYP19A1 gene and the risk of hypertension among midlife women.
Anastrozole in Pulmonary Arterial Hypertension (AIPH): A Randomized, Double-Blind Placebo-Controlled Trial.
Antihypertensive effects of an aromatase inhibitor in the spontaneously hypertensive rat.
Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients.
Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).
Estrogens are neuroprotective factors for hypertensive encephalopathy.
Genetic Variant in the CYP19A1 Gene Associated with Coronary Artery Disease.
Sex and body mass index specific regulation of blood pressure by CYP19A1 gene variants.
Sex- and Obesity-specific Association of Aromatase (CYP19A1) Gene Variant with Apolipoprotein B and Hypertension.
Hypertension, Pregnancy-Induced
Aromatase and estrogen 2-hydroxylase activities of human placental microsomes in pregnancy-induced hypertension.
Hypertension, Pulmonary
Anastrozole in Pulmonary Arterial Hypertension (AIPH): A Randomized, Double-Blind Placebo-Controlled Trial.
Metformin Reverses Development of Pulmonary Hypertension via Aromatase Inhibition.
Hyperthyroidism
Aromatase activity of human adipose tissue stromal cells: effects of thyroid hormones and progestogens.
Inhibition of follicle-stimulating hormone induction of aromatase activity in porcine granulosa cells by thyroxine and triiodothyronine.
Thyroid hormone modulates offspring sex ratio in a turtle with temperature-dependent sex determination.
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Hypesthesia
A prospective study of aromatase inhibitor therapy initiation and self-reported side effects.
Hypoglycemia
Ultra-High-Performance Liquid Chromatography-Electrospray Ionization-Mass Spectrometry for High-Neuroanatomical Resolution Quantification of Brain Estradiol Concentrations.
Hypogonadism
A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom).
Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma.
Androgen deficiency, diabetes, and the metabolic syndrome in men.
Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood.
Aromatase inhibition for the treatment of idiopathic hypogonadotropic hypogonadism in men with premature ejaculation.
Aromatase inhibitors in male sex.
Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects.
Clinical Use of Aromatase Inhibitors in Adult Males.
Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion.
Cognition is not modified by large but temporary changes in sex hormones in men.
Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone.
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred.
Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels.
Effect of Lifestyle Intervention on the Hormonal Profile of Frail, Obese Older Men.
Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels.
Efficacy of Non-Testosterone-Based Treatment in Hypogonadal Men: A Review.
Estradiol assays--The path ahead.
High aromatase activity in hypogonadal men is associated with higher spine bone mineral density, increased truncal fat and reduced lean mass.
How does obesity affect fertility in men - and what are the treatment options?
Hypogonadism Associated with Cyp19a1 (Aromatase) Posttranscriptional Upregulation in Celf1 Knockout Mice.
Hypogonadism in a male-to-female transsexual with super obesity.
Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism.
MECHANISMS IN ENDOCRINOLOGY: Estradiol as a male hormone.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Oxytocin mediates the estrogen-dependent contractile activity of endothelin-1 in human and rabbit epididymis.
Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone.
Sex steroids and sexual desire in a man with a novel mutation of aromatase gene and hypogonadism.
Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone.
The Effect of Aromatase on the Reproductive Function of Obese Males.
The effect of excess body fat on female and male reproduction.
The imbalance of sex-hormones related to depressive symptoms in obese men.
The use of D-chiro-Inositol in clinical practice.
Therapeutic uses of aromatase inhibitors in men.
Treatment of the Hypogonadal Infertile Male-A Review.
Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5alpha-reductase and steroid aromatase.
Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads.
[Anabolic steroid induced hypogonadism in men: overview and case report].
Hypospadias
A loss of estrogen signaling in the aromatase deficient mouse penis results in mild hypospadias.
Dysregulated expression of androgen metabolism genes and genetic analysis in hypospadias.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Hypotension
Indinavir inhibits the expression of cytoplasmic aromatase and nuclear SREBP in the hippocampus of reperfusion injury-induced ischemic rats.
Megestrol acetate inhibits the expression of cytoplasmic aromatase through nuclear C/EBP? in reperfusion injury-induced ischemic rat hippocampus.
Hypothyroidism
Exemestane-induced subclinical hypothyroidism : a case report.
Hypothyroidism affects lipid and glycogen content and peroxisome proliferator-activated receptor ? expression in the ovary of the rabbit.
Macroorchidism in childhood and adolescence: an update.
Ovarian cysts in prepubertal girls.
Short term hypothyroidism affects ovarian function in the cycling rat.
[Macroorchidism: A case report.]
Infarction, Middle Cerebral Artery
Aromatase cytochrome P450 and extragonadal estrogen play a role in ischemic neuroprotection.
Estrogen synthesis in the central nucleus of the amygdala following middle cerebral artery occlusion: role in modulating neurotransmission.
Infections
Aromatase expression in the cerebellum of the dog infected with canine distemper virus.
Aromatase in normal and diseased liver.
Endotoxin induced TLR4 signaling downregulates CYP19A1 expression through CEBPB in buffalo granulosa cells.
Immediate breast reconstruction surgery with expander/direct implant and use of acellular dermal matrix: Does hormone therapy increases the risk of infection?
Induction of cyclin D2 in rat granulosa cells requires FSH-dependent relief from FOXO1 repression coupled with positive signals from Smad.
Ligula intestinalis infection is associated with alterations of both brain and gonad aromatase expression in roach ( Rutilus rutilus).
Liver receptor homolog-1 stimulates the progesterone biosynthetic pathway during follicle-stimulating hormone-induced granulosa cell differentiation.
Localization and regulation of aromatase liver receptor homologue-1 in the developing rat testis.
Infertility
A randomized comparison of ovulation induction and hormone profile between the aromatase inhibitor anastrozole and clomiphene citrate in women with infertility.
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
Aromatase (Cyp19) expression is up-regulated by targeted disruption of Dax1.
Aromatase expression and role of estrogens in male gonad : a review.
Aromatase inhibition for ovarian stimulation: future avenues for infertility management.
Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility.
Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation.
Aromatase Inhibitors for Endometriosis-Associated Infertility; Do We Have Sufficient Evidence?
Aromatase inhibitors for infertility in polycystic ovary syndrome. The beginning or the end of a new era?
Aromatase inhibitors for ovulation and pregnancy in polycystic ovary syndrome.
Aromatase inhibitors for the treatment of infertility.
Aromatase inhibitors in infertility treatment: risks and benefits.
Aromatase inhibitors in ovarian stimulation.
Aromatase inhibitors in ovulation induction.
Aromatase inhibitors in the treatment of endometriosis.
Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics.
Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome.
Clomiphene and anti-oestrogens for ovulation induction in PCOS.
Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome.
Clomiphene citrate or aromatase inhibitors for superovulation in women with unexplained infertility undergoing intrauterine insemination: a prospective randomized trial.
Comparison of clomiphene and letrozole for superovulation in patients with unexplained infertility undergoing intrauterine insemination: A systematic review and meta-analysis.
Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphen citrate gonadotropins in controlled ovarian hyperstimulation: a prospective, simply randomized, clinical trial.
Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle-stimulating hormone in controlled ovarian hyperstimulation: a prospective, randomized, blinded clinical trial.
Correlation between aromatase expression in the eutopic endometrium of symptomatic patients and the presence of endometriosis.
Discovery and development of a novel class of nonsteroidal aromatase inhibitors.
Down-regulation of the CYP19A1 gene in cumulus cells of infertile women with endometriosis.
Editor's Note: Badawy A, Shokeir T, Allam AF and Abdelhady H. Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility. Acta Obstetricia et Gynecologica Scandinavica, 2009; 88:187-191.
Effects of dibutylphthalate and ethynylestradiol on liver peroxisomes, reproduction, and development of zebrafish (Danio rerio).
Efficacy of Non-Testosterone-Based Treatment in Hypogonadal Men: A Review.
Empiric medical therapy with hormonal agents for idiopathic male infertility.
Endometrial thickness in women undergoing IUI with ovarian stimulation. How thick is too thin? A systematic review and meta-analysis.
Epigenetic alterations of CYP19A1 gene in Cumulus cells and its relevance to infertility in endometriosis.
Estimating rates of multiple gestation pregnancies: Sample size calculation from the assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial.
Estrogens and male reproduction.
Estrogens--male hormones?
Evidence-based treatments for couples with unexplained infertility: a guideline.
Genetic or enzymatic disruption of aromatase inhibits the growth of ectopic uterine tissue.
High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome.
How does obesity affect fertility in men - and what are the treatment options?
Identification of NR0B1 as a novel androgen receptor co-repressor in mouse Sertoli cells.
Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene.
In vitro bioassay for human serum follicle-stimulating hormone (FSH) based on L cells transfected with recombinant rat FSH receptor: validation of a model system.
Influence of intrahypothalamic implants of antioestrogen or aromatase inhibitor on development of sterility following neonatal androgenization in female rats.
Inhibition of central nervous system aromatase activity: a mechanism for fenarimol-induced infertility in the male rat.
Is aromatase expression in the endometrium the cause of endometriosis and related infertility?
Letrozole for Female Infertility.
Letrozole for ovulation induction and controlled ovarian hyperstimulation.
Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.
Leydig cell-specific expression of DAX1 improves fertility of the Dax1-deficient mouse.
Liver receptor homologue-1 and steroidogenic factor-1 expression in cultured granulosa cells from patients with endometriosis: A preliminary study.
Menometrorrhagia, infertility, elevated serum estradiol, and hyperprolactinemia resulting from increased aromatase activity (MIEHA syndrome).
Misclassification in Assessment of First Trimester In-utero Exposure to Drugs Used Proximally to Conception: the Example of Letrozole Utilization for Infertility Treatment.
Multilocus analyses of estrogen-related genes reveal involvement of the ESR1 gene in male infertility and the polygenic nature of the pathology.
Mutation of cyp19a1b results in sterile males due to efferent duct obstruction in Nile tilapia.
Novel therapeutic targets to improve IVF outcomes in endometriosis patients: a review and future prospects.
Oral agents for ovulation induction - clomiphene citrate versus aromatase inhibitors.
Oral Drugs for Unexplained Infertility.
Ovulation induction in women with infertility: a new indication for aromatase inhibitors.
Polycystic ovary syndrome and infertility: an update.
Polymorphic variants of CYP17 and CYP19A and risk of infertility in endometriosis.
Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility.
Randomized controlled trial of three doses of letrozole for ovulation induction in patients with unexplained infertility.
Recent advances in the understanding and management of polycystic ovary syndrome.
RETRACTED: Clomiphene citrate or aromatase inhibitors for superovulation in women with unexplained infertility undergoing intrauterine insemination: a prospective randomized trial.
Role of aromatase inhibitor in ovulation induction in patients with poor response to clomiphene citrate.
Sex reversal and aromatase in chicken.
The case for aromatase inhibitors use in Oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in Breast Cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
The Effect of Aromatase on the Reproductive Function of Obese Males.
THE EFFECTS OF MATERNAL HYPOTHYROIDISM ON THE IMMUNOREACTIVITY OF CYTOCHROME P450 AROMATASE IN THE POSTNATAL RAT TESTICLES.
The Genetic Background of Endometriosis: Can ESR2 and CYP19A1 Genes Be a Potential Risk Factor for Its Development?
The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.
The use of D-chiro-Inositol in clinical practice.
Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover.
Treatment of unexplained infertility with aromatase inhibitors or clomiphene citrate: a systematic review and meta-analysis.
Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate.
Use of aromatase inhibitors in practice of gynecology.
[Aromatase inhibitors--is it a new opportunity in the treatment of infertility?]
[Diagnostic value of the detection of aromatase cytochrome P450 and CA125 for endometriosis]
[Semiquantitative analysis of mRNA aromatase expression in eutopic endometrium as a diagnostic marker of endometriosis and estrogen dependent diseases]
Infertility, Female
Aromatase gene (CYP19A1) variants, female infertility and ovarian stimulation outcome: a preliminary report.
Aromatase inhibitors for female infertility: a systematic review of the literature.
Infertility, Male
A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility.
Aromatase inhibitors for male infertility.
Big enough for an aromatase inhibitor? How adiposity affects male fertility.
Do men with normal testosterone-oestradiol ratios benefit from letrozole for the treatment of male infertility?
Effect of letrozole on spermogram parameters and hormonal profile in infertile men: A clinical trial study.
Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ?25 kg/m2.
Estrogen promotes Leydig cell engulfment by macrophages in male infertility.
Insights into the role of androgen receptor in human testicular peritubular cells.
Localization and regulation of aromatase liver receptor homologue-1 in the developing rat testis.
Mutation of cyp19a1b results in sterile males due to efferent duct obstruction in Nile tilapia.
Re: Aromatase inhibitors for male infertility.
Re: aromatase inhibitors for male infertility.
The effect of obesity on human reproductive health and foetal life.
Transgenic mice expressing p450 aromatase as a model for male infertility associated with chronic inflammation in the testis.
Use of the aromatase inhibitor letrozole to treat male infertility.
[A study on intratesticular aromatase activity in male infertility]
[A study on testicular aromatase activity--spermatogenic damage in high testicular E2 models of rat]
Inflammatory Bowel Diseases
Thrombotic risk and immobility in residents of long-term care facilities.
Inflammatory Breast Neoplasms
Profile of Steroid Receptors and Increased Aromatase Immunoexpression in Canine Inflammatory Mammary Cancer as a Potential Therapeutic Target.
Insulin Resistance
Acupuncture does not ameliorate metabolic disturbances in the P450 aromatase inhibitor-induced rat model of polycystic ovary syndrome.
Aromatase deficiency in a male patient - Case report and review of the literature.
Aromatase Inhibition Reduces Insulin Sensitivity in Healthy Men.
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-? and GPER signalling.
Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection.
Association between Metabolic Syndrome and Cancer.
Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition.
Deletion of tumor necrosis factor-alpha receptor type 1 exacerbates insulin resistance and hepatic steatosis in aromatase knockout mice.
Deregulation of WNT2/FZD3/?-catenin pathway compromises the estrogen synthesis in cumulus cells from patients with polycystic ovary syndrome.
Effect of polymorphisms in selected genes involved in pituitary-testicular function on reproductive hormones and phenotype in aging men.
Endogenous hormone metabolism as an exposure marker in breast cancer chemoprevention studies.
Estrogen and adiposity--utilizing models of aromatase deficiency to explore the relationship.
Genetic Determinants of Circulating Estrogen Levels and Evidence of a Causal Effect of Estradiol on Bone Density in Men.
Growth factor-mediated regulation of aromatase activity in human skin fibroblasts.
Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors.
Increased adipose tissue aromatase activity improves insulin sensitivity and reduces adipose tissue inflammation in male mice.
Increased adipose tissue in male and female estrogen receptor-alpha knockout mice.
Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer.
Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
Liuwei Dihuang Pills alleviate the polycystic ovary syndrome with improved insulin sensitivity through PI3K/Akt signaling pathway.
Marine-derived omega-3 Fatty acids.
Melatonin: A Molecule for Reducing Breast Cancer Risk.
Metformin, Estrogen Replacement Therapy and Gonadotropin Inhibition Fail to Improve Insulin Sensitivity in a Girl with Aromatase Deficiency.
Obesity-associated Breast Cancer: Analysis of risk factors.
Oestradiol replacement treatment and glucose homeostasis in two men with congenital aromatase deficiency: evidence for a role of oestradiol and sex steroids imbalance on insulin sensitivity in men.
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Serotonin transporter deficiency drives estrogen-dependent obesity and glucose intolerance.
Sex- and Obesity-specific Association of Aromatase (CYP19A1) Gene Variant with Apolipoprotein B and Hypertension.
Testosterone treatment increases androgen receptor and aromatase gene expression in myotubes from patients with PCOS and controls, but does not induce insulin resistance.
The effect of adipocyte-macrophage cross-talk in obesity-related breast cancer.
The metabolic syndrome: A high-risk state for cancer?
The role of AMH in the pathophysiology of polycystic ovarian syndrome.
The role of estrogen and estrogen receptor-alpha in male adipose tissue.
The use of D-chiro-Inositol in clinical practice.
Use of Network Pharmacology to Explore the Mechanism of Gegen (Puerariae lobatae Radix) in the Treatment of Type 2 Diabetes Mellitus Associated with Hyperlipidemia.
Variants in the aromatase gene and on the Y-chromosome are not associated with adult height or insulin resistance in a UK population.
Intellectual Disability
Genetics of androgen metabolism in women with infertility and hypoandrogenism.
Ischemic Stroke
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
Association of Genetically Predicted Serum Estradiol With Risk of Thromboembolism in Men: A Mendelian Randomization Study.
Increased P450 aromatase levels in post-menopausal women after acute ischemic stroke.
Joint Instability
Transmission of relaxin and estrogens to suckling canine pups via milk and possible association with hip joint laxity.
Keloid
Eruptive keloids associated with aromatase inhibitor therapy.
Klinefelter Syndrome
Evaluation of boys with marked breast development at puberty.
Immunoexpression of androgen receptors and aromatase in testes of patient with Klinefelter's syndrome.
Re: successful testicular sperm retrieval in adolescents with Klinefelter syndrome treated with at least 1 year of topical testosterone and aromatase inhibitor.
Successful testicular sperm retrieval in adolescents with Klinefelter syndrome treated with at least 1 year of topical testosterone and aromatase inhibitor.
Language Disorders
The aromatase gene CYP19A1: several genetic and functional lines of evidence supporting a role in reading, speech and language.
Leiomyoma
A case of benign metastasizing leiomyoma treated by surgical castration followed by an aromatase inhibitor, anastrozole.
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients.
Adenomyosis: the pathophysiology of an oestrogen-dependent disease.
Aromatase activity in uterine leiomyomata.
Aromatase and leiomyoma of the uterus.
Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis.
Aromatase expression in uterine leiomyomata is regulated primarily by proximal promoters I.3/II.
Aromatase inhibitor therapy for uterine bleeding in a postmenopausal woman with leiomyomata.
Aromatase inhibitors for uterine fibroids.
Aromatase: Contributions to Physiology and Disease in Women and Men.
Benign leiomyoma with multiple metastases to vertebrae and calvarium: An index case with comprehensive review of endocrine targets.
CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma.
Decreased expression of aromatase in the Ishikawa and RL95-2 cells by the isoflavone, puerarin, is associated with inhibition of c-jun expression and AP-1 activity.
Detection of aromatase cytochrome P-450 in endometrial biopsy specimens as a diagnostic test for endometriosis.
Effect of aminoglutethimide on androstenedione aromatase activity in human uterine leiomyoma.
Effect of the aromatase inhibitor anastrozole on uterine and leiomyoma doppler blood flow in patients scheduled for hysterectomy: a pilot study.
Effects of letrozole on proliferation and apoptosis in cultured leiomyoma cells treated with prostaglandin E(2).
Endocrine disorders associated with inappropriately high aromatase expression.
Endometriosis: the pathophysiology as an estrogen-dependent disease.
Expression of the CYP19 gene and its product aromatase cytochrome P450 in human uterine leiomyoma tissues and cells in culture.
Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas.
Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study.
High aromatase expression in uterine leiomyoma tissues of African-American women.
High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome.
In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism.
Inhibition of in situ expression of aromatase P450 in leiomyoma of the uterus by leuprorelin acetate.
Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment.
Medical therapy for fibroids: An overview.
Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications.
Overexpression of aromatase P450 in leiomyoma tissue is driven primarily through promoter I.4 of the aromatase P450 gene (CYP19).
Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium.
Protein Expression of Estrogen Receptors ? and ? and Aromatase in Myometrium and Uterine Leiomyoma.
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.
Retroperitoneal leiomyomata as a cause of bilateral hydronephrosis and lumbosciatic pain.
Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women.
Selective aromatase inhibition by pyridoglutethimide, an analogue of aminoglutethimide.
Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor.
Suicide inactivation of aromatase in human placenta and uterine leiomyoma by 5 alpha-dihydronorethindrone, a metabolite of norethindrone, and its effect on steroid-producing enzymes.
Treatment of symptomatic uterine leiomyoma with letrozole.
Use of aromatase inhibitors in practice of gynecology.
[Effects of metformin on the expression of estrogen synthetase and ER mRNA in uterine leiomyoma tissues].
[Possibilities to use the aromatase inhibitors for the treatment of the uterine fibroids]
Leiomyomatosis
Intravenous leiomyomatosis treated with aromatase inhibitor therapy.
Intravenous leiomyomatosis treated with radical hysterectomy and adjuvant aromatase inhibitor therapy.
Long-term efficacy and safety of aromatase inhibitor use for leiomyomatosis peritonealis disseminata.
Successful management of a leiomyomatosis peritonealis disseminata with an aromatase inhibitor.
Leiomyosarcoma
Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis.
Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor.
Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.
Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors.
Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Leprosy
Influence of Genetic Ancestry on INDEL Markers of NFK?1, CASP8, PAR1, IL4 and CYP19A1 Genes in Leprosy Patients.
Leukemia
Characterization of 17 beta-hydroxysteroid dehydrogenase IV.
Evaluation of selected lichens from iceland for cancer chemopreventive and cytotoxic activity.
Expression and regulation of aromatase and 17 beta-hydroxysteroid dehydrogenase type 4 in human THP 1 leukemia cells.
Ontogeny of elongation and gene expression in the early developing porcine conceptus.
[The morphological and molecular biological signs of impaired endometrial receptivity in infertility in women suffering from external genital endometriosis].
Leukemia, Lymphocytic, Chronic, B-Cell
Regression of chronic lymphocytic leukemia with aromatase inhibitor-letrozole?
Leukemia, Myeloid
Expression and regulation of aromatase and 17 beta-hydroxysteroid dehydrogenase type 4 in human THP 1 leukemia cells.
Leukemia, T-Cell
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
Leukopenia
The efficacy of acupoint stimulation for the management of therapy-related adverse events in patients with breast cancer: a systematic review.
Leydig Cell Tumor
Aromatase activity in a rat Leydig cell tumor.
Aromatase messenger RNA is derived from the proximal promoter of the aromatase gene in Leydig, Sertoli, and germ cells of the rat testis.
Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor.
Inhibition of Leydig tumor cell steroidogenesis by 10-propargylestr-4-ene-3,17-dione, an irreversible aromatase inhibitor.
Oestrogen secreting Leydig cell tumour and GnRH agonist in-vivo and in-vitro studies.
The structure of cDNA clones encoding the aromatase P-450 isolated from a rat Leydig cell tumor line demonstrates differential processing of aromatase mRNA in rat ovary and a neoplastic cell line.
Li-Fraumeni Syndrome
Hsp90 and PKM2 Drive the Expression of Aromatase in Li-Fraumeni Syndrome Breast Adipose Stromal Cells.
Withdrawal: Hsp90 and PKM2 drive the expression of aromatase in Li-Fraumeni syndrome breast adipose stromal cells.
Lichen Sclerosus et Atrophicus
Lichen Sclerosus in a Breast Cancer Survivor on an Aromatase Inhibitor: A Case Report.
Lipedema
Adipose stem cells from lipedema and control adipose tissue respond differently to adipogenic stimulation in vitro.
Adipose Stem Cells from Lipedema and Control Adipose Tissue Respond Differently to Adipogenic Stimulation In Vitro.
Liver Cirrhosis
Aromatase in human liver and its diseases.
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Liver Cirrhosis, Biliary
Aromatase in normal and diseased liver.
Liver Diseases
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Hydroxylation and sulfation of sex steroid hormones in inflammatory liver.
Liver Neoplasms
Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells.
Endocrine disorders associated with inappropriately high aromatase expression.
Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Merlin, the product of NF2 gene, is associated with aromatase expression and estrogen formation in human liver tissues and liver cancer cells.
Metabolic profiles of androgens in malignant human liver cell lines.
Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma.
Synchronous presentation of breast cancer and hepatocellular carcinoma in a postmenopausal woman: dual action of aromatase inhibitor on breast and hepatic cancer cells?
Lordosis
Blockade of lordosis by androst-1,4,6-triene-3,17-dione (ATD) and tamoxifen in female hamsters primed with testosterone propionate.
Male rats with same-sex preference show higher immobility in the forced swim test, but similar effects of fluoxetine and desipramine than males that prefer females.
The development of female sexual behavior requires prepubertal estradiol.
Lung Diseases
Tissue concentrations of estrogens and aromatase immunolocalization in interstitial pneumonia of human lung.
[Relationship between level of sexual hormone in external blood and aromatase expression in cancer tissues of male patients with lung cancer]
Lung Diseases, Interstitial
Tissue concentrations of estrogens and aromatase immunolocalization in interstitial pneumonia of human lung.
[A Case of Recurrent Breast Cancer with Drug-Induced Interstitial Pneumonia Triggered by the Switch from an Original to a Generic Aromatase Inhibitor].
Lung Neoplasms
Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: A population-based study.
Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas.
Aromatase expression in lung cancer.
Aromatase Expression Predicts Survival in Women with Early-Stage Non Small Cell Lung Cancer.
Aromatase in human lung carcinoma.
Aromatase inhibitors combined with aspirin to prevent lung cancer in preclinical models.
Aromatase inhibitors in human lung cancer therapy.
Changes in aromatase (CYP19) gene promoter usage in non-small cell lung cancer.
Co-expression of estrogen receptor beta and aromatase in Japanese lung cancer patients: Gender-dependent clinical outcome.
CYP19A1 gene polymorphisms and risk of lung cancer.
Cytochrome P450 in non-small cell lung cancer related to exogenous chemical metabolism.
Estrogen receptor 1 gene expression and its combination with estrogen receptor 2 or aromatase expression predicts survival in non-small cell lung cancer.
Estrogen receptor signaling in lung cancer.
Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.
Expression of aromatase CYP19 and its relationship with parameters in NSCLC.
Female reproductive factors, gene polymorphisms in the estrogen metabolism pathway, and risk of lung cancer in chinese women.
Flavonoids as prospective aromatase inhibitors in breast cancer prevention/therapy.
Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer.
Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.
Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.
Prognostic relevance of estrogen receptor ?, ? and aromatase expression in non-small cell lung cancer.
Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma.
Role of Hormone Receptor Expression in Patients With Advanced-Stage Lung Cancer Treated With Chemotherapy.
Smoking out reproductive hormone actions in lung cancer.
Targeting aromatase and estrogen signaling in human non-small cell lung cancer.
The inhibition of aromatase alters the mechanical and rheological properties of non-small-cell lung cancer cell lines affecting cell migration.
The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer.
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Usefulness of predictive tests for cancer treatment.
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
[Relationship between level of sexual hormone in external blood and aromatase expression in cancer tissues of male patients with lung cancer]
Lupus Erythematosus, Cutaneous
Anastrozole-induced subacute cutaneous lupus erythematosus.
Lupus Erythematosus, Systemic
Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus.
Estrogens and autoimmune diseases.
Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus.
The effect of antiestrogen agents on risk of autoimmune disorders in patients with breast cancer.
The management of secondary osteoporosis.
Luteoma
Gestational Hyperandrogenism in Developmental Programming.
Lymphangioleiomyomatosis
A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
Lymphatic Metastasis
Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.
Expression of aromatase in tumor related stroma is associated with human bladder cancer progression.
Glycogen-rich clear cell carcinoma of the breast.
Immunohistochemical study of KiSS1 and KiSS1R expression in human primary breast cancer: Association with breast cancer receptor status, proliferation markers and clinicopathological features.
Lymphedema
Exercise for secondary prevention of breast cancer: moving from evidence to changing clinical practice.
Sex Hormones in Lymphedema.
The efficacy of acupoint stimulation for the management of therapy-related adverse events in patients with breast cancer: a systematic review.
Lymphoma
Effect of Letrozole, a selective aromatase inhibitor, on testicular activities in adult mice: Both in vivo and in vitro study.
Inhibition of estrogen biosynthesis enhances lymphoma growth in mice.
Macroorchidism in childhood and adolescence: an update.
[Macroorchidism: A case report.]
Lymphoma, B-Cell
Betaine ameliorates impaired steroidogenesis and apoptosis in mice granulosa cells induced by high glucose concentration.
Synthesis and Evaluation of Novel Cholestanoheterocyclic Steroids as Anticancer Agents.
Malaria
Is the role of estrogens and estrogen receptors in epilepsy still underestimated?
Topological polar surface area: a useful descriptor in 2D-QSAR.
Malnutrition
Age-related decrease in aromatase and estrogen receptor (ERalpha and ERbeta) expression in rat testes: protective effect of low caloric diets.
Effects of maternal undernutrition during lactation on aromatase, estrogen, and androgen receptors expression in rat testis at weaning.
Impaired hypothalamic-pituitary-gonadal axis function in men with diabetes mellitus.
Maternal malnutrition during lactation affects folliculogenesis, gonadotropins, and leptin receptors in adult rats.
Mammary Neoplasms, Animal
Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor.
Three-component model of oestrogen formation and regulation of intratumoural oestrogen pool in breast neoplasms.
Mania
Sex differences in behavioral and neurochemical effects of gonadectomy and aromatase inhibition in rats.
Melanoma
Aminoglutethimide in malignant melanoma. A phase II study.
Colocalization of aromatase in spinal cord astrocytes: differences in expression and relationship to mechanical and thermal hyperalgesia in murine models of a painful and a non-painful bone tumor.
Marked heterogeneity of aromatase activity in human malignant melanoma tissue.
Polymorphisms in CYP19A1 and NFKB1 genes are associated with cutaneous melanoma risk in southern Brazilian patients.
Memory Disorders
Adverse Effects of Aromatase Inhibition on the Brain and Behavior in a Nonhuman Primate.
Aromatase inhibition abolishes LTP generation in female but not in male mice.
Cognitive Effects of Aromatase and Possible Role in Memory Disorders.
Pharmacological blockade of the aromatase enzyme, but not the androgen receptor, reverses androstenedione-induced cognitive impairments in young surgically menopausal rats.
Meningioma
Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells.
Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study.
Menopause, Premature
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Management of cancer treatment-induced bone loss.
Prevention of osteoporosis after breast cancer.
[ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
[Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
Menorrhagia
Aromatase expression in the eutopic endometrium of myomatous uteri: the influence of the menstrual cycle and oral contraceptive use.
Aromatase inhibitor treatment of menorrhagia and subsequent pregnancy in a patient with familial hyperparathyroidism-jaw tumor syndrome.
Current and Future Medical Therapies for Adenomyosis.
Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies.
The effect of oral contraceptives on aromatase and Cox-2 expression in the endometrium of patients with idiopathic menorrhagia or adenomyosis.
Mesothelioma
Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells.
Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.
Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease.
Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities.
Modulation of reactive oxygen species via ERK and STAT3 dependent signalling are involved in the response of mesothelioma cells to exemestane.
Mesothelioma, Malignant
Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells.
Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease.
Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities.
Metabolic Syndrome
A novel compound heterozygous mutation of the aromatase gene in an adult man: reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome.
Androgen deficiency, diabetes, and the metabolic syndrome in men.
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-? and GPER signalling.
Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse.
Cholesterol feeding prevents adiposity in the obese female aromatase knockout (ArKO) mouse.
Estrogen and adiposity--utilizing models of aromatase deficiency to explore the relationship.
Generation and characterization of a mouse model of the metabolic syndrome: apolipoprotein E and aromatase double knockout mice.
Hepatic glucose intolerance precedes hepatic steatosis in the male aromatase knockout (ArKO) mouse.
Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis.
The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals.
The metabolic syndrome: A high-risk state for cancer?
The regulatory effect of genistein on P450 aromatase and follicle-stimulating hormone receptor in mouse experimental model of menopausal metabolic syndrome.
Migraine Disorders
Contribution of polymorphisms in ESR1, ESR2, FSHR, CYP19A1, SHBG, and NRIP1 genes to migraine susceptibility in Turkish population.
Investigation of polymorphisms in genes involved in estrogen metabolism in menstrual migraine.
New evidence for involvement of ESR1 gene in susceptibility to Chinese migraine.
Potential role of aromatase over estrogen receptor gene polymorphisms in migraine susceptibility: a case control study from North India.
Multiple Endocrine Neoplasia Type 2a
Aromatase in the human central nervous system.
Multiple Myeloma
Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug-induced thrombocytopenia.
RANK ligand inhibition with denosumab for the management of osteoporosis.
Muscle Weakness
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Muscular Atrophy
Shift from androgen to estrogen action causes abdominal muscle fibrosis, atrophy, and inguinal hernia in a transgenic male mouse model.
Musculoskeletal Pain
A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia.
Aromatase inhibitor-associated musculoskeletal pain: taking 'AIM' at a symptom in breast cancer survivors.
Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience.
Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.
Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast Cancer: A Biological Pathway Analysis.
Genotype, allele and haplotype frequencies of four TCL1A gene polymorphisms associated with musculoskeletal toxicity in the South Indian descent.
High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.
Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer.
Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors.
Omega-3 Fatty Acids for Aromatase Inhibitor-Induced Musculoskeletal Pain: Anything Other Than a Placebo Effect?
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.
Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.
Rheumatic disorders and functional disability with aromatase inhibitor therapy.
Myalgia
Current role and safety profile of aromatase inhibitors in early breast cancer.
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
The aromatase inhibitors in early breast cancer: who, when, and why?
The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy.
Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy.
Myocardial Infarction
Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
Aromatase Inhibition Attenuates Desflurane-Induced Preconditioning against Acute Myocardial Infarction in Male Mouse Heart In Vivo.
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
Association of Genetically Predicted Serum Estradiol With Risk of Thromboembolism in Men: A Mendelian Randomization Study.
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
Myocardial Ischemia
Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
Myoma
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Aromatase expression in the eutopic endometrium of myomatous uteri: the influence of the menstrual cycle and oral contraceptive use.
Aromatase Inhibitors: Potential Reproductive Implications.
Comparing the effect of aromatase inhibitor (letrozole) + cabergoline (Dostinex) and letrozole alone on uterine myoma regression,a randomized clinical trial.
Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies.
Minimally invasive approach for myomectomy.
Preoperative treatment with letrozole in patients undergoing laparoscopic myomectomy of large uterine myomas: a prospective non-randomized study.
Protein Expression of Estrogen Receptors ? and ? and Aromatase in Myometrium and Uterine Leiomyoma.
Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women.
The aromatase expression in myomas and myometriums of women in reproduction and perimenopausal age.
The TRAF2 and TRAF6 expression in myomas and myometrium of women in reproduction and perimenopausal age.
The use of D-chiro-Inositol in clinical practice.
[Estrogen biosynthesis in human uterine myoma tissue. The distribution of androstenedione aromatase activity in uterine myoma tissue]
Myopia
Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors.
Myxoma
Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis.
Treatment of aggressive angiomyxoma with aromatase inhibitor prior to surgical resection.
nadph-hemoprotein reductase deficiency
Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.
Inhibition of placental CYP19A1 activity remains as a valid hypothesis for 46,XX virilization in P450 oxidoreductase deficiency.
Neoplasm Metastasis
A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases.
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
Adjuvant Treatment of Early Breast Cancer in the Elderly.
Aromatase in human liver and its diseases.
Aromatase inhibitor for the treatment of primary mucinous carcinoma of the skin with distant metastasis.
Aromatase inhibitors in breast cancer: an update.
Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-?/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer.
Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case-control study of 11,412 women.
Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast cancer.
Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series.
Clinical practice decisions in endocrine therapy.
Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Current role and safety profile of aromatase inhibitors in early breast cancer.
Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?
CYP19A1 Amplification Promotes Acquired Resistance to Aromatase Inhibitors.
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells.
Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Expression of aromatase in tumor related stroma is associated with human bladder cancer progression.
Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.
Glycogen-rich clear cell carcinoma of the breast.
Immunohistochemical study of KiSS1 and KiSS1R expression in human primary breast cancer: Association with breast cancer receptor status, proliferation markers and clinicopathological features.
Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders.
Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort.
Increased frequency of ESR1 mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor.
Invasive solid papillary carcinoma with neuroendocrine differentiation of the breast: a case report and literature review.
Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment.
Long-Term Survival and Complete Response to Anastrozole in Breast Cancer Patient With Cutaneous Metastases Only.
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature.
MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers.
Molecular Barcode Sequencing of the Whole Ligand Binding Domain of the ESR1 Gene in Cell-Free DNA from Patients with Metastatic Breast Cancer.
Obesity-Altered Adipose Stem Cells Promote ER? Breast Cancer Metastasis through Estrogen Independent Pathways.
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Regression of choroidal metastases from breast carcinoma using aromatase inhibitors.
Response of meningeal carcinomatosis from breast cancer to capecitabine monotherapy: a case report.
Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane.
Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer.
Steroid sulfatase inhibitors: Promising new tools for breast cancer therapy?
Successful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone.
Targeting aromatase and estrogen signaling in human non-small cell lung cancer.
The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease.
The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer.
Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.
Validity of Osteoprotegerin and Receptor Activator of NF-?B Ligand for the Detection of Bone Metastasis in Breast Cancer.
[A Case of Late Recurrence of Breast Cancer Causing Multiple Organ Metastases 27 Years Postoperatively].
[A case of liver metastasis of breast cancer responding to letrozole].
[A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy]
[A Case of Recurrent Breast Cancer with Complete Response to Eribulin Monotherapy after Bevacizumab plus Paclitaxel Combination Therapy].
[Aromatase inhibitors in the adjuvant treatment of postmenopausal patients with early breast cancer: a little, a lot or no way?]
[Establishment of metastatic sub-clone from estrogen independent Ishikawa cells and its characterization in vitro and in vivo]
[New drugs in metastatic breast cancer--1997]
[Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy]
[Treatment strategy of breast carcinoma in the elderly patient-surgery, hormone therapy, and chemotherapy]
Neoplasm Micrometastasis
Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial.
Neoplasms
(Anti)estrogenic effects of phytochemicals on human primary mammary fibroblasts, MCF-7 cells and their co-culture.
1. Estrogen antagonists. Aromatase inhibitors, their pharmacology and application.
2-Chloro-s-triazine herbicides induce aromatase (CYP19) activity in H295R human adrenocortical carcinoma cells: a novel mechanism for estrogenicity?
21. The adjuvant treatment of breast cancer.
3D QSAR studies, pharmacophore modeling and virtual screening on a series of steroidal aromatase inhibitors.
6-Hydroximinoandrostenedione, a new specific inhibitor of estrogen biosynthesis and its effect on T47D human breast cancer cells.
7,8-Dihydroxycoumarin exerts antitumor potential on DMBA-induced mammary carcinogenesis by inhibiting ER?, PR, EGFR, and IGF1R: involvement of MAPK1/2-JNK1/2-Akt pathway.
9-cis retinoic acid improves developmental competence and embryo quality during in vitro maturation of bovine oocytes through the inhibition of oocyte TNF-{alpha} gene expression.
A benzimidazole fungicide, benomyl, and its metabolite, carbendazim, induce aromatase activity in a human ovarian granulose-like tumor cell line (KGN).
A CASE OF AN AROMATASE-PRODUCING SERTOLI CELL TUMOR PRESENTING WITH GYNECOMASTIA.
A Case of Estrogen-secreting Adrenocortical Carcinoma with Subclinical Cushing's Syndrome.
A case of estrogen-secreting adrenocortical carcinoma: Comprehensive immunohistochemical analysis of disorganized steroid genesis.
A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype.
A comparison of human H295R and rat R2C cell lines as in vitro screening tools for effects on aromatase.
A Dehydrogenase Dual Hydrogen Abstraction Mechanism Promotes Estrogen Biosynthesis: Can We Expand the Functional Annotation of the Aromatase Enzyme?
A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance.
A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription.
A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.
A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors.
A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene.
A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7, 12-dimethylbenz[a]anthracene-induced rat mammary tumors.
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
A novel nonradioactive method for measuring aromatase activity using a human ovarian granulosa-like tumor cell line and an estrone ELISA.
A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.
A pilot study of sampling subcutaneous adipose tissue to examine biomarkers of cancer risk.
A risk assessment of atrazine use in California: human health and ecological aspects.
A role for the androgen receptor in the treatment of male breast cancer.
A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy.
A steroidogenic factor-1-binding site and cyclic adenosine 3',5'-monophosphate response element-like elements are required for the activity of the rat aromatase promoter in rat Leydig tumor cell lines.
A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer.
A three-dimensional model of CYP19 aromatase for structure-based drug design.
Aberrant expression of aromatase in breast cancer tissues.
Ability of lymphocytes infiltrating breast-cancer tissue to convert androstenedione.
Abnormal production of androgens in women with breast cancer.
Absence of the K303R estrogen receptor ? mutation in breast cancer patients exhibiting different responses to aromatase inhibitor anastrozole neoadjuvant treatment.
Acceleration of mammary neoplasia in aromatase transgenic mice by 7,12-dimethylbenz[a]anthracene.
Access to care issues adversely affect breast cancer patients in Mexico: oncologists' perspective.
Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.
Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.
Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17?-estradiol biosynthesis in endometrial carcinoma microenvironment.
Activation of peroxisome proliferator-activated receptor-gamma and retinoid X receptor inhibits aromatase transcription via nuclear factor-kappaB.
Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.
Activin signaling through type IB activin receptor stimulates aromatase activity in the ovarian granulosa cell-like human granulosa (KGN) cells.
Acupuncture for cancer pain and related symptoms.
Adaptation of an Evidence-Based Arthritis Program for Breast Cancer Survivors on Aromatase Inhibitor Therapy Who Experience Joint Pain.
Adaptation of Estrogen-regulated Genes in Long-term Estradiol Deprived MCF-7 Breast Cancer Cells.
Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells.
Adaptive changes results in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors.
Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance.
Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients.
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer.
Adherence to Adjuvant Hormonal Therapy and Its Relationship to Breast Cancer Recurrence and Survival Among Low-income Women.
Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives.
Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients.
Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?
Adjuvant endocrine therapy effects on bone mineral density and microstructure in women with breast cancer.
Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Adjuvant Treatment of Early Breast Cancer in the Elderly.
Adjuvant treatment of elderly breast cancer patients.
Adult granulosa cell tumors of the ovary: a retrospective study of 30 cases with respect to the expression of steroid synthesis enzymes.
Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma.
Adverse Drug Event-based Stratification of Tumor Mutations: A Case Study of Breast Cancer Patients Receiving Aromatase Inhibitors.
Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy.
Adverse Outcome Pathways for Regulatory Applications: Examination of Four Case Studies With Different Degrees of Completeness and Scientific Confidence.
AKT activation predicts outcome in breast cancer patients treated with tamoxifen.
Alcohol Promotes Mammary Tumor Development via the Estrogen Pathway in Estrogen Receptor Alpha-Negative HER2/neu Mice.
Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial.
Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer.
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors.
Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology.
Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor.
Altering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitors.
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Aminoglutethimide as an aromatase inhibitor in the treatment of cancer.
Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review.
Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.
An aroma of complexity: how the unique genetics of aromatase (CYP19A1) explain diverse phenotypes from hens and hyenas to human gynecomastia, and testicular and other tumors.
An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells.
An integrated view of aromatase and its inhibition.
An oestrogen-producing seminoma responsible for gynaecomastia.
An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor- positive early breast cancer.
Analogues of aminoglutethimide: selective inhibition of cholesterol side-chain cleavage.
Analysis of Obesity-Related Factors and their Association with Aromatase Expression in Canine Malignant Mammary Tumours.
Analysis of the aromatase cytochrome P450 gene in human breast cancers.
Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients.
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.
Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies.
Anastrozole.
Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
Androgen- and estrogen-receptor mediated activities of 4-hydroxytestosterone, 4-hydroxyandrostenedione and their human metabolites in yeast based assays.
Androgens and androgen receptors in breast cancer.
Androgens inhibit aromatase expression through DAX-1: insights into the molecular link between hormone balance and Leydig cancer development.
Androstenedione and androst-5-ene-3 beta,17 beta-diol stimulate DMBA-induced rat mammary tumors--role of aromatase.
Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer.
Anti-Estrogenic and Anti-Cell Proliferative Effect of Allyl Isothiocyanate in Chemoprevention of Chemically Induced Mammary Carcinogenesis in Rats.
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.
Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors.
Anti-tumor effects of letrozole.
Antiaromatase agents: preclinical data and neoadjuvant therapy.
Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Antitumor activity of the aromatase inhibitor FCE 24928 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone.
Antitumor and endocrine effects of an aromatase inhibitor (CGS 16949A) on DMBA-induced rat mammary tumor.
Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors.
Antitumor effect of pyridoglutethimide, an aromatase inhibitor, on 7,12-dimethylbenz(a)anthracene-induced mammary tumors of rat.
Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors in rats.
Antitumor effects of SEF19, a new nonsteroidal aromatase inhibitor, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in rats.
Application of aromatase inhibitors in endocrine responsive breast cancers.
Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence.
Aromatase (CYP19) promoter gene polymorphism and risk of nonviral hepatitis-related hepatocellular carcinoma.
Aromatase Acetylation Patterns and Altered Activity in Response to Sirtuin Inhibition.
Aromatase activity and CYP19 gene expression in breast cancers.
Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging.
Aromatase activity and expression in breast cancer and benign breast tissue stromal cells.
Aromatase activity and interleukin-6 production by normal and malignant breast tissues.
Aromatase activity in a rat Leydig cell tumor.
Aromatase activity in adipose tissue from breast quadrants: a link with tumour site.
Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases.
Aromatase activity in breast tissue.
Aromatase activity in human hepatocellular carcinoma. Relationship with the degree of histologic differentiation.
Aromatase activity in human ovarian cancer.
Aromatase activity in microsomes from rat ventral prostate and Dunning R3327H rat prostatic adenocarcinoma.
Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies.
Aromatase activity in primary and metastatic human breast cancer.
Aromatase activity in uterine leiomyomata.
Aromatase and breast cancer.
Aromatase and comparative response to its inhibitors in two types of endometrial cancer.
Aromatase and COX in breast cancer: enzyme inhibitors and beyond.
Aromatase and COX-2 expression in human breast cancers.
Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas.
Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast.
Aromatase and intracrinology of estrogen in hormone-dependent tumors.
Aromatase and its inhibitors in breast cancer treatment--overview and perspective.
Aromatase and its inhibitors.
Aromatase and prostate cancer.
Aromatase and regulating the estrogen:androgen ratio in the prostate gland.
Aromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor behavior.
Aromatase excess in cancers of breast, endometrium and ovary.
Aromatase Explains Why Testosterone Increases Breast Cancer Rate.
Aromatase expression and its localization in human breast cancer.
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
Aromatase expression and regulation in breast and endometrial cancer.
Aromatase expression in a feminizing adrenocortical tumor.
Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis.
Aromatase expression in human germinomas with possible biological effects.
Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study.
Aromatase expression in normal human oral keratinocytes and oral squamous cell carcinoma.
Aromatase expression in ovarian epithelial cancers.
Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival.
Aromatase expression in the human breast.
Aromatase expression in the human male.
Aromatase expression in the normal human adult adrenal and in adrenocortical tumors: biochemical, immunohistochemical, and molecular studies.
Aromatase expression in women's cancers.
Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells.
Aromatase Expression Predicts Survival in Women with Early-Stage Non Small Cell Lung Cancer.
Aromatase expression was not detected by immunohistochemistry in endometrial cancer.
Aromatase gene expression in adipose tissue: relationship to breast cancer.
Aromatase in colon carcinoma.
Aromatase in endometriosis and uterine leiomyomata.
Aromatase in human breast carcinoma.
Aromatase in human common epithelial ovarian neoplasms.
Aromatase in human liver and its diseases.
Aromatase in human lung carcinoma.
Aromatase in hyperplasia and carcinoma of the human prostate.
Aromatase in nontumoral and malignant human liver tissues and cells.
Aromatase in the human choriocarcinoma JEG-3: inhibition by R 76 713 in cultured cells and in tumors grown in nude mice.
Aromatase in the normal breast and breast cancer.
Aromatase induction in tamoxifen-resistant breast cancer: Role of phosphoinositide 3-kinase-dependent CREB activation.
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.
Aromatase inhibition and experimental antitumor activity of FCE 24304, MDL 18962 and SH 489.
Aromatase inhibition and inactivation.
Aromatase inhibition by bioavailable methylated flavones.
Aromatase inhibition by R 83 842, the dextro isomer of R 76 713, in JEG-3 choriocarcinoma grown in ovariectomized nude mice.
Aromatase inhibition by synthetic lactones and flavonoids in human placental microsomes and breast fibroblasts--a comparative study.
Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary.
Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers.
Aromatase inhibition: translation into a successful therapeutic approach.
Aromatase inhibitor adjuvant chemotherapy of breast cancer results in cancer therapy induced bone loss.
Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
Aromatase inhibitor and bone.
Aromatase inhibitor development and hormone therapy: a perspective.
Aromatase inhibitor development for treatment of breast cancer.
Aromatase Inhibitor Therapy As Effective Rescue in a Patient With Tamoxifen-Refractory Metastatic Granulosa Cell Tumor of the Ovary.
Aromatase inhibitor treatment of menorrhagia and subsequent pregnancy in a patient with familial hyperparathyroidism-jaw tumor syndrome.
Aromatase inhibitor-associated bone loss: clinical considerations.
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Aromatase inhibitors and antiepileptic drugs: a computational systems biology analysis.
Aromatase inhibitors and breast cancer prevention.
Aromatase inhibitors and hormone-dependent cancers.
Aromatase inhibitors and other novel agents in breast cancer treatment.
Aromatase inhibitors and their antitumor effects in model systems.
Aromatase inhibitors as potential cancer chemopreventives.
Aromatase inhibitors as solely treatment in postmenopausal breast cancer patients.
Aromatase Inhibitors Evolution as Potential class of drugs in the treatment of Postmenopausal Breast Cancer Women.
Aromatase inhibitors for breast cancer: pharmacoeconomic considerations.
Aromatase Inhibitors for Ovarian Stimulation in Patients with Breast Cancer.
Aromatase inhibitors in breast cancer.
Aromatase inhibitors in gynecologic cancers.
Aromatase inhibitors in human lung cancer therapy.
Aromatase inhibitors in ovarian cancer: is there a role?
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.
Aromatase inhibitors in the breast cancer therapy and their potential using in the prevention setting.
Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature.
Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity.
Aromatase inhibitors prevent spontaneous granular cell tumors in the distal female reproductive tract of Sprague-Dawley rats.
Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings.
Aromatase inhibitors--a viable option for recurrent granulosa cell tumour of ovary: overview and case report.
Aromatase inhibitors--gene discovery.
Aromatase inhibitors--IV. Regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3,17-dione.
Aromatase inhibitors.
Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones.
Aromatase inhibitors: cellular and molecular effects.
Aromatase inhibitors: future directions.
Aromatase inhibitors: rationale for use following antiestrogen therapy.
Aromatase inhibitors: Role in postmenopausal breast cancer.
Aromatase inhibitors: structural features and biochemical characterization.
Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter.
Aromatase messenger RNA is derived from the proximal promoter of the aromatase gene in Leydig, Sertoli, and germ cells of the rat testis.
Aromatase over expression transgenic murine models for aromatase inhibitor studies.
Aromatase p450 expression in a feminizing adrenal adenoma presenting as isosexual precocious puberty.
Aromatase P450 expression in human pituitary adenomas.
Aromatase resistance mechanisms in model systems in vivo.
Aromatase, breast cancer and obesity: a complex interaction.
Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
Aromatase, the enzyme responsible for estrogen biosynthesis, is expressed by human and rat glioblastomas.
Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-?/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer.
Aromatase: Contributions to Physiology and Disease in Women and Men.
Aromatisation of androstenedione by human breast cancer tissue: correlation with hormone receptor activity and possible biologic significance.
Aromatization of androgens by human breast cancer.
Arsenic-induced cancer cell phenotype in human breast epithelia is estrogen receptor-independent but involves aromatase activation.
Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies.
Assisted reproduction and fertility preservation techniques in cancer patients.
Association between Metabolic Syndrome and Cancer.
Association of Aromatase With Bladder Cancer Stage and Long-Term Survival: New Insights Into the Hormonal Paradigm in Bladder Cancer.
Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women.
Atrazine and breast cancer: A framework assessment of the toxicological and epidemiological evidence.
Atrazine promotes RM1 prostate cancer cell proliferation by activating STAT3 signaling.
Atrazine-induced aromatase expression is SF-1 dependent: implications for endocrine disruption in wildlife and reproductive cancers in humans.
Atrazine-induced changes in aromatase activity in estrogen sensitive target tissues.
Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells.
Barriers to Acupuncture Use Among Breast Cancer Survivors: A Cross-Sectional Analysis.
Basal Cells Show Increased Expression of Aromatase and Estrogen Receptor ? in Prostate Epithelial Lesions of Male Aging Rats.
Bcl-2 and Bax are differentially expressed in hyperplastic, premalignant, and malignant lesions of mammary carcinogenesis.
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
Benign leiomyoma with multiple metastases to vertebrae and calvarium: An index case with comprehensive review of endocrine targets.
Benign metastasising leiomyoma: a progressive disease despite chemical and surgical castration.
Benzoxazole derivatives as new generation of anti-breast cancer agents.
Betaine ameliorates impaired steroidogenesis and apoptosis in mice granulosa cells induced by high glucose concentration.
Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy.
Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
Bioactive compounds from the fern Lepisorus contortus.
Bioactivity of natural biflavonoids in metabolism-related disease and cancer therapies.
Biochemical and molecular mechanisms for the association between obesity, chronic Inflammation, and breast cancer.
Biochemical control of breast aromatase.
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells.
Biological rationale for endocrine therapy in breast cancer.
Biological significance of aromatase activity in human breast tumors.
Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Black breast cancer survivors experience greater upper extremity disability.
Bone health in adult cancer survivorship.
Bowel obstruction due to endometriosis in the rectovaginal septum.
BRCA1/BARD1 complex interacts with steroidogenic factor 1--A potential mechanism for regulation of aromatase expression by BRCA1.
Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status.
Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival.
Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.
Breast Cancer Prevention: Time for Change.
Breast cancer update.
Breast Cancer: Rank Ligand Inhibition.
Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo.
Breast tumor aromatase: functional role and transcriptional regulation.
Brenner tumor of the ovary: immunoanalysis of steroidogenic enzymes in 23 cases.
By the way, doctor. I've had an ER-positive breast cancer tumor removed. Now I am getting ready for follow-up therapy. I've heard that the aromatase inhibitors are better than tamoxifen. What is your opinion?
C19 adrenal steroids enhance prostaglandin F2 alpha output by human endometrium in vitro.
Cancer treatment-related bone loss: a review and synthesis of the literature.
CC chemokine ligand 2 (CCL2) stimulates aromatase gene expression in mammary adipose tissue.
CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma.
CCAAT/enhancer binding protein delta up-regulates aromatase promoters I.3/II in breast cancer epithelial cells.
Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen.
CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
Challenges in clinical patient management.
Changes in aromatase (CYP19) gene promoter usage in non-small cell lung cancer.
Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.
Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
Characterization of aromatase cytochrome P-450 mRNA in rat perinatal brain, ovary and a Leydig tumor cell line: evidence for the existence of brain specific aromatase transcripts.
Characterization of letrozole in human hair using LC-MS/MS and confirmation by LC-HRMS: Application to a doping case.
Chemoprevention of breast cancer.
Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.
Chemopreventive and antioxidant activity of 6-substituted imidazo[2,1-b]thiazoles.
Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats.
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Cholesterol import and steroidogenesis are biosignatures for gastric cancer patient survival.
Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray.
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
Clinical importance of intratumoral aromatase.
Clinical significance of aromatase protein expression in axillary node negative breast cancer.
Clinical use of aromatase inhibitors in the treatment of breast cancers.
Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer.
Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor treated ER-positive breast cancer.
Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model.
Co-expression of estrogen receptor beta and aromatase in Japanese lung cancer patients: Gender-dependent clinical outcome.
Collagen and prostaglandin E? regulate aromatase expression through the PI3K/AKT/IKK and the MAP kinase pathways in adipose stromal cells.
Colocalization of aromatase in spinal cord astrocytes: differences in expression and relationship to mechanical and thermal hyperalgesia in murine models of a painful and a non-painful bone tumor.
Combination effects of dietary soy and methylselenocysteine in a mouse model of prostate cancer.
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance.
Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Combined treatment with specific ligands for PPARgamma:RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells.
Comparative studies of aromatase inhibitors in relation to the significance of estrogen synthesis in human mammary tumors.
Comparative validation of the SP6 antibody to Ki67 in breast cancer.
Comparing exercise responses to aerobic plus resistance training between postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy women.
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer.
Comparison of Increased Aromatase versus ER{alpha} in the Generation of Mammary Hyperplasia and Cancer.
Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours.
Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Complete response to exemestane in a patient with a desmoid tumor.
Computational methods for the design of potent aromatase inhibitors.
Computational Studies in Drug Design against Cancer.
Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by these Genes.
Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale?
Concurrent or Sequential Hormonal and Radiation Therapy in Breast Cancer: A Literature Review.
Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors.
Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors.
Control of aromatase activity in breast tumours: the role of the immune system.
Control of aromatase in breast cancer cells and its importance for tumor growth.
Correlation between bone mineral density and endometrial thickness over time in women with breast cancer history.
Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial.
Correlation of aromatase activity and steroid receptors in human ovarian carcinoma.
Correlation of aromatase activity with histological differentiation of breast cancer--a morphometric analysis.
Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide.
Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis.
Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Cosecretion of estrogen and inhibin B by a feminizing adrenocortical adenoma: impact on gonadotropin secretion.
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
Current and future perspectives on fulvestrant.
Current controversies in the endocrine therapy of advanced breast cancer.
Current strategies for anticancer chemoprevention and chemoprotection.
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.
Cutaneous vasculitis in breast cancer treated with chemotherapy.
Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow.
Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer.
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention.
CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity.
CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors.
CYP19 gene expression and aromatase activity in endometrial cancer tissue: importance of the type of the disease.
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Cytochrome b5 expression in gonadectomy-induced adrenocortical neoplasms of the domestic ferret (Mustela putorius furo).
Cytochrome P450 aromatase expression in human seminoma.
Cytochrome P450 in non-small cell lung cancer related to exogenous chemical metabolism.
Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer.
Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells.
Cytoplasmic estrogen receptor ? as a potential marker in human non-small cell lung carcinoma.
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.
DDE-induced changes in aromatase activity in endometrial stromal cells in culture.
Definition of the elements required for the activity of the rat aromatase promoter in steroidogenic cell lines.
Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
Deletion of tumor necrosis factor-alpha receptor type 1 exacerbates insulin resistance and hepatic steatosis in aromatase knockout mice.
Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts.
Denosumab: A bone antiresorptive drug.
Depsidones inhibit aromatase activity and tumor cell proliferation in a co-culture of human primary breast adipose fibroblasts and T47D breast tumor cells.
Des-acyl ghrelin inhibits the capacity of macrophages to stimulate the expression of aromatase in breast adipose stromal cells.
Design and synthesis of carbon-11-labeled dual aromatase-steroid sulfatase inhibitors as new potential PET agents for imaging of aromatase and steroid sulfatase expression in breast cancer.
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.
Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer.
Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor.
Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation.
Determinants of tissue oestradiol levels in human breast cancer.
Developmental programming: Prenatal bisphenol A treatment disrupts mediators of placental function in sheep.
Diagnostics and Therapy for Malignant (Degenerate) Colon Endometriosis - Three Case Reports.
Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.
Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.
Discordant cellular response to pre-surgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.
Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer.
Distinct nuclear receptor expression in stroma adjacent to breast tumors.
Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast.
Diverse flavonoids from the roots of Millettia brandisiana.
Diverse mechanisms of control of aromatase gene expression.
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers.
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Ductal carcinoma in situ of the breast: a surgical perspective.
DVL1 and DVL3 differentially localize to CYP19A1 promoters and regulate aromatase mRNA in breast cancer cells.
Dynamics and Mechanism of Binding of Androstenedione to Membrane-Associated Aromatase.
Dysregulated estrogen receptor signaling in the hypothalamic-pituitary-ovarian axis leads to ovarian epithelial tumorigenesis in mice.
Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies.
Early breast cancer in the elderly: assessment and management considerations.
Early stage breast cancer treatment and prognostic factors: Post San Antonio Breast Cancer Symposium 2016.
Effect of 4-hydroxyandrostenedione on murine Leydig tumor cell steroidogenesis.
Effect of an aromatase inhibitor, 1,4,6-androstatriene-3,17-dione, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the rat and its mechanism of action in vivo.
Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.
Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats.
Effect of chronic intracerebroventricular administration of an aromatase inhibitor on the expression of socio-sexual behaviors in male Japanese quail.
Effect of Denosumab on Glucose Homeostasis in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors: A Pilot Study.
Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.
Effect of the aromatase inhibitor, MEN 11066, on growth of two different MCF-7 sublines.
Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone.
Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro.
Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer.
Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer.
Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model.
Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma.
Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.
Effects of Atrazine on Estrogen Receptor ?- and G Protein-Coupled Receptor 30-Mediated Signaling and Proliferation in Cancer Cells and Cancer-Associated Fibroblasts.
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
Effects of in utero tributyltin chloride exposure in the rat on pregnancy outcome.
Effects of lactone derivatives on aromatase (CYP19) activity in H295R human adrenocortical and (anti)androgenicity in transfected LNCaP human prostate cancer cells.
Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells.
Effects of matrix components on aromatase activity in breast stromal cells in culture.
Effects of menopausal hormonal therapy on occult breast tumors.
Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors.
Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: Aromatase inhibition and autophagy.
Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors.
Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione on 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.
Effects of tributyltin chloride on developing mouse oocytes and preimplantation embryos.
Efficacy and economics of hormonal therapies for advanced breast cancer.
Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.
Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Efficient Synthesis of Glutamate Peptide-Estradiol Conjugate for Imaging Estrogen Receptor-Positive Diseases.
Eicosanoids and Adipokines in Breast Cancer: From Molecular Mechanisms to Clinical Considerations.
Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.
Elevated aromatase expression correlates with cervical carcinoma progression.
Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant.
Endocrine aspects of human uterine sarcoma: a preliminary study.
Endocrine characterization of a human ovarian carcinoma (BG-1) established in nude mice.
Endocrine disorders associated with inappropriately high aromatase expression.
Endocrine resistance in breast cancer--An overview and update.
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
Endocrine studies in a male patient with choriocarcinoma and gynecomastia.
Endocrine therapy of advanced disease: analysis and implications of the existing data.
Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
Endocrine Therapy-Related Symptoms and Quality of Life in Female Cancer Survivors in the Yale Fitness Intervention Trial.
Endogenous steroid hormones and local aromatase activity in the breast.
Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors.
Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review.
Endophytic fungi associated with Taxus fuana (West Himalayan Yew) of Pakistan: potential bio-resources for cancer chemopreventive agents.
Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Enzymes of estrogen metabolism in endometrial cancer.
Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer.
Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer.
Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1.
ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.
Estradiol assays--The path ahead.
Estrogen and prostate cancer: An eclipsed truth in an androgen-dominated scenario.
Estrogen biosynthesis in human H295 adrenocortical carcinoma cells.
Estrogen biosynthesis in human uterine adenomyosis.
Estrogen biosynthesis in THP1 cells is regulated by promoter switching of the aromatase (CYP19) gene.
Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy.
Estrogen inhibits cell proliferation through in situ production in human thymoma.
Estrogen metabolism and impaired spermatogenesis in germ cell tumors of the testis.
Estrogen metabolites and breast cancer.
Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible?
Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells.
Estrogen receptor 1 gene expression and its combination with estrogen receptor 2 or aromatase expression predicts survival in non-small cell lung cancer.
Estrogen receptor ? represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer.
Estrogen Receptor Mutations and Changes in Downstream Gene Expression and Signaling.
Estrogen receptor prevents p53-dependent apoptosis in breast cancer.
Estrogen receptor signaling in lung cancer.
Estrogen receptor-beta mediates the protective effects of aromatase induction in the MMTV-Her-2/neu x aromatase double transgenic mice.
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach?
Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor.
Estrogen secreting adrenal adenocarcinoma in an 18-month-old boy: aromatase activity, protein expression, mRNA and utilization of gonadal type promoter.
Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer.
Estrogen signaling in cancer microenvironment and prediction of response to hormonal therapy.
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
Estrogen synthesis in human breast tumor and its inhibition by testololactone and bromoandrostenedione.
Estrogen synthesis in normal and malignant human endometrium.
Estrogen synthesizing rare malignant Brenner tumor of the ovary with the presence of progesterone and androgen receptors in the absence of estrogen receptors.
Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
Estrogen-like and tissue-selective effects of 7-methoxycoumarin from Ficus umbellata (Moraceae): an in vitro and in vivo study.
Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years.
Estrogen-Related Cancer Microenvironment of Breast Carcinoma.
Estrongenic steroid hormones in lung cancer.
Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study.
Evaluation of a bioluminescent mouse model expressing aromatase PII-promoter-controlled luciferase as a tool for the study of endocrine disrupting chemicals.
Evaluation of Local CYP17A1 and CYP19A1 Expression Levels as Prognostic Factors in Postmenopausal Invasive Ductal Breast Cancer Cases.
Evaluation of Multifunctional Hybrid Analogs for Stilbenes, Chalcones and Flavanones.
Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
Evaluation of selected lichens from iceland for cancer chemopreventive and cytotoxic activity.
Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion.
Everolimus.
Examining factors associated with adherence to hormonal therapy in breast cancer patients.
Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin.
Exemestane for breast-cancer prevention in postmenopausal women.
Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy: A comparative study with Exemestane.
Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.
Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.
Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients.
Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.
Expression of aromatase and estrogen receptors in human adrenocortical tumors.
Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer.
Expression of aromatase cytochrome P450 in eutopic endometrium and its application as a diagnostic test for endometriosis.
Expression of aromatase cytochrome P450 in rat H540 Leydig tumor cells.
Expression of aromatase in tumor related stroma is associated with human bladder cancer progression.
Expression of aromatase P450 is increased in spontaneous prolactinomas of aged rats.
Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers.
Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer.
Expression of COX-2 and steroid converting enzymes in breast cancer.
Expression of estrogen receptors (?, ?), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus.
Expression of estrogen receptors-beta and aromatase activity in primary mammary gland tumors.
Expression of P450 Aromatase in Granulosa Cell Tumors and Sertoli-Stromal Cell Tumors of the Ovary: Which Cells Are Responsible for Estrogenesis?
Expression of the forkhead transcription factor FOXL2 correlates with good prognosis in breast cancer patients treated with tamoxifen.
Expression of the insulin-like growth factor (IGF) system and steroidogenic enzymes in canine testis tumors.
Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells.
Extending aromatase inhibitor sensitivity in hormone resistant breast cancer.
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Extranuclear ER? is associated with regression of T47D PKC?-overexpressing, tamoxifen-resistant breast cancer.
Facile synthesis of chrysin-derivatives with promising activities as aromatase inhibitors.
Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
Factors influencing aromatase activity in the breast.
Factors predictive of response to hormone therapy in breast cancer.
Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells.
Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma.
Feminization as a result of both peripheral conversion of androgens and direct estrogen production from an adrenocortical carcinoma.
Feminizing Leydig cell tumor: endocrine and incubation studies.
Feminizing Sertoli cell tumors in boys with Peutz-Jeghers syndrome.
Fertility preservation and PGT-M in women with familial adenomatous polyposis-associated desmoid tumours.
Fertility preservation in gynecologic cancers.
Fertility preservation options in breast cancer patients.
FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.
Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report.
Flavonoids as prospective aromatase inhibitors in breast cancer prevention/therapy.
Forskolin up-regulates aromatase (CYP19) activity and gene transcripts in the human adrenocortical carcinoma cell line H295R.
Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration.
From Endocrinology to Intracrinology.
From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells.
Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: north central cancer treatment group trial n0032.
Functional activation of the estrogen receptor-? and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
Functional Profiling of FSH and Estradiol in Ovarian Granulosa Cell Tumors.
Future directions in cancer prevention.
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells.
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Gender differences in multiple sclerosis: induction of estrogen signaling in male and progesterone signaling in female lesions.
Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: Application of physiologically-based pharmacokinetic modeling to gain quantitative insights.
Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.
Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients.
Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.
Genetic modeling of estrogen metabolism as a risk factor of hormone-dependent disorders.
Genetic modelling of the estrogen metabolism as a risk factor of hormone-dependent disorders.
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers.
Genetic variants of CYP19 (aromatase) and breast cancer risk.
Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model.
Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?
Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.
Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer.
Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors.
Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.
Genomic Profiling of the Steroidogenic Acute Regulatory Protein in Breast Cancer: In Silico Assessments and a Mechanistic Perspective.
Genotypic and Allelic Variability in CYP19A1 among Populations of African and European Ancestry.
Ghrelin and Breast Cancer: Emerging Roles in Obesity, Estrogen Regulation, and Cancer.
Ghrelin and des-acyl ghrelin inhibit aromatase expression and activity in human adipose stromal cells: suppression of cAMP as a possible mechanism.
Glucocorticoid Receptor as a Potential Target to Decrease Aromatase Expression and Inhibit Leydig Tumor Growth.
Glycogen-rich clear cell carcinoma of the breast.
Gonadotropin releasing hormone-independent precocious puberty in a 5 year-old girl with suprasellar germ cell tumor secreting beta-hCG and alpha-fetoprotein.
Gossypol enantiomers potently inhibit human placental 3?-hydroxysteroid dehydrogenase 1 and aromatase activities.
GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patients.
Grape seed extract is an aromatase inhibitor and a suppressor of aromatase expression.
Growth and characterization of N-methyl-N-nitrosourea-induced mammary tumors in intact and ovariectomized rats.
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience.
Growth factor-mediated regulation of aromatase activity in human skin fibroblasts.
Growth-inhibition of t47d human breast-cancer cells by the new antiaromatase steroid 3-methylene-1,4-androstadien-17-one.
Guideline No. 392-Classification and Management of Endometrial Hyperplasia.
HDAC inhibitor entinostat restores responsiveness of letrozole resistant MCF-7Ca xenografts to AIs through modulation of Her-2.
Health care factors associated with survival among women with breast cancer on hormone therapy in Rio de Janeiro, Brazil, 2004 - 2010.
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine Resistance.
Hedera nepalensis K. Koch: A Novel Source of Natural Cancer Chemopreventive and Anticancerous Compounds.
HER2 and hormone receptor-positive breast cancer-blocking the right target.
HER2 overexpressing metastatic breast cancer.
Hetero- and isosexual pseudoprecocity associated with testicular sex-cord tumors in an 8 year-old male.
Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism.
High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child.
High aromatase expression in uterine leiomyoma tissues of African-American women.
High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.
High expression of estrogen receptor alpha and aromatase in glial tumor cells is associated with gender-independent survival benefits in glioblastoma patients.
High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
High gene expression of estrogen and progesterone receptors is associated with decreased t cell infiltration in patients with NSCLC.
High TGFbeta1, estrogen receptor, and aromatase gene expression in a large cell calcifying sertoli cell tumor (LCCSCT): implications for the mechanism of oncogenesis.
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response.
Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature.
How do I recommend extended adjuvant hormonal therapy?
HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines.
Human carcinogenic risk assessment based on hormonal effects in a carcinogenicity study in rats with the antifungal agent, fluconazole.
Human trophoblast xenografts in athymic mice: a model for peripheral aromatization.
Hyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in mice.
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.
IKKbeta mediates cell shape-induced aromatase expression and estrogen biosynthesis in adipose stromal cells.
Imidazolylmethylbenzophenones as highly potent aromatase inhibitors.
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
Immunohistochemical analysis of aromatase in metastatic lymph nodes of breast cancer.
Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues.
Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells.
Immunohistochemical localisation of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours.
Immunohistochemical studies of steroidogenic enzymes (aromatase, 17 alpha-hydroxylase and cholesterol side-chain cleavage cytochromes P-450) in sex cord-stromal tumors of the ovary.
Immunohistochemical study of KiSS1 and KiSS1R expression in human primary breast cancer: Association with breast cancer receptor status, proliferation markers and clinicopathological features.
Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders.
Immunolocalization of aromatase in human breast disorders using different antibodies.
Immunolocalization of aromatase P-450 in ovarian tissue from pregnant and nonpregnant mares and in ovarian tumours.
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer.
Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort.
Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy.
Importance of local aromatase activity in hormone-dependent breast cancer: a review.
Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival.
Improving Adherence to Endocrine Therapy in Women With HR-Positive Breast Cancer.
In silico analysis of nsSNPs in CYP19A1 gene affecting breast cancer associated aromatase enzyme.
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
In situ aromatization enhances breast tumor estradiol levels and cellular proliferation.
In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.
In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione.
In vitro interactions between mammary fibroblasts (Hs 578Bst) and cancer epithelial cells (MCF-7) modulate aromatase, steroid sulfatase and 17?-hydroxysteroid dehydrogenases.
In vitro maturation with letrozole priming: Can it be a solution for patients with cancerophobia? A pilot study.
In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6.
In vivo visualization of aromatase in animals and humans.
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Incidence of comorbidities in women with breast cancer treated with tamoxifen or an aromatase inhibitor: an Australian population-based cohort study.
Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor.
Increase of antitumor activity of cisplatin using agonist of gonadotropin-realising hormone and inhibitor of aromatase on the model of ascites ovarian tumor.
Increased 5?-Reductase Type 2 Expression in Human Breast Carcinoma following Aromatase Inhibitor Therapy: The Correlation with Decreased Tumor Cell Proliferation.
Induction of apoptosis in hormone refractory breast cancer: horizontal modulation is superior to vertical.
Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women.
Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation.
Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients.
Inhibition of aromatase activity and of endocrine-responsive tumor growth by 10-propargylestr-4-ene-3, 17-dione and its 17-propionate derivative.
Inhibition of aromatase activity by flavonoids.
Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.
Inhibition of cyclic AMP-triggered aromatase gene expression in human choriocarcinoma cells by antisense oligodeoxynucleotide.
Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells.
Inhibition of estrogen biosynthesis and regression of mammary tumors by aromatase inhibitors.
Inhibition of growth and appearance of estrogen-dependent rat mammary tumors by 10-propargylestr-4-ene-3,17-dione, an aromatase inhibitor.
Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens.
Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation.
Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts.
Inhibition of Leydig tumor cell steroidogenesis by 10-propargylestr-4-ene-3,17-dione, an irreversible aromatase inhibitor.
Inhibition of leydig tumor growth by farnesoid X receptor activation: The in vitro and in vivo basis for a novel therapeutic strategy.
Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3,17-dione.
Inhibition of steroid sulphatase activity by steroidal methylthiophosphonates: potential therapeutic agents in breast cancer.
Inhibition of tumor necrosis factor alpha-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol.
Inhibitors of aromatase prevent degradation of the enzyme in cultured human tumour cells.
Inhibitory effect of a new androstenedione derivative, 14 alpha-hydroxy-4-androstene-3,6,17-trione (14 alpha-OHAT) on aromatase activity of human uterine tumors.
Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats.
Inhibitory Effect of Luteolin on Estrogen Biosynthesis in Human Ovarian Granulosa Cells by Suppression of Aromatase (CYP19).
Inhibitory Effects of Calcitriol on the Growth of MCF-7 Breast Cancer Xenografts in Nude Mice: Selective Modulation of Aromatase Expression in vivo.
Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells.
Inhibitory effects of Scutellaria barbata D. Don. and Euonymus alatus Sieb. on aromatase activity of human leiomyomal cells.
Initial studies with [11C]vorozole positron emission tomography detect over-expression of intra-tumoral aromatase in breast cancer.
INSIGHTS ON AROMATASE IMMUNOHISTOCHEMISTRY: VARIATIONS BETWEEN INTRINSIC MOLECULAR SUBTYPES OF BREAST CANCERS.
Insomnia in breast cancer: Independent symptom or symptom cluster?
Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis.
Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer.
Insulin-like growth factor-I, regulating aromatase expression through steroidogenic factor 1, supports estrogen-dependent tumor Leydig cell proliferation.
Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer.
Interstitial Leydig Cell Tumorigenesis-Leptin and Adiponectin Signaling in Relation to Aromatase Expression in the Human Testis.
Interventions for the Treatment of Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: A Systematic Review and Meta-analysis.
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors.
Intratumoral aromatase in human breast, endometrial, and ovarian malignancies.
Intratumoral aromatase model: the effects of letrozole (CGS 20267).
Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma.
Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment.
Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.
Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.
Investigation of antiaromatase activity using hepatic microsomes of Nile tilapia (Oreochromis niloticus).
Investigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinoline and uracil derivatives.
Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers.
IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.
Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?
Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Is there a role for hormone replacement therapy after breast cancer?
Isolation and evaluation of kaempferol glycosides from the fern Neocheiropteris palmatopedata.
JunD and JunB Integrate Prostaglandin E2 Activation of Breast Cancer-Associated Proximal Aromatase Promoters.
Keratinocyte growth factor (KGF) induces aromatase activity in cultured MCF-7 human breast cancer cells.
Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Laboratory testing for endometriosis.
Lack of evidence for aromatase expression in human ovarian epithelial carcinoma.
Lack of genomic rearrangements involving the aromatase gene CYP19A1 in breast cancer.
Lactoferrin-decorated vs PEGylated zein nanospheres for combined aromatase inhibitor and herbal therapy of breast cancer.
Late recurrence of breast carcinoma metastasis to the hypopharynx: a case report.
Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line.
Leptin induces CREB-dependent aromatase activation through COX-2 expression in breast cancer cells.
Leptin regulation of aromatase activity in adipose stromal cells from regularly cycling women.
Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer.
Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.
Letrozole as second-line hormonal treatment for recurrent low-grade endometrial stromal sarcoma: A case report and review of the literature.
Letrozole efficacy in the treatment of granulosa cell tumor of the ovary: a case report.
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma.
Lichen Sclerosus in a Breast Cancer Survivor on an Aromatase Inhibitor: A Case Report.
Ligands for the peroxisomal proliferator-activated receptor gamma and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose.
Linkage of routinely collected oncology clinical data with health insurance claims data--an example with aromatase inhibitors, tamoxifen, and all-cause mortality.
Liver Receptor Homologue-1 expression in ovarian epithelial and granulosa cell tumours.
Local aromatase activity alterations in breast cancer tissues: A potential way of decision support for clinicians.
Local aromatase activity in human breast tissues.
Local aromatase expression in human prostate is altered in malignancy.
Local endocrine effects of aromatase inhibitors within the breast.
Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
Localization of inhibin alpha-, betaA- and betaB-subunits and aromatase in ovarian follicles with granulosa theca cell tumor (GTCT) in 6 mares.
Localized aberrant expression of cytochrome P450 aromatase in primary and metastatic malignant tumors of human liver.
Locally advanced breast cancer.
Locally produced estrogen through aromatization might enhance tissue expression of pituitary tumor transforming gene and fibroblast growth factor 2 in growth hormone-secreting adenomas.
Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.
Long-term implications of bone loss in breast cancer.
Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma.
Long-term treatment of residual or recurrent low-grade endometrial stromal sarcoma with aromatase inhibitors: A report of two cases and a review of the literature.
Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells.
Loss of estrogen inactivation in colonic cancer.
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.
Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
Lung cancer chemoprevention: difficulties, promise and potential agents?
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Macroorchidism in childhood and adolescence: an update.
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Major hyperestrogenism in a feminizing adrenocortical adenoma despite a moderate overexpression of the aromatase enzyme.
Malignant Brenner tumor. A histologic, morphometrical, immunohistochemical, and ultrastructural study.
Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells.
Mammary steroid metabolizing enzymes in relation to hyperplasia and tumorigenesis in the dog.
Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
Management of bone disease in women after breast cancer.
Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience.
Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Management of early breast cancer in patients bearing germline BRCA mutations.
Management of lymphangioleiomyomatosis.
Management of operable breast cancer in older women.
MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity.
MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors.
Mechanism-based categorization of aromatase inhibitors: a potential discovery and screening tool.
Mechanisms of resistance to aromatase inhibitors.
Medical treatment of endometriosis.
Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity.
Melatonin modulates aromatase activity and expression in endothelial cells.
Melatonin modulates aromatase activity in MCF-7 human breast cancer cells.
Melatonin promotes differentiation of 3T3-L1 fibroblasts.
Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy.
Menopause is a Determinant of Breast Adipose Inflammation.
Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature.
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
Metastatic breast cancer: an updating.
Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1.
Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.
Microbial transformation of anti-cancer wsteroid exemestane and cytotoxicity of its metabolites against cancer cell lines.
Microenvironmental regulation of estrogen signals in breast cancer.
MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.
MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers.
Microsomal aromatase in testicular tumour tissue: increased activity in choriocarcinoma compared to embryonal carcinoma.
miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.
Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Modeling of diarylalkyl-imidazole and diarylalkyl-triazole derivatives as potent aromatase inhibitors for treatment of hormone-dependent cancer.
Modulation of Aromatase by Phytoestrogens.
Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.
Modulation of aromatase expression in human breast tissue.
Modulation of expression of 17-Hydroxylase/17,20 lyase (CYP17) and P450 aromatase (CYP19) by inhibition of MEK1 in a human ovarian granulosa-like tumor cell line.
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Molecular analysis of aberrant expression of aromatase in breast cancer tissues.
Molecular and epidemiological analyses of abnormal expression of aromatase in breast cancer.
Molecular approach to common causes of female infertility.
Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma.
Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Molecular effects of oestrogen deprivation in breast cancer.
Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance.
MR 20492 and MR 20494: two indolizinone derivatives that strongly inhibit human aromatase.
Mucinous carcinoma in an octogenarian: Treatment and management of breast cancer in the elderly.
Multidisciplinary Clinical Considerations in the Treatment of Pediatric Epithelial Ovarian Cancer.
Musculoskeletal manifestations in patients with malignant disease.
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.
Nandrolone and stanozolol induce Leydig cell tumor proliferation through an estrogen-dependent mechanism involving IGF-I system.
Natural Products as Anticancerous Therapeutic Molecules with Special Reference to Enzymatic Targets Topoisomerase, COX, LOX and Aromatase.
Nature-derived anticancer steroids outside cardica glycosides.
NCCN Task Force Report: Bone Health and Cancer Care.
NCCN Task Force Report: Bone Health in Cancer Care.
Necrotizing leukocytoclastic small vessel vasculitis associated with letrozole: A case report?.
Neoadjuvant endocrine therapy for breast cancer: an overlooked option?
Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review.
Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects.
Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer.
Neoflavonoids and Tetrahydroquinolones as Possible Cancer Chemopreventive Agents.
Network-guided prediction of aromatase inhibitor response in breast cancer.
Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer.
New and translational perspectives of oestrogen deprivation in breast cancer.
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
New development in intracrinology of breast carcinoma: therapeutic horizons after aromatase inhibitors.
New endocrine approaches in the treatment of breast cancer.
New experimental models for aromatase inhibitor resistance.
New insights into endocrine therapy for young women with breast cancer.
New insights on the pathogenesis of endometriosis and novel non-surgical therapies
New medical treatments for endometriosis.
New ruthenium(II)-letrozole complexes as anticancer therapeutics.
New small-molecule compound Hu-17 inhibits estrogen biosynthesis by aromatase in human ovarian granulosa cancer cells.
Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer.
Novel aromatase inhibitors selection using induced fit docking and extra precision methods: Potential clinical use in ER-alpha-positive breast cancer.
Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer.
Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review.
Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design.
Novel Molecular Markers for Breast Cancer.
Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Obesity and breast cancer - Role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue.
Obesity-Altered Adipose Stem Cells Promote ER? Breast Cancer Metastasis through Estrogen Independent Pathways.
Occult breast tumor reservoir: biological properties and clinical significance.
Oestrogen formation in breast: clinical and biological importance.
Oestrogen producing adrenocortical adenoma: clinical, biochemical and immunohistochemical studies.
Oestrogen secreting Leydig cell tumour and GnRH agonist in-vivo and in-vitro studies.
Oestrogens and prostate cancer.
Oestrone sulphatase activity in normal and malignant breast tissues: relationship with tumour location.
On the significance of in situ production of oestrogens in human breast cancer tissue.
Oncologic risks of autologous fat grafting to the breast.
Oncology Acupuncture for Chronic Pain in Cancer Survivors: A Reflection on the American Society of Clinical Oncology Chronic Pain Guideline.
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Optimizing resource allocation for breast cancer prevention and care among Hong Kong Chinese women.
Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.
Orbital fat regeneration following hormonal treatment of metastatic breast carcinoma.
Organoruthenium(II) Complexes Bearing an Aromatase Inhibitor: Synthesis, Characterization, in Vitro Biological Activity and in Vivo Toxicity in Zebrafish Embryos.
Osteoporosis and musculoskeletal complications related to therapy of breast cancer.
Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions.
Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications.
Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer.
Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes.
Ovarian suppression failure during GnRH agonist treatment: A report of three breast cancer patients.
Ovarian Tumors With Functioning Stroma: A Clinicopathologic Study With Special Reference to Serum Estrogen Level, Stromal Morphology, and Aromatase Expression.
Over expression of aromatase protein is highly related to MMPs levels in human breast carcinomas.
Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.
Overexpression of aromatase leads to development of testicular leydig cell tumors : an in vivo model for hormone-mediated TesticularCancer.
Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice.
Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities.
Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients.
Overview of long term care of breast cancer survivors.
PAAn-1b and PAAn-E: two phosphorothioate antisense oligodeoxynucleotides inhibit human aromatase gene expression.
Paraneoplastic hypocalcemia-induced heart failure in advanced breast cancer: A case report and literature review.
Passenger protein determines translocation versus retention in the endoplasmic reticulum for aromatase expression.
Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
PCP4/PEP19 upregulates aromatase gene expression via CYP19A1 promoter I.1 in human breast cancer SK-BR-3 cells.
PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer.
Peripheral and ovarian venous concentrations of various steroid hormones in virilizing ovarian tumors.
Peripheral precocious puberty in a girl with an intracranial hCG-producing tumor: case report and literature review.
Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy.
Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
PET probe with Aggregation Induced Emission characteristics for the specific turn-on of aromatase.
Pharmacogenomics of endocrine therapy in breast cancer.
Pharmacogenomics of third-generation aromatase inhibitors.
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Pharmacology of vorozole.
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.
Phase II trial of anastrozole in women with asymptomatic müllerian cancer.
Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.
Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors.
Phytochemicals for breast cancer prevention by targeting aromatase.
Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5.
Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients.
Pneumocystis Pneumonia and Acute Kidney Injury Induced by Everolimus Treatment in a Patient with Metastatic Breast Cancer.
Polymorphisms and endometriosis: a systematic review and meta-analyses.
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Polymorphisms in CYP19A1 and NFKB1 genes are associated with cutaneous melanoma risk in southern Brazilian patients.
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue.
Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
Potent enzyme-activated inhibition of aromatase by a 7 alpha-substituted C19 steroid.
Potential alternative progestin therapy for low-grade endometrial stromal sarcoma: A case report.
Potential effect of Olea europea leaves, Sonchus oleraceus leaves and Mangifera indica peel extracts on aromatase activity in human placental microsomes and CYP19A1 expression in MCF-7 cell line: Comparative study.
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer.
Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
Potential utility of natural products as regulators of breast cancer-associated aromatase promoters.
Pre-clinical applications of transgenic mouse mammary cancer models.
Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer.
Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Prediction of hormone sensitivity for breast cancers.
Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
Predictive modes of action of pesticides in uterine adenocarcinoma development in rats.
Predictor for supraphysiologic serum estradiol elevation on hCG triggering day of controlled ovarian stimulation using letrozole and gonadotropins in women with estrogen-dependent cancers.
Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.
Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.
Preliminary studies of aromatase in human neoplastic endometrium.
Prenatal alcohol exposure increases the susceptibility to develop aggressive prolactinomas in the pituitary gland.
Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.
Presence of aromatase inhibitors in cycads.
Preventative therapies for healthy women at high risk of breast cancer.
Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Prevention and treatment of breast cancer by suppressing aromatase activity and expression.
Prevention of breast cancer: current state of the science and future opportunities.
Prevention of ER-negative breast cancer.
Prevention of ER-negative breast cancer: where do we stand?
Prevention of Recurrent Mucinous Borderline Ovarian Tumor with Aromatase Inhibitor.
Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor.
Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.
Prevention, diagnosis and treatment of osteoporosis following menopause induced due to oncological disease.
Preventive Therapy for Breast Cancer.
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Pro-Apoptotic Effects of Estetrol on Long-Term Estrogen-Deprived Breast Cancer Cells and at Low Doses on Hormone-Sensitive Cells.
Product of aromatase activity in intact LNCaP and MCF-7 human cancer cells.
Production of androgens and estrogens by tubular adenomas which developed in ovaries of mutant mice of Sl/Slt genotype.
Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer.
Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
Prognostic impact of cyclooxygenase-2 in breast cancer.
Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer.
Prognostic value of breast cancer aromatase.
Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.
Prospects of Wedelolactone as a Chemotherapeutic Agent in Gynecological Cancers; Clue From its In-vitro and In-silico Investigation.
Prostaglandin E2 down-regulates sirtuin 1 (SIRT1), leading to elevated levels of aromatase, providing insights into the obesity-breast cancer connection.
Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells.
Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Protein Expression of Estrogen Receptors ? and ? and Aromatase in Myometrium and Uterine Leiomyoma.
Protein kinase A-dependent synergism between GATA factors and the nuclear receptor, liver receptor homolog-1, regulates human aromatase (CYP19) PII promoter activity in breast cancer cells.
Protocol for Exercise Program in Cancer and Cognition (EPICC): A randomized controlled trial of the effects of aerobic exercise on cognitive function in postmenopausal women with breast cancer receiving aromatase inhibitor therapy.
QSAR modeling of aromatase inhibitory activity of 1-substituted 1,2,3-triazole analogs of letrozole.
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.
Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer.
Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer.
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast.
Quantitative Proteomic Profiling Identifies a Potential Novel Chaperone Marker in Resistant Breast Cancer.
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
Radiogenic angiosarcoma of the breast: case report and systematic review of the literature.
Rainbow trout, Oncorhynchus mykiss, as a model for aromatase inhibition.
Randomized Controlled Trial of a Home-Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors.
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.
RANK ligand inhibition with denosumab for the management of osteoporosis.
Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer.
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: a literature review.
Recent advances in computational design of potent aromatase inhibitors: open-eye on endocrine-resistant breast cancers.
Recent Developments in Oxazole Derivatives as Anticancer Agents: Review on Synthetic Strategies, Mechanism of Action and SAR studies.
Recent progress in development of aromatase inhibitors.
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Reduction of estrogen production by interleukin-6 in a human granulosa tumor cell line may have implications for endometriosis-associated infertility.
Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
Regulation of aromatase activity by cytokines, PGE2 and 2-methoxyoestrone-3-O-sulphamate in fibroblasts derived from normal and malignant breast tissues.
Regulation of aromatase activity within the breast.
Regulation of aromatase and sulphatase in breast tumour cells.
Regulation of aromatase by nuclear receptors.
Regulation of aromatase expression by the nuclear receptor LRH-1 in adipose tissue.
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.
Regulation of aromatase expression in human ovarian surface epithelial cells.
Regulation of aromatase expression: Potential therapeutic insight into breast cancer treatment.
Regulation of aromatase gene expression in purified germ cells of adult male rats: effects of transforming growth factor beta, tumor necrosis factor alpha, and cyclic adenosine 3',5'-monosphosphate.
Regulation of aromatase in cancer.
Regulation of aromatase induction by nuclear receptor coregulator PELP1.
Regulation of estrogen synthesis in postmenopausal women.
Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women.
Relationship between physical activity practice and metabolic profile of postmenopausal women under treatment with aromatase inhibitors for breast cancer.
Relationship between tumour aromatase activity, tumour characteristics and response to therapy.
Relevance of Aromatase Inhibitors in Breast Cancer Treatment.
Relevance of pituitary aromatase and estradiol on the maintenance of the population of prolactin-positive cells in male mice.
Response of estrogen receptor-positive intraabdominal fibromatosis to aromatase inhibitor therapy.
Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression.
Retinol inhibits aromatase activity and expression in vitro.
Retraction. Molecular mechanism of inhibition of sodium butyrate on activation of tumor associated aromatase promoters.
Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor.
Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer.
Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Metastatic Breast Cancer.
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Role of aromatase inhibitors in the treatment of breast cancer.
Role of CRE-binding protein (CREB) in aromatase expression in breast adipose.
Role of melatonin in the epigenetic regulation of breast cancer.
Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast.
Roles for miRNAs in endocrine resistance in breast cancer.
RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
RU486 is a potent inhibitor of aromatase induction in human breast adipose tissue stromal cells.
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Screening of potential cancer preventing chemicals as aromatase inhibitors in an in vitro assay.
Selection of optimal adjuvant endocrine therapy for early-stage breast cancer.
Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Selective estrogen receptor modulation: concept and consequences in cancer.
Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention.
Selective regulation of aromatase expression for drug discovery.
Selective spatial upregulation of intratumoral stromal aromatase in breast cancer patients: evidence for imbalance of local estrogen metabolism.
Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites.
Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis.
Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast.
Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.
Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole.
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
Sertoli Cell Tumor of Testes in a Child with Peutz-Jeghers syndrome.
Sertoli-Leydig cell tumor of the ovary, a rare cause of precocious puberty in a 12-month-old infant.
Serum inhibin B concentration in a prepubertal boy with gynecomastia and Peutz-Jeghers syndrome.
Sex Differences and Effects of Estrogenic Compounds on the Expression of Inflammatory Molecules by Astrocytes Exposed to the Insecticide Dimethoate.
Sex differences in behavioral and neurochemical effects of gonadectomy and aromatase inhibition in rats.
Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Sex steroid metabolism in benign and malignant intact prostate biopsies: individual profiling of prostate intracrinology.
Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma.
Sexual dysfunction and infertility as late effects of cancer treatment.
SGK3 sustains ER? signaling and drives acquired aromatase inhibitor resistance through maintaining endoplasmic reticulum homeostasis.
Sheep gene mapping: assignment of ALDOB, CYP19, WT and SOX2 by somatic cell hybrid analysis.
Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens.
Significance of aromatase activity in human breast cancer.
Singapore Cancer Network (SCAN) Guidelines for Bisphosphonate Use in the Adjuvant Breast Cancer Setting.
Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
Single or Multiple Access Channels to the CYP450s Active Site? An Answer from Free Energy Simulations of the Human Aromatase Enzyme.
Single- and Multi-Locus Association Tests Incorporating Phenotype Heterogeneity.
SIRT1 is involved in adrenocortical cancer growth and motility.
SIRT1 Positively Regulates Breast Cancer Associated Human Aromatase (CYP19A1) Expression.
SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report.
Soy processing influences growth of estrogen-dependent breast cancer tumors.
Stat5 assumes distinct functions in mammary gland development and mammary tumor formation.
Statins and Breast Cancer: Future Directions in Chemoprevention.
Steroid dynamics in the normal and carcinomatous mammary gland.
Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer.
Steroid secretion by masculinizing and "feminizing" Hilus cell tumors.
Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
Steroidal aromatase inhibitors inhibit growth of hormone-dependent breast cancer cells by inducing cell cycle arrest and apoptosis.
Steroidal pyrazolines evaluated as aromatase and quinone reductase-2 inhibitors for chemoprevention of cancer.
Steroidogenesis in an estrogen-producing adrenal tumor in a young woman: comparison with steroid profiles associated with cortisol- and androgen-producing tumors.
Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha.
Stimulation of human tumor xenograft growth by local estrogen biosynthesis in stromal cells.
Stopping treatment can reverse acquired resistance to letrozole.
Stroma-mediated expression of estrogen and its role in cancer.
Stromal spindle cells contain aromatase in human breast tumors.
Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.
Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor ? Transcriptional Activity in Breast Cancer Cell Lines.
Structure-function studies of aromatase and its inhibitors: a progress report.
Study of substrate specificity of human aromatase by site directed mutagenesis.
Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications.
Successful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone.
Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer.
Suicide inactivation of aromatase in human placenta and uterine leiomyoma by 5 alpha-dihydronorethindrone, a metabolite of norethindrone, and its effect on steroid-producing enzymes.
Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: Hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy.
Suppression of aromatase (estrogen synthetase) by red wine phytochemicals.
Suppression of Tumor Necrosis Factor-?-Induced Nuclear Factor ?B Activation and Aromatase Activity by Capsaicin and Its Analog Capsazepine.
Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).
Surgical issues surrounding use of aromatase inhibitors.
Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Sweet's Syndrome Induced by Aromatase Inhibitor in the Treatment of Early Breast Cancer.
Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors.
Synthesis and Evaluation of Novel Cholestanoheterocyclic Steroids as Anticancer Agents.
Synthesis of highly tritium labeled steroids for evaluation of aromatase and steroidsulfatase activities in endometrial tumors.
Synthesis of Resveratrol Derivatives and In Vitro Screening for Potential Cancer Chemopreventive Activities.
Systemic Estrone Production and Injury-Induced Sex Hormone Steroidogenesis after Severe Traumatic Brain Injury: A Prognostic Indicator of Traumatic Brain Injury-Related Mortality.
Systemic treatment of patients with early breast cancer: recent updates and state of the art.
Tamoxifen-failed male breast cancer with a high level of circulating estrogen: report of a case.
Targeting Aberrant p70S6K Activation for Estrogen Receptor Negative Breast Cancer Prevention.
Targeting allosteric sites of human aromatase: a comprehensive in-silico and in-vitro workflow to find potential plant-based anti-breast cancer therapeutics.
Targeting aromatase and estrogen signaling in human non-small cell lung cancer.
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.
Targeting mixed lineage kinases in ER-positive breast cancer cells leads to G2/M cell cycle arrest and apoptosis.
Targeting obesity-related dysfunction in hormonally driven cancers.
Targeting the estrogen receptor in clinical breast cancer.
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.
Targeting the RB-E2F pathway in breast cancer.
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Testicular germ cell tumors exhibit evidence of hormone dependence.
Testicular sex cord-stromal lesions: immunohistochemical analysis of cytokeratin, vimentin and steroidogenic enzymes.
Testosterone Aromatization to Estradiol in Course of Ovarian Functioning Brenner Tumor Associated With Endometrial Carcinoma and Endometriosis (Roncati-Manenti Triad).
TGF-?1 stimulates aromatase expression and estradiol production through SMAD2 and ERK1/2 signaling pathways in human granulosa-lutein cells.
The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.
The anti-cancer potential of crotoxin in estrogen receptor-positive breast cancer: Its effects and mechanism of action.
The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats.
The aromatase enzyme: from cloning to cancer.
The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy.
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
The association of osteoporosis knowledge and beliefs with preventive behaviors in postmenopausal breast cancer survivors.
The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor ? and modulates estrogen-stimulated breast cancer cell proliferation.
The case for aromatase inhibitors use in Oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in Breast Cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression.
The challenges of modelling hormone-receptor positive breast cancer in mice.
The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.
The control and biological importance of intratumoural aromatase in breast cancer.
The CYP19A1 rs700519 Polymorphism and Breast Cancer Susceptibility in China: A Case-Control Study and Updated Meta-Analysis.
The effect of adipocyte-macrophage cross-talk in obesity-related breast cancer.
The effect of aromatase inhibitor 4-hydroxyandrostenedione on steroid receptors in hormone-dependent tissues of the rat.
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
The effect of insulin on aromatase activity in isolated human endometrial glands and stroma.
The effect of medroxyprogesterone acetate on aromatase and DNA polymerase alpha activities in breast tumours.
The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China.
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
The effect of the aromatase inhibitor, 4-(phenylthio)-4-androstene-3,17-dione, on dimethylbenz(A)anthracene-induced rat mammary tumors.
The effect of tumor necrosis factor/cachectin on follicle-stimulating hormone-induced aromatase activity in cultured rat granulosa cells.
The effects of anastrozole on neonatal rat skin.
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
The effects of aromatase overexpression on mammary growth and gene expression in the aromatase x transforming growth factor alpha double transgenic mice.
The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.
The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker.
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.
The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters.
The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory.
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.
The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
The Importance of CYP19A1 in Estrogen Receptor-Positive Cholangiocarcinoma.
The importance of local synthesis of estrogen within the breast.
The Inhibitory Properties of Ethanol Extracts of Some Culinary-Medicinal Mushrooms on the Secretion of Interleukin-8 and Vascular Endothelial Growth Factor by PC3 Cancer Cells.
The interaction between aromatase, metalloproteinase 2,9 and cd44 in breast cancer.
The invisible arm of immunity in common cancer chemoprevention agents.
The masculinized female and investigation of abnormal sexual development.
The metabolic syndrome: A high-risk state for cancer?
The obesity-inflammation-eicosanoid axis in breast cancer.
The Orphan Nuclear Receptor LRH-1 and ER? Activate GREB1 Expression to Induce Breast Cancer Cell Proliferation.
The overexpression of int-5/Aromatase, a novel MMTV integration locus gene, is responsible for D2 mammary tumor cell proliferation.
The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis.
The plant polyphenol butein inhibits testosterone-induced proliferation in breast cancer cells expressing aromatase.
The postmenopausal ovary as an androgen-producing gland; hypothesis on the etiology of endometrial cancer.
The potential of aromatase inhibitors in breast cancer prevention.
The potential role of estrogen in aromatase regulation in the breast.
The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy: A Population-Based Cohort Study.
The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2.
The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease.
The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
The relationship of bone-tumor-induced spinal cord astrocyte activation and aromatase expression to mechanical hyperalgesia and cold hypersensitivity in intact female and ovariectomized mice.
The relevance of preclinical models to the treatment of postmenopausal breast cancer.
The role of aromatase in breast tumors.
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
The role of COX-2 inhibition in breast cancer treatment and prevention.
The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer.
The Role of Hormonal Therapy in Gynecological Cancers-Current Status and Future Directions.
The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model.
The role of soybean extracts and isoflavones in hormone-dependent breast cancer: aromatase activity and biological effects.
The search for ESR1 mutations in breast cancer.
The structure of cDNA clones encoding the aromatase P-450 isolated from a rat Leydig cell tumor line demonstrates differential processing of aromatase mRNA in rat ovary and a neoplastic cell line.
The therapeutic potential of aromatase inhibitors.
The turnover of estrogen receptor ? by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.
The use of D-chiro-Inositol in clinical practice.
The use of rat Leydig tumor (R2C) and human hepatoma (HEPG2) cells to evaluate potential inhibitors of rat and human steroid aromatase.
The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.
The validation of new aromatase monoclonal antibodies for immunohistochemistry--a correlation with biochemical activities in 46 cases of breast cancer.
The VES-13 and G-8 tools as predictors of toxicity associated with aromatase inhibitors in the adjuvant treatment of breast cancer in elderly patients: A single-center study.
Theoretical Study of the Mechanism of Exemestane Hydroxylation Catalyzed by Human Aromatase Enzyme.
Therapeutic approaches for protecting bone health in patients with breast cancer.
Therapeutic observations in MCF-7 aromatase xenografts.
Thioredoxin-mediated redox regulation of resistance to endocrine therapy in breast cancer.
Thrombotic risk and immobility in residents of long-term care facilities.
Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.
Tissue-specific regulation of aromatase promoter II by the orphan nuclear receptor LRH-1 in breast adipose stromal fibroblasts.
Topical estrogen prescribing patterns for urogenital atrophy among women with breast cancer: results of a national provider survey.
Topological polar surface area: a useful descriptor in 2D-QSAR.
Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model.
Toxicity of aromatase inhibitors.
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
trans-Activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y1)-1H-[1]benzopyrano[3,4-f]quinoline (A276575) and its four stereoisomers.
Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture.
Transdermal patches for site-specific delivery of anastrozole: In vitro and local tissue disposition evaluation.
Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis.
Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention.
Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.
Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Treatment Modification in Young Breast Cancer Patients.
Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.
Treatment of aggressive angiomyxoma with aromatase inhibitor prior to surgical resection.
Treatment of established breast cancer in post-menopausal women: role of aromatase inhibitors.
Treatment of Intravenous Leiomyomatosis with Cardiac Extension following Incomplete Resection.
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study.
Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Treg deficiency-mediated TH 1 response causes human premature ovarian insufficiency through apoptosis and steroidogenesis dysfunction of granulosa cells.
Tributyltin or triphenyltin inhibits aromatase activity in the human granulosa-like tumor cell line KGN.
Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.
Tumor microenvironmental growth factors induce long-term estrogen deprivation resistance in breast cancer.
Tumor necrosis factor-alpha activates transcription of inducible repressor form of 3',5'-cyclic adenosine 5'-monophosphate-responsive element binding modulator and represses P450 aromatase and inhibin alpha-subunit expression in rat ovarian granulosa cells by a p44/42 mitogen-activated protein kinase-dependent mechanism.
Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4.
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors.
Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells.
Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer.
Two natural products, trans-phytol and (22E)-ergosta-6,9,22-triene-3?,5?,8?-triol, inhibit the biosynthesis of estrogen in human ovarian granulosa cells by aromatase (CYP19).
Understanding and optimizing bone health in breast cancer.
Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Understanding the mechanisms of aromatase inhibitor resistance.
Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer.
Unravelling exemestane: From biology to clinical prospects.
Unusual Virilization in Girls with Juvenile Granulosa Cell Tumors of the Ovary Is Related to Intratumoral Aromatase Deficiency.
Unveiling the mechanism of action behind the anti-cancer properties of cannabinoids in ER+ breast cancer cells: Impact on aromatase and steroid receptors.
Update on identifying and managing osteoporosis in women with breast cancer.
Upregulation of AIB1, aromatase and ER? provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival.
Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review.
Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.
Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study.
Use of Aromatase Inhibitors in IVF for Fertility Preservation of Non-Breast Cancer Patients: A Case Series.
Use of aromatase inhibitors in large cell calcifying sertoli cell tumors: effects on gynecomastia, growth velocity, and bone age.
Use of aromatase inhibitors in practice of gynecology.
Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.
Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body.
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.
Use of tissue-specific promoters in the regulation of aromatase cytochrome P450 gene expression in human testicular and ovarian sex cord tumors, as well as in normal fetal and adult gonads.
Usefulness of 22-oxa-1,25-dihydroxyvitamin D-3 (OCT) as a single agent or combined therapy with aromatase inhibitor (CGS 16949A) on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Using multigene tests to select treatment for early-stage breast cancer.
Uterine sarcoma and aromatase inhibitors: Tom Baker Cancer Centre experience and review of the literature.
Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report.
Variation in the CYP19A1 gene and risk of colon and rectal cancer.
Virilizing oncocytic adrenocortical carcinoma: clinical and immunohistochemical studies.
Vitamin D mitigates the adverse effects of obesity on breast cancer in mice.
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group.
Weight gain increases human aromatase expression in mammary gland.
What do we know about the mechanisms of aromatase inhibitor resistance?
Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel.
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Women's health, breast health: a review of the gynecologic effects of breast cancer.
Xenograft models for aromatase inhibitor studies.
[A cost-effectiveness study of first-line hormone therapy in post-menopausal patients with metastatic breast cancer on neoadjuvant treatment]
[Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report]
[Analysis of polymorphisms in genes of insulin receptor substrate-1 and enzymes involved in estrogen biosynthesis and metabolism among breast cancer patients with BRCA1 mutations]
[Anticarcinogenic role of melatonin--potential mechanisms].
[Aromatase activity and its gene expression in tumor tissue of smokers and non-smokers with breast cancer]
[Aromatase activity in lymphocytes of cancer patients and healthy subjects]
[Aromatase and breast cancer]
[Aromatase expression in invasive and in situ ductal carcinoma present in the same breast.]
[Aromatase gene expression and its modifying factors in breast tumor tissue]
[Aromatase inhibitors for treatment of advanced breast cancers]
[Aromatase inhibitors in advanced breast cancer]
[Association of CYP19A1 gene rs7176005 single nucleotide polymorphism with breast cancer risk and clinicopathologic features of tumor].
[Bone Marrow Metastases of Breast Cancer Treated with Endocrine Therapy-A Case Report].
[Clinical assessment of neoadjuvant endocrine chemotherapy (stage II) vis-a-vis chemotherapy of breast tumor patients]
[Clinicopathological significance of aromatase expression in breast cancers]
[Correlation between tumor tissue aromatase, histological pattern and reproductive status in patients with breast cancer]
[Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma]
[Current status of adjuvant endocrine therapy for hormone responsive breast cancer]
[Current status of breast cancer chemoprevention]
[Development of a novel aromatase inhibitor, anastrozole (Arimidex)--its basic and clinical studies]
[Development of aromatase inhibitors and analysis of their inhibitory activities]
[Estrogen biosynthesis in human uterine myoma tissue. The distribution of androstenedione aromatase activity in uterine myoma tissue]
[Estrogen metabolism enzymes level association with breast cancer outcome].
[For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard]
[Growth inhibition of MCF-7 human breast cancer cells by aromatase inhibitors]
[Induction of ovulation].
[Inhibiting effect of letrozole combined with curcumin on xenografted endometrial carcinoma growth in nude mice]
[Interrelationship between response to neoadjuvant hormone therapy and hormonal-metabolic status in breast cancer patients]
[Macroorchidism: A case report.]
[Male breast cancer: a review.]
[Male Breast Cancer: What is Different?].
[Metformin does not suppress the aromatase expression in breast cancer tissue of patients with concurrent type 2 diabetes].
[Molecular mechanism of inhibition of sodium butyrate on activation of tumor associated aromatase promoters]
[Neoadjuvant use of the aromatase inhibitor letrozole in uterine cancer: endocrine and clinical effects]
[Palbociclib combinations as new therapeutic strategies in the treatment of HR+/HER2- advanced breast cancer].
[Palliative therapy of breast cancer]
[Pathologic-anatomic parameters for the prognosis of invasive breast cancer following amputation or saving the breast]
[Possibilities to use the aromatase inhibitors for the treatment of the uterine fibroids]
[Preclinical evaluation of aromatase inhibitors antitumor activity]
[Precocious puberty in girls depending on choriogonadotropin - case reports and literature review]
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
[Progenotoxic shift in mammary adipose tissue (adipogenotoxicosis): association with clinical and biological characteristics of breast cancer]
[Prognostic significance of assay of sex hormones, their receptors and enzymes involved in estrogen synthesis and metabolism in endometrial carcinoma]
[Properties of mammary fat in breast cancer patients: topographic, systemic and environmental factors]
[Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy]
[Rare forms of female pseudohermaphroditism: when to investigate?]
[Recent advance of hormonal treatment for breast cancer]
[Relationship among aromatase activity, estrogen receptor and progesterone receptor in ovarian tumors from postmenopausal women]
[Relationship between level of sexual hormone in external blood and aromatase expression in cancer tissues of male patients with lung cancer]
[Relevant mutations in predictive breast cancer pathology].
[Semiquantitative analysis of mRNA aromatase expression in eutopic endometrium as a diagnostic marker of endometriosis and estrogen dependent diseases]
[Strategy of drug development for hormone-dependent tumor]
[The evolving role of endocrine therapy for breast cancer]
[Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
[Tumor tissue aromatase and estrogen levels versus clinical course of endometrial cancer]
[Vitamin D in oncology: Update 2015].
[Which hormone therapy should be used in advanced breast carcinoma in males?]
Neoplasms, Germ Cell and Embryonal
Cytochrome P450 aromatase expression in human seminoma.
[Precocious puberty in girls depending on choriogonadotropin - case reports and literature review]
Neoplastic Cells, Circulating
An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.
Early stage breast cancer treatment and prognostic factors: Post San Antonio Breast Cancer Symposium 2016.
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
Nephrocalcinosis
Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
Nephrotic Syndrome
Central Precocious Puberty as a Complication of Therapy with Adrenocorticotropin (ACTH) and an Aromatase Inhibitor for Refractory Nephrotic Syndrome.
Nerve Compression Syndromes
Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer.
Neuralgia
Neuronal aromatase expression in pain processing regions of the medullary and spinal cord dorsal horn.
Neuroblastoma
Aromatase/Seladin-1 Interactions in Human Neuronal Cell Culture, the Hippocampus of Healthy Rats and Transgenic Alzheimer's Disease Mice.
Effects of vitamin D in the nervous system: Special focus on interaction with steroid hormone signalling and a possible role in the treatment of brain cancer.
Feedback Regulation of SREBP and Aromatase in A beta(25-35)-Supplemented Human Neuroblastoma Cells.
Feedback regulation of SREBP and aromatase in A beta(25-35)-supplemented human neuroblastoma cells.
Neuroblastoma and Alzheimer's disease brain cells contain aromatase activity.
Selective regulation of neurosteroid biosynthesis in human neuroblastoma cells under hydrogen peroxide-induced oxidative stress condition.
Selective transcriptional regulation of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells.
Neurodegenerative Diseases
Aromatase Expression in the Hippocampus of AD Patients and 5xFAD Mice.
Aromatase: a neuroprotective enzyme.
Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds.
Impact of R264C and R264H polymorphisms in human aromatase function.
The lack of Irs2 induces changes in the immunocytochemical expression of aromatase in the mouse retina.
Neuroendocrine Tumors
Everolimus.
Neurofibromatoses
Aromatase excess syndrome presenting with prepubertal gynecomastia in an Egyptian child with type 1 neurofibromatosis.
Neurofibromatosis 1
Aromatase excess syndrome presenting with prepubertal gynecomastia in an Egyptian child with type 1 neurofibromatosis.
Neuroinflammatory Diseases
Aromatase and neuroinflammation in rat focal brain ischemia.
Brain-derived estrogen exerts anti-inflammatory and neuroprotective actions in the rat hippocampus.
Centrally Synthesized Estradiol is a Potent Anti-Inflammatory in the Injured Zebra Finch Brain.
Estrogen as a Neuroprotectant in Both Sexes: Stories From the Bird Brain.
Neuroinflammation induces glial aromatase expression in the uninjured songbird brain.
Reciprocal interactions between prostaglandin E2- and estradiol-dependent signaling pathways in the injured zebra finch brain.
Neutropenia
Recent advances in oncology acupuncture and safety considerations in practice.
Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.
Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
Non-alcoholic Fatty Liver Disease
Aromatase in normal and diseased liver.
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Obesity
A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
Abdominal obesity and intra-abdominal pressure: a new paradigm for the pathogenesis of the hypogonadal-obesity-BPH-LUTS connection.
Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women.
An aromatase polymorphism modulates the relationship between weight and estradiol levels in obese men.
Analysis of Obesity-Related Factors and their Association with Aromatase Expression in Canine Malignant Mammary Tumours.
Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS.
Aromatase Inhibition Ameliorates Decreased LH Output Found in Obese Women.
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.
Aromatase inhibitors in male sex.
Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels.
Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer.
Aromatase, breast cancer and obesity: a complex interaction.
Association of aromatase (TTTAn) repeat polymorphism length and the relationship between obesity and decreased sperm concentration.
Breast Cancer Endocrine Therapy Promotes Weight Gain With Distinct Adipose Tissue Effects in Lean and Obese Female Mice.
Caloric Restriction Reverses Obesity-Induced Mammary Gland Inflammation in Mice.
CC chemokine ligand 2 (CCL2) stimulates aromatase gene expression in mammary adipose tissue.
Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse.
Chemopreventive and Anticancer Property of Selenoproteins in Obese Breast Cancer.
Cholesterol feeding prevents adiposity in the obese female aromatase knockout (ArKO) mouse.
CYP19A1 genetic polymorphisms may be associated with obesity-related phenotypes in Chinese women.
Des-acyl ghrelin inhibits the capacity of macrophages to stimulate the expression of aromatase in breast adipose stromal cells.
Determinants of testosterone levels in human male obesity.
Dietary polyphenols suppress elevated levels of proinflammatory mediators and aromatase in the mammary gland of obese mice.
Effect of aging and obesity on aromatase activity of human adipose cells.
Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer.
Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review.
Effects of aging and obesity on aromatase activity of human adipose cells.
Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity.
Effects of high fat diet-induced obesity on mammary tumorigenesis in the PyMT/MMTV murine model.
Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations.
Ethnic differences in regional adipose tissue oestrogen receptor gene expression.
Exemestane: One part of the chemopreventive spectrum for ER-positive breast cancer.
Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients.
FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.
Genetic polymorphisms and obesity influence estradiol decline during the menopause.
Ghrelin and Breast Cancer: Emerging Roles in Obesity, Estrogen Regulation, and Cancer.
High fat-induced obesity associated with insulin-resistance increases FGF-2 content and causes stromal hyperplasia in rat ventral prostate.
Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors.
HTR1B, ADIPOR1, PPARGC1A, and CYP19A1 and obesity in a cohort of Caucasians and African Americans: an evaluation of gene-environment interactions and candidate genes.
IKKbeta mediates cell shape-induced aromatase expression and estrogen biosynthesis in adipose stromal cells.
IL-10 suppresses TNF-?-induced expression of human aromatase gene in mammary adipose tissue.
Impact of obesity on mammary gland inflammation and local estrogen production.
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women.
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer.
Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer.
Inflammatory Talk: Linking Obesity, NF-{kappa}B, and Aromatase.
Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity.
Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?
Leptin regulation of the p53-HIF1?/PKM2-aromatase axis in breast adipose stromal cells: a novel mechanism for the obesity-breast cancer link.
Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
Melatonin: A Molecule for Reducing Breast Cancer Risk.
Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.
Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase.
Methylseleninic acid is a novel suppressor of aromatase expression.
Obesity and breast cancer - Role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue.
Obesity and breast cancer: progress to understanding the relationship.
Obesity and breast cancer: role of inflammation and aromatase.
Obesity and endocrine therapy: Host factors and breast cancer outcome.
Obesity and nonadherence correlate with elevated serum estradiol levels in postmenopausal women receiving adjuvant aromatase inhibitor therapy.
Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
Obesity during pregnancy affects sex steroid concentrations depending on fetal gender.
Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis.
Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland.
Obesity, aromatase and breast cancer.
Osteopontin promotes aromatase expression and estradiol production in human adipocytes.
Pericardial adipose and aromatase: A new translational target for aging, obesity and arrhythmogenesis?
Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence.
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Prostaglandin E2 Inhibits p53 in Human Breast Adipose Stromal Cells: A Novel Mechanism for the Regulation of Aromatase in Obesity and Breast Cancer.
Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women: a new hypothesis.
Relationship of obesity to blood estrogens.
Research Progress on the Relationship between Obesity-Inflammation-Aromatase Axis and Male Infertility.
Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women.
Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient Population.
The association between adiposity and breast cancer recurrence and survival: A review of the recent literature.
The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome.
The effect of adipocyte-macrophage cross-talk in obesity-related breast cancer.
The Effect of Aromatase on the Reproductive Function of Obese Males.
The effect of obesity on human reproductive health and foetal life.
The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer.
The low density lipoprotein receptor modulates the effects of hypogonadism on diet-induced obesity and related metabolic perturbations.
The role of DENND1A and CYP19A1 gene variants in individual susceptibility to obesity in Turkish population-a preliminary study.
The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease.
Thrombotic risk and immobility in residents of long-term care facilities.
Transcriptome Analysis of Testis from HFD-Induced Obese Rats (Rattus norvigicus) Indicated Predisposition for Male Infertility.
Weight gain and inflammation regulate aromatase expression in male adipose tissue, as evidenced by reporter gene activity.
[Hormone-associated properties and plasticity of omental fat: the relation with clinical-morphological features of endometrial cancer in patients with different obesity phenotypes].
[Obesity and cancer]
Obesity, Abdominal
Abnormal production of androgens in women with breast cancer.
Effect of Testosterone Synthesis and Conversion on Serum Testosterone Levels in Obese Men.
Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity.
Obesity, Metabolically Benign
[Hormone-associated properties and plasticity of omental fat: the relation with clinical-morphological features of endometrial cancer in patients with different obesity phenotypes].
Obesity, Morbid
The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity.
Obstetric Labor, Premature
[Pregnancy after Treatment of Breast Cancer].
Oligospermia
Aromatase inhibitors in male sex.
Do men with normal testosterone-oestradiol ratios benefit from letrozole for the treatment of male infertility?
Effect of aromatase inhibition by delta 1-testolactone on basal and luteinizing hormone-releasing hormone-stimulated pituitary and gonadal hormonal function in oligospermic men.
Effect of chronic aromatase inhibition by delta 1-testolactone on pituitary-gonadal function in oligozoospermic men.
Serum bioactive follicle-stimulating hormone in men with idiopathic azoospermia and oligospermia.
Successful use of aromatase inhibitor letrozole in NOA with an elevated FSH level: a case report.
Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover.
[Long-term therapy of oligozoospermia with the aromatase inhibitor testolactone]
Opioid-Induced Constipation
Acupuncture for cancer pain and related symptoms.
Osteitis Deformans
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Osteoarthritis
Effect of Buthus martensi Karsch on aromatase activity and cytokine-inducted NOS and NO production in osteoblasts and leukaemic cell line FLG 29.1.
Rheumatic disorders and functional disability with aromatase inhibitor therapy.
The chondroprotective effects of dehydroepiandrosterone probably exerted by its conversion to estradiol.
[Menopausal symptoms and quality of life of hormone receptor positive breast cancer patients at different endocrine therapy time].
Osteogenesis Imperfecta
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Osteolysis
Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Osteoma
Two cases of treatment with aromatase inhibitors and development of miliary osteoma cutis-Is there an association?
Osteomalacia
The management of secondary osteoporosis.
Osteonecrosis
An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw.
Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals.
Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review.
Osteoporosis
1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts.
A new day dawns: women without oestrogen or is a balance best?
A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women.
A novel mutation in collagen gene COL1A2 associated with transient regional osteoporosis.
A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism.
A Pooled Analysis of Fall Incidence From Placebo-controlled Trials of Denosumab.
A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
A retrospective study on screening and management of osteoporosis in breast cancer women treated with aromatase inhibitors in Libya.
ACOG Committee Opinion No. 738 Summary: Aromatase Inhibitors in Gynecologic Practice.
ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Alleviating anastrozole induced bone toxicity by selenium nanoparticles in SD rats.
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Antihormonal potential of selected D-homo and D-seco estratriene derivatives.
Aromatase deficiency in men: a clinical perspective.
Aromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral density.
Aromatase in bone cell: association with osteoporosis in postmenopausal women.
Aromatase in bone: roles of Vitamin D3 and androgens.
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.
Aromatase inhibitor adjuvant chemotherapy of breast cancer results in cancer therapy induced bone loss.
Aromatase inhibitor treatment for breast cancer: short-term effect on bone health.
Aromatase inhibitor-associated arthralgia syndrome.
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.
Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer.
Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Aromatase inhibitors and osteoporosis: Comment on the review by Felson and Cummings.
Aromatase inhibitors as potential cancer chemopreventives.
Baseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at initiation of aromatase inhibitor therapy: A descriptive study.
Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis.
Bone complications of cancer treatment in the elderly.
Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.
Bone health in the elderly cancer patient: A SIOG position paper.
Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
Bone Mineral Density at the Time of Initiating Aromatase Inhibitor Therapy Is Associated With Decreased Fractures in Women With Breast Cancer.
Bone mineral density in early breast cancer patients.
Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors.
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption.
Bone: best papers of the year 2017.
Breast cancer and osteoporosis.
Cancer treatment-induced bone loss.
Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.
Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice.
Committee Opinion No. 663: Aromatase Inhibitors in Gynecologic Practice.
Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment.
Correlation of rs749292 and rs700518 polymorphisms in the aromatase gene (CYP19A1) with osteoporosis in postmenopausal Polish women.
CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy.
Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1,25-dihydroxyvitamin D3 in human osteoblasts.
Denosumab: A bone antiresorptive drug.
Disease Progression Modeling Analysis of the Change of Bone Mineral Density by Postoperative Hormone Therapies in Postmenopausal Patients With Early Breast Cancer.
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Divergence from osteoporosis screening guidelines in older breast cancer patients treated with anti-estrogen therapy: A population-based cohort study.
Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors.
Drug-induced osteoporosis: mechanisms and clinical implications.
Effect of Buthus martensi Karsch on aromatase activity and cytokine-inducted NOS and NO production in osteoblasts and leukaemic cell line FLG 29.1.
Effect of estrogen replacement on insulin sensitivity, serum lipid and bone resorption marker in hypogonadal males.
Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation.
Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer.
Emerging bone health issues in women with breast cancer in Hawai'i.
Evaluation of a bioluminescent mouse model expressing aromatase PII-promoter-controlled luciferase as a tool for the study of endocrine disrupting chemicals.
Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
Exercise for secondary prevention of breast cancer: moving from evidence to changing clinical practice.
Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis.
Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors.
Incidence and prevalence of medication-induced osteoporosis: evidence-based review.
Incidence of comorbidities in women with breast cancer treated with tamoxifen or an aromatase inhibitor: an Australian population-based cohort study.
Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates.
Inhibition of estrogen-induced mammary tumor formation in MMTV-aromatase transgenic mice by 4-chlorophenylacetate.
Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.
Local aromatase expression in human prostate is altered in malignancy.
Local estradiol metabolism in osteoblast- and osteoclast-like cells.
Low Aromatase Activity and Estradiol/Sex Hormone Binding Globulin Ratio are Associated with Total Hip Bone Mineral Density and the Presence of Osteoporosis: A Study in Chinese Postmenopausal Women.
Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition.
Managing the risk of osteoporosis in women with a history of early breast cancer.
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Multilocus analysis of estrogen-related genes in Spanish postmenopausal women suggests an interactive role of ESR1, ESR2 and NRIP1 genes in the pathogenesis of osteoporosis.
NCCN Task Force Report: Bone Health and Cancer Care.
NCCN Task Force Report: Bone Health in Cancer Care.
New and emerging concepts in the use of denosumab for the treatment of osteoporosis.
New endocrine therapies for breast cancer.
Osteoporosis and aromatase inhibitors: experience and future prospects.
Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments.
Polymorphisms in the CYP19 gene that influence bone mineral density.
Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: Rationale and design of a randomized controlled trial.
Prevention, diagnosis and treatment of osteoporosis following menopause induced due to oncological disease.
Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.
Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
Saving the bones in breast cancer: aromatase inhibitor-induced osteoporosis.
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Screening for Osteoporosis in Postmenopausal Women With Breast Cancer Receiving Aromatase Inhibitors: Less Is More?
Selective estrogen receptor modulation: concept and consequences in cancer.
Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males.
Sex- and age-related response to aromatase deficiency in bone.
Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment.
Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy.
Symptom management in premenopausal patients with breast cancer.
TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
The associations of CYP19A1 rs700518 polymorphism with bone mineral density and risk of osteoporosis: a meta-analysis.
The effects of oestrogen exposure on bone mass in male to female transsexuals.
The management of secondary osteoporosis.
The obesity of bone.
The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model.
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.
Update on aromatase inhibitors in breast cancer.
Use of MR-based trabecular bone microstructure analysis at the distal radius for osteoporosis diagnostics: a study in post-menopausal women with breast cancer and treated with aromatase inhibitor.
Vertebral fractures cascade: potential causes and risk factors.
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
[Dehydroepiandrosterone(DHEA)and bone metabolism].
[DHEA and bone metabolism]
[Estrogen resistance and aromatase deficiency in humans]
[Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].
[Pharmacogenic osteoporosis beyond cortisone : Proton pump inhibitors, glitazones and diuretics.]
[Role of androgens and DHEA in bone metabolism]
[Surveillance following curative therapy for breast cancer]
[The significance of estrogens on metabolism of bone in men]
[Thrombophlebitis in an Elderly Japanese Woman Treated with Tamoxifen for Breast Cancer].
Osteoporosis, Postmenopausal
A Pooled Analysis of Fall Incidence From Placebo-controlled Trials of Denosumab.
Aromatase in aging women.
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
Aromatase inhibitors and bone.
Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation.
Estrogen production and action.
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis.
Postmenopausal osteoporosis, breast cancer, and aromatase inhibitor.
Prevention of osteoporosis after breast cancer.
RANK ligand inhibition with denosumab for the management of osteoporosis.
Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
Therapeutic approaches for protecting bone health in patients with breast cancer.
Osteosarcoma
Aromatase activity in human osteoblast-like osteosarcoma cell.
Aromatase in bone cell: association with osteoporosis in postmenopausal women.
Local estradiol metabolism in osteoblast- and osteoclast-like cells.
Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.
Ovarian Cysts
A novel compound heterozygous variant in CYP19A1 resulting in aromatase deficiency with normal ovarian tissue.
Aromatase expression in ovarian epithelial cancers.
Aromatase inhibitors in pediatrics.
Genetic and Clinical Spectrum of Aromatase Deficiency in Infancy, Childhood and Adolescence.
Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene.
Hypothyroidism affects lipid and glycogen content and peroxisome proliferator-activated receptor ? expression in the ovary of the rabbit.
Induction of ovarian cysts in progesterone-synchronized immature rats: evidence that suppression of follicular aromatase activity is not a prerequisite for the induction of cystic follicles.
No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome.
[Estrogen biosynthesis in human female adipose tissue in vitro]
[Steroid hormone content and aromatase activity in ovarian cysts of cattle]
Ovarian Diseases
Recurrent severe hyperandrogenism during pregnancy: a case report.
The effects of the aromatase inhibitor delta 1-testolactone on gonadotropin release and steroid metabolism in polycystic ovarian disease.
Ovarian Hyperstimulation Syndrome
Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome.
Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
High ovarian GDF-8 levels contribute to elevated estradiol production in ovarian hyperstimulation syndrome by stimulating aromatase expression.
Melatonin stimulates aromatase expression and estradiol production in human granulosa-lutein cells: relevance for high serum estradiol levels in patients with ovarian hyperstimulation syndrome.
Modulation of steroidogenesis by vitamin D3 in granulosa cells of the mouse model of polycystic ovarian syndrome.
Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study.
The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function.
Two cases of polycystic ovary syndrome with onset of severe ovarian hyperstimulation syndrome following controlled ovarian stimulation with aromatase inhibitors for fertility preservation before breast cancer treatment.
[Luteal letrozole administration decreases serum estrogen level but not the risk of ovarian hyperstimulation syndrome].
Ovarian Neoplasms
Aromatase activity in human ovarian cancer.
Aromatase excess in cancers of breast, endometrium and ovary.
Aromatase expression in ovarian epithelial cancers.
Aromatase expression in women's cancers.
Aromatase in human common epithelial ovarian neoplasms.
Aromatase inhibition in ovarian cancer: repeated signals of efficacy but tools for patient selection remain elusive.
Aromatase inhibitors in ovarian cancer: is there a role?
Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.
Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk.
CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review.
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies.
Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma.
Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review.
Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study.
Immunohistochemical localisation of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours.
Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival.
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer.
KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery.
Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells.
MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers.
Multimodal Treatment of Primary Advanced Ovarian Cancer.
Multiple parameter analyses of human ovarian cancer: morphology, immunohistochemistry, steroid hormone receptors and aromatase.
New small-molecule compound Hu-17 inhibits estrogen biosynthesis by aromatase in human ovarian granulosa cancer cells.
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.
Recent advances in oncology acupuncture and safety considerations in practice.
Recurrent epithelial ovarian cancer and hormone therapy.
Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama.
Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women.
Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.
[Rationale for the approach to the choice of hormone therapy for ovarian cancer].
Ovarian Torsion
Novel CYP19A1 Mutations Extend the Genotype-Phenotype Correlation and Reveal the Impact on Ovarian Function.
Overweight
Adjuvant aromatase inhibitor options in overweight and obese postmenopausal women with breast cancer.
Analysis of Obesity-Related Factors and their Association with Aromatase Expression in Canine Malignant Mammary Tumours.
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.
Body mass index and aromatase inhibitors: a step forward in individualizing therapy for breast cancer patients?
Effects of Obesity and Obesity-Related Molecules on Canine Mammary Gland Tumors.
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women.
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer.
Obesity and endocrine therapy: Host factors and breast cancer outcome.
Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Relationship of estrogen synthesis capacity in the brain with obesity and self-control in men and women.
[Effect of free fatty acids on CYP19A1 (aromatase) gene expression in human adipose tissue stromal vascular fraction cells].
Ovotesticular Disorders of Sex Development
Fertility issues in the management of patients with disorders of sex development.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals.
Paralysis
Mitogen-Activated Protein Kinase (MAPK) and Obesity-Related Cancer.
Paraneoplastic Syndromes
A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.
Paraproteinemias
Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor.
Paresthesia
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Parkinson Disease
Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?
Variants in estrogen-related genes and risk of Parkinson's disease.
Parkinsonian Disorders
Aromatase and its inhibition in Behaviour, Obsessive Compulsive Disorder and Parkinsonism.
Sex differences in autophagy-mediated diseases: toward precision medicine.
Tamoxifen and the risk of Parkinsonism: a case/non-case study.
Periodontitis
Aromatase inhibitor anastrozole modifies cellular functions in gingival fibroblasts and endothelial cells: possible periodontal complications of aromatase inhibitor treatment.
Peripheral Nervous System Diseases
Advising Women Undergoing Treatment for Breast Cancer: A Narrative Review.
Exercise for secondary prevention of breast cancer: moving from evidence to changing clinical practice.
Oncology Acupuncture for Chronic Pain in Cancer Survivors: A Reflection on the American Society of Clinical Oncology Chronic Pain Guideline.
Peritonitis
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Peutz-Jeghers Syndrome
Aromatase expression in human germinomas with possible biological effects.
Aromatase expression in the human male.
Aromatase in the human testis.
Aromatase inhibitors in pediatrics.
High TGFbeta1, estrogen receptor, and aromatase gene expression in a large cell calcifying sertoli cell tumor (LCCSCT): implications for the mechanism of oncogenesis.
Management of prepubertal gynecomastia in two monozygotic twins with peutz-jeghers syndrome: from aromatase inhibitors to subcutaneous mastectomy.
Overexpression of aromatase associated with loss of heterozygosity of the STK11 gene accounts for prepubertal gynecomastia in boys with Peutz Jeghers Syndrome.
Prepubertal gynaecomastia in a boy with Peutz-Jeghers syndrome: managing the aromatase overexpression.
Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor.
Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
Serum inhibin B concentration in a prepubertal boy with gynecomastia and Peutz-Jeghers syndrome.
Pituitary ACTH Hypersecretion
Combined treatment with GH and anastrozole in a pubertal boy with Cushing's disease and postsurgical GH deficiency.
Pituitary Neoplasms
Aromatase P450 expression in human pituitary adenomas.
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Expression of aromatase P450 is increased in spontaneous prolactinomas of aged rats.
G-protein Coupled Estrogen Receptor Expression in Growth Hormone Secreting and Non-Functioning Adenomas.
Locally produced estrogen through aromatization might enhance tissue expression of pituitary tumor transforming gene and fibroblast growth factor 2 in growth hormone-secreting adenomas.
Opposite effects of dihydrotestosterone and estradiol on apoptosis in the anterior pituitary gland from male rats.
Relation among Aromatase P450 and Tumoral Growth in Human Prolactinomas.
Spontaneous ovarian hyperstimulation syndrome and pituitary adenoma: incidental pregnancy triggers a catastrophic event.
Placental Insufficiency
In vitro aromatization of androgens into estrogens in placental insufficiency.
Pleural Effusion
[Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report]
[Anastrozole-resistant breast cancer responsive to exemestane--a case report]
Pneumonia
Patients' preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments.
POEMS Syndrome
Accelerated conversion of dehydroepiandrosterone sulfate to estrogen in a patient with Crow-Fukase syndrome and diabetes mellitus.
Polycystic Ovary Syndrome
1,25-Dihydroxyvitamin D3 increases testosterone-induced 17beta-estradiol secretion and reverses testosterone-reduced connexin 43 in rat granulosa cells.
17 beta-Oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals.
A common polymorphism in the human aromatase gene alters the risk for polycystic ovary syndrome and modifies aromatase activity in vitro.
A mechanism for the suppression of estrogen production in polycystic ovary syndrome.
Acupuncture does not ameliorate metabolic disturbances in the P450 aromatase inhibitor-induced rat model of polycystic ovary syndrome.
Adding the phytoestrogen Cimicifugae Racemosae to clomiphene induction cycles with timed intercourse in polycystic ovary syndrome improves cycle outcomes and pregnancy rates - a randomized trial.
AKR1C3 (type 5 17?-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Aromatase Gene Polymorphism Does Not Influence Clinical Phenotype and Response to Oral Contraceptive Pills in Polycystic Ovary Syndrome Women.
Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation.
Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.
Aromatase inhibitors for infertility in polycystic ovary syndrome. The beginning or the end of a new era?
Aromatase inhibitors for ovulation and pregnancy in polycystic ovary syndrome.
Aromatase inhibitors for PCOS: a systematic review and meta-analysis.
Aromatase inhibitors for subfertile women with polycystic ovary syndrome.
Aromatase inhibitors for subfertile women with polycystic ovary syndrome: summary of a Cochrane review.
Aromatase inhibitors in women with clomiphene citrate resistance: a randomized, double-blind, placebo-controlled trial.
Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women.
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome.
Circulating immunoreactive and bioactive follicle stimulating hormone concentrations in anovulatory infertile women and during gonadotrophin induction of ovulation using a decremental dose regimen.
Combined metformin-clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome.
Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome.
Compartmental ovarian steroidogenesis in polycystic ovary syndrome.
Continuous administration of a P450 aromatase inhibitor induces polycystic ovary syndrome with a metabolic and endocrine phenotype in female rats at adult age.
CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype.
CYP19A1 Gene Expression in Patients with Polycystic Ovarian Syndrome.
Depletion of exosomal circLDLR in follicle fluid derepresses miR-1294 function and inhibits estradiol production via CYP19A1 in polycystic ovary syndrome.
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Elevated and diagnostic androgens of polycystic ovary syndrome.
Estradiol assays--The path ahead.
Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women.
Functional investigation on aromatase in endometrial hyperplasia in polycystic ovary syndrome cases.
Genetic association study from North India to analyze association of CYP19A1 and CYP17A1 with polycystic ovary syndrome.
Granulosa cell aromatase enzyme activity: effects of follicular fluid from patients with polycystic ovary syndrome, using aromatase conversion and [11C]vorozole-binding assays.
Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome.
Letrozole stimulation in endometrial preparation for cryopreserved-thawed embryo transfer in women with polycystic ovarian syndrome: A pilot study.
Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.
MiR-29a regulates the proliferation, aromatase expression, and estradiol biosynthesis of human granulosa cells in polycystic ovary syndrome.
Modulation of steroidogenesis by vitamin D3 in granulosa cells of the mouse model of polycystic ovarian syndrome.
No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome.
Ovarian stimulation drugs alter the metabolite content of the growing follicle: in vivo spectroscopic evaluation of follicle fluid
Placental steroidogenesis in pregnant women with polycystic ovary syndrome.
Promoter methylation of CYP19A1 gene in Chinese polycystic ovary syndrome patients.
Role of epigenetic modifications in the aberrant CYP19A1 gene expression in polycystic ovary syndrome.
Sex steroids, adiposity and smoking in the pathogenesis of idiopathic hirsutism and polycystic ovary syndrome.
SNP rs2470152 in CYP19 is correlated to aromatase activity in Chinese polycystic ovary syndrome patients.
The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome.
The CYP17 MSP AI (T-34C) and CYP19A1 (Trp39Arg) variants in polycystic ovary syndrome: A case-control study.
The insulin-like growth factor system in normal and abnormal human ovarian follicle development.
The synergistic effect of sex hormone-binding globulin and aromatase genes on polycystic ovary syndrome phenotype.
Two cases of polycystic ovary syndrome with onset of severe ovarian hyperstimulation syndrome following controlled ovarian stimulation with aromatase inhibitors for fertility preservation before breast cancer treatment.
Upregulation of Cyp19a1 and PPAR-? in ovarian steroidogenic pathway by Ficus religiosa: A potential cure for polycystic ovary syndrome.
Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial.
Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome.
[Effect of Transcutaneuos Acupoint Electrostimulation on Serum Sex Hormone Levels and Expression of Ovarian Steroid Hormone Metabolic Enzymes in Polycystic Ovary Syndrome Rats].
Polycythemia
A case of erythrocytosis in a patient treated with an aromatase inhibitor for breast cancer.
Aromatase activity after a short-course of letrozole administration in adult men at sea level and at high altitude (with or without excessive erythrocytosis).
Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer.
Aromatase inhibitors in pediatrics.
Polymyalgia Rheumatica
Predictors of fragility fracture and low bone mineral density in patients with a history of parental fracture.
Pre-Eclampsia
Abnormal steroidogenesis and aromatase activity in preeclampsia.
Downregulation of aromatase plays a dual role in preeclampsia.
Higher estrogen levels during pregnancy in Andean than European residents of high altitude suggest differences in aromatase activity.
Placental Aromatase Is Deficient in Placental Ischemia and Preeclampsia.
Redox-Sensitive Transcription Factor NRF2 Enhances Trophoblast Differentiation via Induction of miR-1246 and Aromatase.
Risk of Preeclampsia in Pregnancies After Assisted Reproductive Technology and Ovarian Stimulation.
Steroid profiling in preeclamptic women: evidence for aromatase deficiency.
Precancerous Conditions
IKKbeta mediates cell shape-induced aromatase expression and estrogen biosynthesis in adipose stromal cells.
Pregnancy, Ectopic
Aromatase inhibitor letrozole: a novel treatment for ectopic pregnancy.
Pregnancy, Tubal
Expression of P450 aromatase and 17beta-hydroxysteroid dehydrogenase type 1 at fetal-maternal interface during tubal pregnancy.
Premature Ejaculation
Aromatase inhibition for the treatment of idiopathic hypogonadotropic hypogonadism in men with premature ejaculation.
Primary Ovarian Insufficiency
Cytotoxicity and DNA damage caused from diazinon exposure by inhibiting the PI3K-AKT pathway in porcine ovarian granulosa cells.
Epistasis between CYP19A1 and ESR1 polymorphisms is associated with premature ovarian failure.
Epistasis between FSHR and CYP19A1 polymorphisms is associated with premature ovarian failure.
Failure of FSH to influence aromatization in human adipose tissue.
Prolactinoma
Achievement of fertility in an infertile man with resistant macroprolactinoma using high dose of bromocriptine and a combination of hCG and an aromatase inhibitor.
Aromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor behavior.
Aromatase enzyme expression in acromegaly and its possible relationship with disease prognosis.
Expression of aromatase P450 is increased in spontaneous prolactinomas of aged rats.
Increased expression of aromatase cytochrome P450 enzyme is associated with prolactinoma invasiveness in post-menopausal women.
Relation among Aromatase P450 and Tumoral Growth in Human Prolactinomas.
Relevance of pituitary aromatase and estradiol on the maintenance of the population of prolactin-positive cells in male mice.
The expression of AIB1 correlates with cellular proliferation in human prolactinomas.
The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
prostaglandin-endoperoxide synthase deficiency
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.
Prostatic Diseases
Estrogen Receptor-Related Receptor {alpha} Mediates Up-Regulation of Aromatase Expression by Prostaglandin E2 in Prostate Stromal Cells.
The potential significance of aromatase in the etiology and treatment of prostatic disease.
Prostatic Hyperplasia
Aromatase and other inhibitors in breast and prostatic cancer.
Aromatase in hyperplasia and carcinoma of the human prostate.
Aromatase inhibition in the dog. II. Effect on growth, function, and pathology of the prostate.
Aromatase inhibitors and benign prostatic hyperplasia.
Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer.
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-? and GPER signalling.
Associations of SRD5A2/CYP17/CYP19/VDR gene polymorphisms with the development and clinical progression of benign prostatic hyperplasia: a case-control study in northern Chinese population.
Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia.
Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review.
Bakuchiol suppresses oestrogen/testosterone-induced Benign Prostatic Hyperplasia development through up-regulation of epithelial estrogen receptor ? and down-regulation of stromal aromatase.
Benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E2.
Cactus flower extracts may prove beneficial in benign prostatic hyperplasia due to inhibition of 5alpha reductase activity, aromatase activity and lipid peroxidation.
Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: preliminary results.
Differential effect of keratinocyte growth factor (KGF) on aromatase activity in cultured canine prostatic epithelial cells.
Effect of dual inhibition of 5-alpha-reductase and aromatase on spontaneously developed canine prostatic hypertrophy.
Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia.
Effects of the aromatase inhibitor testolactone on human benign prostatic hyperplasia.
Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia.
Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group.
Estrogens and benign prostatic hyperplasia: rationale for therapy with aromatase inhibitors.
Estrogens and benign prostatic hyperplasia: the basis for aromatase inhibitor therapy.
Expression of enzymes involved in estrogen metabolism in human prostate.
Inhibition of 5 alpha-reductase and aromatase by the ellagitannins oenothein A and oenothein B from Epilobium species.
Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism.
Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors.
Metabolism of androgens in human benign prostatic hyperplasia: aromatase and its inhibition.
Novel aromatase and 5 alpha-reductase inhibitors.
Oestrogens and prostate cancer.
Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia.
Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group.
Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.
Sex steroid metabolism in benign and malignant intact prostate biopsies: individual profiling of prostate intracrinology.
The androgen receptor CAG repeat length polymorphism associates with prostate volume in Finnish men with benign prostatic hyperplasia.
The potential significance of aromatase in the etiology and treatment of prostatic disease.
The role of Eralpha and ERbeta in the prostate: insights from genetic models and isoform-selective ligands.
[Aromatase inhibitors in the medical treatment of benign prostatic hypertrophy]
Prostatic Neoplasms
17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
1?,25-Dihydroxyvitamin D(3) exerts tissue-specific effects on estrogen and androgen metabolism.
5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3.
A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
A Pooled Analysis of Fall Incidence From Placebo-controlled Trials of Denosumab.
Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment.
AKR1C3 (type 5 17?-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk.
Aromatase and other inhibitors in breast and prostatic cancer.
Aromatase and prostate cancer.
Aromatase inhibition in advanced prostatic cancer: preliminary communication.
Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.
Aromatase inhibitors in malignant diseases of aging.
Aromatase inhibitors: a new paradigm in breast cancer treatment.
Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer.
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-? and GPER signalling.
Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-?/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer.
Aromatization of androstenedione to estrogen by benign prostatic hyperplasia, prostate cancer and expressed prostatic secretions.
Assessment of steroidogenic pathways that do not require testosterone as intermediate.
Association of variants in estrogen-related pathway genes with prostate cancer risk.
Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E2.
Bicalutamide Plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer.
Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway.
Bisphosphonates in oncology.
Bone health in the elderly cancer patient: A SIOG position paper.
Cancer treatment-induced bone loss in breast and prostate cancer.
Cancer treatment-related bone disease.
Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer.
Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment.
Current strategies for anticancer chemoprevention and chemoprotection.
Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow.
CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.
Denosumab: A bone antiresorptive drug.
Dietary diethylstilbestrol but not genistein adversely affects rat testicular development.
Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism.
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Drug-induced osteoporosis: mechanisms and clinical implications.
Drugs Causing Bone Loss.
Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy.
Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival.
Effects of lactone derivatives on aromatase (CYP19) activity in H295R human adrenocortical and (anti)androgenicity in transfected LNCaP human prostate cancer cells.
Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases.
Estrogen receptor ? and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
Estrogen receptors ? and ? and aromatase as independent predictors for prostate cancer outcome.
Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Future directions in cancer prevention.
Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers.
Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population.
In vitro kinetic properties of the Thr201Met variant of human aromatase gene CYP19A1: functional responses to substrate and product inhibition and enzyme inhibitors.
Inhibition of aromatase (P450Arom) by some 1-(benzofuran-2-ylmethyl)imidazoles.
Inhibition of aromatase activity and growth suppression by 4-methoxy-4-androstene-3,17-dione in an androgen sensitive human prostatic carcinoma cell line.
Inhibitors of the P450 enzymes aromatase and lyase. Crystallographic and molecular modeling studies suggest structural features of pyridylacetic acid derivatives responsible for differences in enzyme inhibitory activity.
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.
Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism.
Management of advanced prostate cancer.
Management of cancer treatment-induced bone loss.
MECHANISMS IN ENDOCRINOLOGY: Estradiol as a male hormone.
Modulation of aromatase activity by growth factors in an androgen sensitive human prostate cancer cell line, LNCaP.
NCCN Task Force Report: Bone Health and Cancer Care.
NCCN Task Force Report: Bone Health in Cancer Care.
New and emerging concepts in the use of denosumab for the treatment of osteoporosis.
P450-dependent enzymes as targets for prostate cancer therapy.
Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell Line.
Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men.
Predictors of fragility fracture and low bone mineral density in patients with a history of parental fracture.
Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue.
Prevention and treatment of bone loss in patients with nonmetastatic breast or prostate cancer who receive hormonal ablation therapy.
Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors.
Recent advances in oncology acupuncture and safety considerations in practice.
Regulation of aromatase and 5alpha-reductase by 25-hydroxyvitamin D(3), 1alpha,25-dihydroxyvitamin D(3), dexamethasone and progesterone in prostate cancer cells.
Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Risks and benefits of bisphosphonates.
Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis.
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.
Testosterone may speed up the growth of prostate cancer due to aromatase activity.
The CYP19A1 (TTTA)n Repeat Polymorphism May Affect the Prostate Cancer Risk: Evidence from a Meta-Analysis.
The impact of Catechol-O-methyl transferase knockdown on the cell proliferation of hormone-responsive cancers.
The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men.
The management of secondary osteoporosis.
The potential significance of aromatase in the etiology and treatment of prostatic disease.
The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease.
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5alpha-reductase and steroid aromatase.
[ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
[A study on intratesticular aromatase activity in male infertility]
[Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
[Fracture risk associated with drugs other than glucocorticoids].
[Secondary osteoporosis. Cancer treatment-induced bone loss.]
[Treatment effect of breast cancer and prostate cancer on bone.]
Prostatitis
Basal Cells Show Increased Expression of Aromatase and Estrogen Receptor ? in Prostate Epithelial Lesions of Male Aging Rats.
The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis.
Pruritus
Acupuncture for cancer pain and related symptoms.
Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy.
Puberty, Delayed
A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial.
Molecular biology in reproductive endocrinology.
Pharmacological management of children with short stature: the role of aromatase inhibitors.
Use of a specific aromatase inhibitor in delayed puberty.
[Growth rate can be manipulated. Estrogen production in pubertal boys can be blocked by an aromatase inhibitor]
Puberty, Precocious
Adult height in patients with familial male-limited precocious puberty and the role of an aromatase inhibitor in patient management.
Aromatase expression in human germinomas with possible biological effects.
Aromatase inhibitors in male sex.
Aromatase inhibitors in men: effects and therapeutic options.
Aromatase inhibitors in pediatrics.
Aromatase inhibitors in precocious puberty: rationale and experience to date.
Aromatase over expression transgenic murine models for aromatase inhibitor studies.
Aromatase p450 expression in a feminizing adrenal adenoma presenting as isosexual precocious puberty.
Association of aromatase (TTTA)n repeat polymorphisms with central precocious puberty in girls.
Bicalutamide and third-generation aromatase inhibitors in testotoxicosis.
Central Precocious Puberty as a Complication of Therapy with Adrenocorticotropin (ACTH) and an Aromatase Inhibitor for Refractory Nephrotic Syndrome.
Characterization and Management of Testicular Pathology in McCune-Albright Syndrome.
Combined treatment with bicalutamide and anastrozole in a young boy with peripheral precocious puberty due to McCune-Albright Syndrome.
Contemporary issues in precocious puberty.
Decreased hypothalamic aromatization in female rats of true precocious puberty.
Delayed closure of epiphyseal cartilages induced by the aromatase inhibitor anastrozole. Would it help short children grow up?
Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty.
Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome.
Elevated hypothalamic aromatization at the onset of precocious puberty in transgenic female mice hypersecreting human chorionic gonadotropin: effect of androgens.
Is there a role for estrogen activity assays? Recombinant cell bioassay for estrogen: Development and applications.
Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome.
Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome.
Luteinizing hormone-releasing hormone (LHRH)-independent precocious puberty unresponsive to LHRH agonist therapy in two girls lacking features of the McCune-Albright syndrome.
Ovarian cysts in prepubertal girls.
Reproductive endocrinology: Aromatase (TTTA)13 repeat increases risk of central precocious puberty.
Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome.
Testolactone treatment of precocious puberty in McCune-Albright syndrome.
Testotoxicosis: current viewpoint.
The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome.
The effects of oestrogens on linear bone growth.
The role of estrogen in bone growth and maturation during childhood and adolescence.
Therapeutic uses of aromatase inhibitors in men.
Third-generation Aromatase Inhibitor Improved Adult Height in a Japanese Boy with Testotoxicosis.
Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin.
Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.
Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development.
Use of aromatase inhibitors in children and adolescents: what's new?
Use of aromatase inhibitors in precocious puberty.
[Efficacy and safety of letrozole in treatment of McCune-Albright syndrome girls with peripheral precocious puberty].
[Precocious puberty and ovarian follicular cysts]
[Precocious puberty in girls depending on choriogonadotropin - case reports and literature review]
Pulmonary Arterial Hypertension
Anastrozole in Pulmonary Arterial Hypertension (AIPH): A Randomized, Double-Blind Placebo-Controlled Trial.
Pulmonary Disease, Chronic Obstructive
Increased levels of enzymes involved in local estradiol synthesis in chronic obstructive pulmonary disease.
Thrombotic risk and immobility in residents of long-term care facilities.
Pulmonary Fibrosis
Evaluation of aromatase inhibitor on radiation induced pulmonary fibrosis via TGF- ?/Smad 3 and TGF- ?/PDGF pathways in rats.
Purpura
Henoch-Schönlein purpura and aromatase inhibitors.
Rectal Neoplasms
Variation in the CYP19A1 gene and risk of colon and rectal cancer.
Renal Insufficiency, Chronic
Confounder factors masking a Leydig-cell ovarian tumor in a post-menopausal woman treated for androgen-positive receptor breast cancer.
Low-trauma fractures without osteoporosis.
Short Stature in Chronic Kidney Disease Treated with Growth Hormone and an Aromatase Inhibitor.
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Reperfusion Injury
Indinavir inhibits the expression of cytoplasmic aromatase and nuclear SREBP in the hippocampus of reperfusion injury-induced ischemic rats.
Megestrol acetate inhibits the expression of cytoplasmic aromatase through nuclear C/EBP? in reperfusion injury-induced ischemic rat hippocampus.
Respiratory Insufficiency
Adverse Outcome Pathways for Regulatory Applications: Examination of Four Case Studies With Different Degrees of Completeness and Scientific Confidence.
Respiratory Paralysis
Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies.
Retinal Hemorrhage
Retinal hemorrhages in anastrozole users.
Rickets
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Rosacea
Social factors and aromatase gene expression during adult male-to-female sex change in captive leopard grouper Mycteroperca rosacea.
Sarcoma
Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma.
Aromatase cytochrome P450 and estrogen and progesterone receptors in uterine sarcomas: correlation with clinical parameters.
Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study.
Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
Aromatase inhibitor therapy for endometrial stromal sarcoma - two-centre experience.
Aromatase inhibitors in gynecologic cancers.
Complete remission of advanced low-grade endometrial stromal sarcoma after aromatase inhibitor therapy: a case report.
Endocrine aspects of human uterine sarcoma: a preliminary study.
Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis.
Hormonal therapy of endometrial stromal sarcoma.
Hormonal treatment with aromatase inhibitors for patients with endometrial stromal sarcoma.
Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma.
Long-term treatment of residual or recurrent low-grade endometrial stromal sarcoma with aromatase inhibitors: A report of two cases and a review of the literature.
Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole.
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
Polymorphism 1558 C > T in the aromatase gene (CYP19A1) in low-grade endometrial stromal sarcoma.
Potential benefit of hormonal therapy for non-uterine soft tissue sarcoma (STS) - a case report and literature review.
Potential Therapeutic Targets in Uterine Sarcomas.
Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.
Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review.
Uterine sarcoma and aromatase inhibitors: Tom Baker Cancer Centre experience and review of the literature.
Sarcoma, Endometrial Stromal
Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma.
Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study.
Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
Aromatase inhibitor therapy for endometrial stromal sarcoma - two-centre experience.
Aromatase inhibitors in gynecologic cancers.
Complete remission of advanced low-grade endometrial stromal sarcoma after aromatase inhibitor therapy: a case report.
Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis.
Hormonal therapy of endometrial stromal sarcoma.
Hormonal treatment with aromatase inhibitors for patients with endometrial stromal sarcoma.
Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma.
Long-term treatment of residual or recurrent low-grade endometrial stromal sarcoma with aromatase inhibitors: A report of two cases and a review of the literature.
Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole.
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
Polymorphism 1558 C > T in the aromatase gene (CYP19A1) in low-grade endometrial stromal sarcoma.
Potential Therapeutic Targets in Uterine Sarcomas.
Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.
Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review.
Seizures
A comparison of anastrozole and testosterone versus placebo and testosterone for treatment of sexual dysfunction in men with epilepsy and hypogonadism.
Acute inhibition of neurosteroid estrogen synthesis suppresses status epilepticus in an animal model.
Aromatase inhibition by letrozole attenuates kainic acid-induced seizures but not neurotoxicity in mice.
Aromatase inhibition, testosterone, and seizures.
Aromatase inhibitors and antiepileptic drugs: a computational systems biology analysis.
Aromatase inhibitors as add-on treatment for men with epilepsy.
Chronic levetiracetam decreases hippocampal and testicular aromatase expression in normal but not kainic acid-induced experimental model of acute seizures in rats.
Epileptic seizure abolition with aromatase inhibition.
Everolimus.
Is the role of estrogens and estrogen receptors in epilepsy still underestimated?
Psychoneuroendocrine aspects of temporolimbic epilepsy. Part II: Epilepsy and reproductive steroids.
Reproductive endocrine considerations and hormonal therapy for men with epilepsy.
Roles of Testosterone and Estradiol in Mediation of Acute Neuroendocrine and Electroencephalographic Effects of Sevoflurane During the Sensitive Period in Rats.
Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3alpha-androstanediol and 17beta-estradiol.
Testosterone versus testosterone and testolactone in treating reproductive and sexual dysfunction in men with epilepsy and hypogonadism.
Seminoma
Cytochrome P450 aromatase expression in human seminoma.
Estrogen-induced growth inhibition of human seminoma cells expressing estrogen receptor beta and aromatase.
Expression of the insulin-like growth factor (IGF) system and steroidogenic enzymes in canine testis tumors.
Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case-parent triad study in a Norwegian-Swedish population.
Sepsis
Aromatase Blockade Is Associated With Increased Mortality in Acute Illness in Male Mice.
The aromatase inhibitor, 4-hydroxyandrostenedione, restores immune responses following trauma-hemorrhage in males and decreases mortality from subsequent sepsis.
Sertoli Cell Tumor
High TGFbeta1, estrogen receptor, and aromatase gene expression in a large cell calcifying sertoli cell tumor (LCCSCT): implications for the mechanism of oncogenesis.
Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
Sertoli Cell Tumor of Testes in a Child with Peutz-Jeghers syndrome.
Sertoli Cell-Only Syndrome
Overexpression of CYP19A1 aromatase in Leydig cells is associated with steroidogenic dysfunction in subjects with Sertoli cell-only syndrome.
Sertoli-Leydig Cell Tumor
Expression of P450 Aromatase in Granulosa Cell Tumors and Sertoli-Stromal Cell Tumors of the Ovary: Which Cells Are Responsible for Estrogenesis?
Immunohistochemical studies of steroidogenic enzymes (aromatase, 17 alpha-hydroxylase and cholesterol side-chain cleavage cytochromes P-450) in sex cord-stromal tumors of the ovary.
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Sex Cord-Gonadal Stromal Tumors
Expression of P450 Aromatase in Granulosa Cell Tumors and Sertoli-Stromal Cell Tumors of the Ovary: Which Cells Are Responsible for Estrogenesis?
Testicular sex cord-stromal lesions: immunohistochemical analysis of cytokeratin, vimentin and steroidogenic enzymes.
Sexual Infantilism
Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene.
Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries.
Sexually Transmitted Diseases
Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Sialadenitis
Immunolocalization of aromatase in human minor salivary glands of the lower lip with primary Sjögren's syndrome.
Sjogren's Syndrome
Does Aromatase Inhibitors Cause Sjogren's Syndrome and Polyneuropathy?
Skin Diseases
Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events.
Sleep Apnea Syndromes
Obesity and male infertility: a practical approach.
[Obesity and male fertility].
Sleep Initiation and Maintenance Disorders
Acupuncture for symptoms management in Korean breast cancer survivors: a prospective pilot study.
Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
Insomnia caused by aromatase inhibitors; a therapeutic challenge in patients with breast cancer.
Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors.
The Relationship Between Insomnia and Cognitive Impairment in Breast Cancer Survivors.
When should we give aromatase inhibitors for insomnia; early in the day or after dinner?
[Menopausal symptoms and quality of life of hormone receptor positive breast cancer patients at different endocrine therapy time].
Small Cell Lung Carcinoma
Aromatase Expression Predicts Survival in Women with Early-Stage Non Small Cell Lung Cancer.
Spondylitis, Ankylosing
The management of secondary osteoporosis.
Squamous Cell Carcinoma of Head and Neck
Aromatase expression in normal human oral keratinocytes and oral squamous cell carcinoma.
Oestrogens and androgen receptors in oral squamous cell carcinoma.
Status Epilepticus
Aromatase inhibition by letrozole attenuates kainic acid-induced seizures but not neurotoxicity in mice.
steroid 17alpha-monooxygenase deficiency
Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic.
steroid 21-monooxygenase deficiency
A large cohort of disorders of sex development and their genetic characteristics: 6 novel mutations in known genes.
Ambiguous genitalia, impaired steroidogenesis, and Antley-Bixler syndrome in a patient with P450 oxidoreductase deficiency.
Aromatase Inhibitor Increases the Height of Patients with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.
Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.
Stomach Neoplasms
Cholesterol import and steroidogenesis are biosignatures for gastric cancer patient survival.
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Expression and localization of aromatase in human gastric mucosa : Immunohistochemical study using biopsy materials.
Genetic susceptibility factors on genes involved in the steroid hormone biosynthesis pathway and progesterone receptor for gastric cancer risk.
Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer.
Stomatitis
Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
Stroke
Age-dependent effects of testosterone in experimental stroke.
Aromatase and neuroinflammation in rat focal brain ischemia.
Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.
Brain aromatase expression after experimental stroke: topography and time course.
Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use.
Genetic Variations of CYP19A1 Gene and Stroke Susceptibility: A Case-control Study in the Chinese Han Population.
Increased P450 aromatase levels in post-menopausal women after acute ischemic stroke.
Role of aromatase in sex-specific cerebrovascular endothelial function in mice.
[Evaluation of aromatase inhibitors' side effects in clinical and experimental studies]
Sweet Syndrome
Sweet's Syndrome Induced by Aromatase Inhibitor in the Treatment of Early Breast Cancer.
Synovitis
Anti-TNF and sex hormones.
Syphilis
The effects of syphilis on endocrine function of the fetoplacental unit.
Tendinopathy
Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event.
Cephalexin-associated Achilles Tendonitis: Case Report and Review of Drug-induced Tendinopathy.
Mini-Review: Toxic Tendinopathy.
[Drug induced tendon injury].
Tenosynovitis
Mini-Review: Toxic Tendinopathy.
Teratozoospermia
Differential expression of mRNA aromatase in ejaculated spermatozoa from infertile men in relation to either asthenozoospermia or teratozoospermia.
Testicular Neoplasms
Aromatase in the human testis.
Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affecting normal physiology.
Endocrine disorders associated with inappropriately high aromatase expression.
Feminizing Sertoli cell tumors in boys with Peutz-Jeghers syndrome.
Human testicular aromatase: immunocytochemical and biochemical studies.
Microsomal aromatase in testicular tumour tissue: increased activity in choriocarcinoma compared to embryonal carcinoma.
Oestrogen secreting Leydig cell tumour and GnRH agonist in-vivo and in-vitro studies.
Overexpression of aromatase leads to development of testicular leydig cell tumors : an in vivo model for hormone-mediated TesticularCancer.
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Serum inhibin B concentration in a prepubertal boy with gynecomastia and Peutz-Jeghers syndrome.
Use of letrozole as a chemopreventive agent in aromatase overexpressing transgenic mice.
Thecoma
Immunohistochemical studies of steroidogenic enzymes (aromatase, 17 alpha-hydroxylase and cholesterol side-chain cleavage cytochromes P-450) in sex cord-stromal tumors of the ovary.
Localization of inhibin alpha-, betaA- and betaB-subunits and aromatase in ovarian follicles with granulosa theca cell tumor (GTCT) in 6 mares.
Thrombocytopenia
Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug-induced thrombocytopenia.
Thromboembolism
Association of Genetically Predicted Serum Estradiol With Risk of Thromboembolism in Men: A Mendelian Randomization Study.
Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.
The impact of hormonal treatments on quality of life of patients with metastatic breast cancer.
Thrombosis
ACOG Committee Opinion No. 738 Summary: Aromatase Inhibitors in Gynecologic Practice.
ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.
Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: case report and review of the literature.
Aortic Thrombus Extending to Left Subclavian in a Patient With Diffuse Venous Thromboembolism on Aromatase Inhibitor Therapy.
Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice.
Committee Opinion No. 663: Aromatase Inhibitors in Gynecologic Practice.
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Hormonal prevention of breast cancer.
Is Monitoring Mean Platelet Volume Necessary in Breast Cancer Patients?
SERMs for the treatment and prevention of breast cancer.
The effects of aromatase inhibitors on lipids and thrombosis.
[Induction of ovulation].
Torsades de Pointes
Cardiac arrhythmia considerations of hormone cancer therapies.
Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
Trigger Finger Disorder
A Case of Bilateral Trigger Thumbs Secondary to Aromatase Inhibitor.
Triple Negative Breast Neoplasms
Myocardial Function in Premenopausal Women Treated With Ovarian Function Suppression and an Aromatase Inhibitor.
Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer.
Whole Transcriptomic Analysis of Apigenin on TNF? Immuno-activated MDA-MB-231 Breast Cancer Cells.
Trophoblastic Neoplasms
Biological characterization of 10-(2-propynyl) estr-4-ene-3, 17-dione (MDL 18,962), an enzyme-activated inhibitor of aromatase.
Human trophoblast xenografts in athymic mice: a model for peripheral aromatization.
Time-dependent inhibition of aromatase in trophoblastic tumor cells in tissue culture.
Tuberous Sclerosis
Everolimus.
Obesity occurring in apolipoprotein E-knockout mice has mild effects on fertility.
Tumor Lysis Syndrome
Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report.
Turner Syndrome
Is there a role for estrogen activity assays? Recombinant cell bioassay for estrogen: Development and applications.
Unilateral Breast Neoplasms
Transforming growth factor beta 1 levels predict echocardiographic changes at three years after adjuvant radiotherapy for breast cancer.
unspecific monooxygenase deficiency
Follicular fluid steroid and epidermal growth factor content, and in vitro estrogen release by granulosa-luteal cells from patients with polycystic ovaries in an IVF/ET program.
Ureteral Obstruction
Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor.
Urinary Bladder Neck Obstruction
Molecular mechanisms of bladder outlet obstruction in transgenic male mice overexpressing aromatase (Cyp19a1).
Urinary Bladder Neoplasms
Association of Aromatase With Bladder Cancer Stage and Long-Term Survival: New Insights Into the Hormonal Paradigm in Bladder Cancer.
Expression of aromatase in tumor related stroma is associated with human bladder cancer progression.
Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis.
Urinary Incontinence
Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis.
Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.
Urogenital Abnormalities
Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.
Uterine Cervical Neoplasms
Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells.
Elevated aromatase expression correlates with cervical carcinoma progression.
Estrogen formation in endometrial and cervix cancer cell lines: Involvement of aromatase, steroid sulfatase and 17beta-hydroxysteroid dehydrogenases (types 1, 5, 7 and 12).
Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation.
Natural Compound Modulates the Cervical Cancer Microenvironment-A Pharmacophore Guided Molecular Modelling Approaches.
Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium.
Uterine Diseases
Event-free survival following early endometrial events in breast cancer patients treated with anti-hormonal therapy: A nationwide claims data study.
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.
Role of aromatase in endometrial disease.
[Expressions of aromatase protein and sex hormone receptor in endometrial lesions.]
Uterine Hemorrhage
ACOG Committee Opinion No. 738 Summary: Aromatase Inhibitors in Gynecologic Practice.
ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.
Aromatase inhibitor therapy for uterine bleeding in a postmenopausal woman with leiomyomata.
Aromatase inhibitors and the endometrium.
CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma.
Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice.
Committee Opinion No. 663: Aromatase Inhibitors in Gynecologic Practice.
Non-contraceptive health benefits of oral contraceptives.
Resolution of Uterine Arteriovenous Malformation and Maintenance of Reproduction in 20 Women Treated With a GnRH Agonist Concomitantly With an Aromatase Inhibitor and Tranexamic Acid.
The impact of hormonal treatments on quality of life of patients with metastatic breast cancer.
Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
Uterine Neoplasms
Expression of estrogen receptors (?, ?), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus.
Selective degradation of the estrogen receptor in the treatment of cancers.
[Neoadjuvant use of the aromatase inhibitor letrozole in uterine cancer: endocrine and clinical effects]
Vaginosis, Bacterial
Are previous episodes of bacterial vaginosis a predictor for vaginal symptoms in breast cancer patients treated with aromatase inhibitors?
Varicose Veins
Elevated sex steroid hormones in great saphenous veins in men.
Vascular Diseases
Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.
Vasculitis
Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis.
Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: A case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
Cutaneous leukocytoclastic vasculitis associated with letrozole.
Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment.
Cutaneous vasculitis in breast cancer treated with chemotherapy.
Letrozole-induced necrotising leukocytoclastic small vessel vasculitis: First report of a case in the UK.
Leukocytoclastic vasculitis associated with use of aromatase inhibitors.
Necrotizing leukocytoclastic small vessel vasculitis associated with letrozole: A case report?.
Venous Thromboembolism
Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: case report and review of the literature.
Aortic Thrombus Extending to Left Subclavian in a Patient With Diffuse Venous Thromboembolism on Aromatase Inhibitor Therapy.
Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Does Hormone Therapy Use Increase Perioperative Complications in Abdominally Based Microsurgical Breast Reconstruction?
Immediate breast reconstruction surgery with expander/direct implant and use of acellular dermal matrix: Does hormone therapy increases the risk of infection?
Initiation of exemestane in two warfarin-treated patients leading to elevation and variability of INR.
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States.
The aromatase inhibitors in early breast cancer: who, when, and why?
Venous Thrombosis
Adjuvant therapy and thrombosis: how to avoid the problem?
Hormonal prevention of breast cancer.
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis.
Vision Disorders
Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors.
Vitamin D Deficiency
Aromatase inhibitor-induced arthralgia: Is vitamin D deficiency responsible?
Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Vulvodynia
Advising Women Undergoing Treatment for Breast Cancer: A Narrative Review.
Unprovoked Vestibular Burning in Late Estrogen-Deprived Menopause: A Case Series.
Whooping Cough
Dehydroepiandrosterone protects vascular endothelial cells against apoptosis through a Galphai protein-dependent activation of phosphatidylinositol 3-kinase/Akt and regulation of antiapoptotic Bcl-2 expression.
Williams Syndrome
Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase.
Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1?,25-dihydroxyvitamin D3.
Wilms Tumor
Analysis of zebrafish cyp19 promoters.
Estrogen actions on follicle formation and early follicle development.
Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood.
Xerostomia
Recent advances in oncology acupuncture and safety considerations in practice.